WorldWideScience

Sample records for 32p 90y 188re

  1. Monte Carlo Calculation of Radioimmunotherapy with (90)Y-, (177)Lu-, (131)I-, (124)I-, and (188)Re-Nanoobjects: Choice of the Best Radionuclide for Solid Tumour Treatment by Using TCP and NTCP Concepts.

    Science.gov (United States)

    Lucas, S; Feron, O; Gallez, B; Masereel, B; Michiels, C; Vander Borght, T

    2015-01-01

    Radioimmunotherapy has shown that the use of monoclonal antibodies combined with a radioisotope like (131)I or (90)Y still remains ineffective for solid and radioresistant tumour treatment. Previous simulations have revealed that an increase in the number of (90)Y labelled to each antibody or nanoobject could be a solution to improve treatment output. It now seems important to assess the treatment output and toxicity when radionuclides such as (90)Y, (177)Lu, (131)I, (124)I, and (188)Re are used. Tumour control probability (TCP) and normal tissue complication probability (NTCP) curves versus the number of radionuclides per nanoobject were computed with MCNPX to evaluate treatment efficacy for solid tumours and to predict the incidence of surrounding side effects. Analyses were carried out for two solid tumour sizes of 0.5 and 1.0 cm radius and for nanoobject (i.e., a radiolabelled antibody) distributed uniformly or nonuniformly throughout a solid tumour (e.g., Non-small-cell-lung cancer (NSCLC)). (90)Y and (188)Re are the best candidates for solid tumour treatment when only one radionuclide is coupled to one carrier. Furthermore, regardless of the radionuclide properties, high values of TCP can be reached without toxicity if the number of radionuclides per nanoobject increases.

  2. Monte Carlo Calculation of Radioimmunotherapy with 90Y-, 177Lu-, 131I-, 124I-, and 188Re-Nanoobjects: Choice of the Best Radionuclide for Solid Tumour Treatment by Using TCP and NTCP Concepts

    Directory of Open Access Journals (Sweden)

    S. Lucas

    2015-01-01

    Full Text Available Radioimmunotherapy has shown that the use of monoclonal antibodies combined with a radioisotope like 131I or 90Y still remains ineffective for solid and radioresistant tumour treatment. Previous simulations have revealed that an increase in the number of 90Y labelled to each antibody or nanoobject could be a solution to improve treatment output. It now seems important to assess the treatment output and toxicity when radionuclides such as 90Y, 177Lu, 131I, 124I, and 188Re are used. Tumour control probability (TCP and normal tissue complication probability (NTCP curves versus the number of radionuclides per nanoobject were computed with MCNPX to evaluate treatment efficacy for solid tumours and to predict the incidence of surrounding side effects. Analyses were carried out for two solid tumour sizes of 0.5 and 1.0 cm radius and for nanoobject (i.e., a radiolabelled antibody distributed uniformly or nonuniformly throughout a solid tumour (e.g., Non-small-cell-lung cancer (NSCLC. 90Y and 188Re are the best candidates for solid tumour treatment when only one radionuclide is coupled to one carrier. Furthermore, regardless of the radionuclide properties, high values of TCP can be reached without toxicity if the number of radionuclides per nanoobject increases.

  3. Monte Carlo Calculation of Radioimmunotherapy with 90Y-, 177Lu-, 131I-, 124I-, and 188Re-Nanoobjects: Choice of the Best Radionuclide for Solid Tumour Treatment by Using TCP and NTCP Concepts

    Science.gov (United States)

    Lucas, S.; Feron, O.; Gallez, B.; Masereel, B.; Michiels, C.; Vander Borght, T.

    2015-01-01

    Radioimmunotherapy has shown that the use of monoclonal antibodies combined with a radioisotope like 131I or 90Y still remains ineffective for solid and radioresistant tumour treatment. Previous simulations have revealed that an increase in the number of 90Y labelled to each antibody or nanoobject could be a solution to improve treatment output. It now seems important to assess the treatment output and toxicity when radionuclides such as 90Y, 177Lu, 131I, 124I, and 188Re are used. Tumour control probability (TCP) and normal tissue complication probability (NTCP) curves versus the number of radionuclides per nanoobject were computed with MCNPX to evaluate treatment efficacy for solid tumours and to predict the incidence of surrounding side effects. Analyses were carried out for two solid tumour sizes of 0.5 and 1.0 cm radius and for nanoobject (i.e., a radiolabelled antibody) distributed uniformly or nonuniformly throughout a solid tumour (e.g., Non-small-cell-lung cancer (NSCLC)). 90Y and 188Re are the best candidates for solid tumour treatment when only one radionuclide is coupled to one carrier. Furthermore, regardless of the radionuclide properties, high values of TCP can be reached without toxicity if the number of radionuclides per nanoobject increases. PMID:26136812

  4. Evaluation of S-values and dose distributions for {sup 90}Y, {sup 131}I, {sup 166}Ho, and {sup 188}Re in seven lobes of the rat liver

    Energy Technology Data Exchange (ETDEWEB)

    Xie Tianwu; Liu Qian; Zaidi, Habib [Britton Chance Center for Biomedical Photonics, Wuhan National Laboratory for Optoelectronics, Huazhong University of Science and Technology, Wuhan 430074 (China) and Key Laboratory of Biomedical Photonics of Ministry of Education, Huazhong University of Science and Technology, Wuhan 430074 (China); Britton Chance Center for Biomedical Photonics, Wuhan National Laboratory for Optoelectronics, Huazhong University of Science and Technology, Wuhan 430074 (China); Key Laboratory of Biomedical Photonics of Ministry of Education, Huazhong University of Science and Technology, Wuhan 430074 (China) and Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, CH-1211 Geneva (Switzerland); Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, CH-1211 Geneva (Switzerland); Geneva Neuroscience Center, Geneva University, CH-1211 Geneva (Switzerland) and Department of Nuclear Medicine and Molecular Imaging, University Medical Center Gronigen, University of Groningen, 9700 RB Groningen (Netherlands)

    2012-03-15

    Purpose: Rats have been widely used in radionuclide therapy research for the treatment of hepatocellular carcinoma (HCC). This has created the need to assess rat liver absorbed radiation dose. In most dose estimation studies, the rat liver is considered as a homogeneous integrated target organ with a tissue composition assumed to be similar to that of human liver tissue. However, the rat liver is composed of several lobes having different anatomical and chemical characteristics. To assess the overall impact on rat liver dose calculation, the authors use a new voxel-based rat model with identified suborgan regions of the liver. Methods: The liver in the original cryosectional color images was manually segmented into seven individual lobes and subsequently integrated into a voxel-based computational rat model. Photon and electron particle transport was simulated using the MCNPX Monte Carlo code to calculate absorbed fractions and S-values for {sup 90}Y, {sup 131}I, {sup 166}Ho, and {sup 188}Re for the seven liver lobes. The effect of chemical composition on organ-specific absorbed dose was investigated by changing the chemical composition of the voxel filling liver material. Radionuclide-specific absorbed doses at the voxel level were further assessed for a small spherical hepatic tumor. Results: The self-absorbed dose for different liver lobes varied depending on their respective masses. A maximum difference of 3.5% was observed for the liver self-absorbed fraction between rat and human tissues for photon energies below 100 keV. {sup 166}Ho and {sup 188}Re produce a uniformly distributed high dose in the tumor and relatively low absorbed dose for surrounding tissues. Conclusions: The authors evaluated rat liver radiation doses from various radionuclides used in HCC treatments using a realistic computational rat model. This work contributes to a better understanding of all aspects influencing radiation transport in organ-specific radiation dose evaluation for

  5. {sup 188}Re-Labeled Radiopharmaceuticals

    Energy Technology Data Exchange (ETDEWEB)

    Jung, Jae Min [Seoul National University, Seoul (Korea, Republic of)

    2001-10-01

    The search for an ideal radioisotope for radiotherapy continues. As a generator-produced radioisotope emitting both beta and gamma rays with a short physical half-life of 16.9 hr, {sup 188}Re is an excellent candidate for radiotherapy. Its applications include the irradiation of coronary artery to prevent restenosis, treatment of rheumatoid arthritis, treatment of peritoneal effusion. palliation of metastatic bone pain, and treatment of liver cancer.

  6. Production of {sup 186}Re and {sup 188}Re, and synthesis of {sup 188}Re-DTPA

    Energy Technology Data Exchange (ETDEWEB)

    Hashimoto, Kazuyuki; Motoishi, Shoji; Kobayashi, Katsutoshi; Izumo, Mishiroku [Department of Radioisotopes, Japan Atomic Energy Research Institute, Tokai, Ibaraki (Japan); Musdja, Muhammad Yanis

    1999-08-01

    Production of radioactive rhenium isotopes {sup 186}Re and {sup 188}Re, and synthesis of {sup 188}Re-DTPA have been studied. For {sup 186}Re, a production method by the {sup 185}Re(n, {gamma}) {sup 186}Re reaction in a reactor has been established. For {sup 188}Re, a production method by the double neuron capture reaction of {sup 186}W, which produces a {sup 188}W/{sup 188}Re generator, has been established. For synthesis of {sup 188}Re-DTPA, the optimum conditions, including pH, the amounts of regents and so on, have been determined. (author)

  7. Synthesis of {sup 188}Re-DMSA complex using carrier-free {sup 188}Re

    Energy Technology Data Exchange (ETDEWEB)

    Hashimoto, Kazuyuki; Izumo, Mishiroku [Japan Atomic Energy Research Inst., Tokai, Ibaraki (Japan). Tokai Research Establishment; Islam, M.S.

    1997-03-01

    The synthesis of rhenium-DMSA labelled compound using carrier-free {sup 188}Re from the {sup 188}W/{sup 188}Re generator has been carried out. Stannous chloride was used as the reducing agent for reduction of rhenium and ascorbic acid was used as an antioxidant in the reaction media. The dependence of the yield of Re-DMSA complex upon the concentration of reducing agent, pH, reaction time, anti-oxidant, carrier and temperature was investigated. Under optimum conditions, the yield of Re-DMSA complexes were more than 98% for the carrier-free as well as carrier-added {sup 188}Re. The stability of the Re-DMSA complexes at different pH and time were also investigated. It was found that the Re-DMSA complex was very stable and did not undergo any changes or decomposition with the changes of pH from its initial values even after 48 hours of pH change for carrier-free as well as carrier-added complexes. (author)

  8. Compartmental and dosimetric studies of anti-CD20 labelled with {sup 188}Re; Estudo compartimental e dosimetrico do Anti-CD20 marcado com {sup 188}Re

    Energy Technology Data Exchange (ETDEWEB)

    Kuramoto, Graciela Barrio

    2016-10-01

    The radioimmunotherapy (RIT) uses MAbs conjugated to radionuclides α or β{sup -} emitters, both for therapy. Your treatment is based on the irradiation and tumor destruction, preserving the normal organs as the excess radiation. Radionuclides β{sup -} emitters as {sup 131}I, {sup 90}Y, {sup 188}Re {sup 177}Lu and are useful for the development of therapeutic radiopharmaceuticals and, when coupled with MAb and Anti-CD20 it is important mainly for the treatment of non-Hodgkin's lymphomas (NHL). {sup 188}Re (E{sub β} = 2.12 MeV; E{sub γ} = 155 keV; t1/2 = 16.9 h) is an attractive radionuclide for RIT. However, {sup 188}Re can be obtained from a radionuclide generator of {sup 188}W/{sup 188}Re, commercially available, making it convenient for use in research and for clinical routine. The CR of IPEN has a project aimed at the production of radiopharmaceutical {sup 188}Re-Anti-CD20, where the radionuclide can be obtained from a generator system {sup 188}W/{sup 188}Re. With this proposed a study to assess the efficiency of this labeling technique for treatment in accordance compartmental and dosimetry. The objective of this study was to compare the marking of anti-CD20 MAb with {sup 188}Re with the marking of the antibody with {sup 90}Y, {sup 131}I, {sup 177}Lu and {sup 99m}Tc (for their similar chemical characteristics) and {sup 211}At, {sup 213}Bi, {sup 223}Ra and {sup 225}Ac); through the study of labeling techniques reported in literature, the proposal of a compartmental model to evaluate its pharmacokinetic and dosimetric studies, high interest for therapy. The result of the study shows a favorable kinetics for {sup 188}Re, by their physical and chemical characteristics compared to the other evaluated radionuclides. The compartment proposed study describes the metabolism of {sup 188}Reanti- CD20 through a compartment mammillary model, which by their pharmacokinetic analysis, performed compared to products emitters β{sup -131}I-labeled anti CD20, {sup 177

  9. 188W/188Re Generator System and Its Therapeutic Applications

    Directory of Open Access Journals (Sweden)

    A. Boschi

    2014-01-01

    Full Text Available The 188Re radioisotope represents a useful radioisotope for the preparation of radiopharmaceuticals for therapeutic applications, particularly because of its favorable nuclear properties. The nuclide decay pattern is through the emission of a principle beta particle having 2.12 MeV maximum energy, which is enough to penetrate and destroy abnormal tissues, and principle gamma rays (Eγ=155 keV, which can efficiently be used for imaging and calculations of radiation dose. 188Re may be conveniently produced by 188W/188Re generator systems. The challenges related to the double neutron capture reaction route to provide only modest yield of the parent 188W radionuclide indeed have been one of the major issues about the use of 188Re in nuclear medicine. Since the specific activity of 188W used in the generator is relatively low (<185 GBq/g, the eluted Re188O4- can have a low radioactive concentration, often ineffective for radiopharmaceutical preparation. However, several efficient postelution concentration techniques have been developed, which yield clinically useful Re188O4- solutions. This review summarizes the technologies developed for the preparation of 188W/188Re generators, postelution concentration of the 188Re perrhenate eluate, and a brief discussion of new chemical strategies available for the very high yield preparation of 188Re radiopharmaceuticals.

  10. A study on indirect radiolabeling of IgG with carrier free 188Re

    Institute of Scientific and Technical Information of China (English)

    2003-01-01

    188Re labeled monoclonal antibodies are potential candidates for use in radioimmunotherapy. S-Bz-MAG3 as a bifunctional chelating agent was used for labeling of IgG with carrier free 188Re by pre-radiolabeling of the chelating approach. The conjugation conditions were optimized. The stability of 188Re-MAG3-IgG in vitro was high. The results may be useful to the studies of 188Re labeled MAbs for radioimmunotherapy.

  11. Preparation and Biological Evaluation of 188Re Labeled Monoclonal Antibody TGLA

    Institute of Scientific and Technical Information of China (English)

    WEN; Kai; ZHANG; Jun-li; CHEN; Bao-jun; CUI; Hai-ping

    2012-01-01

    <正>Monoclonal antibody TGLA is a specific targeting CD20 chimeric antibody. It can kill tumor cells and inhibit tumor cells’ growth effectively, which has been applied to clinical therapy of lymphoma cell B. 188 Re is easy to get, and emits both β and γ rays. 188Re labeled monoclonal antibody TGLA can be used for the study of lymphoma therapy and imaging. This work got the product 188Re-TGLA by direct labeling

  12. Preparation and primary biological evaluation of novel nitrido-188Re complexes/lipiodol

    Institute of Scientific and Technical Information of China (English)

    WANG Guanquan; WEI Hongyuan; LUO Shunzhong; HE Jiaheng; YANG Yuqing; WANG Wenjin; XIONG Xiaoling

    2008-01-01

    Two new nitrido-188Re complexes were prepared by a modified method in high yield.These complexes were stable in vitro.The biodistribution in normal mice showed that these nitrido-188Re complexes could accumulate in liver and dissipate quickly from almost all organs.TAE was performed with the use of lipiodol solutions of two complexes to rabbit VX2 liver tumor models.SPECT images showed that the two lipiodol solutions could remain in tumor for about 9 h (188ReN-NEPTDD/lipiodol) and 12 h (188ReN-NEMMPTDD/Iipiodol),respectively.

  13. Preparation and bio-distribution of bone tumor therapeutic agent 188Re-TCTMP

    Institute of Scientific and Technical Information of China (English)

    JIANG Shu-Bin; LUO Shun-Zhong; DENG Hou-Fu; BIN Wen-Zeng; WANG Wen-Jin; WEI Hong-Yuan; LIU Guo-Ping

    2004-01-01

    TCTMP ( 1,4,8,11-tetraaza cyclotetradecyl- 1,4,8,11-tetramethylene phosphonate) was synthesized and coupled with 188Re. The 188Re-TCTMP's coupling condition, stability and bio-distribution in mice were investigated.The results showed that satisfactory yield of 188Re could be obtained under the conditions of media pH=2.0, 0.8~1.6 mg of SnCl2 and 50 mg of ligand. 188Re-TCTMP was stable (complexation yield >95%) in 8 d without protection of N2. The result of bio-distribution indicated that 188Re-TCTMP had a strong affinity to skeleton and very low non-target tissue's uptake, and the amount of 188Re-TCTMP in blood was (0.06±0.02)%ID/g 6 h after injection,whereas the concentration of 188Re-HEDP (1-hydroxy-ethylidene diphosphonate) in blood was (0.28±0.05)%ID/g 6 hafter injection. Compared with 188Re-HEDP, 188Re-TCTMP exhibits better potential for the treatment of metastases.

  14. Levels of 188Re nucleus populated in thermal neutron capture reaction

    Science.gov (United States)

    Běrziņš, J.; Krasta, T.; Simonova, L.; Balodis, M.; Bondarenko, V.; Jentschel, M.; Urban, W.; Tomandl, I.

    2016-03-01

    Levels of 188Re populated in thermal neutron capture reaction with enriched 187Re targets have been studied. Single γ-ray spectrum of 188Re, measured with the high-resolution crystal diffraction spectrometer GAMS5, as well as γγ-coincidence experiments performed with high efficiency Ge detectors, allowed to develop model-independent level scheme of the doubly-odd 188Re nucleus up to ˜ 1.5 MeV excitation energy. Analysis of the established 188Re level scheme in terms of the quasiparticle-plus-rotor model indicates coexistence of axially-deformed and triaxial structures in the energy range above 400 keV.

  15. Exploitation of nano alumina for the chromatographic separation of clinical grade 188Re from 188W: a renaissance of the 188W/188Re generator technology.

    Science.gov (United States)

    Chakravarty, Rubel; Shukla, Rakesh; Ram, Ramu; Venkatesh, Meera; Tyagi, Avesh Kumar; Dash, Ashutosh

    2011-08-15

    The (188)W/(188)Re generator using an acidic alumina column for chromatographic separation of (188)Re has remained the most popular procedure world over. The capacity of bulk alumina for taking up tungstate ions is limited (∼50 mg W/g) necessitating the use of very high specific activity (188)W (185-370 GBq/g), which can be produced only in very few high flux reactors available in the world. In this context, the use of high-capacity sorbents would not only mitigate the requirement of high specific activity (188)W but also facilitate easy access to (188)Re. A solid state mechanochemical approach to synthesize nanocrystalline γ-Al(2)O(3) possessing very high W-sorption capacity (500 mg W/g) was developed. The structural and other investigations of the material were carried out using X-ray diffraction (XRD), transmission electron microscopy (TEM), Brunauer Emmett Teller (BET) surface area analysis, thermogravimetric-differential thermal analysis (TG-DTA), and dynamic light scattering (DLS) techniques. The synthesized material had an average crystallite size of ∼5 nm and surface area of 252 ± 10 m(2)/g. Sorption characteristics such as distribution ratios (K(d)), capacity, breakthrough profile, and elution behavior were investigated to ensure quantitative uptake of (188)W and selective elution of (188)Re. A 11.1 GBq (300 mCi) (188)W/(188)Re generator was developed using nanocrystalline γ-Al(2)O(3), and its performance was evaluated for a period of 6 months. The overall yield of (188)Re was >80%, with >99.999% radionuclidic purity and >99% radiochemical purity. The eluted (188)Re possessed appreciably high radioactive concentration and was compatible for the preparation of (188)Re labeled radiopharmaceuticals.

  16. Preparation and biodistribution of 188Re-labeled folate conjugated human serum albumin magnetic cisplatin nanoparticles (188Re-folate-CDDP/HSA MNPs in vivo

    Directory of Open Access Journals (Sweden)

    Tang QS

    2011-11-01

    Full Text Available Qiu-Sha Tang1,*, Dao-Zhen Chen2,*, Wen-Qun Xue2, Jing-Ying Xiang2, Yong-Chi Gong1, Li Zhang2, Cai-Qin Guo21Department of Pathology and Pathophysiology, Medical College, Southeast University, Nanjing, Jiangsu; 2Central Laboratory, Wuxi Hospital for Maternal and Child Health Care, Affiliated Medical School of Nanjin, Wuxi, Jiangsu, China *Authors contributed equally to this workBackground: The purpose of this study was to develop intraperitoneal hyperthermic therapy based on magnetic fluid hyperthermia, nanoparticle-wrapped cisplatin chemotherapy, and magnetic particles of albumin. In addition, to combine the multiple-killing effects of hyperthermal targeting therapy, chemotherapy, and radiotherapy, the albumin-nanoparticle surfaces were linked with radionuclide 188Re-labeled folic acid ligand (188Re-folate-CDDP/HSA.Methods: Human serum albumin was labeled with 188Re using the pre-tin method. Reaction time and optimal conditions of labeling were investigated. The particles were intravenously injected into mice, which were sacrificed at different time points. Radioactivity per gram of tissue of percent injected dose (% ID/g was measured in vital organs. The biodistribution of 188Re-folate-CDDP/HAS magnetic nanoparticles was assessed.Results: Optimal conditions for 188Re-labeled folate-conjugated albumin combined with cisplatin magnetic nanoparticles were: 0.1 mL of sodium gluconate solution (0.3 mol/L, 0.1 mL of concentrated hydrochloric acid with dissolved stannous chloride (10 mg/mL, 0.04 mL of acetic acid buffer solution (pH 5, 0.2 mol/L, 30 mg of folate-conjugated albumin combined with cisplatin magnetic nanoparticles, and 188ReO4 eluent (0.1 mL. The rate of 188Re-folate-CDDP-HSA magnetic nanoparticle formation exceeded 90%, and radiochemical purity exceeded 95%. The overall labeling rate was 83% in calf serum at 37°C. The major uptake tissues were the liver, kidney, intestine, and tumor after the 188Re-folate-CDDP/HSA magnetic nanoparticles

  17. Rhenium-188: Availability from the W-188/Re-188 Generator and Status of Current Applications

    Energy Technology Data Exchange (ETDEWEB)

    Pillai, M R A [Bhabha Atomic Research Centre, Mumbai, India; Dash, A [Bhabha Atomic Research Centre, Mumbai, India; Knapp Jr, Russ F [ORNL

    2012-01-01

    Rhenium-188 is one of the most readily available generator derived and useful radionuclides for therapy emitting - particles (2.12 MeV, 71.1% and 1.965 MeV, 25.6%) and imageable gammas (155 KeV, 15.1%). The 188W/188Re generator is an ideal source for the long term (4-6 months) continuous availability of no carrier added (nca) 188Re suitable for the preparation of radiopharmaceuticals for radionuclide therapy. The challenges associated with the double neutron capture route of production of the parent 188W radionuclide have been a major impediment in the progress of application of 188Re. Tungsten-188 of adequate specific activity can be prepared only in 2-3 of the high flux reactors operating in the World. Several useful technologies have been developed for the preparation of clinical grade 188W/188Re generator. Since the specific activity of 188W used in the generator is relatively low (<5 Ci/g), the eluted 188ReO4- can have low radioactive concentration often insufficient for radiopharmaceutical preparation. However, several efficient post elution concentration techniques have been developed that yield clinically useful 188ReO4-. Rhenium-188 has been used for the preparation of therapeutic radiopharmaceuticals for the management of diseases such as bone metastasis, rheumatoid arthritis and primary cancers. Several early phase clinical studies using radiopharmaceuticals based on 188Re-labeled phosphonates, antibodies, peptides, lipiodol and particulates have been reported. This article reviews the availability, and use of188Re including a discussion of why broader use of 188Re has not progressed as ecpected as a popular radionuclide for therapy.

  18. Nanocrystalline zirconia: a novel sorbent for the preparation of (188)W/(188)Re generator.

    Science.gov (United States)

    Chakravarty, Rubel; Shukla, Rakesh; Tyagi, A K; Dash, Ashutosh; Venkatesh, Meera

    2010-02-01

    Nanocrystalline zirconia, a novel high capacity sorbent material was synthesized and tested for its utility in the preparation of (188)W/(188)Re generators. The structural investigation of the material was carried out using X-ray diffraction, surface area determination, FTIR and TEM micrograph analysis. Various experimental parameters were optimized to separate (188)Re from (188)W. The capacity of the material was found to be approximately 325mgW/g at the optimum pH. A chromatographic (188)W/(188)Re generator was developed using this material from which >80% of (188)Re generated could be eluted with 0.9% saline solution, with high radionuclidic, radiochemical and chemical purity and appreciably high radioactive concentration suitable for radiopharmaceutical applications.

  19. External beam radiotherapy synergizes 188Re-liposome against human esophageal cancer xenograft and modulates 188Re-liposome pharmacokinetics

    Directory of Open Access Journals (Sweden)

    Chang CH

    2015-05-01

    Full Text Available Chih-Hsien Chang,1,2 Shin-Yi Liu,3 Chih-Wen Chi,3 Hsiang-Lin Yu,1 Tsui-Jung Chang,1 Tung-Hu Tsai,4 Te-Wei Lee,1 Yu-Jen Chen3–5 1Isotope Application Division, Institute of Nuclear Energy Research, Taoyuan, Taiwan; 2Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, 3Department of Medical Research MacKay Memorial Hospital, 4Institute of Traditional Medicine, National Yang-Ming University, 5Department of Radiation Oncology, MacKay Memorial Hospital, Taipei, Taiwan Abstract: External beam radiotherapy (EBRT treats gross tumors and local microscopic diseases. Radionuclide therapy by radioisotopes can eradicate tumors systemically. Rhenium 188 (188Re-liposome, a nanoparticle undergoing clinical trials, emits gamma rays for imaging validation and beta rays for therapy, with biodistribution profiles preferential to tumors. We designed a combinatory treatment and examined its effects on human esophageal cancer xenografts, a malignancy with potential treatment resistance and poor prognosis. Human esophageal cancer cell lines BE-3 (adenocarcinoma and CE81T/VGH (squamous cell carcinoma were implanted and compared. The radiochemical purity of 188Re-liposome exceeded 95%. Molecular imaging by NanoSPECT/CT showed that BE-3, but not CE81T/VGH, xenografts could uptake the 188Re-liposome. The combination of EBRT and 188Re-liposome inhibited tumor regrowth greater than each treatment alone, as the tumor growth inhibition rate was 30% with EBRT, 25% with 188Re-liposome, and 53% with the combination treatment at 21 days postinjection. Combinatory treatment had no additive adverse effects and significant biological toxicities on white blood cell counts, body weight, or liver and renal functions. EBRT significantly enhanced the excretion of 188Re-liposome into feces and urine. In conclusion, the combination of EBRT with 188Re-liposome might be a potential treatment modality for esophageal cancer. Keywords: Radionuclide

  20. Comparative studies of antibody anti-CD20 labeled with {sup 188}Re; Estudo comparativo da marcacao do anticorpo anti-CD20 com {sup 188}Re

    Energy Technology Data Exchange (ETDEWEB)

    Dias, Carla Roberta de Barros Rodrigues

    2010-07-01

    Nuclear Medicine is an unique and important modality in oncology and the development of new tumor-targeted radiopharmaceuticals for both diagnosis and therapy is an area of interest for researchers. Rituximab (RTX) is a quimeric monoclonal antibody (mAb) (IgG 1) that specifically binds to CD20 antigen with high affinity and has been successfully used for the treatment of Non-Hodgkin Lymphoma (NHL) of cell B. The CD20 antigen is expressed over more than 90% of cell B NHL. Technetium-99m ({sup 99m}Tc) and rhenium-188 ({sup 188}Re) are an attractive radionuclide pair for clinical use due to their favorable decay properties for diagnosis ({sup 99m}Tc: T{sub 1/2} = 6 h, {gamma} radiation = 140 keV) and therapy ({sup 188}Re: T{sub 1/2} = 17 h, maximum {beta} energy = 2.12 MeV) and to their availability in the form of {sup 99}Mo/{sup 99}mTc and {sup 188}W/{sup 188}Re generators. The radionuclides can be conjugated to mAb using similar chemical procedures. The aim of this work was to study the labeling of anti-CD20 mAb (RTX) with {sup 188}Re using two techniques: the direct labeling method [{sup 188}Re(V)] and the labeling method via the carbonyl nucleus [{sup 188}Re(I)]. Besides the quality control, the radiolabeled mAb was submitted to in vivo, in vitro and ex vivo biological studies. For the direct labeling, RTX was reducing by incubation with 2-mercaptoethanol for generating sulphydryl groups (-SH) and further labeled with {sup 188}Re(V), in a study of several parameters in order to reach an optimized formulation. The labeling via the carbonyl nucleus both {sup 99}mTc and {sup 188}Re were employed through 2 different procedures: (1) labeling of intact RTX with {sup 99}mTc(I) and (2) reduced RTX (RTX{sub red}) labeled with {sup 99}mTc(I)/{sup 188}Re(I). Also a parameter study was performed to obtain an optimized formulation. The quality control method for evaluating the radiochemical purity showed a good labeling yield (93%) for the direct method. The labeling method

  1. 188Re-LABELED HYPERBRANCHED POLYSULFONAMINE AS A ROBUST TOOL FOR TARGETED CANCER DIAGNOSIS AND RADIOIMMUNOTHERAPY

    Institute of Scientific and Technical Information of China (English)

    Nan Li; Yue Jin; Li-zhe Xue; Pei-yong Li; De-yue Yan; Xin-yuan Zhu

    2013-01-01

    Hyperbranched polysulfonamine (HPSA) is a promising biomaterial due to its highly branched spherical architecture and efficient intracellular translocation.To realize the functionalization of HPSA,both N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP) for tethering the human-mouse chimeric monoclonal antibody CH12 and N-hydroxy succinimidyl S-acetylmercaptoacetyltriglycinate (NHS-MAG3) for labeling 188Re were sequentially grafted onto the primary amine terminals of HPSA via covalent linkages,attaining the SPDP-HPSA-MAG3 intermediate.In order to reserve the structural integrity of CH12,the fragment crystallizable (Fc) region was also processed by oxidation of oligosaccharide moieties with sodium periodate and then reacted with N-(κ-maleimidoundecanoic acid) hydrazide (KMUH).After chelating 188Re with MAG3 group,the SPDP was reduced to PDP and connected onto the maleinimide group at the Fc region.As a result,both the epidermal growth factor receptor vIII (EGFRvIII) targeted monoclonal antibody CH12 and the radionuclide 188Re were conjugated to the HPSA-based vehicles,forming the 188Re-labeled and CH12-tethered HPSA (CH12-HPSA-188Re).The molecular weight and in vitro stability of CH12-HPSA-l88Re were evaluated by gel electrophoresis and paper chromatography.On one hand,the CH12-HPSA-188Re could specifically bind to the EGFRvIII-positive human hepatocarcinoma cells in vitro.On the other hand,it could also target at the tumor tissue of nude mice in vivo.Hence,the CH12-HPSA-188Re could effectively target at the human hepatocarcinoma and facilitate the tumor detection and targeted radioimmunotherapy.

  2. Preliminary study of metabolic radiotherapy with {sup 188}Re via small animal imaging

    Energy Technology Data Exchange (ETDEWEB)

    Antoccia, A. [Dept. of Biology, Univ. Roma3, V.le G. Marconi, I-00146 Rome (Italy); INFN, Sezione Roma3, Via della Vasca Navale 84, I-00146 Rome (Italy); Baldazzi, G. [Dept. of Physics, Univ. Bologna, V.le C. Berti-Pichat 6/2, I-40127 Bologna (Italy); INFN, Sezione Bologna, V.le C. Berti-Pichat 6/2, I-40127 Bologna (Italy); Bello, M. [Dept. of Physics, Univ. Padova, Via F. Marzolo 8, I-35131 Padova (Italy); INFN - LNL, V.le dell' Universita 2, I-35020 Legnaro(Italy)

    2006-01-15

    {sup 188}Re is a {beta}{sup -} (Emax=2.12 MeV) and {gamma} (155 keV) emitter. Since its chemistry is similar to that of the largely employed tracer, {sup 99m}Tc, molecules of hyaluronic acid (HA) have been labelled with {sup 188}Re to produce a target specific radiopharmaceutical. The radiolabeled compound, i.v. injected in healthy mice, is able to accumulate into the liver after a few minutes. To study the effect of metabolic radiotherapy in mice, we have built a small gamma camera based on a matrix of YAP:Ce crystals, with 0.6x0.6x10 mm{sup 3} pixels, read out by a R2486 Hamamatsu PSPMT. A high-sensitivity 20 mm thick lead parallel-hole collimator, with hole diameter 1.5 mm and septa of 0.18 mm, is placed in front of the YAP matrix. Preliminary results obtained with various phantoms containing a solution of {sup 188}Re and with C57 black mice injected with the {sup 188}Re-HA solution are presented. To increase the space resolution and to obtain two orthogonal projections simultaneously we are building in parallel two new cameras to be positioned at 90 degrees. They use a CsI(Tl) matrix with 1x1x5 mm{sup 3} pixels read out by H8500 Hamamatsu Flat panel PMT.

  3. Preliminary study of metabolic radiotherapy with 188Re via small animal imaging

    CERN Document Server

    Baldazzi, G; Muciaccio, A; Navarria, Francesco Luigi; Pancaldi, G; Perrotta, A; Zuffa, M; Boccaccio, P; Uzunov, N; Bello, M; Bernardini, D; Mazzi, U; Moschini, G; Riondato, M; Rosato, A; Garibaldi, F; Pani, R; Antoccia, A; De Notaristefani, F; Hull, G; Cencelli, V O; Sgura, A; Tanzarella, C

    2006-01-01

    188Re is a beta- (Emax = 2.12 MeV) and gamma (155 keV) emitter. Since its chemistry is similar to that of the largely employed tracer, 99mTc, molecules of hyaluronic acid (HA) have been labelled with 188Re to produce a target specific radiopharmaceutical. The radiolabeled compound, i.v. injected in healthy mice, is able to accumulate into the liver after a few minutes. To study the effect of metabolic radiotherapy in mice, we have built a small gamma camera based on a matrix of YAP:Ce crystals, with 0.6x0.6x10 mm**3 pixels, read out by a R2486 Hamamatsu PSPMT. A high-sensitivity 20 mm thick lead parallel-hole collimator, with hole diameter 1.5 mm and septa of 0.18 mm, is placed in front of the YAP matrix. Preliminary results obtained with various phantoms containing a solution of 188Re and with C57 black mice injected with the 188Re-HA solution are presented. To increase the space resolution and to obtain two orthogonal projections simultaneously we are building in parallel two new cameras to be positioned at...

  4. Formulation, radiopharmaceutical kinetics and dosimetry of the {sup 188}Re(V)-DMSA complex; Formulacion, radiofarmacocinetica y dosimetria del complejo {sup 188}Re(V)-DMSA

    Energy Technology Data Exchange (ETDEWEB)

    Garcia S, L.; Ferro F, G. [Departamento de Materiales Radiactivos. Instituto Nacional de Investigaciones Nucleares, C.P. 52045 Salazar, Estado de Mexico (Mexico); Murphy, C.A. de; Pedraza L, M. [Departamento de Medicina Nuclear, Instituto Nacional de la Nutricion, Salvador Zubiran, Mexico D.F. (Mexico); Azorin N, J. [Departamento de Fisica, Universidad Autonoma Metropolitana Iztapalapa, Mexico D.F. (Mexico)

    1999-07-01

    It was developed through experimental design (ANOVA), a formulation to prepare the {sup 188} Re(V)-Dmsa complex. Likewise, there were realized studies of radiopharmaceutical kinetics and internal dosimetry in animals, its normal and with induced tumors, considering an open bi compartmental model using the MIRD methodology. The {sup 188} Re(V)-Dmsa complex was obtained with a radiochemical purity greater than 95% incubating 30 min at 90 Centigrade under the following formulation: [SnCl{sub 2}] = 1.4 mg/ml, [ascorbic acid] = 0.5 mg/ml, p H = 2.0 - 3.0. The stability test of the formulation, shows that after 48 h of its preparation, does not produce radiolytic degradation neither chemical decomposition. The radiopharmaceutical kinetics data show an average residence time 7.2h, velocity constant {alpha} = 0.6508h{sup -1} and {beta} = 0.1046 h{sup -1} with an apparent distribution volume 6.9 l. The main elimination via was renal and it was observed osseous caption with an accumulated activity 522.049 {+-} 62 MBq h (residence time 14.1094 {+-} 1.69h). In according with the dosimetric calculations, by each 37 MBq injected, the equivalent dose at the tumor was 9.67{+-} 0.33 Sv/g, for an effective dose 0.292 {+-} 0.0017 mSv/MBq. The images obtained in the gamma camera of the mice with induced tumors, show that do not have significant accumulation in the metabolic organs. The caption in bone and in tumors induced of the {sup 188} Re(V)-Dmsa complex, show its potential for be used as a palliative agent for pain in patients with osseous metastasis and in the treatment of tumors of soft tissue. (Author)

  5. Dosimetric evaluation of anti-CD20 labelled with {sup 188}Re

    Energy Technology Data Exchange (ETDEWEB)

    Barrio, Graciela; Osso Junior, Joao A., E-mail: gracielabarrio@usp.br [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil)

    2011-07-01

    Radioimmunotherapy has the potential to deliver lethal radiation energy directly to malignant cells via targeting of radioisotope-conjugated monoclonal antibodies (MAbs) to specific antigens. B-cell lymphoma is a particularly good candidate for radioimmunotherapy because the disease is inherently radiosensitive, malignant cells in the blood, bone marrow, spleen and lymphonodes are accessible, and MAbs have been developed to B-cell surface antigens that do not shed or modulate. Rituximab (RTX), the human IgG1-type chimeric form of the parent murine antibody ibritumomab, is specifically targeted against CD20, a surface antigen expressed by pre-B and mature human B lymphocytes. The use of rhenium-188 from a {sup 188}W/{sup 188}Re generator system represents an attractive alternative radionuclide for therapy. {sup 188}Re is produced from beta decay of the {sup 188}W parent. In addition to the emission of high-energy electrons (E{beta}= 2118 keV), {sup 188}Re also decays with emission of a gamma photon with an energy of 155 keV in 15% abundance. Besides the therapeutic usefulness of {sup 188}Re, the emission of gamma photon is an added advantage since the biodistribution of {sup 188}Re-labeled antibodies can be evaluated in vivo with a gamma camera. Also, rhenium has chemical properties similar to technetium. Thus, both can be conjugated to antibodies using similar chemistry methods. The objective of this work is to prove the usefulness of this radiopharmaceutical based on dosimetric studies, that are also required by the Brazilian Regulatory Agency (ANVISA). (author)

  6. Labeling of MDP with {sup 188}Re for bone tumour therapy

    Energy Technology Data Exchange (ETDEWEB)

    Barbezan, Angelica B.; Osso Junior, Joao A., E-mail: jaosso@ipen.b [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil)

    2011-07-01

    {sup 188}Re is one of the most attractive radioisotopes for a variety of therapeutic applications in nuclear medicine, due to its physical decay properties, such as {beta}{sup -} emission of 2.12 MeV, {gamma} emission of 155 keV and half life of 16.9 hours. Biphosphonates are potent inhibitors of osteoclastic bone resorption and are effective in several diseases that cause bone fragility and bone metastases. Because of these characteristics, labeled biphosphonates have been studied for bone pathologies, also acting as palliation of bone pain in case of metastasis.The aim of this study was to optimize the labeling of a phosphonate-MDP (Sodium Methylene Diphosphonate) with {sup 188}Re for use in bone pain palliation. {sup 188}Re was obtained by eluting a {sup 188}W-{sup 188}Re generator from POLATOM. The labeling was performed at room temperature using MDP, SnCl{sub 2} as reducing agent and ascorbic acid. The variables studied were: Mass of ligand (3, 6 and 10 mg), reducing agent mass (5, 7, 10 and 11 mg), ascorbic acid mass (1, 3, 5 and 6 mg), pH (1 and 2) and time of reaction (15, 60, 120, 360 and 4320 minutes), that also reflected the stability of the radiopharmaceutical. The radiochemical control, that also measures the labeling efficiency was evaluated by paper chromatography using Whatman 3MM paper and the solvents acetone and 0.9%NaCl. The best formulation was the following: Mass of ligand MDP: 10 mg, mass of SnCl{sub 2}: 5 mg, ascorbic acid mass: 3 mg, time of reaction: 30 minutes, pH: 1. Under optimum conditions, {sup 188}Re MDP radiolabeling yield was 98,07% and the radiopharmaceutical was stable up to 72 h. (author)

  7. Assessment of 188Re marked anti MHC class Ⅱ antibody by peripheral blood mononuclear cells stimulated by donor alloantigen

    Institute of Scientific and Technical Information of China (English)

    DING Guo-ping; CAO Li-ping; LIU Jie; LIU Da-ren; QUE Ri-sheng; ZHU Lin-hua; ZHOU Yi-ming; MAO Ke-jie; HU Jun-an

    2011-01-01

    Background Previous studies showed that anti MHC-Ⅱ monoclone antibody (MAb) only had partial inhibiting effect of alloreactive mixed lymphocyte reaction (MLR) in vitro and it was unsteady and non-persistent. The aim of this research was to determine whether radioactive isotope 188Re marked MHC-Ⅱ antibody could benefit the allograft acceptance in transplantation as compared to normal MHC-Ⅱ antibody.Methods 188Re was incorporated to 2E9/13F(ab')2 which is against swine MHC class Ⅱ antigen (MAb-188Re). Porcine peripheral blood mononuclear (PBMC) cells were examined for proliferation and cytokine mRNA expression after stimulation with MHC-Ⅱ MAb or MAb-188Re.Results The proliferative response of recipient PBMCs in mixed lymphocyte reaction (MLR) to donor alloantigen showed that the stimulation index of MAb-188Re group was significantly lower than the MHC-Ⅱ MAb group and control (P<0.05). mRNA expression of interleukin 2, interferon Y and tumor necrosis factor α (type 1 cytokines) was lower in MAb-188Re group than the MHC-Ⅱ MAb group, while interleukin 10 (type 2 cytokines) was higher in MAb-188Re group in the first 24 hours.Conclusion MAb-188Re could help the graft acceptance by inhibiting T cell proliferation, lowering the expression of type 1 cytokines and elevating the type 2 cytokines produced by PBMC.

  8. In vivo examination of {sup 188}Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer

    Energy Technology Data Exchange (ETDEWEB)

    Chen, K.-T. [Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu 30013, Taiwan (China); Lee, T.-W. [Institute of Nuclear Energy Research, Longtan 32546, Taiwan (China); Lo, Jem-Mau [Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu 30013, Taiwan (China); Institute of Nuclear Engineering and Science, National Tsing Hua University, Hsinchu 30013, Taiwan (China)], E-mail: jmlo@mx.nthu.edu.tw

    2009-05-15

    Introduction: Trastuzumab (Herceptin), a humanized IgG1 monoclonal antibody directed against the extracellular domain of the HER2 protein, acts as an immunotherapeutic agent for HER2-overexpressing human breast cancers. Radiolabeled trastuzumab with {beta}- or {alpha} emitters can be used as radioimmunotherapeutic agent for the similar purpose but with additional radiation effect. Methods: In this study, trastuzumab was labeled with {sup 188}Re for radioimmunotherapy of HER2/neu-positive breast cancer. {sup 188}Re(I)-tricarbonyl ion, [{sup 188}Re(OH{sub 2}){sub 3}(CO){sub 3}]{sup +}, was employed as a precursor for directly labeling the monoclonal antibody with {sup 188}Re. The immunoreactivity of {sup 188}Re(I)-trastuzumab was estimated by competition receptor-binding assay using HER2/neu-overexpressive BT-474 human breast cancer cells. The localization properties of {sup 188}Re(I)-trastuzumab within both tumor and normal tissues of athymic mice bearing BT-474 human breast cancer xenografts (HER2/neu-overexpressive) and similar mice bearing MCF-7 human breast cancer xenografts (HER2/neu-low expressive) were investigated. Results: When incubated with human serum albumin and histidine at 25{sup o}C, {sup 188}Re(I)-trastuzumab was found to be stable within 24 h. The IC{sub 50} of {sup 188}Re(I)-trastuzumab was found to be 22.63{+-}4.57 nM. {sup 188}Re(I)-trastuzumab was shown to accumulate specifically in BT-474 tumor tissue in in vivo biodistribution studies. By microSPECT/CT, the image of {sup 188}Re localized BT-474 tumor was clearly visualized within 24 h. In contrast, {sup 188}Re(I)-trastuzumab uptake in HER2-low-expressing MCF-7 tumor was minimal, and the {sup 188}Re image at the localization of the tumor was dim. Conclusion: These results reveal that {sup 188}Re(I)-trastuzumab could be an appropriate radioimmunotherapeutic agent for the treatment of HER2/neu-overexpressing cancers.

  9. Preparation and quality control of clinic scale {sup 188}W-{sup 188}Re generator

    Energy Technology Data Exchange (ETDEWEB)

    Yin, Duanzhi; Zhou, Wei [Chinese Academy of Sciences, Shanghai (China). Shanghai Inst. of Applied Physics; Hu, Weiqing; He, Weiyu; Zhang, Lei; Min, Xiafeng; Shi, Xichang; Cao, Benhong [Amersham Kexin Pharmaceutical Co. Ltd, Shanghai (China); Wang, Yongxian [Chinese Academy of Sciences, Shanghai (China). Shanghai Inst. of Applied Physics; Amersham Kexin Pharmaceutical Co. Ltd, Shanghai (China)

    2004-07-01

    {sup 188}Re is an excellent candidate for the radionuclide therapy, since it is easily obtained as a ''no-carrier-added'' radioisotope from a {sup 188}W-{sup 188}Re generator. The half-life of 16.9 hours is suitable for tumor treatment and of benefit to minimize toxicity to whole body; Beta emissions with energies of 2.12 MeV (71.6%) and 1.97 MeV (25.1%) are suitable for therapy and the gamma emission of 155 keV (15%) allows imaging and dosimetry. The drug for tumor therapy has been a highlight of the new drug development in recent years. The radionuclide therapy has shown significant effectiveness in the treatment of various cancers. {sup 188}W-{sup 188}Re generator could conveniently provide high levels of carrier-free rhenium-188 at low cost for the treatment of a variety of cancers, cardiovascular diseases as well as the marrow transplantation. (orig.)

  10. Automation of labelling of Lipiodol with high-activity generator-produced 188Re.

    Science.gov (United States)

    Lepareur, Nicolas; Ardisson, Valérie; Noiret, Nicolas; Boucher, Eveline; Raoul, Jean-Luc; Clément, Bruno; Garin, Etienne

    2011-02-01

    This work describes optimisation of the kit formulation for labelling of Lipiodol with high-activity generator-produced rhenium-188. Radiochemical purity (RCP) was 92.52±2.3% and extraction yield was 98.56±1.2%. The synthesis has been automated with a TADDEO module (Comecer) giving a mean final yield of 52.68±9.6%, and reducing radiation burden to the radiochemist by 80%. Radiolabelled Lipiodol ((188)Re-SSS/Lipiodol) is stable for at least 7 days (RCP=91.07±0.9%).

  11. Automation of labelling of Lipiodol with high-activity generator-produced {sup 188}Re

    Energy Technology Data Exchange (ETDEWEB)

    Lepareur, Nicolas, E-mail: n.lepareur@rennes.fnclcc.f [Service de Medecine Nucleaire, Centre Regional de Lutte Contre le Cancer Eugene Marquis, CS 44229, 35042 Rennes (France); INSERM U-991, Foie, Metabolismes et Cancer, 35033 Rennes (France); Universite Europeenne de Bretagne, Rennes (France); Ardisson, Valerie [Service de Medecine Nucleaire, Centre Regional de Lutte Contre le Cancer Eugene Marquis, CS 44229, 35042 Rennes (France); INSERM U-991, Foie, Metabolismes et Cancer, 35033 Rennes (France); Universite Europeenne de Bretagne, Rennes (France); Noiret, Nicolas [Universite Europeenne de Bretagne, Rennes (France); Ecole Nationale Superieure de Chimie de Rennes, UMR CNRS 6226, Chimie Organique et Supramoleculaire, Avenue du General Leclerc, CS 50837, 35708 Rennes Cedex 7 (France); Boucher, Eveline; Raoul, Jean-Luc [INSERM U-991, Foie, Metabolismes et Cancer, 35033 Rennes (France); Universite Europeenne de Bretagne, Rennes (France); Service d' Oncologie Digestive, Centre Regional de Lutte Contre le Cancer Eugene Marquis, CS 44229, 35042 Rennes (France); Clement, Bruno [INSERM U-991, Foie, Metabolismes et Cancer, 35033 Rennes (France); Garin, Etienne [Service de Medecine Nucleaire, Centre Regional de Lutte Contre le Cancer Eugene Marquis, CS 44229, 35042 Rennes (France); INSERM U-991, Foie, Metabolismes et Cancer, 35033 Rennes (France); Universite Europeenne de Bretagne, Rennes (France)

    2011-02-15

    This work describes optimisation of the kit formulation for labelling of Lipiodol with high-activity generator-produced rhenium-188. Radiochemical purity (RCP) was 92.52{+-}2.3% and extraction yield was 98.56{+-}1.2%. The synthesis has been automated with a TADDEO module (Comecer) giving a mean final yield of 52.68{+-}9.6%, and reducing radiation burden to the radiochemist by 80%. Radiolabelled Lipiodol ({sup 188}Re-SSS/Lipiodol) is stable for at least 7 days (RCP=91.07{+-}0.9%).

  12. Biokinetic and dosimetric studies of {sup 188}Re-hyaluronic acid: a new radiopharmaceutical for treatment of hepatocellular carcinoma

    Energy Technology Data Exchange (ETDEWEB)

    Melendez-Alafort, Laura [Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Padova, 35131 Padua (Italy)], E-mail: laura.melendez@unipd.it; Nadali, Anna; Zangoni, Elena [Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Padova, 35131 Padua (Italy); Banzato, Alessandra; Rondina, Maria [Dipartimento di Scienze Oncologiche e Chirurgiche, Universita degli Studi di Padova, Padua (Italy); Rosato, Antonio [Dipartimento di Scienze Oncologiche e Chirurgiche, Universita degli Studi di Padova, Padua (Italy); Istituto Oncologico Veneto, IOV, Padova, Padua (Italy); Mazzi, Ulderico [Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Padova, 35131 Padua (Italy)

    2009-08-15

    Hepatocellular carcinoma (HCC) is the most common primary liver cancer and has very limited therapeutic options. Recently, it has been found that hyaluronic acid (HA) shows selective binding to CD44 receptors expressed in most cancer histotypes. Since the trend in cancer treatment is the use of targeted radionuclide therapy, the aim of this research was to label HA with rhenium-188 and to evaluate its potential use as a hepatocarcinoma therapeutic radiopharmaceutical. Methods: {sup 188}Re-HA was prepared by a direct labelling method to produce a ReO(O-COO){sub 2}-type coordination complex. {sup 188}Re-HA protein binding and its stability in saline, phosphate buffer, human serum and cysteine solutions were determined. Biokinetic and dosimetric data were estimated in healthy mice (n=60) using the Medical Internal Radiation Dose methodology and mouse model beta-absorbed fractions. To evaluate liver toxicity, alanine aminotranferase (AST) and aspartate aminotranferase (ALT) levels in mice were assessed and the liver maximum tolerated dose (MTD) of {sup 188}Re-HA was determined. Results: A stable complex of {sup 188}Re-HA was obtained with high radiochemical purity (>90%) and low serum protein binding (2%). Biokinetic studies showed a rapid blood clearance (T{sub 1/2}{alpha}=21 min). Four hours after administration, {sup 188}Re-HA was almost totally removed from the blood by the liver due to the selective uptake via HA-specific receptors (73.47{+-}5.11% of the injected dose). The liver MTD in mice was {approx}40 Gy after 7.4 MBq of {sup 188}Re-HA injection. Conclusions: {sup 188}Re-HA complex showed good stability, pharmacokinetic and dosimetric characteristics that confirm its potential as a new agent for HCC radiation therapy.

  13. 188Re-labeled McAb 3H11 used as preventive for the peritoneal micrometasis of gastric cancer

    Institute of Scientific and Technical Information of China (English)

    1999-01-01

    In advancing gastric cancer,especial1y when the serous is invaded,the p1antation of cancer cells in peritoneal is common and it affectspatients' survival time severe1y. Based on successfully labeledMcAb (monoclonal antibody) 3H11 with 188Re,we investigated the effect of RIT (Radioimmuno-Therapy) with188Re-3Hll on preventing the peritoneal micrometastasis ofgastric cancer cells in nude mice toincreasethe survival time. After 1×106 BGC-823 gastriccancer cel1s were injectedinto the peritoneal cavityof each mouse, 45BABL/C nude mice weredivided into 9groups. Each group receiveddifferent doses of 188Re-3Hll or188Re-IgG, or salineI.P.16 hours postoperation.The injected volume of each mouse was 1.0mL.The resultsshowed that the survival time depended on theinjected doses during 0 to 37 MBq.Thesurvival time was l70±25.3 dafter 37 MBq 188Re-3H11 were treated.It was over 5times more than that for the saline groupand about 3 times more than that for 37MBq188-Re IgG group (p<0.05).The mice hemogramwere reduced to lowest 14 days afterinjection,but they recovered after 28 d.Conclusion: with proper injection doses,early postoperative 188Re-3H11I.P. iseffective and safe for the prevention of intra-peritoneally injectedgastric cancer cells from surviving,growing and disseminating in nude mice.

  14. 188Re(V)-DMSA revisited: preparation and biodistribution of a potential radiotherapeutic agent with low kidney uptake.

    Science.gov (United States)

    Dadachova, E; Chapman, J

    1998-02-01

    Methods of preparation and biodistribution in mice of tin-free 99Tcm(V)-DMSA and 188Re(V)-DMSA, a potential matching pair of radiopharmaceuticals for diagnosis and therapy of certain cancers, are described. Preparation of tin-free 188Re(V)-DMSA (I) is based on reduction with either SO2-releasing compounds like Na2S2O4 (30 mg Na2S2O4, 10 mg DMSA, 1 mg L-ascorbic acid, 37 degrees C, 60 min incubation), Na2S2O5 (as before, 70 degrees C, 15 min incubation), or HBr (0.2 ml 48% HBr, 0.2 ml 7 M HCl, 10 mg DMSA, 1 mg L-ascorbic acid, 70 degrees C, 60 min incubation). I exhibits significantly lower kidney uptake than tin-containing 188Re(V)-DMSA (II) (2-3% and 49% injected dose per gram organ, 1 h post-injection, respectively). HPLC profiles of I and II are similar. DMSA excess in tin-free 188Re(V)-DMSA is not responsible for the low kidney uptake of I. High kidney uptake of II is explained by formation of a mixed 188Re(V)-Sn-DMSA complex in vivo. Age-linked bone uptake in mice dependent on the maturation of the bone is demonstrated for both I and II.

  15. A review on the current status and production technology for {sup 188}W-{sup 188}Re generator system

    Energy Technology Data Exchange (ETDEWEB)

    Kuznetsov, R. A.; Han, H. S.; Cho, W. K.; Park, U. J.; Kim, Y. M

    1998-11-01

    The current status of {sup 188}W-{sup 188}Re generator production technology were reviewed in PART 1. Main interests were given to the aspects of {sup 188}W reactor production, irradiated targets reprocessing and generator loading technologies, such as alumina type and gel type generators. In order to develop the more convenient and advanced {sup 188}W-{sup 188}Re generator, further studies must be carried out to get the precise evaluation of production and burn-up cross section of {sup 188}W, the more easily realizable generator loading procedure, and also to optimize the column and generator design to compensate the deterioration of generator performance because of parent radionuclide decay. By irradiation of {sup 186}W enriched sample, {sup 188}W-{sup 188}Re generator production experiments were performed to evaluate the possibility of {sup 188}W-{sup 188}Re generator production using HANARO, and PART 2 describes about the experiments. The experimental results shows the possibility of practical {sup 188}W-{sup 188}Re generator production using of low-specific activity {sup 188}W produced in HANARO. (author). 79 refs., 4 tabs., 26 figs.

  16. β-IRRADIATION WITH A LIQUID 188Re-FILLED BALLOON PREVENTS NEOINTIMAL PROLIFERATION IN THE CAROTID OF RABBIT

    Institute of Scientific and Technical Information of China (English)

    朱建国; 崔长琮; 崔翰斌; 胡国英; 马爱群; 王东琦; 付文

    2002-01-01

    Objective To evaluate the role of β-irradiatio n with a liquid 188Re-filled balloon for limiting neointimal prolifer ation. Methods Balloon-overstretched injury was performed in the rabb it carotid artery, then β-irradiation using the liquid 188Re-filled balloon was followed immediately, and the prescribed doses was 0, 15Gy or 20Gy a t 0.5mm from the surface of vessel. All animals survived and were sacrificed at three weeks. Histopathologic analysis was performed. Results In the control group, the neointimal area was larger ( 0.40±0.04)mm2, as compared with (0.23±0.06)mm2 of the 15Gy irradiated g roup and (0.15±0.02)mm2 in the 20Gy group (P<0.05). Conclusion The β-irradiation with a liquid 188Re-f illed balloon is safe and effective.

  17. Synthesis and application of {sup 188}Re-MN-16ET/Lipiodol in a hepatocellular carcinoma animal model

    Energy Technology Data Exchange (ETDEWEB)

    Tang, I-Chang [Isotope Application Division, Institute of Nuclear Energy Research, Taoyuan, Taiwan 32546 (China); Luo, Tsai-Yueh, E-mail: tylo@iner.gov.tw [Isotope Application Division, Institute of Nuclear Energy Research, Taoyuan, Taiwan 32546 (China); Liu, Show-Wen [Chemistry Division, Institute of Nuclear Energy Research, Taoyuan, Taiwan 32546 (China); Chan, Sun-Ho [Department of Nuclear Medicine, Taichung Veterans General Hospital, Taichung, Taiwan 40705 (China); Kung, Hong-Chang [Department of Electronic Engineering, Tung Nan University, Taipei, Taiwan 22202 (China); Peng, Cheng-Liang [Isotope Application Division, Institute of Nuclear Energy Research, Taoyuan, Taiwan 32546 (China); Lin, Wan-Yu; Chang, Yu [Department of Nuclear Medicine, Taichung Veterans General Hospital, Taichung, Taiwan 40705 (China); Lin, Wuu-Jyh [Isotope Application Division, Institute of Nuclear Energy Research, Taoyuan, Taiwan 32546 (China)

    2011-10-15

    Introduction: Hepatocellular carcinoma is the most common form of primary hepatic carcinoma. A new N{sub 2}S{sub 2} tetradentate ligand, N-[2-(triphenylmethyl)thioethyl]-3-aza-19-ethyloxycarbonyl-3- [2-(triphenylmethyl)thioethyl]octadecanoate (H{sub 3}MN-16ET), was introduced and labeled with {sup 188}Re to create {sup 188}Re-MN-16ET in the Lipiodol phase. The potential of {sup 188}Re-MN-16ET/Lipiodol for hepatoma therapy was evaluated in a hepatocellular carcinoma animal model of Sprague-Dawley rats implanted with the N1S1 cell line. Methods: Synthesis of H{sub 3}MN-16ET was described, and characterization was identified by infrared, nuclear magnetic resonance and mass spectra. We compared the effects of transchelating agents (glucoheptonate or tartaric acid) and a reducing agent (stannous chloride) on the complexing of {sup 188}Re-perrhenate and H{sub 3}MN-16ET. Twenty-four rats implanted with hepatoma were injected with 3.7 MBq/0.1 ml of {sup 188}Re-MN-16ET/Lipiodol or {sup 188}Re-MN-16ET via transcatheter arterial embolization. Biodistribution experiments and single-photon emission computed tomography imaging were performed to investigate tumor accumulation. Results: H{sub 3}MN-16ET was proved to easily conjugate with the Re isotope and showed good solubility in Lipiodol. The radiochemical purity of {sup 188}Re-MN-16ET/Lipiodol with 10 mg tartaric acid and stannous chloride was shown to be more than 90%. The major distribution sites of {sup 188}Re-MN-16ET in Sprague-Dawley rats were hepatoma and the liver. However, the radioactivity at the tumor site postadministered with {sup 188}Re-MN-16ET was quickly decreased from 9.15{+-}0.23 (at 1 h) to 2.71%{+-}0.18% of injected dose/g (at 48 h). The biodistribution and micro-single-photon emission computed tomography/computed tomography image data showed that {sup 188}Re-MN-16ET/Lipiodol was selectively retained at the tumor site, with 11.55{+-}1.44, 13.16{+-}1.46 and 10.67%{+-}0.95% of injected dose/g at 1, 24 and 48 h

  18. Lipiodol solution of a lipophilic agent, {sup 188}Re-TDD, for the treatment of liver cancer

    Energy Technology Data Exchange (ETDEWEB)

    Jeong, Jae Min E-mail: jmjng@snu.ac.kr; Kim, Young Joo; Lee, Yoon Sang; Ko, Jun Il; Son, Miwon; Lee, Dong Soo; Chung, June-Key; Park, Jae Hyung; Lee, Myung Chul

    2001-02-01

    Radiolabeled lipiodol has been used for targeting liver cancer. We developed a lipiodol solution of {sup 188}Re-TDD (2,2,9,9-tetramethyl-4,7-diaza-1,10-decanedithiol) and investigated its feasibility for the treatment of liver cancer. The lipiodol solution of {sup 188}Re-TDD was well-retained in the lipiodol phase in vitro. After injection through the tail veins of mice, high lung-uptake was investigated which is evidence of embolizing activity. We also found high accumulation in hepatoma after injection through the hepatic arteries of hepatoma-bearing rats. In conclusion, the lipiodol solution of {sup 188}Re-TDD is a promising agent for liver cancer therapy.

  19. Evaluating the potential of {sup 188}Re-SOCTA-trastuzumab as a new radioimmunoagent for breast cancer treatment

    Energy Technology Data Exchange (ETDEWEB)

    Luo, T.-Y. [Isotope Application Division, Institute of Nuclear Energy Research, P.O. Box 3-27, Longtan, Taoyuan 325, Taiwan (China)], E-mail: tylo@iner.gov.tw; Tang, I-C.; Wu, Y.-L.; Hsu, K.-L. [Isotope Application Division, Institute of Nuclear Energy Research, P.O. Box 3-27, Longtan, Taoyuan 325, Taiwan (China); Liu, S.-W. [Chemistry Division, Institute of Nuclear Energy Research, Taoyuan 325, Taiwan (China); Kung, H.-C. [Department of Electrical Engineering, Tung Nan University, Taipei 222, Taiwan (China); Lai, P.-S. [Department of Chemistry, National Chung Hsing University, Taichung 402, Taiwan (China); Lin, W.-J. [Isotope Application Division, Institute of Nuclear Energy Research, P.O. Box 3-27, Longtan, Taoyuan 325, Taiwan (China)

    2009-01-15

    Introduction: Radioimmunotherapy, which utilizes monoclonal antibodies and therapeutic radioisotopes against antigen-expressing tumor tissues, is an attractive therapeutic approach for cancer therapy. Trastuzumab (Herceptin) is a humanized anti-HER-2/neu monoclonal antibody for breast cancer treatment. In this paper, we introduce a new radioimmunoagent, {sup 188}Re-trastuzumab, via a bifunctional ligand, succinimidyl 3,6-diaza-5-oxo-3-[2-((triphenylmethyl)thio)ethyl] -8-[(triphenylmethyl)thio]octanoate (SOCTA), and evaluate its potential to be a therapeutic radiopharmaceutical for breast cancer treatment. Methods: Equimolar amounts of SOCTA and trastuzumab were selected to react, and the conjugation ratio of SOCTA-trastuzumab was evaluated by the MALDI-TOF method. The immunoreactivity of SOCTA-trastuzumab was compared with nonconjugated trastuzumab in HER-2/neu overexpressing human breast cancer cell BT-474. Biodistribution experiment and microSPECT/CT images of {sup 188}Re-SOCTA-trastuzumab being administered intravenously to SCID mice bearing xenografted BT-474 breast cancer were investigated to evaluate the tumor-targeting capability. Results: The covalent attachment of SOCTA to trastuzumab (at 1:1 molar ratio) resulted in the averaged conjugation ratio of 0.27{+-}0.06 (n=3). The complex could easily be labeled with {sup 188}Re and achieve 95% radiochemical purity (RCP) after 1 h of reaction at room temperature. The in vitro stability study also revealed that the RCP of {sup 188}Re-SOCTA-trastuzumab was at a value of more than 85% after 48 h of incubation with human serum. The immunoreactivity evaluation showed that SOCTA-trastuzumab and nonconjugated trastuzumab had similar binding capacity (B{sub max}) to HER-2/neu receptor in BT-474 cells. The animal experiments showed that {sup 188}Re-SOCTA-trastuzumab accumulated more intensively in the tumor site as compared to normal tissue. Conclusion: We suggest that {sup 188}Re-SOCTA-trastuzumab could be a potential

  20. Comparative study of 188Re( V )-DMSA and 99mTc ( V )-DMSA in tumor model%188Re(V)-DMSA与99mTc(V)-DMSA在肿瘤模型体内的对比研究

    Institute of Scientific and Technical Information of China (English)

    孙逊; 安锐

    2004-01-01

    Objective To compare the biodistribution and imaging characteristics of 188Re(V)-DMSA and 99mTc(V)-DMSA in tumor model, and to discuss the possibility of treating tumors with 188Re(V)-DMSA. Methods The solid neoplasm bearing mice (Ehrlich carcinoma bearing mice) models underwent biodistribution study and static whole body planar imaging after injection of 188Re(V)-DMSA and 99mTc(V)-DMSA respectively. When the mice were sacrificed at different time after the injection, the tumor, blood and contralateral normai muscles were removed, weighted and the radioactivity was measured. Then the radioactivity ratios of target (tumor)-to-blood (T/B),target-to-non targeted (contralateral limbs or muscles) (T/NT) were calculated. ROIs were drawn and T/NT were calculated in planar imagines. Results Two radiopharmaceuticals were mainly concentrated in bone and kidney, and the uptake ratios in tumor were high too.The half-clearance times of these two radiopharmaceuticals in blood were both less than 1h. The greatest T/NT ratio of 99mTc group was higher than 188Re group in planar imagings, but the highest T/B, T/NT ratios of these two radiopharmaceuticals in biodistribution study had no significant difference and were all above 3.0. Conclusion The biodistribution characteristics of 188Re(V)-DMSA and 99mTc( V)-DMSA were similar. 188Re(V)-DMSA has good applied foreground in treating tumors and their metastases.%目的比较188Re(V)-DMSA(五价188Re-二巯基丁二酸钠)和99mTc(V)-DMSA在肿瘤模型体内生物分布与显像的特点,探讨188Re(V)-DMSA用于肿瘤治疗的可能性.方法用188Re(V)-DMSA和99mTc(V)-DMSA对实验性实体肿瘤(小鼠艾氏腹水癌)模型进行生物学分布实验和全身平面显像,并通过脏器克组织百分摄取率(%ID/g)测定法和感兴趣区(ROI)技术进行定量分析,计算各时点两种放射性药物的靶/血、靶/非靶比值.结果两种放射性药物均主要浓聚于骨骼和肾脏,肿瘤组织也有较高的摄

  1. Development of methods of labeling pentavalent DMSA with {sup 99m}Tc and {sup 188}Re; Desenvolvimento de metodos para marcacao de DMSA pentavalente com {sup 99m}Tc e {sup 188}Re

    Energy Technology Data Exchange (ETDEWEB)

    Brambilla, Tania de Paula, email: jtoniolo@ipen.br

    2009-07-01

    Technetium-99 m is the most useful radionuclide in diagnostic imaging procedures in Nuclear Medicine, more than 80 percent of radiopharmaceuticals are {sup 99m}Tc-labeled compounds. {sup 99m}Tc-DMSA(V) has been used for imaging of soft tissue, head and neck tumors. It shows a particularly high specificity for medullary thyroid carcinoma and bone metastases in a variety of cancers. Biodistribution studies of {sup 188}Re-DMSA(V) have shown that its general pharmacokinetic properties are similar to that of {sup 99m}Tc-DMSA(V), so this agent could be used for targeted radiotherapy of these tumors. The aim of this work is the development of methods of labeling DMSA(V) with {sup 99m}Tc and {sup 188}Re. {sup 99m}Tc-DMSA(V) can be prepared by two methods. One of them is the indirect one, through the use of a commercial kit of DMSA (III), by adjusting the pH from 2.5 to {approx} 8.5 with NaHCO{sub 3}. This method was evaluated and optimized presenting high labeling yields. The other method is the direct one, through the preparation of a lyophilised kit ready for labeling with {sup 99m}Tc, being the method of interest of this work, due to the easy of its clinical use. The most adequate formulation of the kit was: 1.71 mg of DMSA, 0.53 mg of SnCl{sub 2}.2H{sub 2}O and 0.83 mg of ascorbic acid (pH 9). Labeling yields higher than 95% were achieved labeling this kit with 1 to 2 m L of {sup 99m}Tc with activities up to 4736 MBq (128 mCi). The kit was stable up to 6 months and biodistribution studies confirmed the quality of the DMSA (V) labeled with {sup 99m}Tc using this kit. The reduction potential of Re is lower than the one for Tc, so the labeling conditions of {sup 188}Re-DMSA(V) are different from the ones used for {sup 99m}Tc- DMSA(V). {sup 188}Re-DMSA(V) is prepared in acid solution, that makes it possible to use the DMSA (III) commercial kit developed for labeling with {sup 99m}Tc, prepared in pH 2.5, for labeling with {sup 188}Re. Labeling yields higher than 95% were

  2. Uptake of the {sup 188}Re(V)-DMSA complex by cervical carcinoma cells in nude mice: pharmacokinetics and dosimetry

    Energy Technology Data Exchange (ETDEWEB)

    Garcia-Salinas, Laura; Ferro-Flores, Guillermina E-mail: gff@nuclear.inin.mxtendilla@acnet.net; Arteaga-Murphy, Consuelo; Pedraza-Lopez, Martha; Hernandez-Gutierrez, Salomon; Azorin-Nieto, Juan

    2001-03-01

    The uptake of the rhenium-188 ({sup 188}Re(V)-DMSA) complex of dimercaptosuccinic acid by cervical carcinoma cells in nude mice was evaluated. The pharmacokinetics and dosimetry calculations in normal rats were also evaluated. The images obtained in mice did not show significant accumulation in metabolic organs and the biodistribution studies showed that 3.52{+-}0.76% of the injected activity per gram (n=4) was taken up by the tumor. This percentage produces a cumulated activity of 35.63{+-}8.40 MBq h and an equivalent dose per injected activity of 260{+-}8.91 mSv/MBq. Pharmacokinetics and dosimetry of the {sup 188}Re(V)-DMSA complex indicate that this radiopharmaceutical could be evaluated in patients with soft tissue tumors, since the risk of radiation damage to the kidney or red bone marrow could not be an obstacle for its application in therapeutic nuclear medicine.

  3. Radiolabeling of rituximab with {sup 188}Re and {sup 99m}Tc using the tricarbonyl technology

    Energy Technology Data Exchange (ETDEWEB)

    Dias, Carla Roberta [Instituto de Pesquisas Energeticas e Nucleares, Av. Professor Lineu Prestes 2242, 05508-000 Sao Paulo (Brazil); Jeger, Simone [Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232 Villigen-PSI (Switzerland); Osso, Joao Alberto [Instituto de Pesquisas Energeticas e Nucleares, Av. Professor Lineu Prestes 2242, 05508-000 Sao Paulo (Brazil); Mueller, Cristina; De Pasquale, Christine; Hohn, Alexander; Waibel, Robert [Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232 Villigen-PSI (Switzerland); Schibli, Roger, E-mail: roger.schibli@psi.c [Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232 Villigen-PSI (Switzerland); Department of Chemistry and Applied Biosciences of the ETH, 8093 Zurich (Switzerland)

    2011-01-15

    Introduction: The most successful clinical studies of immunotherapy in patients with non-Hodgkin's lymphoma (NHL) use the antibody rituximab (RTX) targeting CD20{sup +} B-cell tumors. Rituximab radiolabeled with {beta}{sup -} emitters could potentiate the therapeutic efficacy of the antibody by virtue of the particle radiation. Here, we report on a direct radiolabeling approach of rituximab with the {sup 99m}Tc- and {sup 188}Re-tricarbonyl core (IsoLink technology). Methods: The native format of the antibody (RTX{sub wt}) as well as a reduced form (RTX{sub red}) was labeled with {sup 99m}Tc/{sup 188}Re(CO){sub 3}. The partial reduction of the disulfide bonds to produce free sulfhydryl groups (-SH) was achieved with 2-mercaptoethanol. Radiolabeling efficiency, in vitro human plasma stability as well as transchelation toward cysteine and histidine was investigated. The immunoreactivity and binding affinity were determined on Ramos and/or Raji cells expressing CD20. Biodistribution was performed in mice bearing subcutaneous Ramos lymphoma xenografts. Results: The radiolabeling efficiency and kinetics of RTX{sub red} were superior to that of RTX{sub wt} ({sup 99m}Tc: 98% after 3 h for RTX{sub red} vs. 70% after 24 h for RTX{sub wt}). {sup 99m}Tc(CO){sub 3}-RTX{sub red} was used without purification for in vitro and in vivo studies whereas {sup 188}Re(CO){sub 3}-RTX{sub red} was purified to eliminate free {sup 188}Re-precursor. Both radioimmunoconjugates were stable in human plasma for 24 h at 37{sup o}C. In contrast, displacement experiments with excess cysteine/histidine showed significant transchelation in the case of {sup 99m}Tc(CO){sub 3}-RTX{sub red} but not with pre-purified {sup 188}Re(CO){sub 3}-RTX{sub red}. Both conjugates revealed high binding affinity to the CD20 antigen (K{sub d}=5-6 nM). Tumor uptake of {sup 188}Re(CO){sub 3}-RTX{sub red} was 2.5 %ID/g and 0.8 %ID/g for {sup 99m}Tc(CO){sub 3}-RTX{sub red} 48 h after injection. The values for other

  4. Reduction of β-radiation exposure during preparation of 188Re-labelled Lipiodol for hepatocellular carcinoma treatment.

    Science.gov (United States)

    Lepareur, Nicolas; Laffont, Sophie; Ardisson, Valérie; Noiret, Nicolas; Garin, Etienne

    2012-02-01

    Rhenium-188 (188Re) is of widespread interest for treating various diseases because of its attractive physical and chemical properties. The routine preparation of therapeutic doses of 188Re-labelled tracers can result in significant radiation exposure to the operator. We studied the impact of automating the preparation of 188Re-Lipiodol on the radiochemist's exposure, as well as the importance of the model of syringe shielding. To monitor radiation exposure continuously readable electronic personal dosimeters were used. Thermoluminescence dosimeters were fixed to the probable most exposed fingers of the radiochemist during preparation of the radiotracer and during the syringing. Dose rates were measured using a Babyline. Automation of the synthesis reduced personal dose equivalents from 2.60±4.35 to 1.61±1.20 µSv/GBq [Hp(10)] and from 38.37±55.28 to 21.84±16.14 µSv/GBq [Hp(0.07)]. Dose to the extremities was also reduced (-80% for the right hand; -58% for the left one). The Lemer-Pax PSWG syringe shield led to a slightly lower dose to the hands compared with the Medisystem (1.1±0.27 vs. 1.34±0.6 mSv/GBq for the right finger). Automation of the synthesis leads to a significant decrease in radiation exposure to the operator. The Lemer-Pax PSWG syringe shield provides better hand protection than the smaller Medisystem Mediclic.

  5. Rhenium-188 Production in Hospitals, by W-188/Re-188 Generator, for Easy Use in Radionuclide Therapy

    Directory of Open Access Journals (Sweden)

    Maria Argyrou

    2013-01-01

    Full Text Available Rhenium-188 (Re-188 is a high energy -emitting radioisotope obtained from the tungsten-188/rhenium-188 (W-188/Re-188 generator, which has shown utility for a variety of therapeutic applications in nuclear medicine, oncology, and interventional radiology/cardiology. Re-188 decay is accompanied by a 155 keV predominant energy -emission, which could be detected by -cameras, for imaging, biodistribution, or absorbed radiation dose studies. Its attractive physical properties and its potential low cost associated with a long-lived parent make it an interesting option for clinical use. The setup and daily use of W-188/Re-188 generator in hospital nuclear medicine departments are discussed in detail. The clinical efficacy, for several therapeutic applications, of a variety of Re-188-labeled agents is demonstrated. The high energy of the -emission of Re-188 is particularly well suited for effective penetration in solid tumours. Its total radiation dose delivered to tissues is comparable to other radionuclides used in therapy. Furthermore, radiation safety and shielding requirements are an important subject of matter. In the case of bone metastases treatment, therapeutic ratios are presented in order to describe the efficacy of Re-188 usage.

  6. Evaluation of 188Re-labeled PEGylated nanoliposome as a radionuclide therapeutic agent in an orthotopic glioma-bearing rat model

    Directory of Open Access Journals (Sweden)

    Huang FYJ

    2015-01-01

    Full Text Available Feng-Yun J Huang,1 Te-Wei Lee,2 Chih-Hsien Chang,2 Liang-Cheng Chen,2 Wei-Hsin Hsu,2 Chien-Wen Chang,1 Jem-Mau Lo1 1Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu, Taiwan; 2Institute of Nuclear Energy Research, Longtan, Taiwan Purpose: In this study, the 188Re-labeled PEGylated nanoliposome (188Re-liposome was prepared and evaluated as a therapeutic agent for glioma.Materials and methods: The reporter cell line, F98luc was prepared via Lentivector expression kit system and used to set up the orthotopic glioma-bearing rat model for non-invasive bioluminescent imaging. The maximum tolerated dose applicable in Fischer344 rats was explored via body weight monitoring of the rats after single intravenous injection of 188Re-liposome with varying dosages before the treatment study. The OLINDA/EXM 1.1 software was utilized for estimating the radiation dosimetry. To assess the therapeutic efficacy, tumor-bearing rats were intravenously administered 188Re-liposome or normal saline followed by monitoring of the tumor growth and animal survival time. In addition, the histopathological examinations of tumors were conducted on the 188Re-liposome-treated rats.Results: By using bioluminescent imaging, the well-established reporter cell line (F98luc showed a high relationship between cell number and its bioluminescent intensity (R2=0.99 in vitro; furthermore, it could also provide clear tumor imaging for monitoring tumor growth in vivo. The maximum tolerated dose of 188Re-liposome in Fischer344 rats was estimated to be 333 MBq. According to the dosimetry results, higher equivalent doses were observed in spleen and kidneys while very less were in normal brain, red marrow, and thyroid. For therapeutic efficacy study, the progression of tumor growth in terms of tumor volume and/or tumor weight was significantly slower for the 188Re-liposome-treated group than the control group (P<0.05. As a result, the

  7. 肿瘤骨转移疼痛患者对188Re-HEDP的耐受性研究%The tolerance to 188Re-HEDP treatment in patients with bone pain from osseous metastases

    Institute of Scientific and Technical Information of China (English)

    程爱萍; 陈绍亮; 刘文官; 陈雪芬; 许长德

    2011-01-01

    Objective To study the tolerance to 188Re-1-hydroxy-1 ,1-ethylidene disodium phosphonate(HEDP) in patients with bone pain caused by osseous metastases. Methods Thirty-one patients(10with prostate cancer, 9 with breast cancer, 3 with lung cancer, 5 with liver cancer, 2 with rectal cancer, 1with esophageal cancer and 1 with renal cancer) received a single injection dose of 188Re-HEDP. The patients were divided into four groups according to the injection dose: 20 MBq/kg (6 patients), 30 MBq/kg(6 patients), 40 MBq/kg (9 patients), and 50 MBq/kg (10 patients). Haematological toxicity (WHO grading) of grade Ⅲ- Ⅳ was considered unacceptable. Vital signs and adverse effects after injection were recorded for 8 weeks. Blood counts were measured weekly during a period of 8 weeks. Biochemical parameters and electrocardiogram were assayed at week 4 and 8. Statistical analysis was performed for per-protocol (pp) population (t-test). Results Twenty-seven patients belonged to PP population with 5 in the group of 20 MBq/kg, 5 in the group of 30 MBq/kg, 8 in the group of 40 MBq/kg and 9 in the group of 50 MBq/kg.No obvious adverse effects and no significant change of vital signs, electrocardiogram, liver and renal function were found after injection. Alkaline phosphatase was slightly higher than baseline at week 4 and 8 after therapy, but the difference was not statistically significant. In the 20 MBq/kg group, reversible grade Ⅰ leucopenia was noted in 1 patient. In the 30 MBq/kg group, 2 patients showed reversible grade Ⅰ leucopenia including 1 alone with reversible grade Ⅲ thrombopenia. In the 40 MBq/kg group, reversible grade Ⅰ leucopenia and thrombopenia was observed in 1 patient and reversible grade Ⅱ leucopenia and thrombopenia in another patient. In the .50 MBq/kg group, 3 patients showed reversible grade Ⅱ leucopenia. The lowest level of thrombopenia was at week 4(143.5 × 109/L), leucopenia at week 6 (5.4 × 109/L) and anaemia at week 8(t = 3.1325, 3

  8. {sup 99m}Tc(V)DMSA quantitatively predicts {sup 188}Re(V)DMSA distribution in patients with prostate cancer metastatic to bone

    Energy Technology Data Exchange (ETDEWEB)

    Blower, P.J.; Kettle, A.G.; O' Doherty, M.J.; Coakley, A.J. [Kent and Canterbury Hospital, Canterbury (United Kingdom). Nuclear Medicine Dept.; Knapp, F.F. Jr. [Nuclear Medicine Group, Oak Ridge National Lab., Oak Ridge, TN (United States)

    2000-09-01

    Rhenium-188 dimercaptosuccinic acid complex [{sup 188}Re(V)DMSA], a potential therapeutic analogue of the tumour imaging agent {sup 99m}Tc(V)DMSA, is selectively taken up in bone metastases in patients with prostate cancer. It would be helpful in planning palliative radionuclide therapy if {sup 99m}Tc(V)DMSA could be used to predict tumour and kidney retention of {sup 188}Re(V)DMSA. The aim of this study was to determine the correlation between tumour-to-normal tissue ratios and kidney-to-soft tissue ratios of {sup 99m}Tc(V)DMSA and {sup 188}Re(V)DMSA. This would determine whether a scan with {sup 99m}Tc(V)DMSA, could be used to identify patients for whom {sup 188}Re(V)DMSA treatment would be contra-indicated, and enable prediction of relative kidney and tumour radiation absorbed dose in {sup 188}Re(V)DMSA treatment. Ten patients with prostate carcinoma were recruited following observation of disseminated bone metastases on a recent {sup 99m}Tc-hydroxydiphosphonate bone scan. Whole-body planar scans were obtained at ca. 4 h and 24 h after hydration and injection of 600 MBq {sup 99m}Tc(V)DMSA, and a week later, at similar times after hydration and injection of 370 MBq {sup 188}Re(V)DMSA. A triple-energy window (TEW) scatter correction was applied to the {sup 188}Re scans. Counts per pixel were determined in regions of interest drawn over metastatic sites, kidneys and normal soft tissue. Tumour-to-soft tissue ratios were significantly lower (by a factor of approximately 0.8 after the TEW was applied) on {sup 188}Re scans than on {sup 99m}Tc scans, but the two were highly linearly correlated both in all individual patients and in tumours pooled from all patients together both at 4 h and at 24 h. Kidney-to-soft tissue ratios were similarly correlated and were lower for {sup 188}Re than for {sup 99m}Tc by a similar factor. Both tumour- and kidney-to-soft tissue ratios increased between 4 and 24 h but the latter increased more. In conclusion, only minor differences were

  9. The experimental study on the radioimmunotherapy of the nasopharyngeal carcinoma overexpressing HER2/neu in nude mice model with intratumoral injection of {sup 188}Re-herceptin

    Energy Technology Data Exchange (ETDEWEB)

    Li Guiping [Radiopharmaceutical Research Centre, Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800 (China) and Department of Nuclear Medicine, Nanfang Hospital, First Military Medical University, Guangzhou, 510515 (China)]. E-mail: ligp@fimmu.com; Wang Yongxian [Radiopharmaceutical Research Centre, Shanghai Institute of Applied Physics, the Chinese Academy of Sciences, Shanghai, 201800 (China)]. E-mail: yongxianw@163.com; Huang Kai [Department of Nuclear Medicine, Nanfang Hospital, First Military Medical University, Guangzhou, 510515 (China); Zhang Hui [Department of Nuclear Medicine, Nanfang Hospital, First Military Medical University, Guangzhou, 510515 (China); Peng Wuhe [Department of Nuclear Medicine, Nanfang Hospital, First Military Medical University, Guangzhou, 510515 (China); Zhang Chunfu [Radiopharmaceutical Research Centre, Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800 (China)

    2005-01-01

    The therapeutic efficacy of radioimmunotherapy (RIT) of {sup 188}Re-labeled herceptin, which is a humanized anti-p185-HER2/neu monoclonal antibody (mAb), was studied. The nude mice bearing nasopharyngeal carcinoma (NPC) expressing HER2/neu protooncogene were injected with {sup 188}Re-herceptin intratumorally and intravenously. The biodistribution was observed on day 2 (n=3). The tumor growth inhibition rate (IR) was determined by measurement of tumor volume. In the intratumorally treated mice, tumor uptake of {sup 188}Re-herceptin was significantly greater than in the intravenously treated mice [11.53% injected dose (ID)/g vs. 2.79% ID/g at 48 h], and lower normal organ uptake was also seen. The intratumoral administration of {sup 188}Re-herceptin caused greater inhibition of tumor growth at the fourth week as compared to the intravenous administration. It is concluded that intratumoral administration of {sup 188}Re-herceptin makes high level of radioactivity retained in tumor with significantly lower radioactivity retained in normal tissues, and provides a more effective regional therapy for NPC overexpressing HER2/neu.

  10. A YAP camera for the biodistribution of {sup 188}Re conjugated with Hyaluronic-Acid in 'in vivo' systems

    Energy Technology Data Exchange (ETDEWEB)

    Antoccia, A. [Department of Biology, Roma3 University (Italy); INFN, Roma3 (Italy); Baldazzi, G. [Department of Physics, Bologna University (Italy); INFN, Bologna (Italy); Banzato, A. [Department of Oncology and Surgical Sciences, Padova University (Italy); Bello, M. [INFN, National Laboratories, Legnaro (Italy); Department of Physics, Padova University (Italy); Boccaccio, P. [INFN, National Laboratories, Legnaro (Italy); Bollini, D. [Department of Physics, Bologna University (Italy); INFN, Bologna (Italy); De Notaristefani, F. [INFN, Roma3 (Italy); Department of Electronic Engineering, Roma3 University and INFN (Italy); Mazzi, U. [Department of Pharmaceutical Sciences, Padova University (Italy); Alafort, L.M. [Department of Pharmaceutical Sciences, Padova University (Italy); Moschini, G. [INFN, National Laboratories, Legnaro (Italy); Department of Physics, Padova University (Italy); Navarria, F.L. [Department of Physics, Bologna University (Italy); INFN, Bologna (Italy); Pani, R. [Department of Experimental Medecine and Pathology, Roma1 University (Italy); INFN, Roma1 (Italy); Perrotta, A. [INFN, Bologna (Italy)]. E-mail: perrotta@bo.infn.it; Rosato, A. [Department of Oncology and Surgical Sciences, Padova University (Italy); Istituto Oncologico Veneto, Padova (Italy); Tanzarella, C. [Department of Biology, Roma3 University (Italy); Uzunov, N.M. [INFN, National Laboratories, Legnaro (Italy); Dept. Natural Sciences, Shumen Univ. (Bulgaria)

    2007-02-01

    The aim of the SCINTIRAD experiment is to determine the radio-response of {sup 188}Rhenium (Re) in in vitro cells and the biodistribution in different organs of in vivo mice, and subsequently to assess the therapeutic effect on liver tumours induced in mice. Both the {gamma}- and {beta}- emissions of {sup 188}Re have been exploited in the experiment. The in vivo biodistribution in mice was studied also with a {gamma}-camera using different parallel hole collimators. In the {sup 188}Re spectrum, while the 155 keV {gamma}-peak is useful for imaging, the photons emitted at larger energies and the {beta}-particles act as noise in the image reconstruction. The {gamma}-cameras previously used to image biodistributions obtained with {sup 99}Tc are, therefore, not optimized for use with {sup 188}Re. A new setup of the {gamma}-camera has been studied for {sup 188}Re: 66x66 YAP:Ce crystals (0.6x0.6x10 mm{sup 3}, 5 {mu}m optical insulation) guarantee a FOV of 40x40 mm{sup 2}, a Hamamatsu R2486 PSPMT, 3 in. diameter, converts their light into an electrical signal and allows reconstructing the spatial coordinates of the light spot; incoming photon directions are selected through a lead collimator with 1.5 mm diameter hexagonal holes, 0.18 mm septa, 40 mm thickness. Using this setup, results have been obtained both with {sup 99}Tc filled and {sup 188}Re filled capillaries and wells. The energy spectrum of the collected photons and the spatial resolutions obtainable with the {sup 188}Re source will be presented.

  11. Studies on biodistribution and imaging of 188Re labeled insulin-like growth factor-1 analogue in nude mice bearing human pancreatic carcinoma%188Re-胰岛素样生长因子1类似物在荷人胰腺癌裸鼠体内分布及其显像研究

    Institute of Scientific and Technical Information of China (English)

    邓胜明; 张玮; 章斌; 罗贤文; 吴翼伟

    2008-01-01

    目的 研究188Re标记胰岛素样生长因子l类似物(IGF-1A)在荷人胰腺癌裸鼠体内的分布及其显像.方法 ①直接法标记188Re-IGF-1A并测定标记率.②建立荷人胰腺癌Patu8988裸鼠模型.③188Re-IGF-1A经瘤内注射荷人胰腺癌裸鼠瘤内,分别于注射后15 min、1 h、4 h、24 h、3 d、5 d进行SPECT平面显像.④188ReO4-经瘤内注射后15 min、1 h、2 h、4 h、24 h进行显像,取各时间组裸鼠(n=4)脏器和肿瘤组织,计算每克组织百分注入剂量(%ID/g)及肿瘤/非肿瘤组织放射性摄取比值(T/NT).结果 ①188Re-IGF-1A标记率为(94.07±0.32)%.②瘤内注射188Re-IGF-1A后,肿瘤部位放射性积聚量4 h内差异无统计学意义(F=1.622,P>0.05),且随时间延长,肿瘤与其他脏器的T/NT呈上升趋势,其中肿瘤/肌肉在5 d时最高,达到6531.79±4930.26.③瘤内注射188ReO4-后,在体内初始主要分布于甲状腺、胃、肿瘤、血液,随时间延长,肿瘤部位放射性计数迅速下降.④在24 h,瘤内注射188Re-IGF-1A组肿瘤及肾脏内%ID/g较188ReO4-组高,两者有统计学差异(t=5.877,t=13.287,P<0.01);两组肿瘤内%ID/g比值在24 h达到最高,为74.10倍.⑤瘤内注射188Re-IGF-1A后,SPECT平面显像见瘤内浓聚,5 d时仅见肿瘤部位显影.结论 188Re-IGF-1A对胰腺癌具有良好的亲和力,在肿瘤部位有较高的T/NT,可望作为胰腺癌治疗的药物.%Objective To evaluate the biodistribution and planar gamma carnera jmaging characteristics of 188Re labeled insulin-like growth factor 1 analogue(188Re-IGF-1A)in tumor-bearing mice.Methods ①To label IGF-1A with 188Re directly and to determine the labeling efficiency.②To establish nude mice model which beating human pancreatic carcinoma cell Patu8988.③To scan those nude mice at 15 min,1 h,4 h,24 h,3 d and 5 d after intratumor injection with 188Re-IGF-1A into their tumors.④To scan those nude mice at 15min,1 h,2h,4 h and24 h after intratumor injection with 188ReO4-into their

  12. 2004 Rose Site 32P

    Data.gov (United States)

    US Fish and Wildlife Service, Department of the Interior — Underwater Site 32P was established off Rose Atoll, American Samoa by Dr. James Maragos, U.S. Fish & Wildlife Service, on August 2, 2004. With a start point...

  13. 2012 Rose Site 32P

    Data.gov (United States)

    US Fish and Wildlife Service, Department of the Interior — Underwater Site 32P was established off Rose Atoll, American Samoa by Dr. James Maragos, U.S. Fish & Wildlife Service, on August 2, 2004. With a start point...

  14. Preparation of {sup 188}W/{sup 188}Re generators at base of {sup 188}W-titanium and zirconium tungstates by means of the sol-gel method; Preparacion de generadores {sup 188}W/{sup 188}Re a base de {sup 188}W-tungstenatos de titanio y zirconio mediante el metodo sol-gel

    Energy Technology Data Exchange (ETDEWEB)

    Rosales T, C.J. [Universidad Autonoma del Estado de Mexico, Paseo Colon esq. Paseo Tollocan, 50120 Toluca, Estado de Mexico (Mexico); Monroy G, F.; Rivero G, T.; Rojas N, P. [ININ, Carretera Mexico-Toluca S/N, 52750 Estado de Mexico (Mexico)]. e-mail: c.j.rt@hotmail.com

    2007-07-01

    The {sup 188}Re possess nuclear characteristics that make it attractive for therapeutic application, given their {beta}{sup -} particle emission of high energy 0.764 keV besides the possibility of being able to unite to different ligands. The {sup 188}Re commercial generators use a chromatographic column loaded with alumina where the {sup 188}W is adsorbed and the {sup 188}ReO{sub 4}{sup -} eluted by means of a saline solution. The low capacity of the alumina that only it allows adsorber 0.2% in weight of {sup 188}W demand to use {sup 188}W of a high specific activity. An alternative of production of {sup 188}W / {sup 188}Re generators consists on substituting the high specific activity, for the use of a bigger quantity of {sup 188}W by means of the use of gels with the aid of tungstates. For that, in this work it intends the study of the gel synthesis conditions of {sup 188}W titanium and zirconium tungstates and their effect in the acting of the {sup 188}W / {sup 188}Re generators. The gels were synthesized by means of the sol-gel method starting from titanium and zirconium alcoxis, and solutions of {sup 188}W-sodium tungstates to different pH's. The use of the sol-gel methodology diminishes the time of synthesis of these gels almost in 60% in relation to the precipitation method commonly used. (Author)

  15. Development of pharmaceuticals with radioactive rhenium for cancer therapy. Production of {sup 186}Re and {sup 188}Re, synthesis of labeled compounds and their biodistributions

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    1998-03-01

    Production of the radioactive rhenium isotopes {sup 186}Re and {sup 188}Re, and synthesis of their labeled compounds have been studied together with the biodistributions of the compounds. This work was carried out by the Working Group on Radioactive Rhenium, consisting of researchers of JAERI and some universities, in the Subcommittee for Production and Radiolabeling under the Consultative Committee of Research on Radioisotopes. For {sup 186}Re, production methods by the {sup 185}Re(n,{gamma}){sup 186}Re reaction in a reactor and by the {sup 186}W(p,n){sup 186}Re reaction with an accelerator, which can produce nocarrier-added {sup 186}Re, have been established. For {sup 188}Re, a production method by the double neutron capture reaction of {sup 186}W, which produces a {sup 188}W/{sup 188}Re generator, has been established. For labeling of bisphosphonate, DMSA, DTPA, DADS, aminomethylenephosphonate and some monoclonal antibodies with the radioactive rhenium isotopes, the optimum conditions, including pH, the amounts of reagents and so on, have been determined for each compound. The biodistributions of each of the labeled compounds in mice have been also obtained. (author)

  16. In vivo distribution and metabolism of 188Re-iodized oil-carboxymethyl chitosan-nanoparticles in the S180 tumor-bearing mice%188Re-碘化油-羧甲基壳聚糖-纳米微粒在荷S180肉瘤小鼠体内分布与代谢

    Institute of Scientific and Technical Information of China (English)

    王洪震; 贾正平; 郝彦明; 钱荣勋; 董启榕; 徐又佳

    2011-01-01

    背景:188Re标记的放射性药物在体内发生 Re核索脱落也不会对人体造成严重的辐射损伤.188Re-碘化油有可能成为一种具有临床应用价值的内照射治疗肿瘤的药物.目的:研究羧甲基壳聚糖载药纳米微球的制备及在荷S180肉瘤小鼠体内分布及代谢.方法:将188Re-碘化油通过羧甲基壳聚糖纳米微球包裹,将其注射于荷S180肉瘤小鼠体内,通过 SPECT法观察188Re-碘化油-羧甲基壳聚糖-纳米微粒在荷瘤鼠中的显像.结果与结论:采用羧甲基壳聚糖-纳米微粒对188Re-碘化油标记率达(94.9±0.2)%;肝、肾是188Re-碘化油-羧甲基壳聚糖-纳米微粒的主要分布器官;骨、肌肉、小肠等脏器摄取较少,且随着时间的延长而下降;脑内未测得放射性,各比值随着时间的延长而有增加的趋势,分别在注射显像剂后6~10 h达到峰值.说明羧甲基壳聚糖-纳米微粒对188Re的包裹效果良好;188Re-碘化油-羧甲基壳聚糖-纳米微粒在正常骨、肌肉、小肠基本无摄取,但48 h浓聚于肉瘤组织内,肿瘤与脾、胃、肠、股骨、肌肉、脂肪组织放射性比值高.%BACKGROUND: 188Re labeled radiopharmaceuticals in body occur Re nuclear cable off which will not cause serious radiation damage of the body. 188Re-iodized oil may become a kind of clinical application of drugs within the radiation treatment of cancer.OBJECTIVE: To study preparation of drug-loaded nano-carboxymethyl chitosan microspheres and in vivo distribution and metabolism in the S180 tumor-bearing mice.METHODS: 188Re-lipiodol was wrapped by carboxymethyl chitosan nanoparticles, the wrapped 188Re-lipiodol was injected into the mice bearing S180 sarcoma. Imaging of 188Re-iodized oil-carboxymethyl chitosan-nanoparticles in the tumor-bearing mice was observed by single photon emission computed tomography.RESULTS AND CONCLUSION: Labeling rate of 188Re-lipiodol which labeled by carboxymethyl chitosan-nanoparticles was (94.9±0

  17. {sup 188}Re-HTDD-lipiodol solution as a new therapeutic agent for transhepatic arterial administration in liver cancer: a preclinical study using liver-cancer model in rabbit

    Energy Technology Data Exchange (ETDEWEB)

    Paeng, J. C.; Jeong, J. M.; Lee, Y. S. [College of Medicine, Seoul National Univ., Seoul (Korea, Republic of)] [and others

    2001-07-01

    {sup 188}Re-HTDD-lipiodol solution was developed and reported to be a new therapeutic material for transhepatic arterial embolization (TAE) of liver cancer. In this study we compared the tissue retention of {sup 188}Re-HTDD-lipiodol with that of {sup 188}Re-TDD-lipiodol using liver-cancer model in rabbit. Cancer cell line VX2 was inoculated into 7 rabbits and grown up to larger than 3 cm. TAE was performed with {sup 188}Re-TDD-lipiodol in 3 rabbits and with {sup 188}Re-HTDD-lipiodol in 4 rabbits. Conjugated planar scans were performed at 1, 2, 6, 24, 48 hours after TAE. From these images, the mean life of radioactivity retention in tumor was calculated, and the required dose for human application as also calculated from the mean life and MIRDOSE3 software. The mean lifes of radioactivity in liver were 10.2{+-}1.0 hr in TDD group and 17.6{+-}0.8 hr in HTDD group (p<0.001). The required dose for the tumor to be irradiated 50 Gy of radiation was calculated to be 18 mCi of {sup 188}Re-HTDD-lipiodol for 5.7 cm-sized tumor and 88 mCi for 9,7 cm-sized tumor. By the introduction of long chain alkyl group, {sup 188}Re-HTDD-lipiodol showed significantly better tumor retention than that of {sup 188}Re-TDD-lipiodol. And the required dose of radiation for human application was calculated to be 18 {approx} 88 mCi when using {sup 188}Re-HTDD-lipiodol.

  18. Dosimetry and microdosimetry of {sup 188} Re-anti-CD20 and {sup 131} I-anti-CD20 for the treatment of No Hodgkin lymphomas; Dosimetria y microdosimetria del {sup 188} Re-anti-CD20 y {sup 131} I-anti-CD20 para el tratamiento de linfomas No Hodgkin

    Energy Technology Data Exchange (ETDEWEB)

    Torres G, E

    2007-07-01

    The purpose of this investigation was to prepare {sup 131}I-anti-CD20 and {sup 188}Re-anti-CD20 and to estimate the radiation absorbed dose at macro- and micro- level during a NHL treatment. The work was divided in 4 general objectives: 1) preparation of {sup 131}I-anti-CD20 and {sup 188}Re-anti-CD20, 2) application in patients to obtain biokinetic parameters and estimate the organ absorbed doses 3) estimation of the cellular dosimetry using the MIRD methodology and the MCNP4C2 code and 4) estimation of the cellular microdosimetry using the NOREC code. {sup 188}Re-anti-CD20 was prepared by a direct labelling method using sodium tartrate as a weak ligand. To evaluate the biological recognition a comparative study of the in vitro binding of {sup 188}Re-anti-CD20, {sup 125}I-anti-CD20 (positive control) and {sup 188}Re-anti-CEA (negative control) to normal B Iymphocytes was performed. Biodistribution studies in normal mice were accomplished to assess the in vivo Re-anti-CD20 complex stability. The binding of ' Re-anti-CD20 to cells was in the same range as '251-anti-CD20 (>80%) considered as the positive control. {sup 188}Re-anti-CD20 and '3'1-anti-CD20 prepared were administered in patients diagnosed with B cell NHL at the Centro Medico Siglo XXI (IMSS). The protocol was approved by the hospital's Medical Ethics Committee. AJI patients signed a consent form after receiving detailed information on the aims of the study. N data were the input for the OLINDA/EXM software to calculate the radiation absorbed dose to organs and whole body. Dosimetric studies indicate that after administration of 6.4 GBq and 4.87 to 8.75 GBq of '3'1-anti-CD20 and {sup 188}Re-anti-CD20 respectively, the absorbed dose to total body would be 0.75 Gy which corresponds to the recommended dose for NHL therapies. The calculated organ absorbed doses indicate that {sup 188}Re-anti-CD20 may be used in radioimmunotherapy without the risk of toxicity to red marrow or

  19. 温敏型壳聚糖介入核素188Re内照射抗小鼠移植性肝癌(H22)%Invistagation of antitumor efffect of internal Irradiation of Interventional Radionuclide 188 Re in Thermosensitive Chitosan on Mouse Transplanted Tumor H22

    Institute of Scientific and Technical Information of China (English)

    董峰; 郭红云; 张永东; 梅澍

    2011-01-01

    Objectives To study the inhibitory activity of internal irradiation of interventional radionuclide 188 Re in thermosensitive chitosan on mouse transplanted tumor H22 (liver cancer).Method The tumor-bearing mice were divided into 7 groups randomly, including model control, 188Re(0.1mCi) group, 188Re-S(0.1mCi) group, 188Re + CS(0.1mCi)group, 188Re + CS (0.2mCi)group, 188Re-S + CS 0.1mCi)and188Re-S + CS(0.2mCi)group.The mice tumor was injected with corresponding reagent respectively, and the inhibitoy rate of tumor was observed after administrated.Results The growth of tumors in 188Re + CS group and 188Re-S + CS group was slowed.the tumor inhibitory rate reached the highest level after 6 days therapy, which respectively was 67.35% and 67.81%.Conclusions Internal irradiation of interventional radionuclide 188 Re in thermosensitive ehitosan had the effect of inhibitory mice liver cancer.%目的 研究温敏型壳聚糖(chitonsan CS)介入核素188Re内照射对小鼠移植性肝RW(H22)的抑制作用.方法 建立小鼠肝癌(H22)模型后随机分成7组,即模型对照组、.88Re(0.1mCi)组、188Re-S (0.1mCi)组、188Re +CS (0.1 mci)组、188Re + CS (0.2mCi)组、188Re+硫胶体+壳聚糖(188Re-S + CS 0.1 mCi)组和188Re-S + CS (0.2mCi )组.各组动物瘤内分别注射相应试药,测定肿瘤抑制率.结果 188Re + CS组和188Re-S + CS组肿瘤生长速度减慢,肿瘤生长延迟,肿瘤抑制率在治疗后6d最高,抑制率分别为67.35%和67.81%.结论 温敏型壳聚糖介入核素188Re内照射对小鼠肝癌(H22)具有一定的抑制作用.

  20. Dose-rate distribution of {sup 32}P-glass microspheres for intra-arterial brachytherapy

    Energy Technology Data Exchange (ETDEWEB)

    Guimaraes, Carla C.; Moralles, Mauricio; Sene, Frank F.; Martinelli, Jose R. [Centro de Ciencia e Tecnologia de Materiais, IPEN, Av. Lineu Prestes 2242, Sao Paulo, Sao Paulo 05508-000 (Brazil); Centro do Reator de Pesquisas, Energy and Nuclear Research Institute, IPEN/CNEN, CP 11049, CEP 05422-970, Sao Paulo, Sao Paulo (Brazil); Centro de Ciencia e Tecnologia de Materiais, IPEN, Av. Lineu Prestes 2242, Sao Paulo, Sao Paulo 05508-000 (Brazil)

    2010-02-15

    Purpose: The intra-arterial administration of radioactive glass microspheres is an alternative therapy option for treating primary hepatocellular carcinoma, the main cause of liver cancer death, and metastatic liver cancer, another important kind of cancer induced in the liver. The technique involves the administration of radioactive microspheres in the hepatic artery, which are trapped preferentially in the tumor. Methods: In this work the GEANT4 toolkit was used to calculate the radial dose-rate distributions in water from {sup 32}P-loaded glass microspheres and also from {sup 90}Y-loaded glass microspheres. To validate the toolkit for this application, the authors compared the dose-rate distribution of {sup 32}P and {sup 90}Y point sources in water with data from the International Commission on Radiation Units and Measurements report 72. Results: Tables of radial dose-rate distributions are provided for practical use in brachytherapy planning with these microspheres. Conclusions: The simulations with the microspheres show that the shape of the beta ray energy spectra with respect to the {sup 32}P and {sup 90}Y sources is significantly modified by the glass matrix.

  1. Myeloablative radioimmunotherapy with {sup 188}Re-CD66mAb before stem cell transplantation. No increase of proinflammatory cytokine levels of TNF-{alpha}; Myeloablative Radioimmuntherapie mit {sup 188}Re-CD66mAb vor Stammzelltransplantation. Kein Anstieg proinflammatorischer Zytokinspiegel von TNF-{alpha}

    Energy Technology Data Exchange (ETDEWEB)

    Mutschler, J.; Reske, S.N. [Universitaetsklinik Ulm (Germany). Klinik fuer Nuklearmedizin; Steinbach, G. [Universitaetsklinik Ulm (Germany). Abt. Klinische Chemie; Bunjes, D. [Universitaetsklinik Ulm (Germany). Medizinische Klinik III; Buchmann, I. [Universitaetsklinik Heidelberg (Germany). Abt. fuer Nuklearmedizin

    2009-07-01

    Tumour necrosis factor-{alpha} (TNF-{alpha}) serum levels may increase due to intensive conditioning regimes with high-dose chemotherapy and total body irradiation (TBI) before stem cell transplantation. This increases the risk for developing acute graft versus host disease (aGvHD) after stem cell transplantation. In this prospective study we investigated the influence of radioimmunotherapy with {sup 188}Re-CD-66-mAb on changes on TNF-{alpha} serum levels. Patients, methods: In 18 patients we measured TNF-{alpha} before and up to 96 hours after radioimmunotherapy, in 2 patients in addition following TBI, in 9 patients also following chemotherapy. For measuring TNF-{alpha} we used an automated immunochemiluminescence assay (Immulite 1000 DPC Biermann, Bad Nauheim). The mean follow up period to record incidence of aGVHD was 100 days after stem cell transplantation. Compared to the basal levels before, the levels of TNF-{alpha} after conditioning with {sup 188}Re-CD-66-mAb did not increase significantly and remained in the physiological range. In contrast, these initial physiological cytokine levels increased and became pathological following 48 h after total body irradiation (13.2 {+-} 6.6 pg/ml) and chemotherapy (10.8 {+-} 15.7 pg/ml). In our study we found a low incidence of aGvHD (22.2%, n = 4/18). Conclusion: These results demonstrate that additional conditioning therapy with {sup 188}Re-CD-66-mAb does not increase proinflammatory cytokine levels of TNF-{alpha}. This finding may indicate that additive radioimmunotherapy may not be a significant factor for increasing the rate of conditioning- associated aGvHD. (orig.)

  2. Affinity of hydroxyapatite by radionuclides parent/child in {sup 188}Re/{sup 188}W generator for radiotherapy; Afinidad de la hidroxiapatita por los radionuclidos padre/hijo en el generador {sup 188}Re/{sup 188}W para radioterapia

    Energy Technology Data Exchange (ETDEWEB)

    Carrera D, A. A. [Universidad Autonoma de Zacatecas, Unidad Academica de Ciencias Quimicas, Campus Universitario Siglo XXI, Ejido La Escondida, Carretera a Guadalajara Km. 6 (Mexico); Badillo A, V. [Universidad Autonoma de Zacatecas, Unidad Academica de Estudios Nucleares, Calle Cipres No. 10, Fracc. La Penuela 98068, Zacatecas (Mexico); Badillo A, V. E.; Monroy G, F. [ININ, Carretera Mexico-Toluca s/n, 52750 Ocoyoacac, Estado de Mexico (Mexico)], e-mail: ana_carrera7@hotmail.com

    2009-10-15

    To assess the feasibility of using apatites as matrices of {sup 188}W/{sup 188}Re generator is essential to obtain the distribution coefficients as much of parent radionuclide as child radionuclide in apatite, that is to say to know their affinity for the solid. It was selected the mineral species more representative as adsorbent, the hydroxyapatite Ca{sub 10} (PO{sub 4}){sub 6}(OH){sub 2} it is known for its great capacity of ions retention and by presenting a large affinity for anionic species in their surface. In this paper we use a synthetic hydroxyapatite marketed by Bio-Rad. This paper presents the preliminary results regarding the affinity of hydroxyapatite for the anionic species tungstates (WO{sub 4}{sup 2-}) and perrhenates (ReO{sub 4}{sup -} in EDTA, as background electrolyte expressed as distribution coefficients between two immiscible phases obtained with the help of radioactive tracers {sup 187}W and {sup 188}Re respectively. The retention measures of these ions, traces show that Bio-Gel hydroxyapatite presents moderate values of distribution coefficients for anionic species of W(Vi) in EDTA 0.01 mol/L that are in the range p H 5 to 6.5; the parent radionuclide of generator {sup 188}Re/{sup 188}W is fixed but not enough to consider it a good absorbent. By contrast, the fixation of perrhenate ions is virtually wiped as may be easily removed from a hydroxyapatite column packed with a saline solution. The influence of this saline solution in the removal of perrhenate ions is null practically. (Author)

  3. Calculus of spatial distribution of absorbed dose to cellular level by Monte Carlo simulation for a radio-labelled peptide with {sup 188}Re and with nuclear internalization : preliminary results; Calculo de la distribucion espacial de dosis absorbida a nivel celular por simulacion Monte Carlo para un peptido radiomarcado con {sup 188}Re y con internalizacion nuclear : resultados preliminares

    Energy Technology Data Exchange (ETDEWEB)

    Rojas C, E. L. [ININ, Carretera Mexico-Toluca s/n, 52750 Ocoyoacac, Estado de Mexico (Mexico); Santos C, C. L. [Universidad Autonoma del Estado de Mexico, Paseo Tollocan y Jesus Carranza, Toluca 50120, Estado de Mexico (Mexico)], e-mail: leticia.rojas@inin.gob.mx

    2009-10-15

    The {sup 188}Re is a radionuclide of radiation gamma emitter, useful in obtaining of gamma-graphic images, but it is also emitter of beta radiations and Auger electrons. A bio-molecule directed to a specific receptor of a cancer cell labeled with a emitter radionuclide of beta particles and Auger electrons, as the {sup 188}Re-Tat-Bombesin, it has the potential to be used in radiotherapy of molecular targets for its capacity to penetrate to cellular nucleus. In this system, the radiation dose is distributed in way located at microscopic levels in sub cellular specific places, where Auger emissions contributes of significant way in absorbed dose. The cellular dosimetry is realized in most of cases, using analytic or semi analytical methods, for example the cellular MIRD methodology. However, it is required to complement these calculations simulating the electrons transport and considering experimental bio kinetics data. Therefore, in this work preliminary results are presented of dosimetric calculation to sub cellular level for {sup 188}Re-Tat-Bombesin by Monte Carlo simulation, using the 2008 version of PENELOPE: PENEASY code. The spatial distribution of absorbed dose in membrane, cytoplasm and nucleus, was calculated with geometry of a cell of 10 {mu}m of diameter, a nucleus of 2 {mu}m of ratio and membrane of 0.2 {mu}m of thickness, considering elementary constitution for each cellular compartment proposal in literature. The total number of disintegrations at sub cellular level was evaluated integrating the activity in function of time starting from experimental bio kinetics data in mamma cancer cells MDA-MB231. The preliminary results show that 46.4% of total disintegrations for unit of captured activity by cell occurs in nucleus, 38.4% in membrane and 15.2% in cytoplasm. The due absorbed dose to Auger electrons for 1 Bq of {sup 188}Re located in cellular membrane were respectively of 1.32E-1 and 1.43E-1 Gy in cytoplasm and nucleus. (Author)

  4. Development of activity standard for {sup 90}Y microspheres

    Energy Technology Data Exchange (ETDEWEB)

    Mo, L. [Australian Nuclear Science and Technology Organisation, New Illawarra Road, Lucas Heights, NSW 2234 (Australia) and Institute of Medical Physics, University of Sydney, NSW 2006 (Australia)]. E-mail: lmx@ansto.gov.au; Avci, B. [SIRTeX Medical Limited, Unit F6 Parkview, 16 Mars Road, Lane Cove, NSW 2066 (Australia); James, D. [SIRTeX Medical Limited, Unit F6 Parkview, 16 Mars Road, Lane Cove, NSW 2066 (Australia); Simpson, B. [CSIR National Metrology Laboratory, 15 Lower Hope Road, Rosebank, Cape Town 7700 (South Africa); Van Wyngaardt, W.M. [CSIR National Metrology Laboratory, 15 Lower Hope Road, Rosebank, Cape Town 7700 (South Africa); Cessna, J.T. [National Institute of Standards and Technology, Gaithersburg, MD 20899 (United States); Baldock, C. [Institute of Medical Physics, University of Sydney, NSW 2006 (Australia)

    2005-08-01

    {sup 90}Y microspheres are important therapeutic radiopharmaceuticals used in the treatment of liver cancer through a process known as selective internal radiation therapy. SIR-spheres[reg] is a radiopharmaceutical product that is comprised of {sup 90}Y microspheres suspended in sterile, pyrogen-free water for injection into patients. It is necessary to establish for the SIR-spheres[reg] production the capability of accurately measuring the activity of this product to a traceable national measurement standard. An activity standard for SIR-spheres[reg] was developed from a standard for {sup 90}Y solution, employing a highly quantifiable chemical digestion process. Calibration factors for the manufacturer's ionisation chambers were determined for 1 and 5 ml of the SIR-spheres[reg] product placed in Wheaton vials, for both 34% and 44% of {sup 90}Y microsphere concentration.

  5. Synovectomy of the knee with /sup 90/Y

    Energy Technology Data Exchange (ETDEWEB)

    Spooren, P.F.M.J.; Rasker, J.J.; Arens, R.P.J.H.

    1985-05-01

    In 33 patients with chronic arthritis of the knee, 48 knees were treated with an intra-articular injection of 5 mCi yttrium silicate /sup 90/Y. There were 27 patients with rheumatoid arthritis (RA) and 6 with osteoarthrosis (OA); the mean follow-up period was 33 months. At clinical investigation after 1 year, no signs of pain or swelling were found in 15 knees. In most cases, pain and swelling improved subjectively, with a mean duration of 11 months; in 20 knees, the improvement lasted more than 22 months. When radiographs showed severe destruction, /sup 90/Y treatment was unsuccessful, but an important new finding was that most patients with mild or moderate radiological abormalities appeared to have a long-lasting improvement. The result did not correlate with erythrocyte sedimentation rate (ESR), haemoglobin or Rose titre at the time of injection or at follow up, suggesting that the result of the treatment is more dependent on local factors than on the disease activity. The results of /sup 90/Y treatment in 6 OA knees with persistent swelling were promising regarding swelling, even in patients with moderate radiological abnormalities. The main side-effect was a sometimes painful swelling of the knee, which was always successfully treated with an intra-articular corticosteroid injection. In /sup 90/Y-treated knees, the incidence of unstable joints was not significantly higher than in non-treated knees. In conclusion, /sup 90/Y synovectomy may be a succesful treatment for patients older than 50 years with chronic arthritis of the knee due to RA and probably also OA, even when moderate radiological abnormalities are present.

  6. 放射性核素188Re诱导人乳腺癌ER-75-30细胞的凋亡%Apoptosis of human breast cancer cell induced by radionuclide 188Re

    Institute of Scientific and Technical Information of China (English)

    邹保民; 段小艺; 胡国瑛

    2002-01-01

    目的研究放射性核素188铼(188Re)诱导乳腺癌 ER-75-30细胞凋亡及其与bcl-2和bax基因表达的关系. 方法应用光镜、电镜、流式细胞仪和免疫组化方法检测不同浓度 188Re作用于体外培养的乳腺癌ER-75-30细胞后,诱导细胞凋亡及bcl-2和bax基因表达情况。结果188Re以诱导乳腺癌ER-75-30细胞发生凋亡形态学变化,并且随着188Re浓度增大,凋谢亡率增加,bcl-2表达减弱,bax表达增强。结论188Re能诱导乳腺癌ER-75-30细胞凋谢亡且具有剂量和周期依赖性,bcl-2和bax基因在188Re诱导的细胞凋亡过程中具有重要作用。%AIM To study apoptosis of human breast cancer ER-75-30 cell induced by 188Re and expression of bcl-2 gene and bax gene. METHODS Light microscope, transmissional electron microscope, flow cytometer and immunohistochemical method were used to observed ER-75-30 cells apoptosis after expose to 188Re of different doses and expressing of bcl-2 and bax. RESULTS 188Re can induced ER-75-30 cell producing typical morphologic changes of apoptosis and with the rise of radiation dose, cell apoptosis rate increased, bcl-2 gene decreased and bax gene was enhanced. Cells were blocked in G2/M period. CONCLUSION Radionuclide 188Re can induce tumor cell apoptosis. This effect takes on dose-effect relation and cellcycle dependent. bcl-2 and bax gene play import part in the course.

  7. Development of [{sup 90}Y]DOTA-conjugated bisphosphonate for treatment of painful bone metastases

    Energy Technology Data Exchange (ETDEWEB)

    Ogawa, Kazuma [Advanced Science Research Center, Kanazawa University, Kanazawa 920-8640 (Japan)], E-mail: kogawa@med.kanazawa-u.ac.jp; Kawashima, Hidekazu [Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501 (Japan); Graduate School of Medicine, Kyoto University, Kyoto 606-8507 (Japan); Shiba, Kazuhiro [Advanced Science Research Center, Kanazawa University, Kanazawa 920-8640 (Japan); Washiyama, Kohshin; Yoshimoto, Mitsuyoshi [Division of Health Sciences, Graduate School of Medical Science, Kanazawa University, Kanazawa 920-0942 (Japan); Kiyono, Yasushi [Biomedical Imaging Research Center, University of Fukui, Yoshida-gun 910-1193 (Japan); Radioisotopes Research Laboratory, Kyoto University Hospital, Faculty of Medicine, Kyoto University, Kyoto 606-8507 (Japan); Ueda, Masashi [Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501 (Japan); Radioisotopes Research Laboratory, Kyoto University Hospital, Faculty of Medicine, Kyoto University, Kyoto 606-8507 (Japan); Mori, Hirofumi [Advanced Science Research Center, Kanazawa University, Kanazawa 920-8640 (Japan); Saji, Hideo [Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501 (Japan)

    2009-02-15

    Introduction: Based on the concept of bifunctional radiopharmaceuticals, we have previously developed {sup 186}Re-complex-conjugated bisphosphonate analogs for palliation of painful bone metastases and have demonstrated the utility of these compounds. By applying a similar concept, we hypothesized that a bone-specific directed {sup 90}Y-labeled radiopharmaceutical could be developed. Methods: In this study, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) was chosen as the chelating site, and DOTA was conjugated with 4-amino-1-hydroxybutylidene-1,1-bisphosphonate. [{sup 90}Y]DOTA-complex-conjugated bisphosphonate ([{sup 90}Y]DOTA-HBP) was prepared by coordination with {sup 90}Y, and its biodistribution was studied in comparison to [{sup 90}Y]citrate. Results: In biodistribution experiments, [{sup 90}Y]DOTA-HBP and [{sup 90}Y]citrate rapidly accumulated and resided in the bone. Although [{sup 90}Y]citrate showed a higher level of accumulation in the bone than [{sup 90}Y]DOTA-HBP, the clearances of [{sup 90}Y]DOTA-HBP from the blood and from almost all soft tissues were much faster than those of [{sup 90}Y]citrate. As a result, the estimated absorbed dose ratios of soft tissues to osteogenic cells (target organ) of [{sup 90}Y]DOTA-HBP were lower than those of [{sup 90}Y]citrate. Conclusions: [{sup 90}Y]DOTA-HBP showed superior biodistribution characteristics as a bone-seeking agent and led to a decrease in the level of unnecessary radiation compared to [{sup 90}Y]citrate. Since the DOTA ligand forms a stable complex not only with {sup 90}Y but also with lutetium ({sup 177}Lu), indium ({sup 111}In), gallium ({sup 67/68}Ga), gadolinium (Gd) and so on, complexes of DOTA-conjugated bisphosphonate with various metals could be useful as agents for palliation of metastatic bone pain, bone scintigraphy and magnetic resonance imaging.

  8. Liver radioembolization with {sup 90}Y microspheres. 2. ed.

    Energy Technology Data Exchange (ETDEWEB)

    Bilbao, Jose Ignacio [Clinica Universidad de Navarra, Pamplona (Spain). Dept. de Radiologia; Reiser, Maximilian F. (ed.) [Universitaetsklinikum Muenchen Klinikum Grosshadern, Muenchen (Germany). Inst. fuer Klinische Radiologie

    2014-07-01

    New, up-to-date edition of the only book devoted specifically to the subject. Key basic information on how to use the procedure successfully in clinical practice. Detailed information on candidate selection, vascular anatomy, dosimetry, and treatment evaluation. Thorough summary of published results. This is the second edition of a very well received book devoted specifically to the treatment of liver tumors by radioembolization with {sup 90}Y microspheres. The success of the first edition was based on the provision of all the fundamental information required for successful use of this therapeutic modality in clinical practice. The new edition has been fully updated to cover the most recent advances and includes additional chapters on regulations and emerging trends. Detailed information is provided on the full range of relevant topics, including hepatic vascular anatomy (including variants), dosimetry, assessment of tumor response, and the results achieved using radioembolization alone and in combination with other treatments in patients with primary or metastatic disease. Complications and side-effects are also fully discussed. This book will prove immensely valuable for both beginners and practitioners.

  9. Hanford isotope project strategic business analysis yttrium-90 (Y-90)

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    1995-10-01

    The purpose of this analysis is to address the short-term direction for the Hanford yttrium-90 (Y-90) project. Hanford is the sole DOE producer of Y-90, and is the largest repository for its source in this country. The production of Y-90 is part of the DOE Isotope Production and Distribution (IP and D) mission. The Y-90 is ``milked`` from strontium-90 (Sr-90), a byproduct of the previous Hanford missions. The use of Sr-90 to produce Y-90 could help reduce the amount of waste material processed and the related costs incurred by the clean-up mission, while providing medical and economic benefits. The cost of producing Y-90 is being subsidized by DOE-IP and D due to its use for research, and resultant low production level. It is possible that the sales of Y-90 could produce full cost recovery within two to three years, at two curies per week. Preliminary projections place the demand at between 20,000 and 50,000 curies per year within the next ten years, assuming FDA approval of one or more of the current therapies now in clinical trials. This level of production would incentivize private firms to commercialize the operation, and allow the government to recover some of its sunk costs. There are a number of potential barriers to the success of the Y-90 project, outside the control of the Hanford Site. The key issues include: efficacy, Food and Drug Administration (FDA) approval and medical community acceptance. There are at least three other sources for Y-90 available to the US users, but they appear to have limited resources to produce the isotope. Several companies have communicated interest in entering into agreements with Hanford for the processing and distribution of Y-90, including some of the major pharmaceutical firms in this country.

  10. The Automorphism Groups of the Groups of Order 32p

    CERN Document Server

    Becker, Elaine W

    2009-01-01

    The results of computer computations determining the automorphism groups of the groups of order 32$p$ for $p \\geq 3$ are given in several tables. Presentations for the automorphism groups of the groups of order 32, which in many cases appear as direct product factors in the automorphism groups of order $32p$, are also presented for completeness. Many of the groups of order 32$p$ with a normal sylow $p$-subgroup have automorphism groups of the form: Hol($C_p$)$ \\times $Invariant Factor. A suggestion is made as to how one might determine this invariant factor using only information on the automorphism group of the 2-group associated with the group of order 32$p$, and the normal subgroup of the 2-group associated with the extension of the group of order $32p$. Some general comments on the groups of order $32p^2$ and their automorphism groups are made. A few explicit calculations for the groups of order $32p^2$ are reported here. Knowing the automorphism groups for the groups of order $32p$ enables us to explicit...

  11. SPECT/CT 90Y-Bremsstrahlung images for dosimetry during therapy

    OpenAIRE

    Fabbri, C.; Sarti, G.; Agostini, M; Di Dia, A; Paganelli, G

    2008-01-01

    Background: the characteristics of 90Y, suitable for therapy, are denoted by the lack of γ-emission. Alternative methods, using analogues labelled with 111In or 86Y, are generally applied to image 90Y-conjugates, with some inevitable drawbacks. New generation SPECT/CT image systems offer improved Bremsstrahlung images. The intent of this brief communication is to show that high quality 90Y-Bremsstrahlung SPECT-CT images can be obtained, allowing the biodistribution of pure β-emitter therapeut...

  12. Self-assembled monolayers on gold for the fabrication of radioactive stents

    NARCIS (Netherlands)

    Bommel, van Kjeld J.C.; Friggeri, Arianna; Mateman, Dorine; Geurts, Frank A.J.; Leerdam, Kees G.C.; Verboom, Willem; Veggel, van Frank C.J.M.; Reinhoudt, David N.

    2001-01-01

    An innovative and easily applicable method for the fabrication of radioactive stents, to be used for the treatment of restenosis, is presented. By incorporating the b-emitting radioisotopes 186Re, 188Re, 90Y, or 32P into sulfur-containing adsorbates, it becomes possible to cover a gold surface with

  13. Synthesis of (gamma-/sup 32/P)thiamine triphosphate

    Energy Technology Data Exchange (ETDEWEB)

    Grandfils, C.; Bettendorff, L.; de Rycker, C.; Schoffeniels, E.

    1988-03-01

    We developed a novel chemical synthesis of thiamine triphosphate which allows us to incorporate /sup 32/P in the gamma position. The reaction is based on the condensation of (/sup 32/P)orthophosphoric acid and thiamine diphosphate in the presence of ethyl chloroformate. After purification by two ion-exchange purification steps, the thiamine derivative has a specific radioactivity of 10 Ci/mmol. The average final yield synthesis is about 10%.

  14. Therapy with {sup 90}Y microspheres: radiation protection in new medical therapies; Terapia con microesferas de {sup 90}Y: proteccion radiologica en nuevas terapias medicas

    Energy Technology Data Exchange (ETDEWEB)

    Rojo, Ana; Puerta, Nancy, E-mail: arojo@arn.gob.ar [Autoridad Regulatoria Nuclear (ARN), Buenos Aires (Argentina)

    2013-07-01

    Primary liver cancer is one of the most frequent in the world and with a low cure rate. Radioembolization using 90y spheres is a promising treatment of this pathology and involves the percutaneous vascular application of radioisotope-labeled the order of Micron size particles. The advantages of this technique include the permit administered high doses of radiation to small volumes with low relative toxicity, offer the possibility of treating all the liver including microscopic tumors, and finally, the feasibility of combined with other therapies. Radiation protection in new medical therapies requires justification and optimization, as requirements for their implementation. The application of the principle of optimization in the context of the protection of the patient must be the minimum that it can be reasonably reached compatible with the required doses of treatment dose to healthy tissue. With {sup 90}Y microspheres therapy this optimization applies to the activity of 90y which is administered to the patient, and estimation methods are postulated. in this work are analyzed comparatively these methods, described the early physicists, equations and the limitations of each. Finally, it is concluded that the optimal method to be implemented for the evaluation of the activity of {sup 90}Y manage must be based in a voxel dosimetric model specific for each patient, however, the partitional method may be a good alternative if you don't have the tools to apply the method.

  15. {sup 90}Sr/{sup 90}Y prostatic hyperplasia applicators and its clinical effects

    Energy Technology Data Exchange (ETDEWEB)

    Shanyu Cai [Academia Sinica, Beijing, BJ (China). Inst. of Atomic Energy; Zhi Li; Feng Chen

    1996-10-01

    Several main techniques for the treatment of benign prostatic hyperplasia (BPH) are reviewed simply in this paper. A novel technique of {sup 90}Sr/{sup 90}Y intracavitary therapy is described in detail. In recent years, two different kinds of {sup 90}Sr/{sup 90}Y prostatic hyperplasia applicators including `urethra-type` and `rectum-type` have been developed. The hypertrophic prostate gland can be irradiated by {sup 90}Sr/{sup 90}Y ({beta}) rays through the wall of urethra or rectum. Based on the animal experiments, a thousand cases of BPH have been observed respectively at ten hospitals since 1992. The clinical application indicate that the {sup 90}Sr/{sup 90}Y intracavitary applicator provides a safe, effective, reliable, and non-invasive method in curing BPH. In addition, it is apt for the high risk patients and costs of treatment are low. (author)

  16. Labeling of NGR Peptide With 188Re and Its Biodistribution and SPECT Imaging in Tumor-bearing Nude Mice%NGR短肽的188Re标记及其在荷瘤裸鼠体内的生物分布和SPECT显像

    Institute of Scientific and Technical Information of China (English)

    锁耀宇; 杨卫东; 马晓伟; 汪静

    2011-01-01

    采用188Re标记含有天冬酰胺、甘氨酸、精氨酸(Asn-Gly-Arg,NGR)序列的肿瘤血管靶向性短肽,得到188Re-NGR,观察了188Re-NGR在荷HepG2肝癌细胞严重联合免疫缺陷(Severe Combined Immunodeficiency,SCID)裸鼠肿瘤模型中的生物分布,并对其进行了SPECT显像.结果显示,188Re-NGR的标记率>85%,放化纯度>90%.188Re-NGR在肿瘤模型鼠体内的生物分布显示,注射188Re-NGR后12 h,肿瘤放射性摄取达最高,为(4.62±0.71)%ID/g,24 h时仍有(2.01±0.38)%ID/g,说明标记物在肿瘤内停留时间较长;竞争性抑制组中,12 h肿瘤放射性摄取为(1.43±0.61)%ID/g,明显低于实验组.肿瘤与肌肉组织的放射性摄取比(T/NT)12 h为4.76.注射后1 h肿瘤可显像,4~8 h显像逐渐清晰,12 h时更为清晰.以上结果提示,188Re-NGR具有良好的肿瘤血管靶向性.%To evaluate its radiochemical characteristics, biodistribution and imaging for nude mice bearing HepG2, 188Re-NGR was prepared directly with 2-mercapto-ethanol as reductant and sodium gluconate as middle ligand. The labeling yield of 188 Re-NGR was more than 85%, and the radiochemical purity (RCP) was more than 90%. In vivo, 188Re-NGR can specifically bind with tumor. The tumor uptake was (2.84±0.51)%ID/g at 1 h after injection, the uptake was(4. 62±0. 71)%ID/g at 12 h and remains (2.01±0.38)%ID/g for 24 h, the contrl group was (1.43±0.61)%ID/g. The ratio of tumor to muscle was 4.76 at 12 h. The xenografted tumor became visible at 1 h and was the most clearly at 12 h. The results showed that NGR had the function of good targeting.

  17. Radioembolization and the dynamic role of 90Y PET/CT

    Directory of Open Access Journals (Sweden)

    Alexander S Pasciak

    2014-02-01

    Full Text Available Before the advent of tomographic imaging, it was postulated that decay of 90Y to the 0+ excited state of 90Zr may result in emission of a positron-electron pair. While the branching ratio for pair production is small (~32x10-6, PET has been successfully used to image 90Y in numerous recent patient and phantom studies. 90Y PET imaging has been performed on a variety of PET/CT systems, with and without time-of-flight (TOF and/or resolution recovery capabilities as well as on both BGO and L(YSO based scanners. On all systems, resolution and contrast superior to bremsstrahlung SPECT has been reported. The intrinsic radioactivity present in L(YSO-based PET scanners is a potential limitation associated with accurate quantification of 90Y. However, intrinsic radioactivity has been shown to have a negligible effect at the high activity concentrations common in 90Y radioembolization. Accurate quantification is possible on a variety of PET scanner models, with or without TOF, although TOF improves accuracy at lower activity concentrations. Quantitative 90Y PET images can be transformed into 3D maps of absorbed dose based on the premise that the 90Y activity distribution does not change after infusion. This transformation has been accomplished primarily with the use of 3D dose point-kernel convolution. From a clinical standpoint, 90Y PET provides a superior post-infusion evaluation of treatment technical success owing to its improved resolution. Absorbed dose maps generated from quantitative PET data can be used to predict treatment efficacy and manage patient follow-up. For patients who receive multiple treatments, this information can also be used to provide patient-specific treatment planning for successive therapies, potentially improving response. The broad utilization of 90Y PET has the potential to provide a wealth of dose-response information, which may lead to development of improved radioembolization treatment-planning models in the future.

  18. Rapid 90Sr/90Y determination in water samples using a sequential injection method

    Science.gov (United States)

    Mateos; Gomez; Garcias; Casas; Cerda

    2000-07-01

    We have developed a semiautomatic procedure based on a sequential injection method for 90Sr/90Y determination that allows their radiochemical separation in about 30 min. The method has been tested using 90Sr/90Y solutions with activities lower than 12 Bq. The source is eluted in a pH = 6.5 medium through a MnO2-impregnated cotton filter, where 9OY is preconcentrated in preference by adsorption. 90Y is extracted from the column with hydroxylamine, some 90Sr in the leached solution has also been found. After the radiochemical separation, the total beta-activity of the leached solution has been determined using a low background alpha-beta proportional counter and, assuming the presence of 90Sr and 90Y at t = 0, the solution of the Bateman equations allows the initial concentration of both isotopes to be obtained. We have verified that the addition of some ions usually found in water samples (Cl-, HCO3-, NO3-, SO4(2-), Ca2+, Mg2+) does not interfere with the yield of the radiochemical process, (90 +/- 10)%. The method has been applied to 90Sr/90Y determination in mineral waters, and even in thermal waters, where the salt concentration can be about 3500 mg/l, the radiochemical yield remains greater than 80%.

  19. {sup 90}Y-oxine-ethiodol, a potential radiopharmaceutical for the treatment of liver cancer

    Energy Technology Data Exchange (ETDEWEB)

    Yu Junfeng; Haefeli, U.O. E-mail: hafeliu@ccf.org; Sands, Mark; Dong Yonghua

    2003-05-01

    Ethiodol (or lipiodol) is selectively retained in hepatocellular carcinoma and is used as a vehicle to deliver radioactive agents following intraarterial hepatic infusion. We prepared the lipophilic complex {sup 90}Y-oxine with a radiolabeling efficiency of 97.6{+-}1.1%. After extraction into ethiodol, a stability test in serum at 37 deg. C showed that 87.8% of the {sup 90}Y remained ethiodol-bound for 7 days. Bremsstrahlung imaging of a rabbit for 48 h confirmed that the homogeneous mixture of radiolabeled {sup 90}Y-oxine and ethiodol stayed in the targeted liver lobe. This radiopharmaceutical is thus a potential candidate for the treatment of non-resectable liver cancer.

  20. Portable {sup 90}SR/{sup 90}Y prostatic hyperplasia applicators

    Energy Technology Data Exchange (ETDEWEB)

    Cai, Shanyu; Tang, Kejian; Zhou, Changling [China Institute of Atomic Energy (China); Li, Zhi [Zhelimumen Hospital (China)

    1998-07-01

    In order to seek a new method of curing the benign prostatic hyperplasia (BPH), two different kinds of {sup 9} {sup 0}Sr/9{sup 0}Y intracavity applicators, including a 'urethra-type' and a 'rectum-type', have been developed in China since 1991. The structural design and radiation characteristics of the {sup 90}Sr/{sup 90}Y prostatic hyperplasia applicator are given in this paper. The hypertrophic prostate gland can be irradiated through the wall of the urethra or rectum by {sup 90}Sr/{sup 90}Y beta rays and small quantity of bremsstrahlung radiation from the applicator. Clinical tests indicate that the {sup 90}Sr/{sup 90}Y prostatic hyperplasia applicators provide a safe, effective, non-invasive and economical therapeutic method for BPH. It is especially applicable for old and high-risk patients. (author)

  1. A dosimetry evaluation of 90y-stent implantation in intracoronary radiation treatment

    Directory of Open Access Journals (Sweden)

    Karimian Alireza

    2013-01-01

    Full Text Available Ionizing particles have been used for the treatment of atherosclerosis. Internal irradiation is commonly carried out by means of several methods (catheter-based systems, radioactive stents or balloons to reduce the probability of restenosis. 90Y, due to some of its characteristics, is an appropriate radioisotope for intravascular brachytherapy. However, since there are some critical tissues in the vicinity of the heart like the breast and lymph nodes, it is necessary to perform a dosimetry calculation around the artery under radiotherapy to justify the treatment method. In this study, a 3-D dose distribution was obtained for the coronary vessel and its surrounding tissues for a standard 90Y stent in a MCNPX program. The results were compared with other investigations on restenosis prevention using 90Y-coated stents. The calculations represented a 28-day cumulative dose between 1230 cGy and 2400 cGy at 0.1 mm from the stent surface, while this quantity was about 23.8 cGy at 8.5 mm from the stent surface. An assessment of the dose equivalent and effective dose was also performed at r = 8.5 mm for the mentioned surrounding tissues which may be located in the area, based on the latest changes in ICRP recommendations. Additionally, the dose equivalent calculated within the treatment period for these organs was compared with published dosimetry data for 90Sr/90Y seed sources in order to evaluate radiation protection concerns about these two radiotherapy methods. It has been found that, depending on stent parameters, 90Y stent implantation might increase the unfavorable side effects for the patient, but to a much lesser degree than the other methods.

  2. Same-day {sup 90}Y radioembolization: implementing a new treatment paradigm

    Energy Technology Data Exchange (ETDEWEB)

    Gabr, Ahmed; Kallini, Joseph Ralph; Gates, Vanessa L.; Hickey, Ryan; Desai, Kush; Thornburg, Bartley; Marshall, Karen; Salzig, Krystina; Williams, Melissa; Del Castillo, Carlene; Hohlastos, Elias; Lewandowski, Robert J. [Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, Department of Radiology, Section of Interventional Radiology, Chicago, IL (United States); Kulik, Laura; Ganger, Daniel [Northwestern University, Department of Medicine, Division of Hepatology, Chicago, IL (United States); Baker, Talia [Northwestern University, Department of Surgery, Division of Transplantation, Comprehensive Transplant Center, Chicago, IL (United States); Salem, Riad [Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, Department of Radiology, Section of Interventional Radiology, Chicago, IL (United States); Northwestern University, Department of Surgery, Division of Transplantation, Comprehensive Transplant Center, Chicago, IL (United States); Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Department of Medicine, Division of Hematology and Oncology, Chicago, IL (United States)

    2016-12-15

    To assess the feasibility of conducting pretreatment mesenteric angiography, coil embolization, {sup 99m}Tc macroaggregated albumin ({sup 99m}Tc-MAA) scintigraphy, and {sup 90}Y radioembolization treatment in a single, same-day, combined outpatient encounter. This was a retrospective study of 78 patients treated during the period 2008 - 2015 who were managed in a single outpatient encounter under the guidance of the Interventional Radiology Department and The Nuclear Medicine Department. Pretreatment planning was performed by reviewing baseline imaging and estimated perfused liver volume bearing the tumor. The region of interest was estimated using 3-D software; this value was used for dosimetry planning. Maximum lung shunting fractions of 10 % for hepatocellular carcinoma and 5 % for liver metastases were assumed. Subsequently, hepatic angiography and {sup 99m}Tc-MAA scintigraphy were performed followed by {sup 90}Y treatment in one outpatient encounter. Total in-room procedure time was recorded. All patients underwent same-day angiography, {sup 99m}Tc-MAA scintigraphy and {sup 90}Y radioembolization. Of the 78 patients, 16 received multiple segmental treatments to both lobes, 44 received treatment to the right lobe, and 18 received treatment to the left lobe. The median dose was 106 Gy. The median number of {sup 90}Y vials needed was two (range one to six). The median in-room time was 160 min (75 - 250 min). The residential status of the patients was as follows, 18 % (14/78) were local residents, 55 % (43/78) traveled from outside the city limits, 18 % (14/78) were from out-of-state, and 9 % (7/78) were resident abroad. Of the 78 patients, 61 (77 %) had hepatocellular carcinoma, and 17 (22 %) had liver metastases. The median lung dose was 3.5 Gy. This study demonstrated the feasibility of same-day {sup 90}Y evaluation and treatment while maintaining the principles of safe and effective {sup 90}Y infusion including tumoricidal dosimetry (lobar, segmentectomy

  3. Disproof of solar influence on the decay rates of 90Sr/90Y

    CERN Document Server

    Kossert, Karsten

    2014-01-01

    A custom-built liquid scintillation counter was used for long-term measurements of 90Sr/90Y sources. The detector system is equipped with an automated sample changer and three photomultiplier tubes, which makes the application of the triple-to-double coincidence ratio (TDCR) method possible. After decay correction, the measured decay rates were found to be stable and no annual oscillation could be observed. Thus, the findings of this work are in strong contradiction to those of Parkhomov [1] who reported on annual oscillations when measuring 90Sr/90Y with a Geiger-M\\"uller counter. Sturrock et al. [2] carried out a more detailed analysis of the experimental data from Parkhomov and claimed to have found correlations between the decay rates and processes inside the Sun. These findings are questionable, since they are based on inappropriate experimental data as is demonstrated in this work. A frequency analysis of our activity data does not show any significant periodicity.

  4. Comparison of (90)Y activity measurements in nuclear medicine in Germany.

    Science.gov (United States)

    Kossert, Karsten; Bokeloh, Karen; Ehlers, Marion; Nähle, Ole; Scheibe, Olaf; Schwarz, Uwe; Thieme, Klaus

    2016-03-01

    In 2014, PTB and the company Eckert & Ziegler organized a national comparison exercise to determine the activity of a (90)Y solution. One aim of the comparison was to assess the measurement capability of hospitals and medical practices in Germany. P6-type vials were filled with aliquots of a radioactive (90)Y solution and then sent to 19 participants who were asked to measure the activity in the ampoules as well as in their own standard geometry using syringes. Most of the submitted results have a deviation of less than ±10% from the PTB reference activity when measured in the P6-type vials. The spread is somewhat larger when measured in a syringe geometry. The comparison revealed that some participants have difficulties in applying decay corrections and only a few participants were capable of estimating realistic measurement uncertainties.

  5. Radiopharmaceutical development based on human blood albumin microspheres and 90Y

    Science.gov (United States)

    Petriev, V. M.; Vlasova, O. P.; Postnov, A. A.; Epstein, N. B.

    2017-01-01

    New radiopharmaceutial (RP) based on human serum albumin microspheres (MSA) and 90Y was developed for treatment of liver cancer. The optimized synthesis using chelation resulted in approximately 80% yield with high specific activity. The RP developed was tested in mice with inoculated sarcoma-37. In two weeks the tumor size reduced by 43% after the treatment with the dose of 500 μCi injected into the tumor site.

  6. Efficiency calibration of a liquid scintillation counter for {sup 90}Y Cherenkov counting

    Energy Technology Data Exchange (ETDEWEB)

    Vaca, F. [Huelva Univ. (Spain). Dept. de Fisica Aplicada e Ingenieria Electrica; Manjon, G. [Departamento de Fisica Aplicada, E.T.S. de Arquitectura, Universidad de Sevilla, Av. Reina Mercedes, 2, E-41012 Sevilla (Spain); Garcia-Leon, M. [Departamento de Fisica Atomica, Molecular y Nuclear, Facultad de Fisica, Universidad de Sevilla, Av. Reina Mercedes, s/n. Apartado 1061, E-41080 Sevilla (Spain)

    1998-04-01

    In this paper a complete and self-consistent method for {sup 90}Sr determination in environmental samples is presented. It is based on the Cherenkov counting of {sup 90}Y with a conventional liquid scintillation counter. The effects of color quenching on the counting efficiency and background are carefully studied. A working curve is presented which allows to quantify the correction in the counting efficiency depending on the color quenching strength. (orig.). 6 refs.

  7. (90) Y/(177) Lu-labelled Cetuximab immunoconjugates: radiochemistry optimization to clinical dose formulation.

    Science.gov (United States)

    Chakravarty, Rubel; Chakraborty, Sudipta; Sarma, Haladhar Dev; Nair, K V Vimalnath; Rajeswari, Ardhi; Dash, Ashutosh

    2016-07-01

    Radiolabelled monoclonal antibodies (mAbs) are increasingly being utilized in cancer theranostics, which is a significant move toward tailored treatment for individual patients. Cetuximab is a recombinant, human-mouse chimeric IgG1 mAb that binds to the epidermal growth factor receptor with high affinity. We have optimized a protocol for formulation of clinically relevant doses (~2.22 GBq) of (90) Y-labelled Cetuximab and (177) Lu-labelled Cetuximab by conjugation of the mAb with a suitable bifunctional chelator, N-[(R)-2-amino-3-(paraisothiocyanato-phenyl)propyl]-trans-(S,S)-cyclohexane-1,2-diamine-N,N,N',N″,N″-pentaacetic acid (CHX-A″-DTPA). The radioimmunoconjugates demonstrated reasonably high specific activity (1.26 ± 0.27 GBq/mg for (90) Y-CHX-A″-DTPA-Cetuximab and 1.14 ± 0.15 GBq/mg for (177) Lu-CHX-A″-DTPA-Cetuximab), high radiochemical purity (>95%) and appreciable in vitro stability under physiological conditions. Preliminary biodistribution studies with both (90) Y-CHX-A″-DTPA-Cetuximab and (177) Lu-CHX-A″-DTPA-Cetuximab in Swiss mice bearing fibrosarcoma tumours demonstrated significant tumour uptake at 24-h post-injection (p.i.) (~16%ID/g) with good tumour-to-background contrast. The results of the biodistribution studies were further corroborated by ex vivo Cerenkov luminescence imaging after administration of (90) Y-CHX-A″-DTPA-Cetuximab in tumour-bearing mice. The tumour uptake at 24 h p.i. was significantly reduced with excess unlabelled Cetuximab, suggesting that the uptake was receptor mediated. The results of this study hold promise, and this strategy should be further explored for clinical translation.

  8. Peptide receptor radionuclide therapy with {sup 90}Y-DOTATOC in recurrent meningioma

    Energy Technology Data Exchange (ETDEWEB)

    Bartolomei, Mirco; Bodei, Lisa; De Cicco, Concetta; Grana, Chiara Maria; Baio, Silvia Melania; Arico, Demetrio; Paganelli, Giovanni [European Institute of Oncology, Division of Nuclear Medicine, Milan (Italy); Cremonesi, Marta [European Institute of Oncology, Division of Medical Physics, Milan (Italy); Botteri, Edoardo [European Institute of Oncology, Division of Epidemiology and Biostatistics, Milan (Italy); Sansovini, Maddalena [Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Radiometabolic Medicine Division, Meldola (Italy)

    2009-09-15

    Meningiomas are generally benign and in most cases surgery is curative. However, for high-grade histotypes or partially resected tumours, recurrence is fairly common. External beam radiation therapy (EBRT) is usually given in such cases but is not always effective. We assessed peptide receptor radionuclide therapy (PRRT) using {sup 90}Y-DOTATOC in a group of patients with meningioma recurring after standard treatments in all of whom somatostatin receptors were strongly expressed on meningioma cell surfaces. Twenty-nine patients with scintigraphically proven somatostatin subtype 2 receptor-positive meningiomas were enrolled: 14 had benign (grade I), 9 had atypical (grade II) and 6 had malignant (grade III) disease. Patients received intravenous {sup 90}Y-DOTATOC for 2-6 cycles for a cumulative dose in the range of 5-15 GBq. Clinical and neuroradiological evaluations were performed at baseline, during and after PRRT. The treatment was well tolerated in all patients. MRI 3 months after treatment completion showed disease stabilization in 19 of 29 patients (66%) and progressive disease in the remaining 10 (34%). Better results were obtained in patients with grade I meningioma than in those with grade II-III, with median time to progression (from beginning PRRT) of 61 months in the low-grade group and 13 months in the high-grade group. PRRT with {sup 90}Y-DOTATOC can interfere with the growth of meningiomas. The adjuvant role of this treatment, soon after surgery, especially in atypical and malignant histotypes, deserves further investigation. (orig.)

  9. Utilization of a novel electrochemical {sup 90}Sr/{sup 90}Y generator for the preparation of {sup 90}Y-labeled RGD peptide dimer in clinically relevant dose

    Energy Technology Data Exchange (ETDEWEB)

    Chakraborty, Sudipta; Chakravarty, Rubel; Pillai, Maroor Raghavan Ambikalmajan; Dash, Ashutosh [Bhabha Atomic Research Centre, Mumbai (India). Radiopharmaceuticals Div.; Sarma, Haladhar Dev [Bhabha Atomic Research Centre, Mumbai (India). Radiation Biology and Health Sciences Div.

    2014-09-01

    The work reported in this paper provides a systematic study towards the development of an optimized strategy for preparation of a clinically relevant dose of {sup 90}Y-labeled dimeric RGD peptide derivative, DOTA-E[c(RGDfK)]{sub 2} [DOTA-(RGD){sub 2}] for in vivo targeted therapy utilizing {sup 90}Y obtained from a novel electrochemical {sup 90}Sr/{sup 90}Y generator. The performance of the generator was evaluated to ensure its suitability for providing {sup 90}Y in adequate quantity and purity required for formulation of clinically relevant dose for PRRT. {sup 90}Y-DOTA-(RGD){sub 2} was synthesized in high yield (86.2 ± 2.5%) and radiochemical purity (98.4 ± 0.5%) using clinically relevant dose (∝ 3.8 GBq) of {sup 90}Y. In vitro stability studies revealed that the radiolabeled conjugate retained its radiochemical purity in normal saline and human serum. Preliminary biodistribution studies carried out in C57/BL6 mice bearing melanoma tumors showed that the preparation exhibited significant tumor uptake (5.30 ± 0.78% of injected activity at 30 min post-injection) with good tumor to background ratio. The optimized radiolabeling protocol seems to be an attractive strategy which is largely viewed as a springboard to realize scope of developing {sup 90}Y labeled cyclic RGD peptides for targeted therapy of tumors over-expressing integrin-α{sub ν}β{sub 3} receptors. (orig.)

  10. Essential thrombocythemia treated with oral sup(32)P

    Energy Technology Data Exchange (ETDEWEB)

    Yu, H.D.; Oh, B.S.; Jang, W.S.; Roh, K.H.; Park, B.I.; Cho, M.K. (National Police Hospital, Seoul (Republic of Korea))

    1983-04-01

    A 65-year old man was admitted due to protracted gum bleeding after dental surgery. The peripheral blood smear showed thrombocytosis(1,160,000/mm/sup 3/) with bizarre, giant platelets. The paltelet adhesiveness revealed 28% (normal control 31-85%) by Salzman method and the platelet aggregation revealed moderately delayed response to collagen, but normal responsiveness to A.D,P, and no responsiveness to epinephrine, the spleen scan(sup(99m)Tc-NaTcO/sub 4/) showed the finding of splenic infraction. The gum bleeding ceased after transfusion of 8 units of platelet rich plasma, and he was treated with oral sup(32)P(2.5mCi/m/sub 2/) under the diagnosis of essential thrombocythemia. The platelet count returned toward normal 2 months after treatment, and he was in good healthy condition.

  11. End-stage renal disease after treatment with {sup 90}Y-DOTATOC

    Energy Technology Data Exchange (ETDEWEB)

    Cybulla, M.; Weiner, S.M.; Otte, A. [Dept. of Internal Medicine, University Hospital Freiburg (Germany)

    2001-10-01

    DOTA-D-Phe{sup 1}-Tyr{sup 3}-octreotide (DOTATOC), a newly developed somatostatin analogue which can be stably labelled with the {beta}-emitter yttrium-90, can be used for receptor-mediated internal radiotherapy. A 78-year-old woman suffering from a carcinoid of the small intestine with multiple metastases in the liver as well as mesenteric and supraclavicular lymph node metastases was treated with this therapy after the disease had progressed under other chemotherapy options employed years previously. The patient received four single doses of {sup 90}Y-DOTATOC at 6-week intervals, yielding a cumulative dose of 9,620 MBq (5,659 MBq/m{sup 2}). Restaging revealed stable metastatic disease. Serum creatinine and urea nitrogen levels were within the normal range prior to starting and during DOTATOC therapy. However, 15 months after cessation of DOTATOC therapy, a progressive deterioration of renal function occurred, leading to end-stage renal disease. Urinalysis revealed a slight proteinuria of 700 mg/day without haematuria, leucocyturia or casts. There was no obvious risk factor for chronic renal insufficiency except DOTATOC therapy. However, it was not feasible to use kidney biopsy to prove the presence of radiation-induced nephritis. Intermittent haemodialysis was started as the creatinine clearance declined to below 10 ml/min. Diuresis was not affected. The presented case shows delayed renal insufficiency after a relatively low cumulative dose of {sup 90}Y-DOTATOC (5,659 MBq/m{sup 2}). This serious adverse event indicates that further studies are needed to evaluate which dose of {sup 90}Y-DOTATOC, under which renal protection regimen, will provide optimal management, balancing risks and benefits. (orig.)

  12. Characterization of tumor dose heterogeneity for 90Y microsphere therapies using voxel- based dosimetry

    Directory of Open Access Journals (Sweden)

    Justin Mikell

    2014-03-01

    Full Text Available Purpose: Dosimetry for 90Y microsphere therapies (YMT with Standard (SM and Partition (PM models provide only uniform dose estimates to tumor and liver. Our objective is to calculate tumor dose heterogeneity, known to effect response, using voxel-based dosimetry and investigate the limitations of SM and PM.Methods: Voxel-based dosimetry was performed on 17 YMT patients using Monte Carlo DOSXYZnrc. 90Y activity and tissue/density distributions were based on quantitative 90Y bremsstrahlung SPECT/CT. Tumors (n=31, liver, and treatment lobe/segments were segmented on diagnostic CT or MR. Dose volume histograms (DVH were created for tumors and normal liver. Bland-Altman analysis compared voxel-based mean absorbed doses to tumor and liver with SM and PM. Tumor and normal liver absorbed dose heterogeneity were investigated through metrics: integral uniformity (IU, D10/D90, COV. Correlations of heterogeneity with voxel-based mean doses and volumes were evaluated.Results: Heterogeneity metrics (mean ± 1σ for tumor dose were COV = 0.48 ± 0.28, D10/D90 = 4.7 ± 3.9, and IU = 0.8 ± 0.18. Heterogeneity metrics correlated with tumor volume (r > 0.58 but not tumor mean doses (r < 0.20. Voxel-based tumor mean doses correlated with PM (r = 0.84 but not SM (r = 0.08. Both yielded poor limits of agreement with of 83 ± 174 and -28 ± 181 Gy, respectively. Normal liver heterogeneity metrics (mean ± 1σ were COV = 0.83 ± 0.29, D10/D90 = 12 ± 15, and IU = 0.97 ± 0.03. Only D10/D90 (r = 0.49 correlated with mean normal liver absorbed dose. Voxel-based normal liver/lobe mean doses correlated with PM (r = 0.96, but had poor limits of agreement (26 ± 29 Gy.Conclusion: Tumor doses have high levels of heterogeneity that increase with volume but are independent of dose. Voxel-based DVH and dose heterogeneity metrics will promote accurate characterization of tumor response following YMT.--------------------------------------Cite this article as: Mikell J, Mourtada F

  13. PET optimization for improved assessment and accurate quantification of {sup 90}Y-microsphere biodistribution after radioembolization

    Energy Technology Data Exchange (ETDEWEB)

    Martí-Climent, Josep M., E-mail: jmmartic@unav.es; Prieto, Elena; Elosúa, César; Rodríguez-Fraile, Macarena; Domínguez-Prado, Inés; Vigil, Carmen; García-Velloso, María J.; Arbizu, Javier; Peñuelas, Iván; Richter, José A. [Nuclear Medicine Department, Clínica Universidad de Navarra, 36, Pío XII Avenue, 31008 Pamplona (Spain)

    2014-09-15

    Purpose: {sup 90}Y-microspheres are widely used for the radioembolization of metastatic liver cancer or hepatocellular carcinoma and there is a growing interest for imaging {sup 90}Y-microspheres with PET. The aim of this study is to evaluate the performance of a current generation PET/CT scanner for {sup 90}Y imaging and to optimize the PET protocol to improve the assessment and the quantification of {sup 90}Y-microsphere biodistribution after radioembolization. Methods: Data were acquired on a Biograph mCT-TrueV scanner with time of flight (TOF) and point spread function (PSF) modeling. Spatial resolution was measured with a{sup 90}Y point source. Sensitivity was evaluated using the NEMA 70 cm line source filled with {sup 90}Y. To evaluate the count rate performance, {sup 90}Y vials with activity ranging from 3.64 to 0.035 GBq were measured in the center of the field of view (CFOV). The energy spectrum was evaluated. Image quality with different reconstructions was studied using the Jaszczak phantom containing six hollow spheres (diameters: 31.3, 28.1, 21.8, 16.1, 13.3, and 10.5 mm), filled with a 207 kBq/ml {sup 90}Y concentration and a 5:1 sphere-to-background ratio. Acquisition time was adjusted to simulate the quality of a realistic clinical PET acquisition of a patient treated with SIR-Spheres{sup ®}. The developed methodology was applied to ten patients after SIR-Spheres{sup ®} treatment acquiring a 10 min per bed PET. Results: The energy spectrum showed the{sup 90}Y bremsstrahlung radiation. The {sup 90}Y transverse resolution, with filtered backprojection reconstruction, was 4.5 mm in the CFOV and degraded to 5.0 mm at 10 cm off-axis. {sup 90}Y absolute sensitivity was 0.40 kcps/MBq in the center of the field of view. Tendency of true and random rates as a function of the {sup 90}Y activity could be accurately described using linear and quadratic models, respectively. Phantom studies demonstrated that, due to low count statistics in {sup 90}Y PET

  14. 90Y-DOTA-CHS Microspheres for Live Radiomicrosphere Therapy: Preliminary In Vivo Lung Radiochemical Stability Studies

    Directory of Open Access Journals (Sweden)

    Alejandro Amor-Coarasa

    2014-01-01

    Full Text Available Chitosan (CHS is used to prepare microspheres of 31 ± 8 µm size. Surface modification with p-SCN-Bn-DOTA was performed. A maximum 90Y capacity was found to be 12.1 ± 4.4 µCi/particle. The best obtained labeling yield was 87.7 ± 0.6%. More than 90% in vitro stability was found. Particle in vitro degradation half-life in PBS was found to be greater than 21 days. In vivo studies with 90Y-DOTA-CHS showed more than 95% of the injected activity (decay corrected in the lungs 24 hours after tail vein administration. 90Y-DOTA-CHS in vivo label stability was superior to resin microspheres. The addition of p-SCN-Bn-DOTA served as a radioprotectant for bone marrow as the 5% 90Y released, during the first 24 hours, was quickly eliminated via urine.

  15. Time optimization of (90)Sr measurements: Sequential measurement of multiple samples during ingrowth of (90)Y.

    Science.gov (United States)

    Holmgren, Stina; Tovedal, Annika; Björnham, Oscar; Ramebäck, Henrik

    2016-04-01

    The aim of this paper is to contribute to a more rapid determination of a series of samples containing (90)Sr by making the Cherenkov measurement of the daughter nuclide (90)Y more time efficient. There are many instances when an optimization of the measurement method might be favorable, such as; situations requiring rapid results in order to make urgent decisions or, on the other hand, to maximize the throughput of samples in a limited available time span. In order to minimize the total analysis time, a mathematical model was developed which calculates the time of ingrowth as well as individual measurement times for n samples in a series. This work is focused on the measurement of (90)Y during ingrowth, after an initial chemical separation of strontium, in which it is assumed that no other radioactive strontium isotopes are present. By using a fixed minimum detectable activity (MDA) and iterating the measurement time for each consecutive sample the total analysis time will be less, compared to using the same measurement time for all samples. It was found that by optimization, the total analysis time for 10 samples can be decreased greatly, from 21h to 6.5h, when assuming a MDA of 1Bq/L and at a background count rate of approximately 0.8cpm.

  16. An overview of DNA fingerprinting with sup 32 P nucleotides

    Energy Technology Data Exchange (ETDEWEB)

    Pappas, G.G.

    1992-01-01

    The DNA probes radiolabeled with {sup 32}P, a primary tool employed by researchers in the life sciences for > 20 yr, are used by private companies, state-run laboratories, and the FBI to generate autoradiographs displaying the unique banding patterns that constitute the DNA fingerprint. The ability to identify an individual or animal from a biological sample has profound implications. Unidentified bodies, unrecognizable remains, and missing children can be tested and the DNA fingerprint compared to those of family members for positive identification. Paternity can be established before a child's birth. Immigration disputes can easily be resolved. Other uses include pedigree determination and testing for cell-line cross-contamination. Using a DNA fingerprint to determine the guilt or innocence of an individual allegedly involved in a violent crime is very controversial and has great legal and moral implications for society. Forensic laboratories have been challenged to ensure a level of quality control and quality assurance consistent with the weight given to these tests when used as evidence in a court of law.

  17. Brachytherapy on restenosis. {sup 32}P radioisotope in animal model

    Energy Technology Data Exchange (ETDEWEB)

    Bergoc, R.; Rivera, E.; Cocca, C.; Martin, G.; Cricco, G. [Buenos Aires Univ. (Argentina). School of Pharmacy and Biochemistry; Croci, M.; Guzman, L.

    2000-05-01

    Despite a notorious decline in age-adjusted death rates for cardiovascular pathologies, coronary artery disease still remains as the main cause of mortality above the age of 40 in men and 60 in women. More than 25% of death in persons over the age of 35 are due to coronary disease. In about 50% of men and 30% of women, the first manifestation of the disease is an acute myocardial infarction and 10% a sudden cardiac death. In Argentina it is estimated that in 1998 about 100.000-115.000 people suffered as first manifestation of coronary illness a myocardial acute infarct. Angioplasty has an important and well established site in the treatment of the coronary illness and restenosis represents the principal complication of this method for myocardial re-vascularization. About a 35-40% of treated arteries present restenosis within the first six month the intervention with the concomitant need of re-interventions, re-hospitalizations, by-pass surgery, work discontinuity and the high cost for the health system. A number of drugs were tested as anti-restenosis: anticoagulants, aspirin, antispasmodics and lipid-lowering agents but none was clearly efficient; also, experimental studies in which intravascular irradiation with different source types and energies, radiation doses and doses rate to prevent restenosis was utilized; however, there is no consensus in many aspects of this intravascular brachytherapy. The first step in this work was to induce the experimental model in rabbits. Afterwards, by means of the balloon methodology and stent implantation, brachytherapy experiments were carried out to evaluate the biological effect on different layers of arteries, with different Doses using a beta particle emitting radioisotope ({sup 32}P). The arteriosclerotic lesions were induced in New Zealand rabbits through the administration of a diet with high cholesterol content. Angioplastic interventions on femoral arteries were done with balloon methodology and controlled by

  18. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.

    Science.gov (United States)

    Wagner, Henry N; Wiseman, Gregory A; Marcus, Carol S; Nabi, Hani A; Nagle, Conrad E; Fink-Bennett, Darlene M; Lamonica, Dominick M; Conti, Peter S

    2002-02-01

    90Y-ibritumomab tiuxetan is a novel radioimmunotherapeutic agent recently approved for the treatment of relapsed or refractory low-grade, follicular, or CD20+ transformed non-Hodgkin's lymphoma (NHL). (90)Y-ibritumomab tiuxetan consists of a murine monoclonal antibody covalently attached to a metal chelator, which stably chelates (111)In for imaging and (90)Y for therapy. Both health care workers and patients receiving this therapy need to become familiar with how it differs from conventional chemotherapy and what, if any, safety precautions are necessary. Because (90)Y is a pure beta-emitter, the requisite safety precautions are not overly burdensome for health care workers or for patients and their families. (90)Y-ibritumomab tiuxetan is dosed on the basis of the patient's body weight and baseline platelet count; dosimetry is not required for determining the therapeutic dose in patients meeting eligibility criteria similar to those used in clinical trials, such as shielding during dose preparation and administration; primary lead shielding should be avoided because of the potential exposure risk from bremsstrahlung. Because there are no penetrating gamma-emissions associated with the therapy, (90)Y-ibritumomab tiuxetan is routinely administered on an outpatient basis. Furthermore, the risk of radiation exposure to patients' family members has been shown to be in the range of background radiation, even without restrictions on contact. There is therefore no need to determine activity limits or dose rate limits before patients who have been treated with (90)Y radioimmunotherapy are released, as is necessary with patients who have been treated with radiopharmaceuticals that contain (131)I. Standard universal precautions for handling body fluids are recommended for health care workers and patients and their family members after (90)Y-ibritumomab tiuxetan administration. In summary, (90)Y-ibritumomab tiuxetan introduces (90)Y into clinical practice and expands the role

  19. Occupational radiation exposure of medical staff performing {sup 90}Y-loaded microsphere radioembolization

    Energy Technology Data Exchange (ETDEWEB)

    Laffont, Sophie; Ardisson, Valerie; Lenoir, Laurence [Cancer Institute, Centre Eugene Marquis, Department of Nuclear Medicine, Rennes (France); Rolland, Yan; Rohou, Tanguy [Cancer Institute, Centre Eugene Marquis, Department of Interventional Radiology, Rennes (France); Edeline, Julien [University of Rennes 1, Rennes (France); Comprehensive Cancer Center, Institute Eugene Marquis, Department of Medical Oncology, Rennes (France); INSERM, U-991, Liver Metabolisms and Cancer, Rennes (France); Pracht, Marc; Sourd, Samuel Le [Comprehensive Cancer Center, Institute Eugene Marquis, Department of Medical Oncology, Rennes (France); Lepareur, Nicolas [Cancer Institute, Centre Eugene Marquis, Department of Nuclear Medicine, Rennes (France); INSERM, U-991, Liver Metabolisms and Cancer, Rennes (France); Garin, Etienne [Cancer Institute, Centre Eugene Marquis, Department of Nuclear Medicine, Rennes (France); University of Rennes 1, Rennes (France); INSERM, U-991, Liver Metabolisms and Cancer, Rennes (France)

    2016-05-15

    Radioembolization of liver cancer with {sup 90}Y-loaded microspheres is increasingly used but data regarding hospital staff exposure are scarce. We evaluated the radiation exposure of medical staff while preparing and injecting {sup 90}Y-loaded glass and resin microspheres especially in view of the increasing use of these products. Exposure of the chest and finger of the radiopharmacist, nuclear medicine physician and interventional radiologist during preparation and injection of 78 glass microsphere preparations and 16 resin microsphere preparations was monitored. Electronic dosimeters were used to measure chest exposure and ring dosimeters were used to measure finger exposure. Chest exposure was very low for both products used (<10 μSv from preparation and injection). In our experience, finger exposure was significantly lower than the annual limit of 500 mSv for both products. With glass microspheres, the mean finger exposure was 13.7 ± 5.2 μSv/GBq for the radiopharmacist, and initially 17.9 ± 5.4 μSv/GBq for the nuclear medicine physician reducing to 13.97 ± 7.9 μSv/GBq with increasing experience. With resin microspheres, finger exposure was more significant: mean finger exposure for the radiopharmacist was 295.1 ± 271.9 μSv/GBq but with a reduction with increasing experience to 97.5 ± 35.2 μSv/GBq for the six most recent dose preparations. For administration of resin microspheres, the greatest mean finger exposure for the nuclear medicine physician (the most exposed operator) was 235.5 ± 156 μSv/GBq. Medical staff performing {sup 90}Y-loaded microsphere radioembolization procedures are exposed to safe levels of radiation. Exposure is lower than that from treatments using {sup 131}I-lipiodol. The lowest finger exposure is from glass microspheres. With resin microspheres finger exposure is acceptable but could be optimized in accordance with the ALARA principle, and especially in view of the increasing use of radioembolization. (orig.)

  20. Long-term effect of /sup 90/Y pituitary implantation in acromegaly

    Energy Technology Data Exchange (ETDEWEB)

    Jadresic, A.; Jimenez, L.E.; Joplin, G.F.

    1987-01-01

    This report examines the long-term trends in GH levels and pituitary function in a group of 38 acromegalic patients who were selected insofar as we were able to follow them up for more than 10 years after a single dose /sup 90/Y interstitial pituitary irradiation as the sole treatment. Mean serum GH had fallen from 106 to 24 mIU/l within 3-6 months and then slowly declined to 4 mIU/l after 10 years. GH levels of less than or equal to 5 mIU/l during a 50 g oral glucose tolerance test were obtained in 8% of patients at 3-6 months and in 18% at 1 year, the cumulative percentage increasing to 53% at 10, and 76% at 14 years. The percentage of patients requiring hormone replacement therapy rose from nil pre-implant to 16% by 3-6 months, and then slowly increased to 39% by 14 years. Serial coned radiographs of the pituitary fossa were available for 32 patients. By 10 years, 16 showed thickening of the dorsum sellae and/or reduction of at least one diameter by 3 mm. Concerning symptoms, all 29 patients whose GH level fell to less than or equal to 5 mIU/l showed improvements, 22 becoming asymptomatic. Seven patients with lesser falls in GH levels (from a mean of 193 to a mean of 15 mIU/l) all improved, one becoming asymptomatic. Two showed no variation. These results show that /sup 90/Y pituitary implants have a cumulative effect over the years in inducting remission and hypopituitarism in acromegalic patients, the early decline in GH levels being swifter than from other forms of irradiation.

  1. Inflammation-induced synergetic enhancement of nanoparticle treatments with DOXIL® and 90Y-Lactosome for orthotopic mammary tumor

    Science.gov (United States)

    Kurihara, Kensuke; Ueda, Motoki; Hara, Isao; Hara, Eri; Sano, Kohei; Makino, Akira; Ozeki, Eiichi; Yamamoto, Fumihiko; Saji, Hideo; Togashi, Kaori; Kimura, Shunsaku

    2016-05-01

    Polymeric micelles (Lactosome) in the size of 20-30 nm were labeled with radionuclides of 111In (111In-DOTA-Lactosome) for SPECT imaging and 90Y (90Y-DOTA-Lactosome) for β-ray irradiation for mammary tumor in mice. The tumor site at the femoral right leg grafted with 4T1 cells was clearly imaged at 24 h after the intravenous injection. Biodistribution revealed that the half-life time of 111In-DOTA-Lactosome was 11 h, which enabled the nanoparticle selectively accumulated in tumor site due to the enhanced permeability and retention (EPR) effect. The anti-tumor therapeutic effect of 90Y-DOTA-Lactosome was observed depending on the dose frequency and amount. Under the condition of the percutaneous ethanol injection treatment, the therapeutic effect of 90Y-DOTA-Lactosome was enhanced due to the super EPR effect. Owing to the super EPR effect, co-administration of 90Y-DOTA-Lactosome and DOXIL® inhibited the tumor growth during 15 days with their administrations.

  2. Radioembolization with {sup 90}Y-labeled microspheres. Post-therapeutic therapy validation with Bremsstrahlung-SPECT; Radioembolisation mit {sup 90}Y-markierten Mikrosphaeren. Posttherapeutische Therapievalidierung mit Bremsstrahlungs-SPECT

    Energy Technology Data Exchange (ETDEWEB)

    Grosser, Oliver S. [Universitaetsklinikum Magdeburg A.oe.R. (Germany). Klinik fuer Radiologie und Nuklearmedizin; Medizinische Hochschule Hannover (Germany). Stabsstelle Strahlenschutz und Medizinische Physik; Nultsch, Madeleine; Laatz, Kathleen [Universitaetsklinikum Magdeburg A.oe.R. (Germany). Klinik fuer Radiologie und Nuklearmedizin] [and others

    2011-07-01

    During the last years angiographic Selective Internal Radiotherapy (SIRT) with {sup 90}Y-labelled microspheres has become a common technique for the local-ablative treatment of cancer patients. SIRT is a palliative therapy concept for the treatment of liver malignancies. As a result of {sup 90}Y-decay as {beta}{sup -}-emitter without a concomitant gamma radiation, Bremsstrahlung imaging is needed to validate the distribution achieved by radioembolisation. This article demonstrates the method of imaging through phantom measurement and shows the advantages of post-therapeutic tomography by means of a patient study. Approaches for further optimization of Bremsstrahlung imaging are discussed. (orig.)

  3. Comparative Efficacy of 177Lu and 90Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models

    Energy Technology Data Exchange (ETDEWEB)

    Frost, Sophia; Frayo, Shani; Miller, Brian W.; Orozco, Johnnie J.; Booth, Garrett C.; Hylarides, Mark; Lin, Yukang; Green, Damian J.; Gopal, Ajay K.; Pagel, John M.; Back, Tom; Fisher, Darrell R.; Press, Oliver W.

    2015-03-01

    Pretargeted radioimmunotherapy (PRIT) is a multi-step method of selectively delivering high doses of radiotherapy to tumor cells while minimizing exposure to surrounding tissues. Yttrium-90 (90Y) and lutetium-177 (177Lu) are two of the most promising beta-particle emitting radionuclides used for radioimmunotherapy, which despite having similar chemistries differ distinctly in terms of radiophysical features. These differences may have important consequences for the absorbed dose to tumors and normal organs. Whereas 90Y has been successfully applied in a number of preclinical and clinical radioimmunotherapy settings, there have been few published pretargeting studies with 177Lu. We therefore compared the therapeutic potential of targeting either 90Y or 177Lu to human B-cell lymphoma xenografts in mice.

  4. {sup 90}Y microspheres prepared by sol-gel method, promising medical material for radioembolization of liver malignancies

    Energy Technology Data Exchange (ETDEWEB)

    Łada, Wiesława, E-mail: w.lada@ichtj.waw.pl [Institute of Nuclear Chemistry and Technology, 03-195 Warsaw, Dorodna 16 (Poland); Iller, Edward [National Centre for Nuclear Research, Radioisotope Centre POLATOM, 05-400 Otwock, Andrzej Sołtan 7 (Poland); Wawszczak, Danuta [Institute of Nuclear Chemistry and Technology, 03-195 Warsaw, Dorodna 16 (Poland); Konior, Marcin, E-mail: marcin.konior@polatom.pl [National Centre for Nuclear Research, Radioisotope Centre POLATOM, 05-400 Otwock, Andrzej Sołtan 7 (Poland); Dziel, Tomasz [National Centre for Nuclear Research, Radioisotope Centre POLATOM, 05-400 Otwock, Andrzej Sołtan 7 (Poland)

    2016-10-01

    A new technology for the production of radiopharmaceutical {sup 90}Y microspheres in the form of spherical yttrium oxide grains obtained by sol-gel method has been described. The authors present and discuss the results of investigations performed in the development of new production technology of yttrium microspheres and determination of their physic-chemical properties. The final product has the structure of spherical yttrium oxide grains with a diameter 25–100 μm, is stable and free from contaminants. Irradiation of 20 mg samples of grains with diameter of 20–50 μm in the thermal neutron flux of 1.7 × 10{sup 14} cm{sup −2} s{sup −1} at the core of MARIA research nuclear reactor allowed to obtain microspheres labelled with the {sup 90}Y isotope on the way of the nuclear reaction {sup 89}Y(n, γ){sup 90}Y. Specific activity of irradiated microspheres has been determined by application of absolute triple to double coincidence ratio method (TDCR) and has been evaluated at 190 MBq/mg Y. {sup 90}Y microspheres prepared by the proposed technique can be regarded as a promising medical material for radioembolization of liver malignancies. - Highlights: • Sol-gel methods for preparation of spherical yttrium trioxide grains have been proposed. • Determination condition for irradiation {sup 89}Y{sub 2}O{sub 3} grains in nuclear reactor • Evaluation of specific activity of {sup 90}Y microspheres • Estimation of {sup 90}Y microspheres as promising medical material for radioembolization.

  5. Three dosimetry models of lipoma arborescens treated by {sup 90}Y synovectomy

    Energy Technology Data Exchange (ETDEWEB)

    O’Doherty, Jim, E-mail: jim.odoherty@kcl.ac.uk [Department of Medical Physics-Nuclear Medicine, Royal Surrey County Hospital, Guildford GU2 7XX, United Kingdom and Division of Imaging Sciences, PET Imaging Centre at St. Thomas’ Hospital, King' s College London, London SE1 7EH (United Kingdom); Clauss, Ralf [Department of Nuclear Medicine, Royal Surrey County Hospital, Guildford GU2 7XX (United Kingdom); Scuffham, James [Department of Medical Physics-Nuclear Medicine, Royal Surrey County Hospital, Guildford GU2 7XX (United Kingdom); Khan, Aman [Department of Rheumatology, Royal Surrey County Hospital, Guildford GU2 7XX (United Kingdom); Petitguillaume, Alice; Desbrée, Aurélie [Service de Dosimétrie Interne, Institut de Radioprotection et de Sûreté Nucléaire, 92260 Fontenay-aux-Roses (France)

    2014-05-15

    Purpose: Lipoma arborescens (LA) is a benign intra-articular lipomatous proliferation of the synovial membrane. This extremely rare condition has previously been treated by intra-articular{sup 90}Y radiosynoviorthesis but dosimetry literature on this form of radionuclide therapy is nonexistent. The authors detail methodology for successful treatment of LA and provide for the first time estimates of radiation dosimetry. The authors also analyze the biodistribution of the radiopharmaceutical over the course of the patient's treatment through sequential imaging. Methods: A patient with bilateral LA underwent intracavity injection of{sup 90}Y citrate colloid to the right and left knee joint spaces (181 and 198 MBq, respectively). SPECT/CT datasets were acquired over 9 days to quantify the biodistribution and kinetics of the radiopharmaceutical. Radiation dosimetry was performed using the MIRD schema (through OLINDA software), a custom voxel-based method, and a direct Monte Carlo calculation (OEDIPE). Results: Follow-up MRI showed marked reduction in LA size in both knees. Mean absorbed doses to the LA were 21.2 ± 0.8 and 42.9 ± 2.3 Gy using OLINDA, 8.1 ± 0.3 and 16.7 ± 0.5 Gy using voxel based methodology, and 8.2 ± 0.3 and 15.7 ± 0.5 Gy for OEDIPE in the right and left LA, respectively. Distribution of the radiopharmaceutical within the joint space alters over the imaging period, with less than 1% of the remaining activity having moved posteriorly in the knee cavity. No uptake was detected outside of the joint space after assessment with whole-body scintigraphy. Conclusions: An activity of approximately 185 MBq successfully relieved clinical symptoms of LA. There was good correlation between direct Monte Carlo and voxel based techniques, but OLINDA was shown to overestimate the absorbed dose to the tumor. Accurate dosimetry may help select an activity more tailored to the specific size and location of the LA.

  6. Radioembolisation with {sup 90}Y-microspheres: dosimetric and radiobiological investigation for multi-cycle treatment

    Energy Technology Data Exchange (ETDEWEB)

    Cremonesi, Marta; Ferrari, Mahila; Pedroli, Guido [European Institute of Oncology, Unit of Medical Physics, Milan (Italy); Bartolomei, Mirco; Arico, Demetrio; De Cicco, Concetta [European Institute of Oncology, Division of Nuclear Medicine, Milan (Italy); Orsi, Franco; Bonomo, Guido [European Institute of Oncology, Unit of Interventistic Radiology, Milan (Italy); Mallia, Andrew [Gamma Unit, Radiology Department, St. Luke' s Hospital (Malta); Paganelli, Giovanni [European Institute of Oncology, Division of Nuclear Medicine, Milan (Italy)

    2008-11-15

    Radioembolisation with {sup 90}Y-microspheres is a new locoregional treatment of hepatic lesions, usually applied as single cycle. Multi-cycle treatments might be considered as a strategy to improve the risk-benefit balance. With the aim to derive suitable information for patient tailored therapy, available patients' dosimetric data were reviewed according to the linear-quadratic model and converted into biological effective dose (BED) values. Single vs. multi-cycle approaches were compared through radiobiological perspective. Twenty patients with metastatic lesions underwent radioembolisation. The {sup 90}Y-administered activity (AA) was established in order to respect a precautionary limit dose (40 Gy) for the non-tumoral liver (NTL). BED was calculated setting {alpha}/{beta} = 2.5 Gy (NTL), 10 Gy (tumours); T{sub 1/2,eff} = T{sub 1/2,phys} = 64.2 h; T{sub 1/2,rep} = 2.5 h (NTL), 1.5 h (tumours). The BED to NTL was considered as a constraint for multi-cycle approach. The AA for two cycles and the percent variations of AA, tumour dose, BED were estimated. In one-cycle, for a prescribed BED to NTL of 64 Gy (NTL dose = 40 Gy), AA was 1.7 (0.9-3.2) GBq, tumour dose was 130 (65-235) Gy, and tumour BED was 170 (75-360) Gy. Considering two cycles, {proportional_to}15% increase was found for AA and dose to NTL, with unvaried BED for NTL. Tumour dose increase was 20 (10-35) Gy; tumour BED increase was 10 (3-11) Gy. In different protocols allowing 80 Gy to NTL, the BED sparing estimated was {proportional_to}50 Gy (two cycles) and 65 Gy (three cycles). From a radiobiological perspective, multi-cycle treatments would allow administering higher activities with increased tumour irradiation and preserved radiation effects on NTL. Trials comparing single vs. multiple cycles are suggested. (orig.)

  7. Dosimetry characterization of the commercial CaF{sub 2} for beta radiation of {sup 90}Sr + {sup 90}Y; Caracterizacao dosimetrica de CaF{sub 2} comercial para radiacao beta de {sup 90}Sr + {sup 90}Y

    Energy Technology Data Exchange (ETDEWEB)

    Oliveira, Mercia L.; Caldas, Linda V.E. [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil)], e-mail: mlolivei@ipen.br, e-mail: lcaldas@ipen.br

    2003-07-01

    This work studies the dosimetric characteristics of the CaF{sub 2} commercial dosimetry for detection of {sup 90}Sr + {sup 90}Y beta radiation for using in the calibration of flat and concave appliers. Were determined the repetitiousness and linearity of answers of the samples, and their calibration curves.

  8. Monitoring Kidney Function in Neuroendocrine Tumor Patients Treated with 90Y-DOTATOC

    DEFF Research Database (Denmark)

    Arveschoug, Anne K; Kramer, Stine M J; Iversen, Peter;

    2015-01-01

    and during a 4-hour and a 24-hour amino acid (AA) infusion protocol. We measured the Glomerular Filtration Rate (GFR) in 28 patients before and 3, 6, 12, and 18 months after 90Y-DOTATOC therapy. We used standardized 51Cr-EDTA plasma clearance (Cr-GFR) and estimated GFR (eGFR) by the simplified 4 variable...... Modification of Diet in Renal Disease based on serum creatinine values. Further, we determined GFR in 15 patients treated with a 4-hour infusion of AA compared to 13 patients with a 24-hour infusion at 3, 6, 12 and 18 months after therapy. Pre-existing risk factors associated with kidney failure were seen...... in 82% of the patients. We observed a significant reduction in Cr-GFR up to 12 months after PRRT (mean loss 27 ml/min/1,73 m2 (32%)). The eGFR continuously overestimated the Cr-GFR with a bias of 8%. There was no significant difference between the two AA protocols, however, the 24-hour AA protocol...

  9. A complete dosimetric characterization of two {sup 90}Sr-{sup 90}Y dermatologic applicators

    Energy Technology Data Exchange (ETDEWEB)

    Coelho, T.S. [Instituto de Pesquisas Energeticas e Nucleares, IPEN/CNEN, Sao Paulo (Brazil); Fernandes, M.A.R. [Faculdade de Medicina de Botucatu, UNESP, Departamento de Dermatologia e Radioterapia, Sao Paulo (Brazil); Yoriyaz, H., E-mail: hyoriyaz@ipen.b [Instituto de Pesquisas Energeticas e Nucleares, IPEN/CNEN, Sao Paulo (Brazil); Antonio, P.L. [Instituto de Pesquisas Energeticas e Nucleares, IPEN/CNEN, Sao Paulo (Brazil)

    2011-03-11

    A complete dosimetric characterization of two Amershan {sup 90}Sr-{sup 90}Y dermatologic applicators is described in this present work. The dosimetric parameters analyzed are: percentage depth dose curve, radial dose distribution, non-uniformity and asymmetry. Both applicators are planar-circular having 22.57 and 9.0 mm diameters. In the range where the percentage depth dose goes from 100% down to 20%, the measured percentage depth dose and that obtained by the Monte Carlo simulation have shown maximum discrepancy of 5.3% for both applicators. The radial dose distribution has been measured at several depths using a GafChromic EBT QD+ films and it was also calculated by simulation. The discrepancies found did not exceed 5.9% up to the depth of 1.8 mm, where the percentage depth dose drops to 40% of the maximum. The maximum non-uniformity and asymmetry are 1.7% and 5.3% for the first applicator and 22.7% and 25.9% for the second applicator, respectively. Both applicators meet the specification for the maximum non-uniformity established by the adopted protocol, whose limit is 30%. As for the asymmetry the limit is 20% and the second applicator exceeded it in about 5.9%.

  10. Alterations in 32P-labelled intermediates during flux activation of human platelet glycolysis

    NARCIS (Netherlands)

    Akkerman, Jan Willem N.; Driver, H.A.; Dangelmaier, C.A.; Holmsen, H.

    1984-01-01

    Using a newly developed isotopic tracer technique for the measurement of 32P-labelled intermediates in glycolysis and nucleotide metabolism in platelets, we studied the variations in 32P-labelled intermediates during activation of the glycolytic flux by cyanide and platelet-activating agents. The ma

  11. Can the decay rate of 32p be changed by mechanic motion?

    Institute of Scientific and Technical Information of China (English)

    DING YouQian; SUN HongQing; YANG ZhiHong; LIANG XiaoHu; WANG XiaoRong; ZHANG ShengDong; CUI AnZhi

    2009-01-01

    The influence of mechanic motion on the decay rate of 32p was studied by means of liquid scintillation counting (LSC). The results indicate that, on the Northern Hemisphere, the half life of 32p in anticlock-wise circular centrifuge rotation (radius 10 cm, 4000 r/min) equals the one in natural conditions within 0.6 percent uncertainty.

  12. Can the decay rate of 32P be changed by mechanic motion?

    Institute of Scientific and Technical Information of China (English)

    2009-01-01

    The influence of mechanic motion on the decay rate of 32P was studied by means of liquid scintillation counting (LSC). The results indicate that, on the Northern Hemisphere, the half life of 32P in anticlockwise circular centrifuge rotation (radius 10 cm, 4000 r/min) equals the one in natural conditions within 0.6 percent uncertainty.

  13. 瘤内注射90Y-SAg治疗小鼠肝癌移植瘤的实验研究%Experimental study of intratumor injection of 90Y-SAg for the treatment of liver cancer in mice

    Institute of Scientific and Technical Information of China (English)

    牟培源; 陈靖; 王建晨; 何千舸; 蒋小良; 金美娟; 李芳

    2006-01-01

    目的:探讨瘤内注射放射性核素钇-90(90Y)与超抗原(SAg)混悬液90Y-SAg治疗小鼠肝癌移植瘤的效果.方法:30只荷瘤小鼠随机分为三组,每组10只,分别瘤内注射0.1 ml SAg和0.1 ml (100 μci)90Y(A组)、0.1 ml (100 μci)90Y(B组)、0.1 ml SAg(C组). 结果:注射后2周:B组、C组肿瘤生长率分别为0.18±0.12和0.21±0.17,两组差异不显著(P>0.05);A组呈负生长,生长率为-0.28±0.23,与B组和C组比较均有显著性差异(P<0.01);A、B、C三组肿瘤坏死率分别为0.36±0.18、0.11±0.09、0.10±0.06, B组和C组均为轻度坏死,两组间差异不显著(P>0.05),A组为中度坏死,与B组和C组比较有显著性差异(P<0.01). 结论:瘤内注射90Y-SAg疗效优于单一的 90Y或SAg注射,是一种有效的治疗小鼠肝癌移植瘤方法.

  14. (90)Y microspheres prepared by sol-gel method, promising medical material for radioembolization of liver malignancies.

    Science.gov (United States)

    Łada, Wiesława; Iller, Edward; Wawszczak, Danuta; Konior, Marcin; Dziel, Tomasz

    2016-10-01

    A new technology for the production of radiopharmaceutical (90)Y microspheres in the form of spherical yttrium oxide grains obtained by sol-gel method has been described. The authors present and discuss the results of investigations performed in the development of new production technology of yttrium microspheres and determination of their physic-chemical properties. The final product has the structure of spherical yttrium oxide grains with a diameter 25-100μm, is stable and free from contaminants. Irradiation of 20mg samples of grains with diameter of 20-50μm in the thermal neutron flux of 1.7×10(14)cm(-2)s(-1) at the core of MARIA research nuclear reactor allowed to obtain microspheres labelled with the (90)Y isotope on the way of the nuclear reaction (89)Y(n, ɤ)(90)Y. Specific activity of irradiated microspheres has been determined by application of absolute triple to double coincidence ratio method (TDCR) and has been evaluated at 190MBq/mg Y. (90)Y microspheres prepared by the proposed technique can be regarded as a promising medical material for radioembolization of liver malignancies.

  15. A multicentre comparison of quantitative (90)Y PET/CT for dosimetric purposes after radioembolization with resin microspheres

    DEFF Research Database (Denmark)

    Willowson, Kathy P; Tapner, Michael; Bailey, Dale L

    2015-01-01

    PURPOSE: To investigate and compare the quantitative accuracy of (90)Y imaging across different generation PET/CT scanners, for the purpose of dosimetry after radioembolization with resin microspheres. METHODS: A strict experimental and imaging protocol was followed by 47 international sites using...

  16. A systematic comparative evaluation of 90Y-labeled bifunctional chelators for their use in targeted therapy.

    Science.gov (United States)

    Chakravarty, Rubel; Chakraborty, Sudipta; Dash, Ashutosh

    2014-02-01

    This paper describes a systematic comparative evaluation of five commonly used bifunctional chelators, namely,p-isothiocyanato benzyl derivatives of diethylenetriaminepentacetic acid (DTPA-NCS), trans-cyclohexyl diethylenetriaminepentaceticacid (CHX-A″-DTPA-NCS), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA-NCS), 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA-NCS), and 3,6,9,15-tetraazabicyclo [9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triacetic acid (PCTA-NCS), on the basis of their ability to complex 90Y at room temperature, in vitro and in vivo stability and clearance pattern in biological system. The results of the experiments carried out revealed that CHX-A″-DTPA-NCS was the most promising option as it could be radiolabeled with 90Y at room temperature with highest specific activity and demonstrated high in vitro stability in human serum and in presence of challenging metal ions commonly present inhuman plasma. The clearance pattern in Swiss mice revealed that 90Y-CHX- A″-DTPA-NCS cleared through the kidneys with minimum retention in any other major organ. Thus, the use of cyclohexyl-DTPA based bifunctional chelators would increase the scope of making 90Y-labeled agents suitable for targeted therapy.

  17. Feasibility of bremsstrahlung dosimetry for direct dose estimation in patients undergoing treatment with {sup 90}Y-ibritumomab tiuxetan

    Energy Technology Data Exchange (ETDEWEB)

    Arrichiello, C.; Aloj, L.; Mormile, M.; D' Ambrosio, L.; Caraco, C.; De Martinis, F. [Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione ' ' G. Pascale' ' , Nuclear Medicine Department, Napoli (Italy); Frigeri, F.; Arcamone, M.; Pinto, A. [Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione ' ' G. Pascale' ' , Hematology-Oncology, Napoli (Italy); Stem Cells Transplantation Unit, Department of Hematology, Napoli (Italy); Lastoria, S. [Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione ' ' G. Pascale' ' , Nuclear Medicine Department, Napoli (Italy); Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione ' ' G. Pascale' ' , IRCCS, Napoli (Italy)

    2012-06-15

    Radioimmunotherapy with {sup 90}Y-ibritumomab tiuxetan has been used successfully used in the treatment of CD20-positive non-Hodgkin's lymphoma (NHL). Pretherapy imaging with {sup 111}In-ibritumomab tiuxetan has been used in provisional dosimetry studies. Posttherapy imaging of {sup 90}Y-ibritumomab tiuxetan for clinical use is appealing as it would simplify the data acquisition process and allow measurements of actual doses absorbed during treatment. The study included 29 patients with non-Hodgkin's lymphoma, of whom 16 (group I) received a pretherapy {sup 111}In-ibritumomab tiuxetan diagnostic study and {sup 90}Y-ibritumomab tiuxetan treatment 1 week later, and 13 (group II) received only {sup 90}Y-ibritumomab tiuxetan treatment. Planar imaging and blood sampling were performed in all patients. The doses absorbed by organs at risk were calculated using a whole-body average attenuation correction factor (relative dosimetry approach) and, in the case of the {sup 111}In-ibritumomab tiuxetan image sets, also using organ-specific attenuation correction factors (absolute dosimetry method). Red marrow absorbed doses were based on gamma counting of blood samples. The estimated red marrow absorbed doses from {sup 111}In and {sup 90}Y data were equivalent. In all cases, the doses absorbed by organs at risk were found to be within prescribed limits. The relative dosimetry approach applied to both the {sup 90}Y and {sup 111}In data significantly underestimated the doses relative to those obtained with the {sup 111}In absolute dosimetry method which is generally accepted as the reference method (MIRD 16). In the case of {sup 111}In, the relative dosimetry approach values were highly correlated (R {sup 2} = 0.61) with the reference method values. Relative dosimetry estimates may be adjusted multiplying by a correction factor of 2.8. The {sup 90}Y-ibritumomab tiuxetan relative dosimetry data correlated poorly with the reference method values (R {sup 2} = 0.02). Based

  18. Intra-arterial treatment with {sup 90}Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital

    Energy Technology Data Exchange (ETDEWEB)

    Lambert, Bieke; Mertens, Jeroen; Oltenfreiter, Ruth [Ghent University Hospital, Department of Nuclear Medicine, Ghent (Belgium); Sturm, Emiel; Defreyne, Luc [Ghent University Hospital, Department of Vascular and Interventional Radiology, Ghent (Belgium); Smeets, Peter [Ghent University Hospital, Department of Radiology, Ghent (Belgium); Troisi, Roberto [Ghent University Hospital, Department of Hepatobiliary Surgery and Liver Transplantation, Ghent (Belgium); Vlierberghe, Hans van [Ghent University Hospital, Department of Gastroenterology and Hepatology, Ghent (Belgium)

    2011-12-15

    We report on our experience in terms of eligibility, safety, response and survival for treatment of hepatocellular carcinoma (HCC) with {sup 90}Y microspheres. Secondly, we investigated the urinary excretion of {sup 90}Y following treatment. We retrospectively reviewed all HCC patients referred to our department for {sup 90}Y microsphere treatment. We recorded reasons for not proceeding to actual treatment. In case treatment was performed, we assessed the tolerance (Common Terminology Criteria for Adverse Events v3.0, CTCAE v3.0), the response [modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria] and long-term survival (Kaplan-Meier). The urinary excretion was estimated by 12-h urine collections post-injection for analysis in a gamma counter. Forty-three HCC patients were referred for radioembolization. Fourteen patients were excluded, mainly due to unfavourable {sup 99m}Tc-macroaggregated albumin (MAA) distribution. Twenty-nine patients were treated with {sup 90}Y microspheres (TheraSphere, mean activity 2.17 GBq). In four patients severe clinical adverse events were encountered, however only in one case clearly related to the therapy. Twenty patients were assessable by mRECIST: complete response in 15%, partial response in 35%, stable disease in 30% and progression in 20% were observed. A median survival of 12.3 months (95% confidence interval 9.4-15.2) was estimated. Concerning the substudy on urinary excretion, only 0.0025% of the administered activity was excreted in the urine within the first 12 h following TheraSphere. Following a strict workup before admitting patients to radioembolization with TheraSphere, we found good clinical tolerance in the vast majority of patients. Radiological response assessment yielded an overall response rate of 50%, when evaluated early following treatment. Urine analysis showed consistently only low activities of {sup 90}Y excreted in the urine. (orig.)

  19. Gastric injury from {sup 90}Y to left hepatic lobe tumors adjacent to the stomach: fact or fiction?

    Energy Technology Data Exchange (ETDEWEB)

    Gates, Vanessa L.; Hickey, Ryan; Marshall, Karen; Williams, Melissa; Salzig, Krystina; Lewandowski, Robert J. [Robert H. Lurie Comprehensive Cancer Center, Department of Radiology, Section of Interventional Radiology, Northwestern Memorial Hospital, Chicago, IL (United States); Salem, Riad [Robert H. Lurie Comprehensive Cancer Center, Department of Radiology, Section of Interventional Radiology, Northwestern Memorial Hospital, Chicago, IL (United States); Northwestern University, Department of Medicine, Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL (United States)

    2015-12-15

    Radioembolization with {sup 90}Y microspheres is a locoregional radiation therapy for unresectable hepatic neoplasm. Non-target delivery of {sup 90}Y microspheres resulting in gastrointestinal (GI) symptoms is a recognized complication; there is minimal knowledge regarding the radiation effect to the gastric wall from left hepatic lobe {sup 90}Y treatments. Our aim was to study the incidence of GI complications when the target tissue (hepatic parenchyma ± tumor) is in close proximity to the gastric wall. We hypothesized that liver (tumor) to stomach proximity does not correlate with increased toxicity. Between November 2011 and September 2013, we studied all patients who underwent left lobe radioembolization with {sup 90}Y glass microspheres. With Institutional Review Board (IRB) approval, we retrospectively reviewed MRI/CT images of these patients, identifying a subset of patients with the left hepatic lobe <1 cm from the gastric wall. Patients were seen in clinic 1 month posttreatment and subsequently at 3-month intervals. Short- and long-term gastric adverse events were tabulated. Ninety-seven patients successfully underwent left hepatic lobe {sup 90}Y microsphere radioembolization in which the average distance from the liver to the stomach wall was 1.0 ± 2.8 mm. The average dose for patients who received radioembolization to the left hepatic lobe was 109 ± 57 Gy. Fifty patients had tumor within 1 cm of the gastric wall. The average dose for patients who received radioembolization to the left hepatic lobe with tumor within 1 cm of the gastric wall was 121 ± 41 Gy. There were no reportable or recordable medical events. Of the patients, 34 % reported abdominal pain that was grade 1-2; 65 % of the patients reported no abdominal pain. None of the 97 patients developed a clinically evident GI ulcer. Patients with left lobe tumors adjacent to or abutting the stomach do not exhibit acute or chronic radiation effects following radioembolization with glass

  20. Lethal effects of /sup 32/P decay on transfecting activity of Bacillus subtillis phage phie DNA

    Energy Technology Data Exchange (ETDEWEB)

    Loveday, K.S.

    1979-07-15

    Disintegration of /sup 32/P present in the DNA of Bacillus subtilis phage phie (a phage containing double-strand DNA) results in the loss of viability of intact phage as well as transfecting activity of isolated DNA. Only 1/12 of the /sup 32/P disintegrations per phage DNA equivalent inactivities the intact phage while nearly every disintegration inactivates the transfecting DNA. This result provides evidence for a single-strand intermediate in the transfection of B. subtilis by phie DNA.

  1. Role of neutron and proton system in spin cut off parameter and entropy of {sup 89,90}Y

    Energy Technology Data Exchange (ETDEWEB)

    Rahmatinejad, A. [Department of Physics, Faculty of Science, University of Zanjan, Zanjan (Iran, Islamic Republic of); Razavi, R., E-mail: rrazavin@ihu.ac.ir [Physics Department, Faculty of Science, Imam Hossein Comprehensive University, Tehran (Iran, Islamic Republic of); Kakavand, T. [Department of Physics, Faculty of Science, Imam Khomeini International University, Qazvin (Iran, Islamic Republic of)

    2015-09-15

    The nuclear level densities, entropies and spin cut off parameters have been determined in {sup 89,90}Y nuclei using the BCS model with inclusion of pairing interaction. The results have a good agreement with the recent experimental data on the level densities measured by the Oslo group. In addition, the entropy excess of {sup 90}Y compared to {sup 89}Y as a function of temperature has been extracted. Also, the role of neutron and proton systems in the entropy excess as well as the spin cut off excess have been investigated using the entropy excess ratio and spin cut off excess ratio introduced in our previous publication. The role of the neutron system at low temperatures, the temperatures below critical temperature, in the semi-magic nucleus {sup 89}Y is similar compared to the closed shell proton system in the tin isotopes.

  2. Role of neutron and proton system in spin cut off parameter and entropy of 89,90Y

    Science.gov (United States)

    Rahmatinejad, A.; Razavi, R.; Kakavand, T.

    2015-09-01

    The nuclear level densities, entropies and spin cut off parameters have been determined in 89,90Y nuclei using the BCS model with inclusion of pairing interaction. The results have a good agreement with the recent experimental data on the level densities measured by the Oslo group. In addition, the entropy excess of 90Y compared to 89Y as a function of temperature has been extracted. Also, the role of neutron and proton systems in the entropy excess as well as the spin cut off excess have been investigated using the entropy excess ratio and spin cut off excess ratio introduced in our previous publication. The role of the neutron system at low temperatures, the temperatures below critical temperature, in the semi-magic nucleus 89Y is similar compared to the closed shell proton system in the tin isotopes.

  3. Determination of Radiation Absorbed Dose to Primary Liver Tumors and Normal Liver Tissue Using Post Radioembolization 90Y PET

    Directory of Open Access Journals (Sweden)

    Shyam Mohan Srinivas

    2014-10-01

    Full Text Available Background: Radioembolization with Yttrium-90 (90Y microspheres is becoming a more widely used transcatheter treatment for unresectable hepatocellular carcinoma (HCC. Using post-treatment 90Y PET/CT scans,the distribution of microspheres within the liver can be determined and quantitatively assessesed . We studied the radiation dose of 90Y delivered to liver and treated tumors.Methods: This retrospective study of 56 patients with HCC, including analysis of 98 liver tumors, measured and correlated the dose of radiation delivered to liver tumors and normal liver tissue using glass microspheres (TheraSpheres® to the frequency of complications with mRECIST. 90Y PET/CT and triphasic liver CT scans were used to contour treated tumor and normal liver regions and determine their respective activity concentrations. An absorbed dose factor was used to convert the measured activity concentration (Bq/mL to an absorbed dose (Gy.Results: The 98 studied tumors received a mean dose of 169 Gy (mode 90-120 Gy;range 0-570 Gy. Tumor response by mRECIST criteria was performed for 48 tumors that had follow up scans. There were 21 responders (mean dose 215 Gy and 27 nonresponders (mean dose 167 Gy. The association between mean tumor absorbed dose and response suggests a trend but did not reach statistical significance (p=0.099. Normal liver tissue received a mean dose of 67 Gy (mode 60-70 Gy; range 10-120 Gy. There was a statistically significant association between absorbed dose to normal liver and the presence of two or more severe complications (p=0.036.Conclusion: Our cohort of patients showed a possible dose response trend for the tumors. Collateral dose to normal liver is nontrivial and can have clinical implications. These methods help us understand whether patient adverse events, treatment success, or treatment failure can be attributed to the dose which the tumor or normal liver received.

  4. Development of anthropomorphic hand phantoms for personal dosimetry in 90Y-Zevalin preparation and patient delivering.

    Science.gov (United States)

    Ciolini, R; d'Errico, F; Traino, A C; Paternostro, E; Laganà, A; Romei, C; Pazzagli, F; Del Gratta, A

    2014-01-01

    Anthropomorphic tissue-equivalent hand phantoms were achieved to measure the extremity dose involved in Zevalin (90)Y-labelling and patient delivering procedure for radioimmunotherapy treatment of non-Hodgkin lymphoma. The extremity doses to hands and wrists of operators were measured by using thermoluminescent detectors mounted on the developed phantoms. Measurements of chest- and lens-equivalent doses performed on a Rando phantom are also reported.

  5. Dosimetric comparison of electron beam and 9{sup 0}Sr+{sup 90}Y applicator for keloids treatment

    Energy Technology Data Exchange (ETDEWEB)

    Coelho, Talita S.; Tada, Ariane; Antonio, Patricia L.; Yoriyaz, Helio, E-mail: tasallesc@usp.b [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil); Fernandes, Marco A.R., E-mail: marco@cetea.com.b [UNESP, Botucatu, SP (Brazil). Faculdade de Medicina. Dept. de Dermatologia e Radioterapia Rubiao Junior

    2009-07-01

    Studies have been shown that among several methods that have been used for the treatment of keloids the surgical excision followed by the adjuvant radiotherapy presents the lowest relapsed rate of the injury. In this work a comparative dosimetric study has been performed using a 4 MeV electron beam from a Varian Clinac 2100C linear accelerator at the radiotherapy service of the Hospital das Clinicas of UNESP-HC, Botucatu-SP and an Amershan {sup 90}Sr+{sup 90}Y brachytherapy applicator with 1491 MBq of activity. Percentage depth dose curves from ionization chamber measurements and through Monte Carlo simulation have been obtained and compared. Dose measurements have been obtained using parallel plates ionization chamber (Esradin A12) and extrapolation mini-chamber developed at IPEN. The dose calculations have been obtained using the well-known Monte Carlo radiation transport code MCNP-4C. Maximum dose differences obtained between measured/calculated values for {sup 90}Sr+{sup 90}Y applicator and for the electron beam were, respectively: 7.8 % and 8.0%. The profiles of the depth and superficial tissue dose distribution produced by the electron beam revealed themselves flatter and more homogeneous than those produced by the {sup 90}Sr+{sup 90}Y applicator, especially to wider fields, which cannot be obtained with beta therapy applicators because of their geometric limitations. In conclusion this present work has shown that {sup 90}Sr+{sup 90}Y applicators could be efficient for small and very superficial lesions but in most cases electron beam sources are more adequate especially for large and deeper lesions. (author)

  6. Update on the rational use of (90Y-ibritumomab tiuxetan in the treatment of follicular lymphoma

    Directory of Open Access Journals (Sweden)

    Martina Lehnert

    2009-07-01

    Full Text Available Martina Lehnert, Heinz Ludwig, Niklas Zojer 1st Department of Medicine, Center for Oncology and Hematology, Wilhelminenspital, Vienna, AustriaAbstract: The development of radiolabeled antibodies against CD20 has facilitated targeted treatment of follicular lymphoma (FL. By using 90Y-ibritumomab tiuxetan (Zevalin®, a radionuclide (yttrium-90, linked by the chelator tiuxetan to the antibody ibritumomab is brought into the vicinity of lymphoma cells. By the so-called cross-fire effect, this beta emitter has the capacity to destroy not only the lymphoma cells having bound the antibody, but also neighboring lymphoma cells. Currently this antibody is licensed in the European Union for use in relapsed or refractory FL. It is anticipated that this drug will also be approved for use as consolidation therapy after successful first-line treatment. Here we first will review the published literature supporting the use of 90Y-ibritumomab tiuxetan in the aforementioned indications and emerging data showing applicability of ibritumomab tiuxetan as sole first-line therapy for FL, as well as in the transplant setting. Possible strategies of incorporating ibritumomab tiuxetan into the treatment algorithm of FL are discussed.Keywords: follicular lymphoma, 90Y-ibritumomab tiuxetan

  7. Development and biological evaluation of {sup 90}Y-BPAMD as a novel bone seeking therapeutic agent

    Energy Technology Data Exchange (ETDEWEB)

    Rabiei, Ali; Shamsaei, Mojtaba [Amir Kabir University of Technology, Tehran (Iran, Islamic Republic of). Energy Engineering and Physics Dept.; Yousefnia, Hassan; Zolghadri, Samaneh; Jalilian, Amir Reza [Nuclear Science and Technology Research Institute (NSTRI), Tehran (Iran, Islamic Republic of); Enayati, Razieh [Islamic Azad Univ. (IAU), Tehran (Iran, Islamic Republic of). Faculty of Engineering

    2016-07-01

    Nowadays, the bone-seeking radiopharmaceuticals play an important role in the treatment of the bone-related pathologies. Whereas various phosphonate ligands have already been identified, a DOTA-based bisphosphonate, 4-{[(bis(phosphonomethyl))carbamoyl]methyl}-7,10-bis(carboxymethyl) -1,4,7,10-tetraazacyclododec-1-yl (BPAMD) with better characteristics has recently been synthesized. In this study, {sup 90}Y-BPAMD was developed with radiochemical purity >98% and the specific activity of 3.52 TBq/mmol in the optimized conditions as a new bone-seeking therapeutic agent. The complex demonstrated significant stability at room temperature and in human serum even after 48 h. At even low amount of hydroxyapatite (5 mg), more than 90% binding to hydroxyapatite was observed. Biodistribution studies after injection of the complex into the Syrian rats showed major accumulation of the labelled compound in the bone tissue and an insignificant uptake in the other organs all the times after injection. Generally, {sup 90}Y-BPAMD demonstrated interesting characteristics compared to the other {sup 90}Y bone-seeking agents and even {sup 166}Ho-BPAMD, and can be considered as a new bone-seeking candidate for therapeutic applications.

  8. Acetylcholine increases the breakdown of triphosphoinositide of rabbit iris muscle prelabelled with [32P] phosphate.

    Science.gov (United States)

    Abdel-Latif, A A; Akhtar, R A; Hawthorne, J N

    1977-01-15

    1. Paired iris smooth muscles from rabbits were incubated for 30 min at 37 degrees C in an iso-osmotic salt medium containg glucose, inositol, cytidine and [32P]phosphate. 2. One of the pair was then incubated at 37 degrees C for 10 min in unlabelled medium containing 10mM-2-deoxyglucose and the other was incubated in the presence of acetylcholine plus eserine (0.05mM each). 2-Deoxyglucose, which was included in the incubation medium to minimize the biosynthesis of triphosphoinositide from ATP and diphosphoinositide, decreased the amount of labelled ATP by 71% and inhibited further 32P incorporation from ATP into triphosphoinositide by almost 30%. 3. Acetylcholine (0.05mM) increased significantly the loss of 32P from triphosphoinositide (the 'triphosphoinositide effect') in 32P-labelled iris muscle. This effect was measured both chemically and radiochemically. It was also observed when 32Pi was replaced by myo-[3H]inositol in the incubation medium. 4. The triphosphoinositide effect was blocked by atropine but not by D-tubocurarine. Further, muscarinic but not nicotinic agonists were found to provoke this effect. 5. Acetylcholine decreased by 28% the 32P incorporation into triphosphoinositide, presumably by stimulating its breakdown. This decrement in triphosphoinositide was blocked by atropine, but not by D-tubocurarine. 6. The triphosphoinositide effect was accompanied by a significant increase in 32P labelling, but not tissue concentration, of phosphatidylinositol and phosphatidic acid. The possible relationship between the loss of 32P label from triphosphoinositide in response to acetylcholine and the concomitant increase in that of phosphatidylinositol and phosphatidic acid is discussed. 7. The presence of triphosphoinositide phosphomonoesterase, the enzyme that might be stimulated in the iris smooth muscle by the neurotransmitter, was demonstrated, and, under our methods of homogenization and assay, more than 80% of its activity was localized in the

  9. 188Re标记叶酸偶联白蛋白纳米微球对SKOV3人卵巢癌生长抑制作用研究*%The Inhibitory Effects of 188Re-Labeled Folate Coupling with Magnetic Albumin Nanoparticles on SKOV3 Ovarian Cancer in Vivo

    Institute of Scientific and Technical Information of China (English)

    唐秋莎; 陈道桢; 臧嘉; 郭彩琴

    2013-01-01

    Objective To investigate the effects of isotope labeled folate targeting albumin nanoparticles (188Re-fo-late-CDDP/HAS MNP) on human SKOV3 ovarian cancer cells in vivo. Methods The human SKOV3 ovarian cancer model was established in mice. Sixty-four tumor-bearing mice were randomly divided into eight groups:(A) negative control group, (B) chemotherapy group, (C) radiotherapy alone group, (D) hyperthermia alone group, (E) chemotherapy combined with radio-therapy group, (F) chemotherapy combined with hyperthermia therapy group, (G) radiotherapy combined with hyperthermia therapy group and (H) hyperthermia, chemotherapy and radiotherapy combined treatment group. After treatment, the cell pro-liferation and tumor growth were observed. The inhibitory rate of tumor mass was measured. The histopathological changes of tumor were observed in all groups. Results The quality of tumor was significantly lower in treatment groups than that of control group (P<0.05). There was the lowest quality of tumor in hyperthermia, chemotherapy and radiotherapy combined treatment group than that of other treatment groups (P<0.05). Conclusion The combination of magnetic induction hyper-thermia, chemotherapy, targeted radionuclide of radiation exposure can effectively inhibit the growth of ovarian cancer, which has the potential application for ovarian cancer treatment.%目的观察核素标记叶酸靶向白蛋白纳米微球(188Re-folate-CDDP/HAS MNP)对SKOV3人卵巢癌细胞生长作用的影响。方法建立人卵巢癌细胞SKOV3裸鼠模型,并将64只荷瘤鼠随机分成8组,每组8只,分别为(A)阴性对照组;(B)采用CDDP方案化疗的单纯化疗组;(C)核素靶向内照射的单纯放疗组;(D)磁感应热疗的单纯热疗组;(E)化疗联合放疗组;(F)化疗联合热疗治疗组;(G)放疗联合热疗治疗组;(H)热疗、化疗、放疗联合治疗组。各组经治疗后,观察肿瘤生长增殖情况,计算肿瘤质量抑

  10. Changes of decay rates of radioactive 111In and 32P induced by mechanic motion

    Institute of Scientific and Technical Information of China (English)

    2007-01-01

    The changes of decay rates of radionuclide 111In(electron capture) and 32P(β decay) induced by exter-nal mechanic motion are studied. The results indicate that,in the external circular rotation in clockwise and anticlockwise centrifuge on Northern Hemisphere(radius 8 cm,2000 r/min) ,the half life of 111In compared with the referred(2.83 d) is decreased at 2.83% and increased at 1.77%,respectively;the half life of 32P compared with the referred(14.29 d) is decreased at 3.78% and increased at 1.75%,respec-tively. When the clockwise and anticlockwise rotations increase to 4000 r/min,the half life of 111In is decreased at 11.31% and increased at 6.36%,respectively;the half life of 32P is decreased at 10.08% and increased at 4.34%,respectively. When the circular rotation is removed,the decay rates of 111In and 32P return back to the referred,respectively. It is found that the external circular rotations in clockwise and anticlockwise centrifuge selectively increased and decreased the decay rates of 111In and 32P,respec-tively,and the effects are strongly dependent on the strength of circular rotation. It is suggested that these effects may be caused by the chiral interaction.

  11. Design and construction of a prototype for the obtention of {sup 32}P; Diseno y construccion de un prototipo para la obtencion de {sup 32}P

    Energy Technology Data Exchange (ETDEWEB)

    Duarte A, C

    2003-07-01

    The {sup 32} P are a pure emitting radioisotope of maximum energy of 1.71 MeV with half life of 14.28 days that he has applications in the industry, in agriculture, in medicine, in biology and in ecology (6,11,12,13,17,21,22,23,24,25,26,27,28,29,30,31,32 33).The {sup 32} P can be used in the industry like radiotracer in the investigation of some operations and processes and as element of measurement of some industrial meters. In agriculture is used as radiotracer (29) in the investigation of diverse biological processes that have to do with the production of diverse nutritious products. In medicine has uses but very therapeutic mainly in the treatment of some become cancerous (28, 31, 25, 27) in the diagnosis of blood disorders (24) and like part of materials of production of aortic prosthesis (6). The {sup 32} P are also used in the molecular investigation in biology and in genetics (33), and in studies of ecosystems (32) and of DNA (22). One can obtain the {sup 32} P by means of diverse nuclear reactions depending on the material used as matter it prevails, since it doesn't exist in the nature. But anyone in the ways of obtaining it it should imply a process of radiochemical separation that involves so many steps like they are required, depending on the material used as matter prevails, of the purity with which he wants himself to obtain and of the resources that it has available. The objective of this work was design, to build and to prove a prototype to obtain the {sup 32} P to leave of the irradiation of S {alpha} with fast neutrons at experimental level, which implies also to design a process that contemplates diverse stages and procedures for each one of them. The process was outlined in five stages: matter purification prevails, preparation of irradiation capsules, irradiation of irradiation capsules, transport and opening capsules of irradiation and radiochemical separation. In the last stage it was where uses the prototype of radiochemical separation

  12. Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia model.

    Directory of Open Access Journals (Sweden)

    Johnnie J Orozco

    Full Text Available Radioimmunotherapy (RIT for treatment of hematologic malignancies has primarily employed monoclonal antibodies (Ab labeled with 131I or 90Y which have limitations, and alternative radionuclides are needed to facilitate wider adoption of RIT. We therefore compared the relative therapeutic efficacy and toxicity of anti-CD45 RIT employing 90Y and 177Lu in a syngeneic, disseminated murine myeloid leukemia (B6SJLF1/J model. Biodistribution studies showed that both 90Y- and 177Lu-anti-murine CD45 Ab conjugates (DOTA-30F11 targeted hematologic tissues, as at 24 hours 48.8 ± 21.2 and 156 ± 14.6% injected dose per gram of tissue (% ID/g of 90Y-DOTA-30F11 and 54.2 ± 9.5 and 199 ± 11.7% ID/g of 177Lu-DOTA-30F11 accumulated in bone marrow (BM and spleen, respectively. However, 90Y-DOTA-30F11 RIT demonstrated a dose-dependent survival benefit: 60% of mice treated with 300 µCi 90Y-DOTA-30F11 lived over 180 days after therapy, and mice treated with 100 µCi 90Y-DOTA-30F11 had a median survival 66 days. 90Y-anti-CD45 RIT was associated with transient, mild myelotoxicity without hepatic or renal toxicity. Conversely, 177Lu- anti-CD45 RIT yielded no long-term survivors. Thus, 90Y was more effective than 177Lu for anti-CD45 RIT of AML in this murine leukemia model.

  13. Laboratory and field studies with /sup 32/P labeled Toxorhynchites rutilus rutilus

    Energy Technology Data Exchange (ETDEWEB)

    Smittle, B.J.; Focks, D.A.

    1986-12-01

    Females and eggs of Toxorhynchites r. rutilus were labeled with /sup 32/P by feeding fourth-stage larvae /sup 32/P labeled Aedes aegypti larvae. Eggs from females up to 3 weeks in age had detectable levels of radioactivity and individual eggs contained ca. 0.3% of the mother's total radioactivity. Comparisons of labeled and unlabeled females in indoor and outdoor cage tests indicated that survival and fecundity of the 2 groups were approximately equal. No differences were noted for dispersal and fecundity of labeled and control females released in field tests. The /sup 32/P-labeled Tx. r. rutilus females behave similarly to unlabeled females, and this method of radiolabeling provides a sound tool for tracking laboratory-reared females released into an area with an indigenous population.

  14. Hepatic Toxicity After Radioembolization of the Liver Using {sup 90}Y-Microspheres: Sequential Lobar Versus Whole Liver Approach

    Energy Technology Data Exchange (ETDEWEB)

    Seidensticker, Ricarda; Seidensticker, Max; Damm, Robert; Mohnike, Konrad [Universitaetsklinikum Magdeburg, Klinik fuer Radiologie and Nuklearmedizin (Germany); Schuette, Kerstin; Malfertheiner, Peter [Universitaetsklinikum Magdeburg, Klinik fuer Gastroenterologie, Hepatologie und Infektiologie (Germany); Buskirk, Mark Van [Data Reduction (United States); Pech, Maciej; Amthauer, Holger; Ricke, Jens, E-mail: jens.ricke@med.ovgu.de [Universitaetsklinikum Magdeburg, Klinik fuer Radiologie and Nuklearmedizin (Germany)

    2012-10-15

    Purpose: {sup 90}Y-radioembolization (RE) is a promising technique for delivering high doses of radiation to liver tumors but may result in compromise of liver function. To gain further perspective, we evaluated the toxicity rates of sequential lobar versus 'whole liver' {sup 90}Y-radioembolization. Methods: Thirty-four patients with liver malignancy in noncirrhotic livers were included; {sup 90}Y-radioembolization was performed as either whole liver or sequential lobar treatment in 17 patients each. Standard clinical and liver specific laboratory parameters as well as MR imaging before treatment and at follow-up (6 and 12 weeks) after radioembolization were evaluated for toxicity using the Common Terminology Criteria for Adverse Events (CTCAE). Volumetry of the liver, tumor, and spleen and measurement of portal vein diameter also were performed. Results: Three months after whole liver RE, 14 liver-related grade 3/4 events were recorded versus 2 events after sequential lobar treatment (P < 0.05). Three patients treated with whole liver RE suffered from radioembolization-induced liver disease (REILD). Pathological increases in bilirubin at 3 months were observed for the whole liver group only (52.3 vs. 18.7 {mu}mol/l, P = 0.012). Total liver volume did not change significantly in either group, but shrinkage of the initially treated hepatic lobe with compensatory hypertrophy of the subsequently treated lobe was observed in the sequential lobar group (P < 0.05). Portal vein diameter increased significantly in whole liver-treated patients only (+17% vs. +6.6%, P = 0.043). Conclusions: Noncirrhotic patients undergoing sequential lobar radioembolization had less hepatic toxicity compared to whole liver embolization. The sequential approach should be the preferred strategy.

  15. Clinical and laboratory toxicity after intra-arterial radioembolization with (90y-microspheres for unresectable liver metastases.

    Directory of Open Access Journals (Sweden)

    Maarten L J Smits

    Full Text Available OBJECTIVE: To investigate clinical and laboratory toxicity in patients with unresectable liver metastases, treated with yttrium-90 radioembolization ((90Y-RE. METHODS: Patients with liver metastases treated with (90Y-RE, between February 1(st 2009 and March 31(st 2012, were included in this study. Clinical toxicity assessment was based on the reporting in patient's charts. Laboratory investigations at baseline and during a four-month follow-up were used to assess laboratory toxicity according to the Common Terminology Criteria for Adverse Events version 4.02. The occurrence of grade 3-4 laboratory toxicity was stratified according to treatment strategy (whole liver treatment in one session versus sequential sessions. Response assessment was performed at the level of target lesions, whole liver and overall response in accordance with RECIST 1.1 at 3- and 6 months post-treatment. Median time to progression (TTP and overall survival were calculated by Kaplan-Meier analysis. RESULTS: A total of 59 patients, with liver metastases from colorectal cancer (n = 30, neuroendocrine tumors (NET (n = 6 and other primary tumors (n = 23 were included. Clinical toxicity after (90Y-RE treatment was confined to grade 1-2 events, predominantly post-embolization symptoms. No grade 3-4 clinical toxicity was observed, whereas laboratory toxicity grade 3-4 was observed in 38% of patients. Whole liver treatment in one session was not associated with increased laboratory toxicity. Three-months disease control rates for target lesions, whole liver and overall response were 35%, 21% and 19% respectively. Median TTP was 6.2 months for target lesions, 3.3 months for the whole liver and 3.0 months for overall response. Median overall survival was 8.9 months. CONCLUSION: The risk of severe complications or grade 3-4 clinical toxicity in patients with liver metastases of various primary tumors undergoing (90Y-RE is low. In contrast, laboratory toxicity grade 3

  16. Development of a dosimetric system for {sup 90}Sr + {sup 90}Y betatherapy applicators; Desenvolvimento de um sistema de dosimetria para aplicadores de betaterapia de {sup 90}Sr + {sup 90}Y

    Energy Technology Data Exchange (ETDEWEB)

    Coelho, Talita Salles

    2010-07-01

    The {sup 90}Sr+{sup 90}Y applicators, used in betatherapy for prevention of keloids and pterigium, are imported and many times their dosimetric features are shown only in an illustrated form by the manufacturers. The exhaustive routine of the medical physicists in the clinic do not make possible the accomplishment of procedures for the confirmation of these parameters. This work presents the development of a methodology for the dosimetry of {sup 90}Sr+{sup 90}Y betatherapy applicators. The Monte Carlo code MCNP5 was used for the simulation of the percentage depth dose curves and dose distribution profiles produced by these applicators. The experimental measurements of the radial and axial radiation attenuation, have been done with a mini-extrapolation chamber, thermoluminescent dosimeters and radiographic films. The experimental results have been compared with the simulated values. Both percentage depth dose curves and the radial dose profiles, the theoretical and the experimental ones, have presented good agreement, which may validate the use of the MCNP5 for these simulations, confirming the viability of the usage of this method in procedures of beta emitter sources dosimetry. (author)

  17. Thermoluminescent dosimetry of beta radiations of {sup 90} Sr/ {sup 90} Y using amorphous ZrO{sub 2}; Dosimetria termoluminiscente de radiaciones beta de {sup 90} Sr/ {sup 90} Y usando ZrO{sub 2} amorfo

    Energy Technology Data Exchange (ETDEWEB)

    Rivera M, T. [CICATA-Legaria, IPN, Legaria Num. 694, 11500 Mexico D.F. (Mexico); Olvera T, L.; Azorin N, J.; Barrera R, M.; Soto E, A.M. [UAM-I, 09340 Mexico D.F. (Mexico)

    2005-07-01

    In this work the results of studying the thermoluminescent properties (Tl) of the zirconium oxide in its amorphous state (ZrO{sub 2}-a) before beta radiations of {sup 90} Sr/ {sup 90} Y are presented. The amorphous powders of the zirconium oxide were synthesized by means of the sol-gel technique. The sol-gel process using alkoxides like precursors, is an efficient method to prepare a matrix of zirconium oxide by hydrolysis - condensation of the precursor to form chains of Zr-H{sub 3} and Zr-O{sub 2}. One of the advantages of this technique is the obtention of gels at low temperatures with very high purity and homogeneity. The powders were characterized by means of thermal analysis and by X-ray diffraction. The powders of ZrO{sub 2}-a, previously irradiated with beta particles of {sup 90} Sr/{sup 90} Y, presented a thermoluminescent curve with two peaks at 150 and 257 C. The dissipation of the information of the one ZrO{sub 2}-a was of 40% the first 2 hours remaining constant the information for the following 30 days. The reproducibility of the information was of {+-} 2.5% in standard deviation. The studied characteristics allow to propose to the amorphous zirconium oxide as thermoluminescent dosemeter for the detection of beta radiation. (Author)

  18. Thermoluminescent dosimetry of beta radiations of {sup 90} Sr/ {sup 90} Y using ZrO{sub 2}: Eu; Dosimetria termoluminiscente de radiaciones beta de {sup 90} Sr/ {sup 90} Y usando ZrO{sub 2}: Eu

    Energy Technology Data Exchange (ETDEWEB)

    Olvera T, L.; Azorin N, J.; Barrera S, M.; Soto E, A.M. [UAM-I, 09340 Mexico D.F. (Mexico); Rivera M, T. [CICATA-IPN, Legaria 694, 11500 Mexico D.F. (Mexico)

    2005-07-01

    In this work the results of studying the thermoluminescent properties (TL) of the doped zirconium oxide with europium (ZrO{sub 2}: Eu{sup 3+}) before beta radiations of {sup 90}Sr/ {sup 90}Y are presented. The powders of ZrO{sub 2}: Eu{sup 3+} were obtained by means of the sol-gel technique and they were characterized by means of thermal analysis and by X-ray diffraction. The powders of ZrO{sub 2}: Eu{sup 3+}, previously irradiated with beta particles of {sup 90}Sr/ {sup 90}Y, presented a thermoluminescent curve with two peaks at 204 and 292 C respectively. The TL response of the ZrO{sub 2}: Eu{sup 3+} as function of the absorbed dose was lineal from 2 Gy up to 90 Gy. The fading of the information of the ZrO{sub 2}: Eu{sup 3+} was of 10% the first 2 hours remaining almost constant the information by the following 30 days. The ZrO{sub 2} doped with the (Eu{sup 3+}) ion it was found more sensitive to the beta radiation that the one of zirconium oxide without doping (ZrO{sub 2}) obtained by the same method. Those studied characteristics allow to propose to the doped zirconium oxide with europium like thermoluminescent dosemeter for the detection of the beta radiation. (Author)

  19. Palmyra Atoll Site 32P 8/17/2006 44-45M

    Data.gov (United States)

    US Fish and Wildlife Service, Department of the Interior — One-meter-square (1 meter x 1 meter) benthic substrate at Palmyra Atoll, site 32P (05 53.796N, 162 07.065W), between 44 and 45 meters along a permanent transect.

  20. Rose Atoll Site 32P 8/2/2004 38-39M

    Data.gov (United States)

    US Fish and Wildlife Service, Department of the Interior — One-meter-square (1 meter x 1 meter) benthic substrate at Rose Atoll, site 32P (14 32.361S, 168 09.430W), between 38 and 39 meters along a permanent transect.

  1. Rose Atoll Site 32P 8/2/2004 42-43M

    Data.gov (United States)

    US Fish and Wildlife Service, Department of the Interior — One-meter-square (1 meter x 1 meter) benthic substrate at Rose Atoll, site 32P (14 32.361S, 168 09.430W), between 42 and 43 meters along a permanent transect.

  2. Rose Atoll Site 32P 2/22/2012 44-45M

    Data.gov (United States)

    US Fish and Wildlife Service, Department of the Interior — One-meter-square (1 meter x 1 meter) benthic substrate at Rose Atoll, site 32P (14 32.361S, 168 09.430W), between 44 and 45 meters along a permanent transect.

  3. Palmyra Atoll Site 32P 8/17/2006 43-44M

    Data.gov (United States)

    US Fish and Wildlife Service, Department of the Interior — One-meter-square (1 meter x 1 meter) benthic substrate at Palmyra Atoll, site 32P (05 53.796N, 162 07.065W), between 43 and 44 meters along a permanent transect.

  4. Palmyra Atoll Site 32P 8/17/2006 26-27M

    Data.gov (United States)

    US Fish and Wildlife Service, Department of the Interior — One-meter-square (1 meter x 1 meter) benthic substrate at Palmyra Atoll, site 32P (05 53.796N, 162 07.065W), between 26 and 27 meters along a permanent transect.

  5. Rose Atoll Site 32P 8/2/2004 11-12M

    Data.gov (United States)

    US Fish and Wildlife Service, Department of the Interior — One-meter-square (1 meter x 1 meter) benthic substrate at Rose Atoll, site 32P (14 32.361S, 168 09.430W), between 11 and 12 meters along a permanent transect.

  6. Palmyra Atoll Site 32P 8/17/2006 41-42M

    Data.gov (United States)

    US Fish and Wildlife Service, Department of the Interior — One-meter-square (1 meter x 1 meter) benthic substrate at Palmyra Atoll, site 32P (05 53.796N, 162 07.065W), between 41 and 42 meters along a permanent transect.

  7. Palmyra Atoll Site 32P 8/17/2006 20-21M

    Data.gov (United States)

    US Fish and Wildlife Service, Department of the Interior — One-meter-square (1 meter x 1 meter) benthic substrate at Palmyra Atoll, site 32P (05 53.796N, 162 07.065W), between 20 and 21 meters along a permanent transect.

  8. Studies on production of high specific activity {sup 99}Mo and {sup 90}Y by Szilard Chalmers reaction

    Energy Technology Data Exchange (ETDEWEB)

    Tomar, B.S.; Steinebach, O.M.; Terpstra, B.E.; Bode, P.; Wolterbeek, H.T. [TU Delft (Netherlands). Section for Radiation and Isotopes for Health

    2010-07-01

    Attempts have been made to use Szilard Chalmers reaction to prepare {sup 99}Mo and {sup 90}Y in high specific activity. Experiments were carried out using irradiation of freshly prepared oxinate complexes of molybdenum and yttrium in the HOR reactor of Reactor Institute at TU Delft. The irradiated target was dissolved in dichloromethane and the radionuclides were separated by solvent extraction into aqueous phase. Detailed investigations on the effect of pH of aqueous solution, irradiation time and target amount was also carried out to optimize the enrichment factor and yield. The highest enrichment factor for {sup 99}Mo was found to be around 200 with a yield close to 30%. In the case of {sup 90}Y, solvent extraction method did not yield high enrichment factors. Slightly higher enrichment factors were achieved with ion exchange method. Studies were also carried out with yttrium oxide nano-powder. Speciation study of {sup 99}Mo in the separated aqueous fraction showed it to be present as {sup 99}MoO{sub 4}{sup 2-} ion. The results appear to be quite promising for large scale production of {sup 99}Mo for medical applications. (orig.)

  9. Design and construction of a prototype for the obtention of {sup 32} P; Diseno y construccion de un prototipo para la obtencion de {sup 32} P

    Energy Technology Data Exchange (ETDEWEB)

    Alanis M, J. [ININ, Departamento de Materiales Radiactivos, 52045 Ocoyoacac, Estado de Mexico (Mexico)

    2003-12-15

    In the National Institute of Nuclear Research (ININ) it was designed, built and proved a prototype to obtain {sup 32}P in form of H{sub 3} {sup 32}PO{sub 4}, starting from irradiated S{alpha}. The beginning of the prototype it is based on a distillation system in dry of the S{alpha} in nitrogen atmosphere, and in the formation of the ion {sup 32}PO{sub 4}{sup 3-} in acid solution. Due to the handling of radioactive material during the process, the prototype is inside a hot cell and it has a cylindrical oven that opens up lengthwise to the half, with controller of temperature and with a system of empty air for to transport reagents and products. The air-vacuum system is provided of filters and traps. The tests showed a recovery from 14 to 15% of the activity obtained during the irradiation. (Author)

  10. Somatostatin-based radiopeptide therapy with [{sup 177}Lu-DOTA]-TOC versus [{sup 90}Y-DOTA]-TOC in neuroendocrine tumours

    Energy Technology Data Exchange (ETDEWEB)

    Romer, A.; Seiler, D.; Brunner, P.; Ng, Q.K.T.; Mueller-Brand, J. [University Hospital Basel, Institute of Nuclear Medicine, Basel (Switzerland); Marincek, N.; Walter, M.A. [University Hospital Basel, Institute of Nuclear Medicine, Basel (Switzerland); University Hospital Bern, Institute of Nuclear Medicine, Bern (Switzerland); Koller, M.T. [University Hospital Basel, Basel Institute for Clinical Epidemiology and Biostatistics, Basel (Switzerland); Maecke, H.R. [University Hospital Basel, Division of Radiochemistry, Basel (Switzerland); Rochlitz, C. [University Hospital Basel, Department of Oncology, Basel (Switzerland); Briel, M. [University Hospital Bern, Institute of Nuclear Medicine, Bern (Switzerland); University Hospital Basel, Basel Institute for Clinical Epidemiology and Biostatistics, Basel (Switzerland); McMaster University, Department of Clinical Epidemiology and Biostatistics, Hamilton (Canada); Schindler, C. [University of Basel, Swiss Tropical and Public Health Institute, Basel (Switzerland)

    2014-02-15

    Somatostatin-based radiopeptide treatment is generally performed using the β-emitting radionuclides {sup 90}Y or {sup 177}Lu. The present study aimed at comparing benefits and harms of both therapeutic approaches. In a comparative cohort study, patients with advanced neuroendocrine tumours underwent repeated cycles of [{sup 90}Y-DOTA]-TOC or [{sup 177}Lu-DOTA]-TOC until progression of disease or permanent adverse events. Multivariable Cox regression and competing risks regression were employed to examine predictors of survival and adverse events for both treatment groups. Overall, 910 patients underwent 1,804 cycles of [{sup 90}Y-DOTA]-TOC and 141 patients underwent 259 cycles of [{sup 177}Lu-DOTA]-TOC. The median survival after [{sup 177}Lu-DOTA]-TOC and after [{sup 90}Y-DOTA]-TOC was comparable (45.5 months versus 35.9 months, hazard ratio 0.91, 95 % confidence interval 0.63-1.30, p = 0.49). Subgroup analyses revealed a significantly longer survival for [{sup 177}Lu-DOTA]-TOC over [{sup 90}Y-DOTA]-TOC in patients with low tumour uptake, solitary lesions and extra-hepatic lesions. The rate of severe transient haematotoxicities was lower after [{sup 177}Lu-DOTA]-TOC treatment (1.4 vs 10.1 %, p = 0.001), while the rate of severe permanent renal toxicities was similar in both treatment groups (9.2 vs 7.8 %, p = 0.32). The present results revealed no difference in median overall survival after [{sup 177}Lu-DOTA]-TOC and [{sup 90}Y-DOTA]-TOC. Furthermore, [{sup 177}Lu-DOTA]-TOC was less haematotoxic than [{sup 90}Y-DOTA]-TOC. (orig.)

  11. Rapid determination of {sup 90}Sr impurities in freshly 'generator eluted'{sup 90}Y for radiopharmaceutical preparation

    Energy Technology Data Exchange (ETDEWEB)

    Bonardi, Mauro L. [LASA, Universita degli Studi di Milano and INFN-Milano, via F.lli Cervi 201, I-20090 Segrate, Milano (Italy); Martano, Luigi [Division of Nuclear Medicine, European Institute of Oncology, via G. Ripamonti 435, I-20141 Milano (Italy); Groppi, Flavia [LASA, Universita degli Studi di Milano and INFN-Milano, via F.lli Cervi 201, I-20090 Segrate, Milano (Italy); Chinol, Marco [Division of Nuclear Medicine, European Institute of Oncology, via G. Ripamonti 435, I-20141 Milano (Italy)], E-mail: marco.chinol@ieo.it

    2009-10-15

    {sup 90}Y is one of the most useful radionuclides for radioimmunotherapeutic applications and has a half-life (t{sub 1/2}=64.14 h) suitable for most therapeutic applications, beta particles of high energy and decays to a stable daughter. It is significant that {sup 90}Y is available conveniently and inexpensively from a radionuclide 'generator' by decay of its parent, {sup 90}Sr. Nevertheless, current and planned clinical applications with [{sup 90}Y] labelled compounds employ activity levels that cannot be readily obtained from an in-house generator, but from commercial sources. We have evaluated Eichrom's Sr-resin, either as an 'in-house' generator or as a fast QC method for analysis of {sup 90}Y solutions. In particular, for the development as a generator, we investigated the percentage of the radio-Sr in the first 8 M HNO{sub 3} eluate: in this fraction the concentration of {sup 90}Sr must be smaller than 10{sup -5}% (recommendations of the International Commission on Radiological Protection). For evaluation as a rapid QC method, we analyzed the concentration of {sup 90}Y in all the fractions containing 'only' radio-Sr: {sup 90}Y should not be present in these eluates. After the collection of {beta}{sup -} and {gamma} spectra and analysis of them, we concluded that commercial Sr-resin minicolumn cannot give us the results expected; we developed an in-house system loaded with 4 mL of Sr-resin which gave better results as a generator and a rapid QC method.

  12. Molecular response assessed by {sup 68}Ga-DOTANOC and survival after {sup 90}Y microsphere therapy in patients with liver metastases from neuroendocrine tumours

    Energy Technology Data Exchange (ETDEWEB)

    Filippi, Luca; Salvatori, Rita; Bagni, Oreste [Santa Maria Goretti Hospital, Department of Nuclear Medicine, Latina (Italy); Scopinaro, Francesco [Sant' Andrea Hospital, Department of Nuclear Medicine, Rome (Italy); Pelle, Giuseppe; Cianni, Roberto [Santa Maria Goretti Hospital, Department of Interventional Radiology, Latina (Italy); Schillaci, Orazio [University Tor Vergata, Department of Biomedicine and Prevention, Rome (Italy)

    2016-03-15

    We investigated the prognostic role of {sup 68}Ga-DOTANOC in patients affected by hepatic metastases from neuroendocrine tumours (NET) undergoing {sup 90}Y radioembolization ({sup 90}Y-RE). A group of 15 consecutive patients with unresectable NET liver metastases underwent {sup 68}Ga-DOTANOC PET at baseline and 6 weeks after {sup 90}Y-RE. Molecular response was defined as a reduction of >50 % in the tumour-to-spleen ratio (ΔT/S). The patients were divided into two groups (responders with ΔT/S >50 % and nonresponders with ΔT/S <50 %) Patients were followed up by imaging and laboratory tests every 3 months until death or for at least 36 months following {sup 90}Y-RE. Statistical analysis was performed to identify factors predicting overall survival (OS) and progression-free survival (PFS). A decrease in T/S ratio was seen in all patients on {sup 68}Ga-DOTANOC PET scans performed after {sup 90}Y-RE. Nine patients were classified as responders and six as nonresponders. The mean OS in all patients was 31.0 months. Responders had a significantly (p < 0.001) longer OS (mean 36.0 ± 2.5 months) and PFS (mean 29.7 ± 3.4 months) than nonresponders. In a multivariate analysis, none of the other examined variables including age, unilobar vs. bilobar locations, bilirubin levels, radiological response or the presence of extrahepatic disease significantly predicted patient outcome. Molecular response assessed with {sup 68}Ga-DOTANOC PET might be a useful predictor of survival in patients affected by NET liver metastases treated with {sup 90}Y-RE. (orig.)

  13. Electrochemical separation of 90-yttrium in the electrochemical 90Sr/90Y generator and its use for radiolabelling of DOTA-conjugated somatostatin analog [DOTA0, Tyr3] octreotate

    Directory of Open Access Journals (Sweden)

    Petrović Đorđe Ž.

    2012-01-01

    Full Text Available Radiopharmaceuticals based on 90Y are widely used in the treatment of malignant deseases. In order to meet the requirements for their future application, a 90Sr/90Y generator was developed and 90Y eluted from this locally produced generator was used for the radiolabelling of the DOTA-conjugated somatostatin analog [DOTA0,Tyr3] octreotate and the preparation of [90Y-DOTA0,Tyr3] octreotate (90Y-DOTATATE for peptide receptore radionuclide therapy. 90Sr/90Y generator was based on the electrochemical separation of 90Y from 90Sr in a two-cycle electrolysis procedure. Three electrode cells were used to perform both electrolyses. In both cycles, working electrodes were kept on constant potential. The pH of the solution was adjusted to 2.7 of the value before the electrolyses. The radionuclidic purity of the 90Y solution was analysed by ITLC and extraction paper chromatography. The labelling of peptide (100 mg DOTATATE with 90YCl3 was performed at 95°C for 30 minutes. Radiochemical purity was determined by HPLC and chromatographic separation, using a solid SepPak C-18 column. Results obtained confirmed the efficiency of our electrochemical separation technique and quality control methods for 90Y. The achieved efficiency of the 90Sr/90Y generator above 96% of the theoretical value represents a good basis for the further development of this generator. The labelling of the DOTATATE with 90Y exhibited a high efficiency, too: there was less than 1% of 90Y3+in the 90Y-DOTATATE.

  14. Thin CaSO{sub 4}:Dy thermoluminescent dosimeters for calibration of {sup 90}Sr+{sup 90}Y applicators

    Energy Technology Data Exchange (ETDEWEB)

    Antonio, Patricia L. [Instituto de Pesquisas Energeticas e Nucleares, Comissao Nacional de Energia Nuclear, Av. Prof. Lineu Prestes, 2242, 05508-000, Sao Paulo, SP (Brazil); Oliveira, Mercia L. [Centro Regional de Ciencias Nucleares, Comissao Nacional de Energia Nuclear, Av. Prof. Luis Freire, 200, 50740-540, Recife, PE (Brazil); Caldas, Linda V.E., E-mail: lcaldas@ipen.br [Instituto de Pesquisas Energeticas e Nucleares, Comissao Nacional de Energia Nuclear, Av. Prof. Lineu Prestes, 2242, 05508-000, Sao Paulo, SP (Brazil)

    2012-04-15

    Clinical applicators are used in brachytherapy to treat superficial lesions of skin and eye. They should be periodically calibrated according to quality control programs and international recommendations. Thin CaSO{sub 4}:Dy thermoluminescent dosimeters were used to calibrate various applicators with a dermatological applicator as a reference. The obtained absorbed dose rates were compared with those quoted in their calibration certificates. Depth-dose curves were constructed for all the applicators. A mail dosimetry system was developed for calibration of clinical applicators. - Highlights: Black-Right-Pointing-Pointer Absorbed dose rates were obtained for {sup 90}Sr+{sup 90}Y applicators using CaSO{sub 4}:Dy pellets. Black-Right-Pointing-Pointer Depth-dose curves were obtained for all studied applicators. Black-Right-Pointing-Pointer CaSO{sub 4}:Dy dosimeters presented satisfactory results in all realized tests. Black-Right-Pointing-Pointer A mail dosimetry system was developed with CaSO{sub 4}:Dy pellets.

  15. Activity measurement of /sup 33/P and /sup 32/P radionuclide mixture

    Energy Technology Data Exchange (ETDEWEB)

    Hanker, I.; Kansky, Z.

    1984-04-01

    The possibilities are briefly summed up of measuring mixtures of /sup 33/P and /sup 32/P with special regard to the method of simultaneous determination of both radionuclides in a liquid scintillator. This method was experimentally tested for special detection sensitivity and intended special applications in plant physiology and biochemistry using a dioxane scintillator (SLD-31, Spolana Neratovice, CSSR) and a Packard Tri-Carb 300 C, USA. The method gave erroneous results. The main cause of the errors in measurements of the /sup 33/P and /sup 32/P mixture in the SLD-31 was the adsorption of radionuclides on the inner wall of glass tubes. This phenomenon is not accompanied by changes in the quenching index. However, the effectiveness of measurement dropped and the relative contribution of the spectra of the two radionuclides changed with the time following sample preparation. The said effects were removed by adding 0.4% silicon dioxide (Cab-O-Sil M5, Serva) to the liquid scintillator.

  16. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.

    NARCIS (Netherlands)

    Brouwers, A.H.; Eerd-Vismale, J.E.M. van; Frielink, C.; Oosterwijk, E.; Oyen, W.J.G.; Corstens, F.H.M.; Boerman, O.C.

    2004-01-01

    Radioimmunotherapy (RIT) can be performed with various radionuclides. We tested the stability, biodistribution, and therapeutic efficacy of various radioimmunoconjugates ((131)I, (88/90)Y, (177)Lu, and (186)Re) of chimeric antirenal cell cancer monoclonal antibody G250 (mAb cG250) in nude mice with

  17. Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study

    Directory of Open Access Journals (Sweden)

    Marincek Nicolas

    2013-01-01

    Full Text Available Abstract Background We describe the long-term outcome after clinical introduction and dose escalation of somatostatin receptor targeted therapy with [90Y-DOTA]-TOC in patients with metastasized neuroendocrine tumors. Methods In a clinical phase I dose escalation study we treated patients with increasing [90Y-DOTA]-TOC activities. Multivariable Cox regression and competing risk regression were used to compare efficacy and toxicities of the different dosage protocols. Results Overall, 359 patients were recruited; 60 patients were enrolled for low dose (median: 2.4 GBq/cycle, range 0.9-7.8 GBq/cycle, 77 patients were enrolled for intermediate dose (median: 3.3 GBq/cycle, range: 2.0-7.4 GBq/cycle and 222 patients were enrolled for high dose (median: 6.7 GBq/cycle, range: 3.7-8.1 GBq/cycle [90Y-DOTA]-TOC treatment. The incidences of hematotoxicities grade 1–4 were 65.0%, 64.9% and 74.8%; the incidences of grade 4/5 kidney toxicities were 8.4%, 6.5% and 14.0%, and the median survival was 39 (range: 1–158 months, 34 (range: 1–118 months and 29 (range: 1–113 months. The high dose protocol was associated with an increased risk of kidney toxicity (Hazard Ratio: 3.12 (1.13-8.59 vs. intermediate dose, p = 0.03 and a shorter overall survival (Hazard Ratio: 2.50 (1.08-5.79 vs. low dose, p = 0.03. Conclusions Increasing [90Y-DOTA]-TOC activities may be associated with increasing hematological toxicities. The dose related hematotoxicity profile of [90Y-DOTA]-TOC could facilitate tailoring [90Y-DOTA]-TOC in patients with preexisting hematotoxicities. The results of the long-term outcome suggest that fractionated [90Y-DOTA]-TOC treatment might allow to reduce renal toxicity and to improve overall survival. (ClinicalTrials.gov number NCT00978211.

  18. Comparison of yttrium and indium complexes of DOTA-BA and DOTA-MBA: models for (90)Y- and (111)In-labeled DOTA-biomolecule conjugates.

    Science.gov (United States)

    Liu, Shuang; Pietryka, John; Ellars, Charles E; Edwards, D Scott

    2002-01-01

    Yttrium and indium complexes of 1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl)-1-cyclododecylacetylbenzylamine (DOTA-BA) and 1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl)-1-cyclododecylacetyl-R-(+)-alpha-methylbenzylamine (DOTA-MBA) were prepared in order to study solution structures of (90)Y- and (111)In-labeled DOTA-biomolecule conjugates. (90)Y and (111)In complexes M(L) (M = (90)Y and (111)In; L = DOTA-BA and DOTA-MBA) were prepared from the reaction of MCl(3) with DOTA-BA and DOTA-MBA, respectively, in ammonium acetate buffer. A reverse phase HPLC method revealed that both (90)Y and (111)In complexes show only one radiometric peak in their radio-HPLC chromatograms. It was also found that (111)In(DOTA-BA) and (111)In(DOTA-MBA) are more hydrophilic than their corresponding (90)Y analogues, suggesting different coordination spheres in (111)In and (90)Y complexes of the same DOTA conjugate. Complexes M(L) (M = Y and In; L = DOTA-BA and DOTA-MBA) were prepared and characterized by HPLC, LC-MS, and NMR ((1)H and (13)C) methods. The HPLC concordance experiments for (90)Y(DOTA-MBA)/Y(DOTA-MBA) and (111)In(DOTA-MBA)/In(DOTA-MBA) show that the same complex is prepared at both tracer and macroscopic levels. The NMR data ((1)H and (13)C) clearly demonstrates that Y(DOTA-BA) and Y(DOTA-MBA) exist in solution as one predominant isomer. VT NMR data ((1)H and (13)C) show that In(DOTA-BA) and In(DOTA-MBA) are fluxional at room temperature while Y(DOTA-BA) and Y(DOTA-MBA) become fluxional only at elevated temperatures. The fluxionality of these complexes is due to rapid rotation of acetate/acetamide chelating arms and inversion of ethylenic groups of the macrocyclic ring.

  19. Treatment with tandem [{sup 90}Y]DOTA-TATE and [{sup 177}Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy

    Energy Technology Data Exchange (ETDEWEB)

    Seregni, E.; Maccauro, M.; Chiesa, C.; Pascali, C.; Lorenzoni, A.; Bogni, A.; Coliva, A.; Bombardieri, E. [Fondazione IRCCS Istituto Nazionale Tumori, Nuclear Medicine, Milan (Italy); Mariani, L.; Vullo, S.Lo [Fondazione IRCCS Istituto Nazionale Tumori, Statistics and Biometry Unit, Milan (Italy); Mazzaferro, V. [Fondazione IRCCS Istituto Nazionale Tumori, Surgery and Liver Transplantation, Milan (Italy); De Braud, F.; Buzzoni, R. [Fondazione IRCCS Istituto Nazionale Tumori, Medical Oncology, Milan (Italy); Milione, M. [Fondazione IRCCS Istituto Nazionale Tumori, Pathology Department, Milan (Italy)

    2014-02-15

    Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues has been demonstrated to be an effective therapeutic option in patients with disseminated neuroendocrine tumours (NET). Treatment with tandem [{sup 90}Y]DOTA-TATE and [{sup 177}Lu]DOTA-TATE may improve the efficacy of PRRT without increasing the toxicity. In a phase II study we evaluated the feasibility of combined PPRT with a high-energy beta emitter ({sup 90}Y) and a medium-energy beta/gamma emitter ({sup 177}Lu) in patients with metastatic NET refractory to conventional therapy. A group of 26 patients with metastatic NET were treated with four therapeutic cycles of alternating [{sup 177}Lu]DOTA-TATE (5.55 GBq) and [{sup 90}Y]DOTA-TATE (2.6 GBq). A dosimetric evaluation was carried out after administration of [{sup 177}Lu]DOTA-TATE to calculate the absorbed doses in healthy organs. The acute and long-term toxicities of repeated treatment were analysed. PRRT efficacy was evaluated according to RECIST. Administration of tandem [{sup 90}Y]DOTA-TATE and [{sup 177}Lu]DOTA-TATE induced objective responses in 42.3 % of patients with metastatic NET with a median progression-free survival longer than 24 months. Of patients with pretreatment carcinoid syndrome, 90 % showed a symptomatic response or a reduction in tumour-associated pain. The cumulative biologically effective doses (BED) were below the toxicity limit in the majority of patients, in the absence of renal function impairment The results of our study indicates that combined [{sup 90}Y]DOTA-TATE and [{sup 177}Lu]DOTA-TATE therapy is a feasible and effective therapeutic option in NET refractory to conventional therapy. Furthermore, the absence of kidney damage and the evaluated cumulative BEDs suggest that increasing the number of tandem administrations is an interesting approach. (orig.)

  20. Selective intraarterial radionuclide therapy with yttrium-90 (Y-90 microspheres for hepatic neuroendocrine metastases: Initial experience at a single center

    Directory of Open Access Journals (Sweden)

    Arslan Nuri

    2011-01-01

    Full Text Available Background/Aim. Selective intraarterial radionuclide therapy (SIRT with Yttrium-90 (Y-90 microspheres is also known as radioembolization and delivers high doses of radiation to hepatic tumors with minimum healthy liver exposure. The aim of this study was to present our preliminary experience in the role of liver directed radiotherapy with Y-90 microspheres for the treatment of unresectable hepatic metastases from neuroendocrine tumors (NET. Methods. The results of SIRT in 10 patients (5 males, 5 females; mean age 48.7 years; age range 24-73 years with metastatic liver disease from NETs during the period from April 2008 through August 2010 were reviewed. All patients had meticulous pre- and post-imaging studies as a part of their work-up procedure, as well as serologic tests of liver function to determine the extent of liver function damage. The patients who were eligible for SIRT had pretreatment visceral angiography to define and occlude non-target arteries. Results. The mean ± SD administered SIR-Spheres® activity was 1.49 ± 0.42 GBq (range 0.72-2.21 GBq in all the patients. These treatments delivered a dose of 99.73 ± 66.36 Gy (range 49- 420.8 Gy to the target tumors. The estimated dose to the lungs and normal liver was 4.45 ± 1.95 Gy (range 2.4-8.5 Gy and 26.73 ± 14.19 Gy (range 5-58.9 Gy, respectively. Overall response rate of 90% and patient tolerance was satisfactory for most patients. Conclusion. From our limited experience, we can conclude that SIRT with Y-90 microspheres is a safe and efficacious treatment option for patients with liver metastasis of NET without any serious side effects.

  1. Evaluation of EGS4/PRESTA multiple-scattering algorithms for 90Sr/90Y intravascular brachytherapy dosimetry.

    Science.gov (United States)

    Wang, R; Li, X A; Yu, C X

    2000-08-01

    The purpose of this work is to evaluate the EGS4/PRESTA electron multiple-scattering (MS) algorithms for dose calculation in intravascular brachytherapy (IVBT) using a 90Sr/90Y source. The small source size and the small volume of interest in IVBT require very fine spatial resolution, which may break down the constraints of Molière's MS theory as implemented in EGS4. The theory is accurate only when the electron step sizes are large enough to allow the number of collisions omega0 to be much greater than e = 2.7183. When step sizes are too small to allow at least 2.7183 collisions, as may be necessitated by the fine geometry, the algorithm may switch off MS, producing dosimetric artefacts. This study showed that switching off MS could produce a dose deviation of up to 6% when the half-thickness (d/2) of the dose scoring region is comparable with the Moliere minimum step size (t(min) = 2.7183). The effect of switching off MS is negligible if d/2 > t(min) For the case of omega0 > e, if the electron step sizes are chosen to allow five to 40 collisions, with increasing step size, the doses surrounding the source increase and the error decreases. On the other hand, when larger step sizes are chosen, the dose calculation voxel size must also be increased in order for the calculations to converge. A good compromise between accuracy and applicability for IVBT simulation can be made, if the thickness of the scoring region is 0.1 mm and the electron step sizes are in the range allowing 10 to 30 collisions.

  2. {sup 99m}Tc-labelled macroaggregated albumin (MAA) scintigraphy for planning treatment with {sup 90}Y microspheres

    Energy Technology Data Exchange (ETDEWEB)

    Lambert, Bieke; Mertens, Jeroen; Stienaers, Steven; D' Asseler, Yves [Ghent University Hospital, Department of Nuclear Medicine, Ghent (Belgium); Sturm, Emiel J.; Defreyne, Luc [Ghent University Hospital, Department of Interventional Radiology, Ghent (Belgium)

    2010-12-15

    {sup 90}Y microspheres are used for intra-arterial treatment of liver tumours. In the patient preparation, a hepatic angiogram is performed and all arteries that could transport microspheres from the targeted liver vasculature to extrahepatic organs are blocked. {sup 99m}Tc-labelled macroaggregated albumin (MAA) is injected intra-arterially to simulate the treatment and whole-body scintigraphy and single photon emission computed tomography (SPECT) of the abdomen are performed. Various aspects of lung shunt fraction (LSF) estimation were studied: interobserver and intrapatient variability, influence of scan quality and underlying disease. Secondly, the interobserver variability in reading the MAA SPECT of the abdomen was investigated. We reviewed 90 whole-body scans and 20 SPECT scans performed at our institution. Readers were blinded to each other's findings. Scoring the scan quality was based on the visualization of tracer degradation. The mean difference in LSF between the readers was 1%. In 1 of 23 patients who underwent repeated MAA injections a marked change in LSF was observed. No significant differences in LSF were recorded for primary versus secondary liver tumours. There was a correlation between scan quality and LSF, suggesting that low scan quality leads to overestimation of the LSF. Concordant results in ruling out the presence of extrahepatic tracer deposition were reached in 17 of 20 scans (85%). Interobserver and intrapatient variability in LSF calculation was limited. LSF was clearly dependent on scan quality. The underlying disease had no significant impact on the LSF. Interobserver variability for reading the MAA SPECT scans was acceptable. (orig.)

  3. Comparison of /sup 32/P therapy and sequential hemibody irradiation (HBI) for bony metastases as methods of whole body irradiation

    Energy Technology Data Exchange (ETDEWEB)

    Aziz, H.; Choi, K.; Sohn, C.; Yaes, R.; Rotman, M.

    1986-06-01

    We report a retrospective study of 15 patients with prostate carcinoma and diffuse bone metastases treated with sodium /sup 32/P for palliation of pain at Downstate Medical Center and Kings County Hospital from 1973 to 1978. The response rates, duration of response, and toxicities are compared with those of other series of patients treated with /sup 32/P and with sequential hemibody irradiation. The response rates and duration of response are similar with both modalities ranging from 58 to 95% with a duration of 3.3 to 6 months with /sup 32/P and from 75 to 86% with a median duration of 5.5 months with hemibody irradiation. There are significant differences in the patterns of response and in the toxicities of the two treatment methods. Both methods cause significant bone marrow depression. Acute radiation syndrome, radiation pneumonitis, and alopecia are seen with sequential hemibody irradiation and not with /sup 32/P, but their incidence can be reduced by careful treatment planning. Hemibody irradiation can provide pain relief within 24 to 48 h, while /sup 32/P may produce an initial exacerbation of pain. Lower hemibody irradiation alone is less toxic than either upper hemibody irradiation or /sup 32/P treatment.

  4. /sup 32/P studies into phosphate metabolism of cattle with metabolic acidosis

    Energy Technology Data Exchange (ETDEWEB)

    Lachmann, G.; Pfueller, K.; Bier, H.; Mueller, D.; Rummel, G. (Karl-Marx-Universitaet, Leipzig (German Democratic Republic). Sektion Tierproduktion und Veterinaermedizin)

    1984-03-01

    Phosphorus balance and intraveneous injection of /sup 32/P into three bulls showed that hay diet was followed by excretion of only small amounts of phosphorus in the urine (1.5 g/die), with renal net base excretion being 35 mmol/l. Yet, the amounts of phosphorus excretion in urine were high (16.3 g/die) in conditions of metabolic acidosis due to cereal diet, with renal net acid excretion being 78 mmol/l. No negative balance was observed during three weeks of acidosis, in spite of high phosphaturia, since in cattle with acidosis the increase in renal excretion was offsetted by depression of endogenic fecal phosphorus. Endogenic fecal phosphorus accounted for 43% of phosphorus intake with hay diet but only for 7% with cereal diet. Hence, hyperphosphaturia is ruled out as a cause for the genesis of osteopathies in a condition of metabolic acidosis.

  5. The role of colloid 32p synoviorthesis in treatment of haemophilic arthropathy

    Directory of Open Access Journals (Sweden)

    Mortazavi SMJ

    2010-09-01

    Full Text Available "nBackground: Radioactive synoviorthesis by injection of safe radioisotopes into the joints affected to chronic arthritis is accounted as a novel method to treat haemophilic arthropathy. The main goal of this therapy would be decrease in frequency of hemarthrosis and consumption of coagulation factors. In this study we assessed the effect of radioactive synoviorthesis on the frequency of hemarthrosis, factor consumption and other related parameters. "n "nMethods: In an interventional study in Imam Khomeini Hospital in Tehran, Iran, after meeting of inclusion criteria and taking written consent, colloid 32p radiosynovectomy was performed for 56 joints with haemophilic arthropathy. After local anesthesia of injection site, one mci of 32P for large joints (knee and 0.5 mci for small joints (ankle and elbow was injected, respectively. Half of these doses were considered for children (age <12 years. "n "nResults: The mean of age was 16.78 year old (Range: 2.5-36; SD: 7.46 and 98.2% of cases were male. Injected were knee 80.35%, ankle 12.5%, and elbow 7%. The mean of follow-up was 43.63 months (range: 3-102 that at the end, the result was 62% decrease in frequency of hemarthrosis (p=0.0001 and 84% decrease in factor consumption (p=0.0001. However, the involvement of other (non injected joints during follow-up could lower the decrease of mean of total factor consumption."n "nConclusions: Radioactive synoviorthesis can be a cost-effective alternative to decrease hemarthrosis and factor consumption in haemophilic arthropathy.

  6. Phosphorus use efficiency by cotton measured through 32P isotope technique

    Science.gov (United States)

    Marcante, N. C.; Muraoka, T.; Camacho, M. A.; César, F. R. C. F.; Bruno, I. P.

    2012-04-01

    Deficiency of phosphorus (P) is the major limitation to agricultural production in the Brazilian Savannah (Cerrado), which is naturally poor in this nutrient. Most of the P applied by fertilizer in Cerrado soils are converted into low solubility forms and can not be easily absorbed by plants. This occurs for characteristics of adsorption, conditioned by the predominance of low pH and aluminum and iron oxides in the clay fraction. The development of genotypes and cultivars with greater capacity to grow up in soils with low P availability ('phosphorus efficiency') is interesting to improve the agriculture in these areas in a sustainable way. Cotton (Gossypium spp.) is the main product for the fibers used nationally and globally in the textile chain. This study aim was to evaluate the efficiency of absorption and utilization of P by cotton cultivars/genotypes grown in Cerrado soil by the isotopic dilution technique. The soil classified as Ultisols, was labeled with the radioisotope 32P.The experiment was conducted in a greenhouse in a completely randomized design factorial 2 x 17. Factors were considered two levels of P (insufficient = 20 mg kg-1 and sufficient = 120 mg kg-1) and 17 genetic materials of cotton recommended for Cerrado region. Phosphorus levels influenced significantly the shoots dry matter production, the P content and accumulation, the 32P specific activity, the L value and L value less seed cotton P by cultivars and genotypes. The hierarchical clustering analysis used to verify the similarities between the cultivars and genotypes of cotton, classified them into internally homogeneous groups and heterogeneous between different groups. Cultivars FMT 523, FM 910 and CNPA GO 2043 were the most responsive to phosphate fertilizer in sufficient level of P, while the genotype Barbadense 01 and cultivars FM 966LL, IPR Jataí, BRS Aroeira and BRS Buriti were most efficient absorbing P in soils with insufficient level.

  7. Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90 microspheres for unresectable primary and metastatic liver tumors

    Directory of Open Access Journals (Sweden)

    Ozkan Elgin

    2011-08-01

    Full Text Available Abstract Background The aim of this study was to evaluate the success of selective intraarterial radionuclide therapy (SIRT with Yttrium-90 (Y-90 microspheres in liver metastases of different tumors. We also interpreted the contribution of SIRT to survival times according to responder- non responder and hepatic- extra hepatic disease. Methods The clinical and follow-up data of 124 patients who were referred to our department for SIRT between June 2006 and October 2010 were evaluated retrospectively. SIRT has been applied to 78 patients who were suitable for treatment. All the patients had primary liver tumor or unresectable liver metastasis of different malignancies. The treatment was repeated at least one more time in 5 patients to the same or other lobes. Metabolic treatment response evaluated by fluorine-18 fluorodeoxyglucose (F18-FDG positron emission tomography/computed tomography (PET/CT in the 6th week after treatment. F18-FDG PET/CT was repeated in per six weeks periods. The response criterion had been described as at least 20% decrease of SUV value. Also in patients with neuroendocrine tumor serial Gallium-68 (Ga-68 PET/CT was used for evaluation of response. Patients were divided into 2 groups according to their treatment response. Results 68 patients received treatment for the right lobe, seven patients received treatment for the left lobe and 3 patients for both lobes. The mean treatment dose was estimated at 1.62 GBq. In the evaluation of treatment response; 43(55% patients were responder (R and 35 (45% patients were non-responder (NR in the sixth week F18-FDG PET/CT. Mean pretreatment SUVmax value of R group was 11.6 and NR group was 10.7. While only 11 (31% out of 35 NR patients had H disease, 30 (69% out of 43 R patients had H disease (p Conclusions SIRT is a useful treatment method which can contribute to the lengthening of survival times in patients with primary or metastatic unresectable liver malignancies. Also F18-FDG PET

  8. Optimization of energy window for {sup 90}Y bremsstrahlung SPECT imaging for detection tasks using the ideal observer with model-mismatch

    Energy Technology Data Exchange (ETDEWEB)

    Rong Xing; Ghaly, Michael; Frey, Eric C. [Department of Radiology, Johns Hopkins University, Baltimore, Maryland 21287-0859 (United States)

    2013-06-15

    Purpose: In yttrium-90 ({sup 90}Y) microsphere brachytherapy (radioembolization) of unresectable liver cancer, posttherapy {sup 90}Y bremsstrahlung single photon emission computed tomography (SPECT) has been used to document the distribution of microspheres in the patient and to help predict potential side effects. The energy window used during projection acquisition can have a significant effect on image quality. Thus, using an optimal energy window is desirable. However, there has been great variability in the choice of energy window due to the continuous and broad energy distribution of {sup 90}Y bremsstrahlung photons. The area under the receiver operating characteristic curve (AUC) for the ideal observer (IO) is a widely used figure of merit (FOM) for optimizing the imaging system for detection tasks. The IO implicitly assumes a perfect model of the image formation process. However, for {sup 90}Y bremsstrahlung SPECT there can be substantial model-mismatch (i.e., difference between the actual image formation process and the model of it assumed in reconstruction), and the amount of the model-mismatch depends on the energy window. It is thus important to account for the degradation of the observer performance due to model-mismatch in the optimization of the energy window. The purpose of this paper is to optimize the energy window for {sup 90}Y bremsstrahlung SPECT for a detection task while taking into account the effects of the model-mismatch. Methods: An observer, termed the ideal observer with model-mismatch (IO-MM), has been proposed previously to account for the effects of the model-mismatch on IO performance. In this work, the AUC for the IO-MM was used as the FOM for the optimization. To provide a clinically realistic object model and imaging simulation, the authors used a background-known-statistically and signal-known-statistically task. The background was modeled as multiple compartments in the liver with activity parameters independently following a

  9. Sustained safety and efficacy of extended-shelf-life {sup 90}Y glass microspheres: long-term follow-up in a 134-patient cohort

    Energy Technology Data Exchange (ETDEWEB)

    Lewandowski, Robert J.; Minocha, Jeet; Memon, Khairuddin; Riaz, Ahsun; Gates, Vanessa L.; Ryu, Robert K.; Sato, Kent T.; Omary, Reed; Salem, Riad [Northwestern University, Department of Radiology, Chicago, IL (United States)

    2014-03-15

    To validate our initial pilot study and confirm sustained safety and tumor response of extended-shelf-life {sup 90}Y glass microspheres. We hypothesized that for the same planned tissue dose, the increase in number of glass microspheres (decayed to the second week of their allowable shelf-life) administered for the same absorbed dose would result in better tumor distribution of the microspheres without causing additional adverse events. Between June 2007 and January 2010, 134 patients underwent radioembolization with extended-shelf-life {sup 90}Y glass microspheres; data from 84 new patients were combined with data from our 50-patient pilot study cohort. Baseline and follow-up imaging and laboratory data were obtained 1 and 3 months after therapy and every 3 months thereafter. Clinical and biochemical toxicities were prospectively captured and categorized according to the Common Terminology Criteria. Response in the index lesion was assessed using WHO and EASL guidelines. The mean delivered radiation dose was 123 Gy to the target liver tissue. The mean increase in number of microspheres with this approach compared to standard {sup 90}Y glass microsphere dosimetry was 103 %, corresponding to an increase from 3.84 to 7.78 million microspheres. Clinical toxicities included fatigue (89 patients, 66 %), abdominal pain (49 patients, 36.6 %), and nausea/vomiting (25 patients, 18.7 %). Grade 3/4 bilirubin toxicity was seen in three patients (2 %). Two (1 %) of the initial 50-patient cohort showed gastroduodenal ulcers; gastroduodenal ulcers were not seen in any of the subsequent 84 patients. According to WHO and EASL guidelines, response rates were 48 % and 57 %, respectively, and 21 % demonstrated a complete EASL response. This study showed sustained safety and efficacy of extended-shelf-life {sup 90}Y glass microspheres in a larger, 134-patient cohort. The increase in number of microspheres administered theoretically resulted in better tumor distribution of the

  10. 90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma.

    Science.gov (United States)

    Janik, John E; Morris, John C; O'Mahony, Deirdre; Pittaluga, Stefania; Jaffe, Elaine S; Redon, Christophe E; Bonner, William M; Brechbiel, Martin W; Paik, Chang H; Whatley, Millie; Chen, Clara; Lee, Jae-Ho; Fleisher, Thomas A; Brown, Maggie; White, Jeffrey D; Stewart, Donn M; Fioravanti, Suzanne; Lee, Cathryn C; Goldman, Carolyn K; Bryant, Bonita R; Junghans, Richard P; Carrasquillo, Jorge A; Worthy, Tat'Yana; Corcoran, Erin; Conlon, Kevin C; Waldmann, Thomas A

    2015-10-20

    Despite significant advances in the treatment of Hodgkin's lymphoma (HL), a significant proportion of patients will not respond or will subsequently relapse. We identified CD25, the IL-2 receptor alpha subunit, as a favorable target for systemic radioimmunotherapy of HL. The scientific basis for the clinical trial was that, although most normal cells with exception of Treg cells do not express CD25, it is expressed by a minority of Reed-Sternberg cells and by most polyclonal T cells rosetting around Reed-Sternberg cells. Forty-six patients with refractory and relapsed HL were evaluated with up to seven i.v. infusions of the radiolabeled anti-CD25 antibody (90)Y-daclizumab. (90)Y provides strong β emissions that kill tumor cells at a distance by a crossfire effect. In 46 evaluable HL patients treated with (90)Y-daclizumab there were 14 complete responses and nine partial responses; 14 patients had stable disease, and nine progressed. Responses were observed both in patients whose Reed-Sternberg cells expressed CD25 and in those whose neoplastic cells were CD25(-) provided that associated rosetting T cells expressed CD25. As assessed using phosphorylated H2AX (γ-H2AX) as a bioindicator of the effects of radiation exposure, predominantly nonmalignant cells in the tumor microenvironment manifested DNA damage, as reflected by increased expression of γ-H2AX. Toxicities were transient bone-marrow suppression and myelodysplastic syndrome in six patients who had not been evaluated with bone-marrow karyotype analyses before therapy. In conclusion, repeated (90)Y-daclizumab infusions directed predominantly toward nonmalignant T cells rosetting around Reed-Sternberg cells provided meaningful therapy for select HL patients.

  11. Synoviorthesis with colloidal /sup 32/P chromic phosphate for hemophilic arthropathy: clinical follow-up

    Energy Technology Data Exchange (ETDEWEB)

    Rivard, G.E.; Girard, M.; Lamarre, C.; Jutras, M.; Danais, S.; Guay, J.P.; Belanger, R.D.

    1985-11-01

    Thirty-one synoviortheses were performed in 22 joints of 14 hemophilic patients (aged 12 to 28 years) with chronic synovitis and for whom conventional treatments were considered ineffective. Except for patients with inhibitors, conventional treatments included three to six months of adequate prophylactic therapy with the missing coagulation factors, intensive physiotherapy and, when indicated, antiinflammatory agents and orthosis. Colloidal /sup 32/P chromic phosphate was injected intraarticularly in doses of 1.0 mCi for knees and of 0.5 mCi for the other joints. Time of follow-up ranged from two to five years. Frequency and importance of bleeding decreased in all patients. Effect on range of motion was best in knees. In elbows, flexion-extension was improved in four cases, unchanged in five and decreased in one; pronation-supination was decreased in four cases. The results of 13 synoviortheses in four hemophilic patients with high titer factor VIII inhibitors were comparable to those in hemophiliacs with no inhibitors. However, in three of the four patients synoviorthesis had to be repeated after two to four years for recurrence of synovitis. Extraarticular escape of radioactivity was monitored 62 times for 17 synoviortheses in 12 patients; extraarticular counts never exceeded 4% of the intraarticular counts. Chromosome aberrations were found not to be increased after treatment in the seven patients in whom adequate analysis could be done.

  12. Application a {sup 32}P bioassay for P-fertilization of citrus

    Energy Technology Data Exchange (ETDEWEB)

    Song, Sung Jun; U, Zang Kual [Jeju National University, Jeju (Korea, Republic of)

    2009-06-15

    Uptake of phosphorus (as {sup 32}P) by excised root samples from Citrus trees growing in the soil with originally less than 30 mg kg{sup -1} available P was significantly lowered after P-fertilization. This effect became more prominent in the 2nd and 3rd year of the experiment. High concentration of available P in the soil (80mg kg{sup -1}) resulted in a higher P-content in the excised roots and therefore decreased P-uptake. Application of phosphate fertilizer to such soil increased the content of available P but P concentration in Citrus leaves was not significantly changed. Branch length, fruit yield, and Brix sugar in fruit juice were also not influenced. These data show that response to P-fertilization can be tested by leaf analysis, growth or yield measurement. P-uptake of excised roots harvested from the soil with available P above 150 mg kg{sup -1} reached a level of 400 {approx} 500 pg P/mg root, which indicates that P-fertilization is unnecessary at the soil of P-content above this limit.

  13. Ion-implantation and characterization of 32P-radioactive platinum coils for endovascular treatment of intracranial aneurysms

    Science.gov (United States)

    Leblanc, Philippe; Raymond, Jean; Roorda, Sjoerd

    2006-01-01

    We produced and measured over 800 32P-ion-implanted coils for pre-clinical and clinical studies. Platinum coils are intravascular implants most frequently used in the treatment of intracranial aneurysms. This less invasive endovascular approach is safer than conventional surgery, but a frequent drawback is the recurrence of the aneurysm, associated with recanalization, a phenomenon that can be inhibited by the local application of beta radiation. Total coil activities, uniformity, reproducibility and 32P binding to platinum were determined and found to be adequate for this application.

  14. Depth dose distribution in the water for clinical applicators of {sup 90}Sr + {sup 90}Y, with a extrapolation mini chamber; Distribuicao de dose em profundidade na agua para aplicadores clinicos de {sup 90}Sr + {sup 90}Y, com uma mini-camara de extrapolacao

    Energy Technology Data Exchange (ETDEWEB)

    Antonio, Patricia de Lara; Caldas, Linda V.E., E-mail: patrilan@ipen.b, E-mail: lcaldas@ipen.b [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil); Oliveira, Mercia L., E-mail: mercial@cnen.gov.b [Centro Regional de Ciencias Nucleares do Nordeste (CRCN-NE/CNEN-PE), Recife, PE (Brazil)

    2009-07-01

    This work determines the depth dose in the water for clinical applicators of {sup 90}Sr + {sup 90}Y, using a extrapolation mini chamber developed at the IPEN, Sao Paulo, Brazil, and different thickness acrylic plates. The obtained results were compared with the international recommendations and were considered satisfactory

  15. 32P-incorporation PCR for the detection of rearrangements at the TCR-gamma locus.

    Science.gov (United States)

    Short, M A; Evans, P A; Shiach, C R; Jack, A; Richards, S; Morgan, G J

    1996-03-01

    We have adapted and developed a PCR (polymerase chain reaction)-based technique for the T-cell receptor (TCR)-gamma chain gene, which has subsequently been used for routine diagnosis. Variable-region oligonucleotide primers were chosen from subgroups I and II, and the joining region primer was from the J2 segment. The primers were used to perform a 32P-incorporation PCR, and the products were then separated on an 8% denaturing polyacrylamide gel. In our hands, this technique is more reliable than cold methods, when separation is performed on either agarose or nondenaturing polyacrylamide. The radioactive technique was used to look at 102 T-cell proliferations, of which eight of eight T-acute lymphoblastic leukemia (ALL), 24 of 34 T-non-Hodgkin's leukemia (NHL), and 35 of 60 large granular lymphocyte (LGL) expansions were clonal. Of 122 B-cell proliferations investigated, including 72 cases of B-cell lineage ALL, 36 demonstrated a T-cell rearrangement (33 ALLs and three myelomas). Samples from nonlymphoid tumors were tested and produced a normal distribution ladder of PCR products after autoradiography, a pattern also observed with antenatal and preoperative patients. The radiolabel-incorporation method detected an abnormal pattern of a ladder with prominent dark bands in 29 of 122 B-cell and 27 of 102 T-cell cases and in 0 of 49 of the nonlymphoid and normal samples. The abnormal banding patterns obtained in a proportion of the B- and T-cell cases was not readily discernible by nondenaturing-acrylamide or agarose-separation methods.

  16. Experimental dosimetry of a {sup 32}P catheter-based endovascular brachytherapy source

    Energy Technology Data Exchange (ETDEWEB)

    Piermattei, A [Istituto di Fisica, Universita Cattolica S Cuore, Rome (Italy); Fidanzio, A [Istituto di Fisica, Universita Cattolica S Cuore, Rome (Italy); Perrone, F [Azienda Ospedaliera Pisana, UO Fisica Sanitaria, Pisa (Italy); Azario, L [Istituto di Fisica, Universita Cattolica S Cuore, Rome (Italy); Grimaldi, L [Istituto di Fisica, Universita Cattolica S Cuore, Rome (Italy); Viola, P [Istituto di Fisica, Universita Cattolica S Cuore, Rome (Italy); Capote, R [Dpto Fisiologia Medica y Biofisica, Facultad de Medicina, Universidad de Sevilla, Avda Sanchez Pizjuan 4, E41009 Sevilla (Spain)

    2003-08-07

    The experimental dosimetry in a water phantom of a {sup 32}P linear source, 20 mm in length, used for the brachytherapy of coronary vessels is reported. The source content activity, A, was determined by means of a calibrated well ion-chamber and the value was compared with the contained activity reported in the manufacturer's certification. In this field of brachytherapy dosimetry, radiochromic film supplies a high enough spatial resolution. A highly sensitive radiochromic film, that presents only one active layer, was used in this work for the source dosimetry in a water phantom. The radiochromic film was characterized by electron beams produced by a clinical linac. A Monte Carlo calculation of beta spectra in water at different distances along the source transverse bisector axis allowed to take into account the low dependence of film response from the electron beam energy. The adopted experimental set-up, with the source in its catheter positioned on the film plane inside the water phantom, supplies accurate dosimetric information. The measured dose rate to water per unit of source activity at reference distance, D-dot (r{sub 0}, {theta}{sub 0})/A, in units of cGy s{sup -1} GBq{sup -1}, was in agreement with the value reported in the manufacturer's certification within the experimental uncertainty. The radial dose function, g(r), is in good agreement with the literature data. The anisotropy function F(r, {theta}) is also reported. The analysis of the dose profile obtained at 2 mm from the source longitudinal axis shows that the uniformity is within 10% along 75% of the 20 mm treatment length. The adopted experimental set-up seems to be adequate for the quality control procedure of the dose homogeneity distribution in the water medium.

  17. New modalities (setting, fractionation) of radioimmunotherapy by {sup 90}Y-ibritumomab tiuxetan ({sup 90}Y zevalin) in first line treatment of follicular type non Hodgkin malignant lymphomas: efficiency, toxicity and personalized dosimetry approach; Nouvelles modalites (consolidation, fractionnement) de radioimmunotherapie par {sup 90}Y-ibritumomab tiuxetan (Zevalin) en traitement de premiere ligne des lymphomes malin non hodgkiniens de type folliculaire: efficacite, toxicite et approche dosimetrique personnalisee

    Energy Technology Data Exchange (ETDEWEB)

    Morschhauser, F

    2008-12-15

    Rationale: radioimmunotherapy (R.I.T.) with {sup 90}Y-ibritumomab tiuxetan ([{sup 90}Y] Zevalin ) is a new treatment option for patients with relapsed/refractory non Hodgkin follicular lymphoma (F.L.). Efficacy increases when Zevalin is used earlier in the disease course. Currently, Zevalin dosage is based on weight and not dosimetry. This most likely results in a wide range of absorbed dose to critical organs and tumor, which in turn translates in unpredictable efficacy and toxicity. Optimizing R.I.T. with [{sup 90}Y] Zevalin will require its use as part of first-line therapy and implementation of patient-specific dosimetry methods in clinical trials. Objectives and methods: we have consecutively studied 2 new modalities of using Zevalin in first line therapy of F.L.. First, we conducted an international, randomized, phase 3 trial to evaluate the efficacy and safety of consolidation with Zevalin(15 MBq/Kg) in patients with advanced-stage F.L. achieving at least a partial response after induction immuno chemotherapy. A second approach consisted of evaluating a fractionated schedule with 2 doses of Zevalin (11.1 MBq/kg each), 9 to 13 weeks apart, as front line therapy in F.L. patients with high tumor burden. As part of this second approach, we designed a refined imaging-based (planar and 3-dimensional) dosimetry protocol to improve prediction of dose efficacy and toxicity after each dose of zevalin. Data acquisition was performed in 3 centers (Lille, Nantes and Manchester) while data treatment and specific dose calculations for major organ, tumor masses and bone marrow were centralized. Conclusion: Consolidation of first remission with {sup 90}Y-ibritumomab tiuxetan in advanced-stage follicular lymphoma is highly effective with no unexpected toxicities, prolonging P.F.S. by 2 years and resulting in high P.R.-to-C.R. conversion rates regardless of type of first-line induction treatment. Preliminary data show the feasibility of front line fractionated R.I.T. with

  18. Comparison of immunoaffinity chromatography enrichment and nuclease P1 procedures for 32P-postlabelling analysis of PAH- DNA adducts

    NARCIS (Netherlands)

    Randerath, K.; Sriram, P.; Moorthy, B.; Aston, J.P.; Baan, R.A.; Berg, P.T.M. van den; Booth, E.D.; Watson, W.P.

    1998-01-01

    32P-postlabelling analysis for detecting DNA adducts formed by polycyclic aromatic compounds is one of the most widely used techniques for assessing genotoxicity associated with these compounds. In cases where the formation of adducts is extremely low, a crucial step in the analysis is an enrichment

  19. Determination of surface dose rate of indigenous (32)P patch brachytherapy source by experimental and Monte Carlo methods.

    Science.gov (United States)

    Kumar, Sudhir; Srinivasan, P; Sharma, S D; Saxena, Sanjay Kumar; Bakshi, A K; Dash, Ashutosh; Babu, D A R; Sharma, D N

    2015-09-01

    Isotope production and Application Division of Bhabha Atomic Research Center developed (32)P patch sources for treatment of superficial tumors. Surface dose rate of a newly developed (32)P patch source of nominal diameter 25 mm was measured experimentally using standard extrapolation ionization chamber and Gafchromic EBT film. Monte Carlo model of the (32)P patch source along with the extrapolation chamber was also developed to estimate the surface dose rates from these sources. The surface dose rates to tissue (cGy/min) measured using extrapolation chamber and radiochromic films are 82.03±4.18 (k=2) and 79.13±2.53 (k=2) respectively. The two values of the surface dose rates measured using the two independent experimental methods are in good agreement to each other within a variation of 3.5%. The surface dose rate to tissue (cGy/min) estimated using the MCNP Monte Carlo code works out to be 77.78±1.16 (k=2). The maximum deviation between the surface dose rates to tissue obtained by Monte Carlo and the extrapolation chamber method is 5.2% whereas the difference between the surface dose rates obtained by radiochromic film measurement and the Monte Carlo simulation is 1.7%. The three values of the surface dose rates of the (32)P patch source obtained by three independent methods are in good agreement to one another within the uncertainties associated with their measurements and calculation. This work has demonstrated that MCNP based electron transport simulations are accurate enough for determining the dosimetry parameters of the indigenously developed (32)P patch sources for contact brachytherapy applications.

  20. Intraoperative avidination for radionuclide treatment as a radiotherapy boost in breast cancer: results of a phase II study with {sup 90}Y-labeled biotin

    Energy Technology Data Exchange (ETDEWEB)

    Paganelli, Giovanni; De Cicco, Concetta; Carbone, Giuseppe; Pacifici, Monica [European Institute of Oncology, Division of Nuclear Medicine, Milan (Italy); Ferrari, Mahila E.; Cremonesi, Marta; Di Dia, Amalia [European Institute of Oncology, Division of Medical Physics, Milan (Italy); Pagani, Gianmatteo; Galimberti, Viviana; Luini, Alberto [European Institute of Oncology, Division of Senology, Milan (Italy); Leonardi, Maria Cristina; Ferrari, Annamaria; Orecchia, Roberto [European Institute of Oncology, Division of Radiotherapy, Milan (Italy); De Santis, Rita [Sigma-Tau SpA R and D, Rome (Italy); Zurrida, Stefano [European Institute of Oncology, Division of Senology, Milan (Italy); University of Milan School of Medicine, Milan (Italy); Veronesi, Umberto [European Institute of Oncology, Scientific Director, Milan (Italy)

    2010-02-15

    External beam radiotherapy (EBRT) after conservative surgery for early breast cancer requires 5-7 weeks. For elderly patients and those distant from an RT center, attending for EBRT may be difficult or impossible. We investigated local toxicity, cosmetic outcomes, and quality of life in a new breast irradiation technique - intraoperative avidination for radionuclide therapy (IART) - in which avidin is administered to the tumor bed and {sup 90}Y-labelled biotin later administered intravenously to bind the avidin and provide irradiation. Reduced duration EBRT (40 Gy) is given subsequently. After surgery, 50 (ten patients), 100 (15 patients) or 150 mg (ten patients) of avidin was injected into the tumor bed. After 12-24 h, 3.7 GBq {sup 90}Y-biotin (beta source for therapeutic effect) plus 185 MBq {sup 111}In-biotin (gamma source for imaging and dosimetry) was infused slowly. Whole-body scintigraphy and SPECT/CT images were taken for up to 30 h. Shortened EBRT started 4 weeks later. Local toxicity was assessed by RTOG scale; quality of life was assessed by EORTC QOL-30. Of 35 patients recruited (mean age 63 years; range 42-74) 32 received IART plus EBRT. 100 mg avidin provided 19.5 {+-} 4.0 Gy to the tumor bed and was considered the optimum dose. No side-effects of avidin or {sup 90}Y-biotin occurred, with no hematological or local toxicity. Local G3 toxicity occurred in 3/32 patients during EBRT. IART plus EBRT was well accepted, with good cosmetic outcomes and maintained quality of life. IART plus reduced EBRT can accelerate irradiation after conservative breast surgery. (orig.)

  1. {sup 90}Y microsphere treatment of unresectable liver metastases: changes in {sup 18}F-FDG uptake and tumour size on PET/CT

    Energy Technology Data Exchange (ETDEWEB)

    Bienert, Maren [University of Pittsburgh Medical Center (UPMC), Department of Radiology, Pittsburgh, PA (United States); Charite-University Medicine Berlin, Department of Nuclear Medicine, Berlin (Germany); McCook, Barry; Sheetz, Mike; Tutor, Cecilia; Amesur, Nikhil; Avril, Norbert [University of Pittsburgh Medical Center (UPMC), Department of Radiology, Pittsburgh, PA (United States); Carr, Brian I.; Geller, David A. [University of Pittsburgh Medical Center (UPMC), Department of Surgery, Pittsburgh, PA (United States)

    2005-07-01

    The intra-arterial administration of {sup 90}Y microspheres is a new palliative treatment option for unresectable liver metastases. The aim of this study was to quantitatively assess changes in FDG uptake and tumour size following {sup 90}Y microsphere treatment (SIR-Spheres) using {sup 18}F-fluorodeoxyglucose (FDG) PET/CT imaging. Five patients with unresectable liver metastases who had failed multiple prior chemotherapy regimens received seven {sup 90}Y microsphere treatments to a single liver lobe. All patients underwent a baseline PET/CT scan prior to treatment, as well as up to four follow-up PET/CT scans. The tumour area of 30 liver metastases was measured on CT and the FDG uptake was semiquantitatively assessed by calculation of standardised uptake values (SUVs). A total of 18 FDG-PET/CT scans were performed. The SUVs in the 30 treated liver metastases decreased from 6.5{+-}2.3 at baseline to 4.2{+-}1.8 after the first follow-up PET/CT scan (p=0.001). In contrast, the SUVs of untreated metastases increased slightly from 7.2{+-}2.3 to 8.0{+-}0.8. There was no difference in FDG uptake in treated versus untreated normal liver tissue. Using a previously defined threshold of 20% decrease in SUV from baseline to determine response, 20 out of 30 liver metastases were considered to have responded at the first follow-up PET/CT scan approximately 1 month after treatment. In these metastases, the SUV decreased by 47{+-}12%, compared with a slight increase by 5.9{+-}19% in ten non-responding metastases (p=0.0001). The changes in tumour size did not correlate with changes in FDG uptake. On the first follow-up PET/CT scan, the tumour area on CT increased by 3.1{+-}57% in treated metastases compared with 23.3{+-}32% in untreated metastases. A wide range of post-treatment changes of target lesions was observed on CT, including an increase in the size of hypodense lesions, necrotic features and complete resolution of CT abnormalities. The metabolic information obtained from

  2. Pyclen Tri-n-butylphosphonate Ester as Potential Chelator for Targeted Radiotherapy: From Yttrium(III) Complexation to (90)Y Radiolabeling.

    Science.gov (United States)

    Le Fur, Mariane; Beyler, Maryline; Lepareur, Nicolas; Fougère, Olivier; Platas-Iglesias, Carlos; Rousseaux, Olivier; Tripier, Raphaël

    2016-08-15

    The Y(3+) complex of PCTMB, the tri-n-butyl phosphonate ester of pyclen (3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene), was synthesized as well as its Ho(3+) and Lu(3+) analogues. X-ray diffraction analyses revealed isomorphous dimeric M2(PCTMB)2·9H2O (M = Y, Ho, Lu) structures that crystallize in the centrosymmetric P1̅ triclinic space group. (1)H NMR and UV studies in aqueous solutions indicated that Y(3+) complexation is fast, being quantitative in 167 min at pH 3.8 and in 13 min at pH 5.5 (25 °C, acetate buffer, I = 0.150 M, [Y(3+)] = [PCTMB] = 0.2 mM). (1)H NMR DOSY and photon correlation spectroscopy experiments evidenced the formation of aggregates in chloroform with a bimodal distribution that changes slightly with concentration (11-24 and 240-258 nm). The behavior of the acid-assisted dissociation of the complex of Y(3+) with PCTMB was studied under pseudo-first-order conditions, and the half-life of the [Y(PCTMB)] complex in 0.5 M HCl at 25 °C was found to be 37 min, a value that decreases to 2.6 min in 5 M HCl. The Y(3+) complex of PCTMB is thermodynamically very stable, with a stability constant of log KY-PCTMB = 19.49 and pY = 16.7 measured by potentiometry. (90)Y complexation studies revealed fast radiolabeling kinetics; optimal radiolabeling conditions were obtained for (90)Y in acetate medium, PCTMB at 10(-4) to 10(-2) M in acetate buffer pH = 4.75, 15 min at 45-60 °C. In vitro stability studies in human serum showed that [(90)Y(PCTMB)] is quite stable, with about 90% of the activity still in the form of the radiotracer at 24 h and 80% from 48 h to 72 h. A comparison with other ligands such as PCTA, DOTA, and DTPA already used for in vivo application shows that [(90)Y(PCTMB)] is an interesting lipophilic and neutral analogue of these reference chelates for therapeutic applications in aqueous and nonaqueous media.

  3. (Depth-dose curves of the beta reference fields (147)Pm, (85)Kr and (90)Sr/(90)Y produced by the beta secondary standard BSS2.

    Science.gov (United States)

    Brunzendorf, Jens

    2012-08-01

    The most common reference fields in beta dosimetry are the ISO 6980 series 1 radiation fields produced by the beta secondary standard BSS2 and its predecessor BSS. These reference fields require sealed beta radiation sources ((147)Pm, (85)Kr or (90)Sr/(90)Y) in combination with a source-specific beam-flattening filter, and are defined only at a given distance from the source. Every radiation sources shipped with the BSS2 is sold with a calibration certificate of the Physikalisch-Technische Bundesanstalt. The calibration workflow also comprises regular depth-dose measurements. This work publishes complete depth-dose curves of the series 1 sources (147)Pm, (85)Kr and (90)Sr/(90)Y in ICRU tissue up to a depth of 11 mm,when all electrons are stopped. For this purpose, the individual depth-dose curves of all BSS2 sources calibrated so far have been determined, i.e. the complete datasets of all BSS2 beta sources have been re-evaluated. It includes 191 depth-dose curves of 116 different sources comprising more than 2200 data points in total. Appropriate analytical representations of the nuclide-specific depth-dose curves are provided for the first time.

  4. Radioimmunotherapy with {sup 131}I-Rituximab in a Patient with Diffuse Large B-Cell Lymphoma Relapsed After Treatment with {sup 90}Y-Ibritumomab Tiuxetan

    Energy Technology Data Exchange (ETDEWEB)

    Kang, Geon Wook; Kang, Hye Jin; Shin, Dongyeop; Gu, Ha Ra; Choi, Hong Seok; Lim, Sang Moo [Korea Cancer Center Hospital, Seoul (Korea, Republic of)

    2013-12-15

    We report a case that demonstrates the efficacy of radioimmunotherapy (RIT) with radioiodinated rituximab ({sup 131}I-rituximab) for relapsed diffuse large B-cell lymphoma (DLBCL). A 79-year-old male patient with DLBCL initially achieved a complete response (CR) after six cycles of RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) therapy. However, the lymphoma relapsed 20 months later. Although the patient had achieved a second and a third CR after two cycles of {sup 90}Y-ibritumomab tiuxetan, he experienced a third relapse approximately 3 years later. Between March and June 2011, the patient received three cycles of {sup 131}I-rituximab. Although he had achieved partial response after the second cycle, the disease progressed after the third cycle, and the total progression. Free survival was thus 5 months. The patient suffered only relatively mild toxicity (grade 1 thrombocytopenia) during treatment. RIT with {sup 131}I-rituximab is therefore potentially effective in patients with relapsed DLBCL, even after the failure of {sup 90}Y-ibritumomab tiuxetan therapy.

  5. Dosimetry analysis of distribution radial dose profiles of {sup 90}Sr + {sup 90}Y beta therapy applicators using the MCNP-4C code and radio chromium films; Analise dosimetrica de perfis de distribuicoes radiais de doses relativas de um aplicador de betaterapia de {sup 90}Sr + {sup 90}Y utilizando o codigo MCNP-4C e filmes radiocromicos

    Energy Technology Data Exchange (ETDEWEB)

    Coelho, T.S.; Yoriyaz, H. [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil); Fernandes, M.A.R. [Universidade Estadual Paulista Julio de Mesquita Filho (UNESP), Botucatu, SP (Brazil). Fac. de Medicina. Servico de Radioterapia; Louzada, M.J.Q. [Universidade Estadual Paulista Julio de Mesquita Filho (UNESP), Aracatuba, SP (Brazil). Curso de Medicina Veterinaria

    2010-07-01

    Although they are no longer manufactured, the applicators of {sup 90}Sr +{sup 90}Y acquired in the decades of 1990 are still in use, by having half-life of 28.5 years. These applicators have calibration certificate given by their manufacturers, where few have been recalibrated. Thus it becomes necessary to accomplish thorough dosimetry of these applicators. This paper presents a dosimetric analysis distribution radial dose profiles for emitted by an {sup 90}Sr+{sup 90}Y beta therapy applicator, using the MCNP-4C code to simulate the distribution radial dose profiles and radiochromium films to get them experimentally . The results with the simulated values were compared with the results of experimental measurements, where both curves show similar behavior, which may validate the use of MCNP-4C and radiochromium films for this type of dosimetry. (author)

  6. Dosimetry analysis of distributions radials dose profiles of {sup 90}Sr + {sup 90}Y beta therapy applicators using the MCNP-4C code and radio chromium films; Analise dosimetrica de perfis de distribuicoes radias de doses relativas de um aplicador de betaterapia de {sup 90}Sr + {sup 90}Y utilizando o codigo MCNP-4C e filmes radiocromicos

    Energy Technology Data Exchange (ETDEWEB)

    Coelho, Talita S.; Yoriyaz, Helio [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil); Fernandes, Marco A.R., E-mail: tasallesc@gmail.co [UNESP, Botucatu, SP (Brazil). Faculdade de Medicina. Servico de Radioterapia; Louzada, Mario J.Q. [UNESP, Aracatuba, SP (Brazil). Curso de Medicina Veterinaria

    2011-07-01

    Although they are no longer manufactured, the applicators of {sup 90}Sr + {sup 90}Y acquired in the decades of 1990 are still in use, by having half-life of 28.5 years. These applicators have calibration certificate given by their manufacturers, where few have been re calibrated. Thus it becomes necessary to accomplish thorough dosimetry of these applicators. This paper presents a dosimetric analysis distribution radial dose profiles for emitted by an {sup 90}Sr + {sup 90}Y beta therapy applicator, using the MCNP-4C code to simulate the distribution radial dose profiles and radio chromium films to get them experimentally . The results with the simulated values were compared with the results of experimental measurements, where both curves show similar behavior, which may validate the use of MCNP-4C and radio chromium films for this type of dosimetry. (author)

  7. Calibration of {sup 90}Sr+{sup 90}Y chemical applicators using a mini extrapolation chamber as reference system;Calibracao de aplicadores clinicos de {sup 90}Sr+{sup 90}Y utilizando uma mini-camera de extrapolacao como sistema de referencia

    Energy Technology Data Exchange (ETDEWEB)

    Antonio, Patricia L.; Caldas, Linda V.E. [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil); Oliveira, Mercia L. [Centro Regional de Ciencias Nucleares do Nordeste (CRCN-NE/CNEN-PE), Recife, PE (Brazil)

    2009-07-01

    {sup 90}Sr + {sup 90}Y clinical applicators are beta radiation sources utilized in several radiotherapy Brazilian clinics, although don't be more manufactured. These sources are employed in brachytherapy procedures for the treatment of superficial lesions of skin and eyes. International recommendations and previous works determine that dermatological and ophthalmic applicators shall be calibrated periodically, and one of the methods for their calibration consists of the use of an extrapolation chamber. In this work, a method of calibration of {sup 90}Sr + {sup 90}Y clinical applicators was applied using a mini-extrapolation chamber of plane window, developed at the Calibration Laboratory at IPEN, as a reference system. The results obtained were considered satisfactory, when compared with the results given in the calibration certificates of the sources. (author)

  8. Synoviorthesis with /sup 32/P-colloidal chromic phosphate in rheumatoid arthritis. Clinical, histopathologic and arthrographic changes

    Energy Technology Data Exchange (ETDEWEB)

    Onetti, C.M.; Gutierrez, E. (University Hospital, Cordoba (Argentina)); Hliba, E. (National University of Cordoba (Argentina)); Aguirre, C.R. (Hospital Italiano, Cordoba (Argentina))

    Synoviorthesis was performed in 217 joints from 111 patients suffering from different stages of rheumatoid arthritis (RA). /sup 32/P-colloidal chromic phosphate was employed, with an average dose from 6 mCi for large joints (knees) to 0.3 mCi for small peripheral joints such as the MCP or PIP joints. Satisfactory clinical results were observed in 84% of the cases and no significant side effects resulted after a follow-up period from 1 to 10 years. Striking effects after treatment were observed through histopathological studies (light and electron microscopy) and the use of contrast arthography. We concluded that radioactive synovectomy with /sup 32/P-chromate is a very useful method for the local treatment of RA.

  9. Synoviorthesis with 32P-colloidal chromic phosphate in rheumatoid arthritis--clinical, histopathologic and arthrographic changes.

    Science.gov (United States)

    Onetti, C M; Gutiérrez, E; Hliba, E; Aguirre, C R

    1982-01-01

    Synoviorthesis was performed in 217 joints from 111 patients suffering from different stages of rheumatoid arthritis (RA). 32P-colloidal chromic phosphate was employed, with an average dose from 6 mCi for large joints (knees) to 0.3 mCi for small peripheral joints such as average dose from 6 mCi for large joints (knees) to 0.3 mCi for small peripheral joints such as the MCP or PIP joints. Satisfactory clinical results were observed in 84% of the cases and no significant side effects resulted after a follow-up period from 1 to 10 years. Striking effects after treatment were observed through histopathological studies (light and electron microscopy) and the use of contrast arthrography. We concluded that radioactive synovectomy with 32P-chromate is a very useful method for the local treatment of RA.

  10. Injection of sup 32 P colloid into squamous cell carcinoma of the esophagus for local disease control

    Energy Technology Data Exchange (ETDEWEB)

    Perakos, P.G.; Scheer, T.F. (Memorial Hospital of Laramie County and Wyoming College of Human Medicine, Wyoming (USA))

    1989-10-01

    Local treatment of squamous cell carcinoma of the esophagus is only modestly successful. To increase local control, we have developed a procedure to inject a boost dose of radiation into the tumor bed after completion of external beam radiotherapy. The boost dose is given with {sup 32}P, a readily available radiocolloid. {sup 32}P is a pure emitter and poses no significant radiation hazards. It can penetrate 10approx15 mm into the tumor mass and has a half-life of 14.3 days. After determination of the volume to be treated, the colloid is injected with endoscopic guidance using the same technique as used in injection scierotherapy of esophageal varices. We use the Pentax FG 34 JA operating gastroscope and a Bard disposable 0.5 cm 25 Ga retractable injection sclerotherapy needle. We deliver 150approx200 microCurie of {sup 32}P colloid diluted to 20 ml with normal saline at 10 to 20 injection sites. This boosts the radiotherapy dose of 5,500approx6,000 cGy to the range of 7,500approx8,000 cGy. We have treated five patients so far, with length of follow-up ranging from 8approx28 months. Local control and survival results have been excellent and no complications have been associated with the procedure. A combination of external beam radiotherapy and interstitial boost treatment with colloidal {sup 32}P appears to be a safe and effective method of managing squamous cell carcinoma of the esophagus. (author).

  11. Biological effects of brachytherapy using a {sup 32}P-patch on the skin of Sencar mice

    Energy Technology Data Exchange (ETDEWEB)

    Salgueiro, M.J. [Radioisotope Laboratory, School of Pharmacy and Biochemistry, University of Buenos Aires, Junin 956 Piso Bajo, 1113-Buenos Aires (Argentina)], E-mail: jsalgueiro@ffyb.uba.ar; Collia, N. [Radioisotope Laboratory, School of Pharmacy and Biochemistry, University of Buenos Aires, Junin 956 Piso Bajo, 1113-Buenos Aires (Argentina); Duran, H. [CONICET, San Martin (Argentina); School of Science and Technology, University of San Martin, San Martin (Argentina); Radiobiology Department, National Atomic Energy Commission (CNEA), Buenos Aires (Argentina); Palmieri, M. [CONICET, San Martin (Argentina); Biodiversity and Experimental Biology Department, School of Exact and Natural Sciences, University of Buenos Aires, Buenos Aires (Argentina); School of Science and Technology, University of San Martin, San Martin (Argentina); Medina, V. [Radioisotope Laboratory, School of Pharmacy and Biochemistry, University of Buenos Aires, Junin 956 Piso Bajo, 1113-Buenos Aires (Argentina); Ughetti, R.; Nicolini, J. [Research and Development Department, Laboratorios Bacon SAIC, Buenos Aires (Argentina); Zubillaga, M. [Radioisotope Laboratory, School of Pharmacy and Biochemistry, University of Buenos Aires, Junin 956 Piso Bajo, 1113-Buenos Aires (Argentina)

    2009-10-15

    In recent years, specially designed patches containing beta emitters have been developed for contact brachytherapy of skin lesions. The aim of the present work was to evaluate the biological effects of the {sup 32}P-patch on the skin of Sencar mice as a result of a brachytherapy treatment. For this purpose, a {sup 32}P-patch was prepared with Chromic {sup 32}P-phosphate and silicone and the classical model of two-stage skin carcinogenesis was reproduced in Sencar mice. Animals were divided in six groups. Four groups received the contact brachytherapy treatments using a scheme of a single session of 40 and 60 Gy (SD40 and SD60) and a scheme of two sessions of 40 and 60 Gy each (FD40 and FD60). The other two groups were used as controls of the single (CSD) and the fractionated (CFD) treatments. Radiation doses were estimated with equations derived from the MIRD DOSE scheme, and biologically effective doses (BED) were calculated according to equations derived from the linear-quadratic model. The endpoint to evaluate the treatments effects was tumor size after a follow-up period of 44 days. Finally, animals were sacrificed in order to get samples of all tumors for histological analysis and PCNA staining. Erythema, dermatitis and skin ulceration developed in almost all treated animals, but they gradually healed with regeneration of tissue during the follow-up period. Radiation effects on the skin of SD40, SD60, FD40 and FD60 showed a significant reduction of the tumor size with regard to controls, independently of the scheme and the radiation dose considered. PCNA staining scores of control groups were higher than for treated groups, independently of the scheme and the radiation dose considered. This radioactive {sup 32}P-silicone-patch which is easy to prepare and use in the treatment of skin diseases, seems promising as a radioactive device for clinical use.

  12. Determination of Lactic Acid Bacteria Viability in the Small Intestine of Catfish (Pangasius djambal by Using the 32P Radioisotope

    Directory of Open Access Journals (Sweden)

    I. Sugoro

    2015-04-01

    Full Text Available The viability of probiotics is important to be determined, as is its probiotic potency in the small instestine of fish. The result can be used as a basis to determine the feeding frequency of the probiotics to the fish.The aim of this study is to gain information about the viability of lactic acid bacteria (LAB in the small intestine of fish by using the 32P isotope technique. Catfish (Pangasius djambal was used as a test fish, and the LAB with the code of P2.1 PTB was the subject of the experiment. Before its viability was tested, the LAB had been labelled with radioisotope 32P, then mixed into catfish feed. Its viability could be determined by counting the activity of 32P. The results showed that the percentage of LAB viability in the small intestine of catfish declined until day 7. The percentage of LAB viability was decreased at an amount of 30% at day 3. Based on this result, the feeding frequency of LAB P2.1 PTB is every 3 days.

  13. Determination of Lactic Acid Bacteria Viability in the Small Intestine of Catfish (Pangasius djambal by Using the 32P Radioisotope

    Directory of Open Access Journals (Sweden)

    I. Sugoro

    2015-10-01

    Full Text Available The viability of probiotics is important to be determined, as is its probiotic potency in the small instestine of fish. The result can be used as a basis to determine the feeding frequency of the probiotics to the fish.The aim of this study is to gain information about the viability of lactic acid bacteria (LAB in the small intestine of fish by using the 32P isotope technique. Catfish (Pangasius djambal was used as a test fish, and the LAB with the code of P2.1 PTB was the subject of the experiment. Before its viability was tested, the LAB had been labelled with radioisotope 32P, then mixed into catfish feed. Its viability could be determined by counting the activity of 32P. The results showed that the percentage of LAB viability in the small intestine of catfish declined until day 7. The percentage of LAB viability was decreased at an amount of 30% at day 3. Based on this result, the feeding frequency of LAB P2.1 PTB is every 3 days. Received: 04 October 2014 Revised: 26 March 2015; Accepted: 05 April 2015

  14. A multicentre comparison of quantitative {sup 90}Y PET/CT for dosimetric purposes after radioembolization with resin microspheres. The QUEST phantom study

    Energy Technology Data Exchange (ETDEWEB)

    Willowson, Kathy P. [University of Sydney, Institute of Medical Physics, School of Physics, Sydney, NSW (Australia); Tapner, Michael [Sirtex, North Sydney, NSW (Australia); Bailey, Dale L. [Royal North Shore Hospital, Department of Nuclear Medicine, Sydney, NSW (Australia); University of Sydney, Faculty of Health Sciences, Lidcombe (Australia); Collaboration: The QUEST Investigator Team

    2015-07-15

    To investigate and compare the quantitative accuracy of {sup 90}Y imaging across different generation PET/CT scanners, for the purpose of dosimetry after radioembolization with resin microspheres. A strict experimental and imaging protocol was followed by 47 international sites using the NEMA 2007/IEC 2008 PET body phantom with an 8-to-1 sphere-to-background ratio of {sup 90}Y solution. The phantom was imaged over a 7-day period (activity ranging from 0.5 to 3.0 GBq) and all reconstructed data were analysed at a core laboratory for consistent processing. Quantitative accuracy was assessed through measures of total phantom activity, activity concentration in background and hot spheres, misplaced counts in a nonradioactive insert, and background variability. Of the 69 scanners assessed, 37 had both time-of-flight (ToF) and resolution recovery (RR) capability. These current generation scanners from GE, Philips and Siemens could reconstruct background concentration measures to within 10 % of true values over the evaluated range, with greater deviations on the Philips systems at low count rates, and demonstrated typical partial volume effects on hot sphere recovery, which dominated spheres of diameter <20 mm. For spheres >20 mm in diameter, activity concentrations were consistently underestimated by about 20 %. Non-ToF scanners from GE Healthcare and Siemens were capable of producing accurate measures, but with inferior quantitative recovery compared with ToF systems. Current generation ToF scanners can consistently reconstruct {sup 90}Y activity concentrations, but they underestimate activity concentrations in small structures (≤37 mm diameter) within a warm background due to partial volume effects and constraints of the reconstruction algorithm. At the highest count rates investigated, measures of background concentration (about 300 kBq/ml) could be estimated on average to within 1 %, 5 % and 2 % for GE Healthcare (all-pass filter, RR + ToF), Philips (4i8s ToF) and

  15. The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing {sup 90}Y selective internal radiation therapy plus chemotherapy

    Energy Technology Data Exchange (ETDEWEB)

    Gulec, Seza A.; Suthar, Rekha R.; Barot, Tushar C. [Jackson North Medical Center, Florida International University College of Medicine, North Miami Beach, FL (United States); Pennington, Kenneth [Center for Cancer Care, Goshen, IN (United States)

    2011-07-15

    Functional tumor volume (FTV) and total lesion glycolysis (TLG) are measures of metabolic activity of tumors determined by fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT images. These parameters could potentially have clinical value in response to treatment evaluation and disease prognostication. The objectives of this study were to investigate the relationship between functional tumor parameters (FTV and TLG) and clinical outcomes in patients with colorectal cancer liver metastases (CRCLM) undergoing {sup 90}Y-resin microsphere selective internal radiation therapy (SIRT) (SIR-Spheres {sup registered}, Sirtex Medical Limited, Lane Cove, NSW, Australia). FDG PET/CT studies of 20 patients with unresectable CRCLM who underwent {sup 90}Y SIRT under a phase II clinical trial were analyzed. FTV and TLG were calculated using PET VCAR (GE Healthcare, Milwaukee, WI, USA) on pretreatment and 4-week posttreatment scans. The effects of pretreatment and posttreatment functional tumor activity on patient survival were evaluated using Kaplan-Meier survival curves. The median survival in the study group was 14.8 months (range 2.0-27.7 months). The median survival for patients with pretreatment FTV values of above and below 200 cc were 11.2 and 26.9 months, respectively (p < 0.05). The median survival for patients with 4-week posttreatment FTV values of above and below 30 cc were 10.9 and 26.9 months, respectively (p < 0.05). The median survival for patients with pretreatment TLG values of above and below 600 g were 11.2 and 26.9 months, respectively (p < 0.05). The median survival for patients with 4-week posttreatment TLG values of above and below 100 g were 10.9 and 26.9 months, respectively (p < 0.05). Pretreatment and posttreatment FTV and TLG showed very strong association with survival. These values can be useful quantitative criteria for patient selection and disease prognostication when {sup 90}Y SIRT is contemplated in patients with CRCLM. (orig.)

  16. EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with {sup 90}Y-radiolabelled ibritumomab tiuxetan (Zevalin)

    Energy Technology Data Exchange (ETDEWEB)

    Tennvall, Jan [Lund University Hospital, Department of Oncology, Lund (Sweden); Fischer, Manfred; Brans, Boudewijn [University Medical Centre, Department of Nuclear Medicine, Maastricht (Netherlands); Bischof Delaloye, Angelika [Centre Hospitalier Universitaire Vaudois, Service Medecine Nucleaire, Lausanne (Switzerland); Bombardieri, Emilio [Direzione Medicina Nucleare-Centro PET, Istituto Nazionale per la Cura e lo Studio dei Tumori, Milan (Italy); Bodei, Lisa [European Institute of Oncology, Division of Nuclear Medicine, Milan (Italy); Giammarile, Francesco [Centre Leon Berard, Service Medecine Nucleaire, Lyon (France); Lassmann, Michael [Universitaet Wuerzburg, Klinik und Poliklinik fuer Nuklearmedizin, Wuerzburg (Germany); Oyen, Wim [Radboud University, Nijmegen Medical Centre, Department of Nuclear Medicine, Nijmegen (Netherlands)

    2007-04-15

    In January 2004, EMEA approved {sup 90}Y-radiolabelled ibritumomab tiuxetan, Zevalin, in Europe for the treatment of adult patients with rituximab-relapsed or -refractory CD20+ follicular B-cell non-Hodgkin's lymphoma. The number of European nuclear medicine departments using Zevalin is continuously increasing, since the therapy is often considered successful. The Therapy, Oncology and Dosimetry Committees have worked together in order to define some EANM guidelines on the use of Zevalin, paying particular attention to the problems related to nuclear medicine. The purpose of this guideline is to assist the nuclear medicine physician in treating and managing patients who may be candidates for radio-immunotherapy. The guideline also stresses the need for close collaboration with the physician(s) treating the patient for the underlying disease. (orig.)

  17. Matched pairs dosimetry: {sup 124}I/{sup 131}I metaiodobenzylguanidine and {sup 124}I/{sup 131}I and {sup 86}Y/{sup 90}Y antibodies

    Energy Technology Data Exchange (ETDEWEB)

    Lopci, Egesta; Fanti, Stefano [Policlinico S.Orsola-Malpighi and University of Bologna, Bologna (Italy); Chiti, Arturo; Pepe, Giovanna; Antunovic, Lidija [IRCCS Humanitas, Nuclear Medicine, Rozzano, MI (Italy); Castellani, Maria Rita; Bombardieri, Emilio [Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan (Italy)

    2011-06-15

    The technological advances in imaging and production of radiopharmaceuticals are driving an innovative way of evaluating the targets for antineoplastic therapies. Besides the use of imaging to better delineate the volume of external beam radiation therapy in oncology, modern imaging techniques are able to identify targets for highly specific medical therapies, using chemotherapeutic drugs and antiangiogenesis molecules. Moreover, radionuclide imaging is able to select targets for radionuclide therapy and to give the way to in vivo dose calculation to target tissues and to critical organs. This contribution reports the main studies published on matched pairs dosimetry with {sup 124}I/{sup 131}I- and {sup 86}Y/{sup 90}Y-labelled radiopharmaceuticals, with an emphasis on metaiodobenzylguanidine (MIBG) and monoclonal antibodies. (orig.)

  18. Individualized dosimetry-based activity reduction of {sup 90}Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy

    Energy Technology Data Exchange (ETDEWEB)

    Binnebeek, Sofie van; Baete, Kristof; Vanbilloen, Bert; Terwinghe, Christelle; Mortelmans, Luc [University Hospitals Leuven, Nuclear Medicine, Leuven (Belgium); KU Leuven, Department of Imaging and Pathology, Leuven (Belgium); Koole, Michel [University Medical Centre Groningen, Department of Nuclear Medicine, Groningen (Netherlands); Mottaghy, Felix M. [University Hospital Aachen, Department of Nuclear Medicine, Aachen (Germany); Maastricht University Medical Center, Department of Nuclear Medicine, Maastricht (Netherlands); Clement, Paul M. [University Hospitals Leuven, Medical Oncology, Leuven (Belgium); KU Leuven, Laboratory of Experimental Oncology, Leuven (Belgium); Haustermans, Karin [University Hospitals Leuven, Radiation Oncology, Leuven (Belgium); KU Leuven, Department of Oncology, Leuven (Belgium); Cutsem, Eric van; Verslype, Chris [KU Leuven, Department of Oncology, Leuven (Belgium); University Hospitals Leuven, Division of Digestive Oncology, Leuven (Belgium); Verbruggen, Alfons [KU Leuven, Laboratory for Radiopharmacy, Leuven (Belgium); Bogaerts, Kris [KU Leuven, Division of Public Health and Primary Care (I-Biostat), Leuven (Belgium); Deroose, Christophe M. [University Hospitals Leuven, Nuclear Medicine, Leuven (Belgium); KU Leuven, Department of Imaging and Pathology, Leuven (Belgium); UZ Leuven, Nuclear Medicine, Leuven (Belgium)

    2014-06-15

    Assessment of kidney function evolution after {sup 90}Y-DOTATOC peptide receptor radionuclide therapy (PRRT) with capped activity administration based on a 37-Gy threshold of biological effective dose (BED) to the kidney. In a prospective phase II study, patients with metastasized neuroendocrine tumours were evaluated for therapy using 185 MBq {sup 111}In-pentetreotide with amino acid coinfusion. Planar whole-body images were acquired at four time-points after injection and kidney volumes were measured using CT/MRI. BED to the kidneys was estimated using an extended BED formula and biexponential renal clearance. Based on published BED dose-toxicity relationships, we allowed a maximal kidney BED of 37 Gy; if the calculated BED exceeded 37 Gy, treatment activity was reduced accordingly. Kidney function was assessed at baseline and at 18 months, predominantly using {sup 51}Cr-EDTA. The rate of renal function decline was expressed as annual glomerular filtration rate loss (aGFRL). Only 22 of 50 patients reached the 18-months time-point, with most missing patients having died due to disease progression. In the 22 patients who reached 18 months, no rapid kidney function deterioration was observed over the 18 months, aGFRL >33 % was not seen, and only three patients showed an increase of one toxicity grade and one patient an increase of two grades. No significant correlations between kidney volume (p = 0.35), baseline GFR (p = 0.18), risk factors for renal function loss (p = 0.74) and aGFRL were observed. Among the 28 patients who did not reach 18 months, one developed grade 4 kidney toxicity at 15 months after PRRT. Prospective dosimetry using a 37 Gy BED as the threshold for kidney toxicity is a good guide for {sup 90}Y-DOTATOC PRRT and is associated with a low risk of rapid renal function deterioration and evolution to severe nephrotoxicity. (orig.)

  19. Radioembolization of hepatocarcinoma with {sup 90}Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology

    Energy Technology Data Exchange (ETDEWEB)

    Chiesa, C.; Maccauro, M.; Aliberti, G.; Padovano, B.; Seregni, E.; Crippa, F. [Foundation IRCCS Istituto Nazionale Tumori, Nuclear Medicine Division, Milan (Italy); Mira, M.; Negri, A. [University of Milan, Postgraduate Health Physics School, Milan (Italy); Spreafico, C.; Morosi, C.; Civelli, E.; Lanocita, R.; Marchiano, A. [Foundation IRCCS Istituto Nazionale Tumori, Radiology 2, Milan (Italy); Romito, R.; Sposito, C.; Bhoori, S.; Facciorusso, A.; Mazzaferro, V. [Foundation IRCCS Istituto Nazionale Tumori, Surgery 1, Milan (Italy); Camerini, T. [Foundation IRCCS Istituto Nazionale Tumori, Scientific Direction, Milan (Italy); Carrara, M. [Foundation IRCCS Istituto Nazionale Tumori, Health Physics, Milan (Italy); Pellizzari, S. [University La Sapienza, Engineering Faculty, Rome (Italy); Migliorisi, M. [Foundation IRCCS Istituto Nazionale Tumori, Nuclear Medicine Division, Milan (Italy); Foundation IRCCS Istituto Nazionale Tumori, Clinical Engineering, Milan (Italy); De Nile, M.C. [University of Pavia, Physics Faculty, Pavia, Lombardy (Italy)

    2015-10-15

    The aim of this study was to optimize the dosimetric approach and to review the absorbed doses delivered, taking into account radiobiology, in order to identify the optimal methodology for an individualized treatment planning strategy based on {sup 99m}Tc-macroaggregated albumin (MAA) single photon emission computed tomography (SPECT) images. We performed retrospective dosimetry of the standard TheraSphere registered treatment on 52 intermediate (n = 17) and advanced (i.e. portal vein thrombosis, n = 35) hepatocarcinoma patients with tumour burden < 50 % and without obstruction of the main portal vein trunk. Response was monitored with the densitometric radiological criterion (European Association for the Study of the Liver) and treatment-related liver decompensation was defined ad hoc with a time cut-off of 6 months. Adverse events clearly attributable to disease progression or other causes were not attributed to treatment. Voxel dosimetry was performed with the local deposition method on {sup 99m}Tc-MAA SPECT images. The reconstruction protocol was optimized. Concordance of {sup 99m}Tc-MAA and {sup 90}Y bremsstrahlung microsphere biodistributions was studied in 35 sequential patients. Two segmentation methods were used, based on SPECT alone (home-made code) or on coregistered SPECT/CT images (IMALYTICS trademark by Philips). STRATOS trademark absorbed dose calculation was validated for {sup 90}Y with a single time point. Radiobiology was used introducing other dosimetric variables besides the mean absorbed dose D: equivalent uniform dose (EUD), biologically effective dose averaged over voxel values (BED{sub ave}) and equivalent uniform biologically effective dose (EUBED). Two sets of radiobiological parameters, the first derived from microsphere irradiation and the second from external beam radiotherapy (EBRT), were used. A total of 16 possible methodologies were compared. Tumour control probability (TCP) and normal tissue complication probability (NTCP) were

  20. 3D inpatient dose reconstruction from the PET-CT imaging of {sup 90}Y microspheres for metastatic cancer to the liver: Feasibility study

    Energy Technology Data Exchange (ETDEWEB)

    Fourkal, E.; Veltchev, I.; Lin, M.; Meyer, J. [Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 (United States); Koren, S. [Department of Radiation Oncology, Beth Israel Comprehensive Cancer Center, New York, New York 10011 (United States); Doss, M.; Yu, J. Q. [Department of Diagnostic Imaging, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 (United States)

    2013-08-15

    Purpose: The introduction of radioembolization with microspheres represents a significant step forward in the treatment of patients with metastatic disease to the liver. This technique uses semiempirical formulae based on body surface area or liver and target volumes to calculate the required total activity for a given patient. However, this treatment modality lacks extremely important information, which is the three-dimensional (3D) dose delivered by microspheres to different organs after their administration. The absence of this information dramatically limits the clinical efficacy of this modality, specifically the predictive power of the treatment. Therefore, the aim of this study is to develop a 3D dose calculation technique that is based on the PET imaging of the infused microspheres.Methods: The Fluka Monte Carlo code was used to calculate the voxel dose kernel for {sup 90}Y source with voxel size equal to that of the PET scan. The measured PET activity distribution was converted to total activity distribution for the subsequent convolution with the voxel dose kernel to obtain the 3D dose distribution. In addition, dose-volume histograms were generated to analyze the dose to the tumor and critical structures.Results: The 3D inpatient dose distribution can be reconstructed from the PET data of a patient scanned after the infusion of microspheres. A total of seven patients have been analyzed so far using the proposed reconstruction method. Four patients underwent treatment with SIR-Spheres for liver metastases from colorectal cancer and three patients were treated with Therasphere for hepatocellular cancer. A total of 14 target tumors were contoured on post-treatment PET-CT scans for dosimetric evaluation. Mean prescription activity was 1.7 GBq (range: 0.58–3.8 GBq). The resulting mean maximum measured dose to targets was 167 Gy (range: 71–311 Gy). Mean minimum dose to 70% of target (D70) was 68 Gy (range: 25–155 Gy). Mean minimum dose to 90% of target

  1. ANÁLISIS COMPARATIVO DE LOS EFECTOS AGUDOS DE SESIONES DE ENTRENAMIENTO DE FUERZA CON CARGAS DEL 90 Y 30% 1 RM.

    Directory of Open Access Journals (Sweden)

    Jorge Dopico Calvo

    2010-10-01

    Full Text Available En una medición inicial (Pretest se obtuvo la 1RM de 23 sujetos masculinos en el ejercicio press banca, así como la potencia y fuerza media aplicada al 90 y 30% de 1RM (PMED90, FMED90, PMED30, FMED 30. Posteriormente 11 sujetos (Gr90 llevaron a cabo 2 sesiones de entrenamiento con cargas del 90%, mientras los 12 sujetos restantes (Gr30 lo hacían con cargas del 30%. Inmediatamente finalizada cada una de las sesiones se valoraba nuevamente PMED90, FMED90, PMED30, FMED30. Una semana después de la finalización de los entrenamientos se efectuó un Postest. Los resultados mostraron una mejora estadísticamente significativa del rendimiento de Gr30 al final de cada una de las sesiones de entrenamiento, respecto a Pretest y Postest, con el 90% de 1RM, mientras que Gr90 obtuvo mejoras significativas con el 30% respecto a Pretest, pero no respecto a Postest.
    PALABRAS CLAVE: fuerza, potencia, medición, efecto agudo.

  2. Preliminary Study on Hydrogen Permeation and Stability of BaCe0.90Y0.10O3-δ Membrane under Asymmetric Atm osphere

    Institute of Scientific and Technical Information of China (English)

    2001-01-01

    @@High-temperature proton conductors (HTPC) have been extensively studied since I wahara et al?1? reported protonic conduction in SrCeO3-based oxid es. Later, the BaCeO3-based oxides, such as BaCe0.90Yb0.10O3- d (BCYb10) and BaCe0.90Y0.10-O3-d (BCY10), we re fou nd to show higher conductivity?2?. High electronic and protonic conducti vity makes BCY10 a potential membrane for hydrogen separation?3?. Thin f ilms with high density, most probably made by sequential coating on porous subst rates, are imperative in order to promote hydrogen permeation flux?4?. T his makes it more necessary for such membranes to be kept stable and unspoilt un der asymmetric hydrogen-permeation atmosphere at elevated temperatures. In this paper, the stability and hydrogen permeation ability of BCY10 membrane are stud ied by XRD, SEM, energy dispersive X-ray (EDX) analysis, H2-TPR process and hydrogen permeation experiment. The results showed that hydrogen cannot permeate through the BCY10 membrane without surface modification, and its surface cannot keep a uniform perovskite structure in the asymmetric atmosphere.

  3. 188Re-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside

    Science.gov (United States)

    Lepareur, Nicolas; Ardisson, Valérie; Noiret, Nicolas; Garin, Etienne

    2012-01-01

    Hepatocellular carcinoma (HCC) is the 5th most common tumour worldwide and has a dark prognosis. For nonoperable cases, metabolic radiotherapy with Lipiodol labelled with β-emitters is a promising therapeutic option. The Comprehensive Cancer Centre Eugène Marquis and the National Graduate School of Chemistry of Rennes (ENSCR) have jointly developed a stable and efficient labelling of Lipiodol with rhenium-188 (Eβmax = 2.1 MeV) for the treatment of HCC. The major “milestones” of this development, from the first syntheses to the recent first injection in man, are described. PMID:22518301

  4. (188)Re-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside.

    Science.gov (United States)

    Lepareur, Nicolas; Ardisson, Valérie; Noiret, Nicolas; Garin, Etienne

    2012-01-01

    Hepatocellular carcinoma (HCC) is the 5th most common tumour worldwide and has a dark prognosis. For nonoperable cases, metabolic radiotherapy with Lipiodol labelled with β-emitters is a promising therapeutic option. The Comprehensive Cancer Centre Eugène Marquis and the National Graduate School of Chemistry of Rennes (ENSCR) have jointly developed a stable and efficient labelling of Lipiodol with rhenium-188 (E(βmax) = 2.1 MeV) for the treatment of HCC. The major "milestones" of this development, from the first syntheses to the recent first injection in man, are described.

  5. Application of biotinylated and 32P probes for detection of P-fimbriae in urinary E. coli.

    Science.gov (United States)

    Jusková, E; Ciznár, I

    1993-01-01

    Escherichia coli is the common causative agent of urinary tract infections. Twenty-six strains of Escherichia coli were isolated from children with pyelonephritis, symptomatic urinary tract infections and asymptomatic bacteriuria. Biotinylated and 32P-DNA probes were prepared for detection of P-fimbriae in the isolates. Of the 13 strains isolated from patients with pyelonephritis 11 were positive for the presence of the P gene by both probes. Strains isolated from cases of symptomatic urinary tract infections revealed the presence of P gene only in three samples of the total of nine isolated. None of the isolated E. coli strains from asymptomatic bacteriuria was found positive for the presence of the P gene. The biotinylated probe was simple and easily applicable in standard laboratory conditions and therefore the authors recommend it for use in diagnostic laboratories.

  6. 32P-postlabelling analysis of dibenz[a,j]acridine-DNA adducts in mice: identification of proximate metabolites.

    Science.gov (United States)

    Talaska, G; Roh, J; Schamer, M; Reilman, R; Xue, W; Warshawsky, D

    1995-03-30

    N-Heterocyclic polynuclear aromatics are widely-occurring environmental pollutants formed during the pyrolysis of nitrogen-containing organic chemicals. Dibenz[a,j]acridine (DBA), a member of this class, has been shown to be a skin carcinogen in mice. We undertook studies to determine the organ distribution of DBA-DNA adducts and to identify the DBA metabolites which lead to the formation of carcinogen-DNA adducts in vivo. DBA and its metabolites, trans-DBA-1,2-dihydrodiol (DBA-1,2-DHD) trans-DBA-3,4-dihydrodiol (DBA-3,4-DHD) and trans-DBA-5,6-dihydrodiol (DBA-5,6-DHD), were topically applied on mice. DNA was isolated using enzyme-solvent extraction methods, and analyzed for carcinogen-DNA adducts using 32P-postlabelling. In skin, DBA produced two distinct adducts (Adducts 1 and 2). The same two adducts were seen when DBA-3,4-DHD was applied. In addition, the total adduct level elicited by DBA-3,4-DHD was twice that of the parent compound. Two adducts (Adducts 3 and 4) were also seen in mouse skin when DBA-5,6-DHD was applied, but these differed chromatographically from adducts seen with DBA. However, when DBA-3,4-DHD was applied and analyzed using sensitive nuclease P1 32P-postlabelling, all four adducts could be detected. These results suggest that the major route of DBA activation to DNA-binding species in skin is through formation of DBA-3,4-DHD and subsequent metabolism of this compound to a bay-region diol-epoxide. However, we postulate that another activation pathway may proceed through a bis-dihydrodiol-epoxide.

  7. Biodistribution, radiation dosimetry and scouting of {sup 90}Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using {sup 89}Zr-ibritumomab tiuxetan and PET

    Energy Technology Data Exchange (ETDEWEB)

    Rizvi, Saiyada N.F.; Lingen, Arthur van; Hoekstra, Otto S. [VU University Medical Center, Department of Nuclear Medicine and PET Research, PO Box 7057, Amsterdam (Netherlands); Visser, Otto J.; Zijlstra, Josee M.; Huijgens, Peter C. [VU University Medical Center, Department of Haematology, Amsterdam (Netherlands); Vosjan, Maria J.W.D.; Dongen, Guus A.M.S. van [VU University Medical Center, Department of Otolaryngology and Head and Neck Surgery, Amsterdam (Netherlands); Lubberink, Mark [VU University Medical Center, Department of Nuclear Medicine and PET Research, PO Box 7057, Amsterdam (Netherlands); Uppsala University, and Medical Physics, Uppsala University Hospital, Department of Nuclear Medicine and PET, Uppsala (Sweden)

    2012-03-15

    Positron emission tomography (PET) with {sup 89}Zr-ibritumomab tiuxetan can be used to monitor biodistribution of {sup 90}Y-ibritumomab tiuxetan as shown in mice. The aim of this study was to assess biodistribution and radiation dosimetry of {sup 90}Y-ibritumomab tiuxetan in humans on the basis of {sup 89}Zr-ibritumomab tiuxetan imaging, to evaluate whether co-injection of a therapeutic amount of {sup 90}Y-ibritumomab tiuxetan influences biodistribution of {sup 89}Zr-ibritumomab tiuxetan and whether pre-therapy scout scans with {sup 89}Zr-ibritumomab tiuxetan can be used to predict biodistribution of {sup 90}Y-ibritumomab tiuxetan and the dose-limiting organ during therapy. Seven patients with relapsed B-cell non-Hodgkin's lymphoma scheduled for autologous stem cell transplantation underwent PET scans at 1, 72 and 144 h after injection of {proportional_to}70 MBq {sup 89}Zr-ibritumomab tiuxetan and again 2 weeks later after co-injection of 15 MBq/kg or 30 MBq/kg {sup 90}Y-ibritumomab tiuxetan. Volumes of interest were drawn over liver, kidneys, lungs, spleen and tumours. Ibritumomab tiuxetan organ absorbed doses were calculated using OLINDA. Red marrow dosimetry was based on blood samples. Absorbed doses to tumours were calculated using exponential fits to the measured data. The highest {sup 90}Y absorbed dose was observed in liver (3.2 {+-} 1.8 mGy/MBq) and spleen (2.9 {+-} 0.7 mGy/MBq) followed by kidneys and lungs. The red marrow dose was 0.52 {+-} 0.04 mGy/MBq, and the effective dose was 0.87 {+-} 0.14 mSv/MBq. Tumour absorbed doses ranged from 8.6 to 28.6 mGy/MBq. Correlation between predicted pre-therapy and therapy organ absorbed doses as based on {sup 89}Zr-ibritumomab tiuxetan images was high (Pearson correlation coefficient r = 0.97). No significant difference between pre-therapy and therapy tumour absorbed doses was found, but correlation was lower (r = 0.75). Biodistribution of {sup 89}Zr-ibritumomab tiuxetan is not influenced by simultaneous

  8. Clinical impact of {sup 99m}Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with {sup 90}Y-loaded microspheres

    Energy Technology Data Exchange (ETDEWEB)

    Garin, Etienne [Cancer Institute Eugene Marquis, Department of Nuclear Medicine, Rennes (France); University of Rennes 1, Rennes (France); INSERM, U-991, Liver Metabolisms and Cancer, Rennes (France); Rolland, Yan [Cancer Institute Eugene Marquis, Department of Medical Imaging, Rennes (France); Laffont, Sophie [University of Rennes 1, Rennes (France); Edeline, Julien [University of Rennes 1, Rennes (France); INSERM, U-991, Liver Metabolisms and Cancer, Rennes (France); Cancer Institute Eugene Marquis, Department of Medical Oncology, Rennes (France)

    2016-03-15

    Radioembolization with {sup 90}Y-loaded microspheres is increasingly used in the treatment of primary and secondary liver cancer. Technetium-99 m macroaggregated albumin (MAA) scintigraphy is used as a surrogate of microsphere distribution to assess lung or digestive shunting prior to therapy, based on tumoral targeting and dosimetry. To date, this has been the sole pre-therapeutic tool available for such evaluation. Several dosimetric approaches have been described using both glass and resin microspheres in hepatocellular carcinoma (HCC) and liver metastasis. Given that each product offers different specific activities and numbers of spheres injected, their radiobiological properties are believed to lightly differ. This paper summarizes and discusses the available studies focused on MAA-based dosimetry, particularly concentrating on potential confounding factors like clinical context, tumor size, cirrhosis, previous or concomitant therapy, and product used. In terms of the impact of tumoral dose in HCC, the results were concordant and a response relationship and tumoral threshold dose was clearly identified, especially in studies using glass microspheres. Tumoral dose has also been found to influence survival. The concept of treatment intensification has recently been introduced, yet despite several studies publishing interesting findings on the tumor dose-metastasis relationship, no consensus has been reached, and further clarification is thus required. Nor has the maximal tolerated dose to the liver been well documented, requiring more accurate evaluation. Lung dose was well described, despite recently identified factors influencing its evaluation, requiring further assessment. MAA SPECT/CT dosimetry is accurate in HCC and can now be used in order to achieve a fully customized approach, including treatment intensification. Yet further studies are warranted for the metastasis setting and evaluating the maximal tolerated liver dose. (orig.)

  9. The use of gel dosimetry to measure the 3D dose distribution of a {sup 90}Sr/{sup 90}Y intravascular brachytherapy seed

    Energy Technology Data Exchange (ETDEWEB)

    Massillon-JL, G; Minniti, R; Mitch, M G; Soares, C G [Ionizing Radiation Division, National Institute of Standards and Technology, Gaithersburg, MD 20899 (United States); Maryanski, M J [MGS Research, Inc., Madison, CT 06443 (United States)], E-mail: massillon@fisica.unam.mx

    2009-03-21

    Absorbed dose distributions in 3D imparted by a single {sup 90}Sr/{sup 90}Y beta particle seed source of the type used for intravascular brachytherapy were investigated. A polymer gel dosimetry medium was used as a dosemeter and phantom, while a special high-resolution laser CT scanner with a spatial resolution of 100 {mu}m in all dimensions was used to quantify the data. We have measured the radial dose function, g{sub L}(r), observing that g{sub L}(r) increases to a maximum value and then decreases as the distance from the seed increases. This is in good agreement with previous data obtained with radiochromic film and thermoluminescent dosemeters (TLDs), even if the TLDs underestimate the dose at distances very close to the seed. Contrary to the measurements, g{sub L}(r) calculated through Monte Carlo simulations and reported previously steadily decreases without a local maximum as a function of the distance from the seed. At distances less than 1.5 mm, differences of more than 20% are observed between the measurements and the Monte Carlo calculations. This difference could be due to a possible underestimation of the energy absorbed into the seed core and encapsulation in the Monte Carlo simulation, as a consequence of the unknown precise chemical composition of the core and its respective density for this seed. The results suggest that g{sub L}(r) can be measured very close to the seed with a relative uncertainty of about 1% to 2%. The dose distribution is isotropic only at distances greater than or equal to 2 mm from the seed and is almost symmetric, independent of the depth. This study indicates that polymer gel coupled with the special small format laser CT scanner are valid and accurate methods for measuring the dose distribution at distances close to an intravascular brachytherapy seed.

  10. Early post-treatment FDG PET predicts survival after {sup 90}Y microsphere radioembolization in liver-dominant metastatic colorectal cancer

    Energy Technology Data Exchange (ETDEWEB)

    Sabet, Amir; Aouf, Anas; Sabet, Amin; Ghamari, Shahab; Biersack, Hans-Juergen [University Hospital, Department of Nuclear Medicine, Bonn (Germany); Meyer, Carsten; Pieper, Claus C. [University Hospital, Department of Radiology, Bonn (Germany); Mayer, Karin [University Hospital, Department of Medicine and Oncology, Bonn (Germany); Ezziddin, Samer [University Hospital, Department of Nuclear Medicine, Bonn (Germany); Saarland University, Department of Nuclear Medicine, Homburg (Germany)

    2014-10-29

    The aim of this study was to evaluate the predictive value of early metabolic response 4 weeks post-treatment using {sup 18}F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT in patients with unresectable hepatic metastases of colorectal cancer (CRC) undergoing radioembolization (RE) with {sup 90}Y-labelled microspheres. A total of 51 consecutive patients with liver-dominant metastases of CRC were treated with RE and underwent {sup 18}F-FDG PET/CT at baseline and 4 weeks after RE. In each patient, three hepatic metastases with the highest maximum standardized uptake value (SUV{sub max}) were selected as target lesions. Metabolic response was defined as >50 % reduction of tumour to liver ratios. Survival analyses using Kaplan-Meier and multivariate analyses were performed to identify prognostic factors for overall survival (OS). Investigated baseline characteristics included age (>60 years), performance status (Eastern Cooperative Oncology Group >1), bilirubin (>1.0 mg/dl), hepatic tumour burden (>25 %) and presence of extrahepatic disease. The median OS after RE was 7 months [95 % confidence interval (CI) 5-8]; early metabolic responders (n = 33) survived longer than non-responders (p < 0.001) with a median OS of 10 months (95 % CI 3-16) versus 4 months (95 % CI 2-6). Hepatic tumour burden also had significant impact on treatment outcome (p < 0.001) with a median OS of 5 months (95 % CI, 3-7) for patients with >25 % metastatic liver replacement vs 14 months (95 % CI 6-22) for the less advanced patients. Both factors (early metabolic response and low hepatic tumour burden) remained as independent predictors of improved survival on multivariate analysis. These are the first findings to show that molecular response assessment in CRC using {sup 18}F-FDG PET/CT appears feasible as early as 4 weeks post-RE, allowing risk stratification and potentially facilitating early response-adapted treatment strategies. (orig.)

  11. Feasibility and utility of re-treatment with {sup 177}Lu-DOTATATE in GEP-NENs relapsed after treatment with {sup 90}Y-DOTATOC

    Energy Technology Data Exchange (ETDEWEB)

    Severi, Stefano; Sansovini, Maddalena; Ianniello, Annarita; Nicolini, Silvia; Caroli, Paola; Paganelli, Giovanni [Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Nuclear Medicine Unit, Meldola, FC (Italy); Bodei, Lisa [European Institute of Oncology, Division of Nuclear Medicine, Milan (Italy); Ibrahim, Toni [Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Osteoncology and Rare Tumors Center, Meldola (Italy); Di Iorio, Valentina [Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Oncology Pharmacy Laboratory, Meldola (Italy); D' Errico, Vincenzo [Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Medical Physics Unit, Meldola (Italy); Monti, Manuela [Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Unit of Biostatistics and Clinical Trials, Meldola (Italy)

    2015-12-15

    Peptide receptor radionuclide therapy (PRRT) is a valid therapy for grade 1/2 gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs). Although a median progression-free survival (PFS) of more than 20 months is frequently observed, the majority of patients relapse after 2 - 3 years. In the present study, we investigated the use of low dosage re-treatment with {sup 177}Lu-DOTATATE (Lu-PRRT) in patients with GEP-NENs who relapsed after treatment with {sup 90}Y-DOTATOC (Y-PRRT). Upon tumour progression, 26 patients with a PFS of at least 12 months after Y-PRRT were consecutively enrolled in a phase II study of re-treatment with Lu-PRRT. All patients had preserved kidney and haematological parameters and received 14.8 - 18.5 GBq of Lu-PRRT in four or five cycles. The disease control rate (DCR), toxicity, PFS and prognostic factors were evaluated. Median total activity of Lu-PRRT was 16.5 GBq in five cycles. The DCR was 84.6 %, median PFS was 22 months (95 % CI 16 months - not reached) compared to 28 months (95 % CI 20 - 36 months) after Y-PRRT. Tumour burden and number of liver metastases were important prognostic factors. Toxicity was mild after Lu-PRRT re-treatment in the majority of patients, with only two patients with grade 2 and one with grade 3 bone marrow toxicity; one patient had grade 2 and one grade 3 renal toxicity. Patients with GEP-NEN who have previously responded to Y-PRRT are suitable candidates for Lu-PRRT re-treatment on progression. Although our sample size was limited, low-dosage Lu-PRRT was safe, and led to DCR and PFS rates comparable with those observed when Y-PRRT was used as primary treatment. (orig.)

  12. SU-E-T-02: 90Y Microspheres Dosimetry Calculation with Voxel-S-Value Method: A Simple Use in the Clinic

    Energy Technology Data Exchange (ETDEWEB)

    Maneru, F; Gracia, M; Gallardo, N; Olasolo, J; Fuentemilla, N; Bragado, L; Martin-Albina, M; Lozares, S; Pellejero, S; Miquelez, S; Rubio, A [Complejo Hospitalario de Navarra, Pamplona, Navarra (Spain); Otal, A [Hospital Clinica Benidorm, Benidorm, Alicante (Spain)

    2015-06-15

    Purpose: To present a simple and feasible method of voxel-S-value (VSV) dosimetry calculation for daily clinical use in radioembolization (RE) with {sup 90}Y microspheres. Dose distributions are obtained and visualized over CT images. Methods: Spatial dose distributions and dose in liver and tumor are calculated for RE patients treated with Sirtex Medical miscrospheres at our center. Data obtained from the previous simulation of treatment were the basis for calculations: Tc-99m maggregated albumin SPECT-CT study in a gammacamera (Infinia, General Electric Healthcare.). Attenuation correction and ordered-subsets expectation maximization (OSEM) algorithm were applied.For VSV calculations, both SPECT and CT were exported from the gammacamera workstation and registered with the radiotherapy treatment planning system (Eclipse, Varian Medical systems). Convolution of activity matrix and local dose deposition kernel (S values) was implemented with an in-house developed software based on Python code. The kernel was downloaded from www.medphys.it. Final dose distribution was evaluated with the free software Dicompyler. Results: Liver mean dose is consistent with Partition method calculations (accepted as a good standard). Tumor dose has not been evaluated due to the high dependence on its contouring. Small lesion size, hot spots in health tissue and blurred limits can affect a lot the dose distribution in tumors. Extra work includes: export and import of images and other dicom files, create and calculate a dummy plan of external radiotherapy, convolution calculation and evaluation of the dose distribution with dicompyler. Total time spent is less than 2 hours. Conclusion: VSV calculations do not require any extra appointment or any uncomfortable process for patient. The total process is short enough to carry it out the same day of simulation and to contribute to prescription decisions prior to treatment. Three-dimensional dose knowledge provides much more information than

  13. Late and very late catch-up after 90Sr/90Y beta-irradiation for the treatment of coronary in-stent restenosis.

    Science.gov (United States)

    Schiele, Thomas M; Herbst, Jan; Pöllinger, Barbara; Rieber, Johannes; König, Andreas; Sohn, Hae-Young; Krötz, Florian; Leibig, Marcus; Belka, Claus; Klauss, Volker

    2011-03-01

    Since late vessel failure has been speculated as a significant limitation of vascular brachytherapy (VBT), we conducted a prospective clinical evaluation at 6, 12, 24, 36 and 60 months follow-up after irradiation with (90)Sr/(90)Y for in-stent restenosis (ISR) regardless of the patient's symptomatic status. Complete five-year follow-up is reported for 104 consecutive patients. The cumulative rate of death was 13.5% (6 months: 0.96%; 12 months: 2.88%; 24 months: 4.81%; 36 months: 7.69%), of acute myocardial infarction 4.81% (2.88%; 4.81%; 4.81%; 4.81%), of late thrombotic occlusion 4.81% (3.85%; 4.81%; 4.81%; 4.81%), of target lesion revascularization (TLR) 27.9% (8.65%; 12.5%; 17.3%; 21.2%), of target vessel revascularization (TVR) 43.3% (12.5%; 19.2%; 22.1%; 29.8%), and of all major adverse cardiovascular events (MACE) 61.5% (16.3%; 26.9%; 31.7%; 42.3%), respectively. Considered that the annual incidence of TVR after the first year following drug-eluting stenting for in-stent restenosis has been reported as approximately 3% per year, an incidence of 5.8% per year following VBT of our study population clearly indicates a more pronounced, delayed and, even in the fifth year after the index procedure, ongoing restenotic process following beta-irradiation of in-stent restenotic lesions associated with clinically relevant adverse cardiovascular events.

  14. The use of gel dosimetry to measure the 3D dose distribution of a 90Sr/90Y intravascular brachytherapy seed.

    Science.gov (United States)

    Massillon-Jl, G; Minniti, R; Mitch, M G; Maryanski, M J; Soares, C G

    2009-03-21

    Absorbed dose distributions in 3D imparted by a single (90)Sr/(90)Y beta particle seed source of the type used for intravascular brachytherapy were investigated. A polymer gel dosimetry medium was used as a dosemeter and phantom, while a special high-resolution laser CT scanner with a spatial resolution of 100 microm in all dimensions was used to quantify the data. We have measured the radial dose function, g(L)(r), observing that g(L)(r) increases to a maximum value and then decreases as the distance from the seed increases. This is in good agreement with previous data obtained with radiochromic film and thermoluminescent dosemeters (TLDs), even if the TLDs underestimate the dose at distances very close to the seed. Contrary to the measurements, g(L)(r) calculated through Monte Carlo simulations and reported previously steadily decreases without a local maximum as a function of the distance from the seed. At distances less than 1.5 mm, differences of more than 20% are observed between the measurements and the Monte Carlo calculations. This difference could be due to a possible underestimation of the energy absorbed into the seed core and encapsulation in the Monte Carlo simulation, as a consequence of the unknown precise chemical composition of the core and its respective density for this seed. The results suggest that g(L)(r) can be measured very close to the seed with a relative uncertainty of about 1% to 2%. The dose distribution is isotropic only at distances greater than or equal to 2 mm from the seed and is almost symmetric, independent of the depth. This study indicates that polymer gel coupled with the special small format laser CT scanner are valid and accurate methods for measuring the dose distribution at distances close to an intravascular brachytherapy seed.

  15. Improving phosphorus availability from Patos phosphate rock for Eucalyptus: a study with 32P radiotracer; Melhorando a disponibilidade de fosforo da rocha fosforica de Patos para eucalipto: um estudo com radiotracador 32P

    Energy Technology Data Exchange (ETDEWEB)

    Villanueva, Felipe Carlos Alvarez [Instituto de Investigaciones Fundamentales en Agriculturea Tropical (INIFAT), Santiago de las Vegas, La Habana (Cuba)]. E-mail: falvarez@cena.usp.br; Muraoka, Takashi; Trevizam, Anderson Ricardo [Centro de Energia Nuclear na Agricultura (CENA), Piracicaba, SP (Brazil). Lab. de Fertilidade do Solo; Franzini, Vinicius Ide [Sao Paulo Univ., Piracicaba, SP (Brazil). Escola Superior de Agricultura Luiz de Queiroz. Programa de Pos-graduacao em Solos e Nutricao de Plantas; Rocha, Alexandre Prado [Escola de Engenharia de Piracicaba, SP (Brazil)

    2006-01-15

    Eucalyptus plantation in Brazil is generally set on low fertility soils, therefore phosphorus (P) fertilization is mandatory and increases the cost of plantation operation. Using species that more efficiently uptake phosphorus from less soluble sources is an interesting option. However, little is known about eucalyptus regarding its ability of using less soluble forms of phosphorus. The use of P by eucalyptus (E. urophylla, E. grandis, and E. urophylla E. grandis) was studied in greenhouse using a loamy-textured, hipodystrophic Typic Haplustox from the Cerrado region, and 32P isotopic method. The P sources tested were triple superphosphate (TSP), phosphate rock (PR) and the triple superphosphate mixed with PR (TSP+PR). The effectiveness of P sources in terms of increasing dry matter yield was TSP = (TSP + PR) > PR, and the P uptake followed the order (TSP + PR) > TSP > PR for both species plus the hybrid. The increase in P uptake from PR due to TSP influence was 217.3% for E. urophylla, 235.7% for E. grandis, and 28.7% for E. urophylla E. grandis, indicating an enhancement effect of TSP on the effectiveness of PR. The hybrid E. urophylla E. grandis was the most efficient genotype on P soil use and E. grandis most exigent in P fertilizer. (author)

  16. (32)P-postlabelling analysis of 1,3-butadiene-induced DNA adducts in vivo and in vitro.

    Science.gov (United States)

    Zhao, C; Koskinen, M; Hemminki, K

    2000-01-01

    Butadiene monoepoxide (BMO), epoxybutanediol (EBD) and diepoxybutane (DEB) are reactive metabolites of 1,3-butadiene (BD), an important industrial chemical classified as a probable human carcinogen. The covalent interactions of these metabolites with DNA lead to the formation of DNA adducts which may induce mutations or other types of DNA damage, resulting in tumour formation. In the present study, two pairs of diastereomeric N-1-BMO-adenine adducts were identified in the reaction of BMO with 2´-deoxyadenosine-5´-monophosphate (5´-dAMP). The major products formed by reacting EBD with 2´-deoxyguanosine-5´-monophosphate (5´-dGMP) were characterized as diastereomeric N-7-(2´,3´,4´-trihydroxybut-1´-yl)-5´-dGMP by UV and electrospray mass spectrometry. The formation of N-7-BMO-guanine adducts (1´-carbon, 60; 2´carbon, 54/10(4) nucleotides) in BMO-treated DNA was about four times higher than that of N-1-BMO-adenine adducts (1´-carbon, 20; 2´-carbon, 8.7/10(4) nucleotides). However, the recovery of N-1-BMO-adenine adducts in DNA (45 ± 5%) was two times higher than that of N-7-guanine adducts (20 ± 4%) by 32P-postlabelling analysis. Using the 32P-postlabelling/ HPLC assay, N-1-BMO-adenine, N-7-BMO-guanine and N-7-EBDguanine adducts were detected in BMO- or DEB-treated DNA and in liver DNA of rats exposed to BD by inhalation. The amount of N-7-EBD-guanine adducts (11/10(8) nucleotides) in rat liver was about three-fold higher than N-7-BMO-guanine adducts (4.0/10(8) nucleotides). The novel finding of N-1-BMO-adenine adducts formed in vivo may contribute to the understanding of the mechanisms of BD carcinogenic action.

  17. 胶体~(32) P-磷酸铬间质给药对犬累积损伤效应的研究%Cumulative damage effect of ~(32) P-colloidal chromic phosphate interstitial delivery on beagles

    Institute of Scientific and Technical Information of China (English)

    聂琦; 刘璐; 刘志勇; 黄培林; 兰兴昊; 高海林; 吴清华; 孙晋; 黄鹰

    2010-01-01

    目的 探讨胶体~(32)P-磷酸铬(~(32)P-CP)在正常Beagle犬的肝叶或臀大肌行间质注射的安全性.方法 10只Beagle犬,随机分成间质给药不同剂量(185和370 MBq)、不同部位(臀大肌和肝脏)及冷胶体对照5组(n=2).术后不同时间点称量体重,行血液生化学检查,ECT轫致辐射显像,组织形态学动态观察及连续测量体表、血液、尿液和粪便放射性计数率值.计量数据以均数±标准差((x)±s)表示,采用SPSS 13.0软件进行统计分析.结果 给药后ECT示肝脏组全肝显影,放射性分布呈团块状不均匀,肌肉组局部放射性持续浓聚,肝脏未见显影.术后第4组犬体重进行性减少,45 d时较术前减少2.7 kg,余组体重增值均数依序为3.0、1.6、0.8和3.1 kg.第4组血小板、红细胞术后有明显减少.分别于给药后23和45 d死亡,死亡前谷草转氨酶和谷丙转氨酶均有急剧升高;其余组间血液和血生化学差异无统计学意义.术后体表分区测定以注射部位放射性计数率值为最高,其次为膀胱、脾.肝脏组血液峰时为5 rain,峰值分别为0.5×10~7/min和1.0×10~7/min;肌肉组持续在3×10~5/min左右.组织学表现肌肉组和肝脏185 MBq组4周内有充血水肿改变,8周后组织结构恢复正常;肝脏370 MBq组4周内部分肝细胞坏死,6周时见大量肝细胞气球样变,充血水肿明显,肝小叶结构不清.尿液、粪便中放射性计数率肌肉组峰时均数分别为13和12 d,峰值为(42.0 ±3.3)x 10~4/min和(29.6±4.5)×10~4/min;肝脏组峰时为5和9 d,峰值为(49.0±10.2)×10~4/min和(28.5±7.1)×10~4/min.至30 d肌肉组从尿液和粪便中累积排泄率为36.58%和10.62%,肝脏组为23.48%和8.76%.吸收剂量肝脏组肝脏为(30.6 ±2.3)、(55.6±4.4)Gy;肌肉组肌肉注射部位为(53.4±3.1)、(98.1±3.3)Gy,肝脏为(2.3±1.3)、(6.5±1.2)Gy.结论 Beagle犬肝脏间质注射794.39 MBq/m~2,肝脏吸收剂量为56 Gy时有较强肝毒性及全身毒副作用,

  18. Evaluation of Soil Labile Phosphorus Using a Double—Labeling (32P and 33P) Technique

    Institute of Scientific and Technical Information of China (English)

    WANGGUANG-HUO

    1992-01-01

    Isotopic exchangeability of phosphorus in four Chinese soils with and without P application was studied by 32P and 33P double-labeling technique in relation to routine chemical extractions.The results showed that Bray-I and Bray-Ⅱ reagents could extract most of the fast exchangeable P.Not all of the Olsen-P belonged to fast exchangeable P,but it was about the same quantity of fast exchangeable P in a calcareous soil and a neutral soil without P application.Sequential fractionation of the soil phosphorus showed that most of the added radioisotopes in high P fixation red soils were tightly held by iron and aluminium oxides,which could be totally extracted only by 0.1M NaOH solution.In the neutral and calcareous soils most of the radioisotopes added were loosely held on the surface of soil particles and could be extracted by anion exchange resin.Phosphate application increased the resin-P fraction significantly for all the soils studied.

  19. Determination of 32P in urine for early estimation of the neutron exposure level for three victims of the JCO criticality accident.

    Science.gov (United States)

    Nishimura, Yoshikazu; Takeda, Hiroshi; Miyamoto, Kiriko; Watanabe, Yoshito; Kouno, Fuyuki; Kuroda, Noriko; Kim, Hee Sun; Yukawa, Masae

    2002-03-01

    In the criticality accident which occurred on 30 September 1999 at a uranium conversion facility in Tokai-mura, Japan, three workers were severely exposed to neutron and gamma-ray irradiation. Preliminary estimations of doses from blood properties and 24Na concentration in blood were 16-20, 6-10 and 1-4 gamma-ray gray-equivalent (gammaGyEq) respectively for the three workers. For apparent dose estimation, neutron-induced radionuclides in biological materials such as blood, hair and urine were measured. Accordingly, we detected 32p in urine samples. The concentration ratios of 32P in the urine for the three workers showed a similar tendency to those of 24Na in blood. This result indicated that the radioactivity of 32P in urine could be used to estimate the neutron exposure level.

  20. /sup 32/P-Postlabeling test for covalent DNA binding of chemicals in vivo: Application to a variety of aromatic carcinogens and methylating agents

    Energy Technology Data Exchange (ETDEWEB)

    Reddy, M.V.; Gupta, R.C.; Randerath, E.; Randerath, K.

    1984-02-01

    Carcinogen--DNA adducts were detected and determined by /sup 32/P-postlabeling assay after exposure of mouse or rat tissues in vivo to a total of 28 compounds comprising 7 arylamines and derivatives, 3 azo compounds, 2 nitroaromatics, 12 polycyclic aromatic hydrocarbons, and 4 methylating agents. DNA was isolated from mouse skin, mouse liver, and rat liver after treatment with the individual carcinogens, then digested enzymatically to deoxyribonucleoside 3'-monophosphates, which were converted to 5'-/sup 32/P-labeled deoxyribonucleoside 3',5'-bisphosphates by T4 polynucleotide kinase-catalyzed (/sup 32/P)phosphate transfer from (gamma-/sup 32/P)ATP. The nucleotides were resolved by anion-exchange t.l.c. on polyethyleneimine-cellulose and detected by autoradiography. The determination of low levels of DNA binding of the aromatic carcinogens entailed the removal of normal nucleotides prior to the resolution of adduct nucleotides. For this purpose, an alternative procedure employing reversed-phase t.l.c. was devised which offered advantages for the detection of quantitatively minor adducts. The procedures described enabled the detection of 1 aromatic DNA adduct in approximately 10(/sup 8/) normal nucleotides, while the limit of detection of methylated adducts was 1 adduct in approximately 6 X 10(/sup 5/) nucleotides. The results show that a great number of carcinogen-DNA adducts of diverse structure are substrates for /sup 32/P-labeling by polynucleotide kinase-catalyzed phosphorylation. Because covalent DNA adduct formation in vivo appears to be an essential property of the majority of chemical carcinogens, /sup 32/P-postlabeling analysis of carcinogen--DNA adducts in mammalian tissues may serve as a test for the screening of chemicals for potential carcinogenicity.

  1. Boosted selective internal radiation therapy with {sup 90}Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept

    Energy Technology Data Exchange (ETDEWEB)

    Garin, E.; Lenoir, L. [Comprehensive Cancer Center, Institute Eugene Marquis, Department of Nuclear Medicine, CS 44229, Rennes (France); University of Rennes 1, Rennes (France); INSERM, U-991, Liver Metabolisms and Cancer, Rennes (France); Edeline, J. [University of Rennes 1, Rennes (France); Comprehensive Cancer Center, Institute Eugene Marquis, Department of Medical Oncology, CS 44229, Rennes (France); Laffont, S. [Comprehensive Cancer Center, Institute Eugene Marquis, Department of Nuclear Medicine, CS 44229, Rennes (France); Mesbah, H.; Poree, P. [Comprehensive Cancer Center, Institute Eugene Marquis, Department of Medical Informatics, CS 44229, Rennes (France); Sulpice, L. [INSERM, U-991, Liver Metabolisms and Cancer, Rennes (France); Centre Hospitalier Universitaire Pontchaillou, Department of Digestive Surgery, Rennes (France); Boudjema, K. [University of Rennes 1, Rennes (France); INSERM, U-991, Liver Metabolisms and Cancer, Rennes (France); Centre Hospitalier Universitaire Pontchaillou, Department of Digestive Surgery, Rennes (France); Mesbah, M. [University of Pierre et Marie Curie, Paris (France); Guillygomarc' h, A. [Centre Hospitalier Universitaire Pontchaillou, Department of Hepatology, Rennes (France); Quehen, E. [Centre Hospitalier Universitaire Pontchaillou, Department of Radiology, Rennes (France); Pracht, M. [Comprehensive Cancer Center, Institute Eugene Marquis, Department of Medical Oncology, CS 44229, Rennes (France); Raoul, J.L. [Comprehensive Cancer Center, Institute Paoli Calmette, Department of Medical Oncology, Marseille (France); Clement, B. [INSERM, U-991, Liver Metabolisms and Cancer, Rennes (France); Rolland, Y. [Comprehensive Cancer Center, Institute Eugene Marquis, Department of Medical Imaging, CS 44229, Rennes (France); Boucher, E. [INSERM, U-991, Liver Metabolisms and Cancer, Rennes (France); Comprehensive Cancer Center, Institute Eugene Marquis, Department of Medical Oncology, CS 44229, Rennes (France)

    2013-07-15

    To evaluate the impact of dosimetry based on MAA SPECT/CT for the prediction of response, toxicity and survival, and for treatment planning in patients with hepatocellular carcinoma (HCC) treated with {sup 90}Y-loaded glass microspheres (TheraSphere registered). TheraSphere registered was administered to 71 patients with inoperable HCC. MAA SPECT/CT quantitative analysis was used for the calculation of the tumour dose (TD), healthy injected liver dose (HILD), and total injected liver dose. Response was evaluated at 3 months using EASL criteria. Time to progression (TTP) and overall survival (OS) were evaluated using the Kaplan-Meier method. Factors potentially associated with liver toxicity were combined to construct a liver toxicity score (LTS). The response rate was 78.8 %. Median TD were 342 Gy for responding lesions and 191 Gy for nonresponding lesions (p < 0.001). With a threshold TD of 205 Gy, MAA SPECT/CT predicted response with a sensitivity of 100 % and overall accuracy of 90 %. Based on TD and HILD, 17 patients underwent treatment intensification resulting in a good response rate (76.4 %), without increased grade III liver toxicity. The median TTP and OS were 5.5 months (2-9.5 months) and 11.5 months (2-31 months), respectively, in patients with TD <205 Gy and 13 months (10-16 months) and 23.2 months (17.5-28.5 months), respectively, in those with TD >205 Gy (p = 0.0015 and not significant). Among patients with portal vein thrombosis (PVT) (n = 33), the median TTP and OS were 4.5 months (2-7 months) and 5 months (2-8 months), respectively, in patients with TD <205 Gy and 10 months (6-15.2 months) and 21.5 months (12-28.5 months), respectively, in those with TD >205 Gy (p = 0.039 and 0.005). The median OS was 24.5 months (18-28.5 months) in PVT patients with TD >205 Gy and good PVT targeting on MAA SPECT/CT. The LTS was able to detect severe liver toxicity (n = 6) with a sensitivity of 83 % and overall accuracy of 97 %. Dosimetry based on MAA SPECT/CT was

  2. Peptide receptor radionuclide therapy with {sup 90}Y/{sup 177}Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours)

    Energy Technology Data Exchange (ETDEWEB)

    Puranik, Ameya D.; Kulkarni, Harshad R.; Singh, Aviral; Baum, Richard P. [Zentralklinik Bad Berka, THERANOSTICS Centre for Molecular Radiotherapy and Molecular Imaging, ENETS Center of Excellence, Bad Berka (Germany)

    2015-07-15

    Head and neck paragangliomas (HNPGLs) are rare tumours arising from autonomic nervous system ganglia. Although surgery offers the best chance of complete cure, there is associated morbidity due to the crucial location of these tumours. Radiotherapy arrests tumour growth and provides symptomatic improvement, but has long-term consequences. These tumours express somatostatin receptors (SSTR) and hence peptide receptor radionuclide therapy (PRRT) is now a treatment option. We assessed the molecular, morphological and clinical responses of inoperable HNPGLs to PRRT. Nine patients with inoperable HNPGL assessed between June 2006 and June 2014 were included. Four patients had a solitary lesion, four had multifocal involvement and one had distant metastases (bone and lungs). The patients were treated with PRRT using {sup 90}Y/{sup 177}Lu-labelled peptides after positive confirmation of SSTR expression on {sup 68}Ga-DOTATOC PET/CT. All patients received two to four courses of PRRT. Subsequent serial imaging with {sup 68}Ga-DOTATOC PET/CT was carried out every 6 months to assess response to treatment. Clinical (symptomatic) response was also assessed. Based on molecular response (EORTC) criteria, four of the nine patients showed a partial molecular response to treatment seen as significant decreases in SUV{sub max}, accompanied by a reduction in tumour size. Five patients showed stable disease on both molecular and morphological criteria. Six out of nine patients were symptomatic at presentation with manifestations of cranial nerve involvement, bone destruction at the primary site and metastatic bone pain. Molecular responses were correlated with symptomatic improvement in four out of these six patients; while two patients showed small reductions in tumour size and SUV{sub max}. The three asymptomatic patients showed no new lesions or symptomatic worsening. PRRT was effective in all patients, with no disease worsening seen, either in the form of neurological symptoms or

  3. Synthesis and characterization of a novel acryl amide-based yttrium imprinted sorbent via the ATRP approach for the preparation of medical-grade {sup 90}Y

    Energy Technology Data Exchange (ETDEWEB)

    Abedi, Mahvash [Nuclear Schience and Technology Research Institute (NSTRI), Tehran (Iran, Islamic Republic of); Shahid Beheshti Univ., Tehran (Iran, Islamic Republic of). Dept. of Chemistry; Shirvani-Arani, Simindokht; Bahrami-Samani, Ali [Nuclear Schience and Technology Research Institute (NSTRI), Tehran (Iran, Islamic Republic of); Nabid, Mohammad Reza [Shahid Beheshti Univ., Tehran (Iran, Islamic Republic of). Dept. of Chemistry

    2016-05-01

    Because of its favorable radionuclidic properties (pure beta emitter, E{sub βmax} = 2.28 MeV, T{sub 1/2} = 64.1 h), the preparation of carrier free {sup 90}Y is of a great importance in radiopharmacy. Herein, we report the synthesis, characterization, and application of a novel yttrium sorbent prepared on the basis of the ion-imprinting concept. The ion-imprinted polymer (IIP) was prepared by atom transfer radical copolymerization of acryl amide (AAm, functional monomer) and N,N'-methylenebisacrylamide (MBAAm) crosslinking agent in the presence of a complex of yttrium ions (template ions) with a homemade chelator, i.e., 2,2-bis(2-bromo-2-methylpropanoate)propane-1,3-disuccinate (also as initiator). For elimination of yttrium ions, which act as the template, the prepared particles were treated with 50% v:v HCl: H{sub 2}O to produce yttrium-imprinted polymeric sorbent. To control the imprinting effect, corresponding non-imprinted particles (NIP) were prepared in a similar manner except that yttrium ions were not used. The synthesized chemicals for the preparation of the chelator-initiator compound and the product itself were assessed in every step using {sup 1}H-NMR analysis. NIP and YIP were subjected to X-ray diffraction (XRD), infra-red spectroscopy (IR) and BET surface area analysis for characterization studies. Sorption/desorption studies were conducted, and the effects of potentially interfering ions, such as Sr{sup 2+} (α = 119.69) and Zr{sup 4+} (α = 73.01) in presence of radio-yttrium, were investigated (particle size: 50-100 μm, resultant recovery of > 99% within 60 min and a capacity of 33.33 mg Y(III) per gram of sorbent). The results showed that amounts of radio-yttrium as low as 250 μg could be extracted effectively with high radionuclidic and radiochemical purity from macro-gram amounts of strontium.

  4. Combination of chemical separation and data treatment for {sup 55}Fe, {sup 63}Ni, {sup 99}Tc, {sup 137}Cs and {sup 90}Sr/{sup 90}Y activity determination in radioactive waste by liquid scintillation

    Energy Technology Data Exchange (ETDEWEB)

    Mellado, J. [Departament de Quimica Analitica, Facultat de Quimica, Universitat de Barcelona, C/Marti Franques 1, 08028 Barcelona (Spain); Tarancon, A. [Departament de Quimica Analitica, Facultat de Quimica, Universitat de Barcelona, C/Marti Franques 1, 08028 Barcelona (Spain); Garcia, J.F. [Departament de Pintura, Facultat de Belles Arts, Universitat de Barcelona, C/Pau Gargallo 4, 08028 Barcelona (Spain)]. E-mail: jfgarcia@apolo.qui.ub.es; Rauret, G. [Departament de Quimica Analitica, Facultat de Quimica, Universitat de Barcelona, C/Marti Franques 1, 08028 Barcelona (Spain); Warwick, P. [Geoscience Advisory Unit, Southampton Oceanography Centre, Southampton SO14 3ZH (United Kingdom)

    2005-08-01

    Routine operations involving nuclear reactors and decommissioning activities require numerous chemical analyses. Most of the procedures developed for these chemical characterisations involve several separation steps to prepare the sample for measurement. Chemical treatments are time- and manpower-consuming, labour intensive and produce significant quantities of waste. In order to address this problem, we evaluate a data treatment procedure (multivariate calibration-PLS), which we propose as a substitute to some of these separation steps. Mixtures of beta emitter radionuclides of increasing complexity ({sup 90}Sr/{sup 90}Y-{sup 99}Tc, {sup 90}Sr/{sup 90}Y-{sup 99}Tc-{sup 63}Ni-{sup 137}Cs and {sup 90}Sr/{sup 90}Y-{sup 99}Tc-{sup 63}Ni-{sup 137}Cs-{sup 55}Fe) have been measured by liquid scintillation (LS) counting. The influences of quenching and level of activity was evaluated and the activity of unknown samples determined. Despite the spectra overlapping and low resolution of LS, relative errors in the activities quantification of unknown samples inside the range covered by the calibration matrix are lower than 15% whatever the number of radionuclides included in the solution was.

  5. The use of 32P Method to Evaluate the Growth of Lowland Rice Cultivated in a System of Rice Intensification (SRI

    Directory of Open Access Journals (Sweden)

    A. Citraresmini

    2013-08-01

    Full Text Available A pot experiment has been conducted to evaluate the growth of the Dyah Suci, a lowland rice variety, in an SRI (System of Rice Intensification planting system. The phosphorus-32 (32P isotope technique was used to evaluate the growth of plants in relation with their phosphorus uptake. The uptake was assumed to vary in the same direction as the growth of the plant. The 32P uptake is assumed to vary in the opposite direction to the plant’s total phosphorus uptake. Here the 32P uptake is expressed in count per minutes (cpm which is then transformed to disintegration per minute (dpm. The results show that, in terms of promoting the plant’s uptake of phosphorus, the SRI planting system is superior to the conventional planting system, and it is manifested in the higher dry weight of straw and grain. From this experiment it is concluded that the 32P method can be used satisfactorily as a tool for explaining the relation between P-uptake and plant growth

  6. Comparative synchronous fluorescence spectrophotometry and 32P-postlabeling analysis of PAH-DNA adducts in human lung and the relationship to TP53 mutations

    DEFF Research Database (Denmark)

    Andreassen, Åshild; Kure, Elin H.; Nielsen, Per Sabro;

    1996-01-01

    Polycyclic aromatic hydrocarbon (PAH)-DNA adducts were studied in human lung from 39 lung cancer patients by synchronous fluorescence spectrophotometric (SFS) and 32P-postlabeling assays. Regression analysis of the samples failed to detect any correlation between benzo[a]pyrene-diolepoxide (BPDE)...

  7. Procedure to carry out leakage test in beta radiation sealed sources emitters of {sup 90}Sr/{sup 90}Y; Procedimiento para realizar prueba de fuga en fuentes selladas de radiacion beta emisoras de {sup 90}Sr/{sup 90}Y

    Energy Technology Data Exchange (ETDEWEB)

    Alvarez R, J. T., E-mail: trinidad.alvarez@inin.gob.m [ININ, Departamento de Metrologia de Radiaciones Ionizantes, Laboratorio Secundario de Calibracion Dosimetrica, Carretera Mexico-Toluca s/n, 52750 Ocoyoacac, Estado de Mexico (Mexico)

    2010-09-15

    In the alpha-beta room of the Secondary Laboratory of Dosimetric Calibration of the Metrology Department of Ionizing Radiations ophthalmic applicators are calibrated in absorbed dose terms in water D{sub w}; these applicators, basically are emitter sealed sources of pure beta radiation of {sup 90}Sr / {sup 90}Y. Concretely, the laboratory quality system indicates to use the established procedure for the calibration of these sources, which establishes the requirement of to carry out a leakage test, before to calibrate the source. However, in the Laboratory leakage test certificates sent by specialized companies in radiological protection services have been received, in which are used gamma spectrometry equipment s for beta radiation leakage tests, since it is not reliable to detect pure beta radiation with a scintillating detector with NaI crystal, (because it could detect the braking radiation produced in the detector). Therefore the Laboratory has had to verify the results of the tests with a correct technique, with the purpose of determining the presence of sources with their altered integrity and radioactive material leakage. The objective of this work is to describe a technique for beta activity measurement - of the standard ISO 7503, part 1 (1988) - and its application with a detector Gm plane (type pankage) in the realization of leakage tests in emitter sources of pure beta radiation, inside the mark of quality assurance indicated by the report ICRU 76. (Author)

  8. Experimental Study of CT Guided 32P-CP-PLLA Microparticle Implantation in the Treatment of Rabbit VX2 Lung Tumor

    Directory of Open Access Journals (Sweden)

    Donghui PAN

    2011-01-01

    Full Text Available Background and objective 32P-chromic phosphate-poly (L-lactic acid (32P-CP-PLLA microparticle is a novel potent brachytherapy implant, which has good biocompatibility and biodegradability. The aim of this study is to investigate the changes of pathology and PET/CT images in VX2 rabbit tumor after treatment with intratumorol administration of 32P-CP-PLLA microparticles, and to explore the effects and influence of tumor growth and apoptosis related proteins in VX2 lung tumor treatment with 32P-CP-PLLA microparticles. Methods Twenty-four tumor bearing rabbits were randomly divided into 4 groups (6 in each group. Group 1, 2 and 3 were treated groups; group 4 was the control. Under CT guidance, 32P-CPPLLA microparticles were implanted into tumors. Low, medium and high treatment doses were 93 MBq (group 1, 185 MBq (group 2 and 370 MBq (group 3, respectively. 18F-FDG PET/CT was performed at d0, d3, d7 and d14 after intratumoral administration. In the control group, 18F-FDG PET/CT images were acquired at the same time points but without treatment. The standardized uptake value (SUV of tumor regions were calculated. After last PET/CT imaging, the rabbits were euthanized and the tumors were removed for histological and immunohistochemical examination. The pathology and the expression of apoptosis related proteins (bcl-2, bax were compared. Results No significant difference of SUVmax was observed between the treatment groups and the control group at d0. At d14, the SUVmax values for group 1, 2 and 3 were 0.80±0.10, 1.1±0.19 and 2.85±0.15, respectively, and were significantly lower than that of the control group (5.61±0.50(P < 0.05. Significant dose-response relationship was observed in SUVmax between group 1 and group 2, and the SUV values gradually decreased from d7 to d14 after treatment. In group 3, SUVmax gradually increased and reached a peak at d7 then significantly decreased. The SUVmax values of group 3 were significantly lower than those of

  9. Improvement of Arbuscular Mycorrhiza Development by Inoculation of Soil with Phosphate-Solubilizing Rhizobacteria To Improve Rock Phosphate Bioavailability ((sup32)P) and Nutrient Cycling

    OpenAIRE

    Toro, M.; Azcon, R.; Barea, J.

    1997-01-01

    The interactive effect of phosphate-solubilizing bacteria and arbuscular mycorrhizal (AM) fungi on plant use of soil P sources of low bioavailability (endogenous or added as rock phosphate [RP] material) was evaluated by using soil microcosms which integrated (sup32)P isotopic dilution techniques. The microbial inocula consisted of the AM fungus Glomus intraradices and two phosphate-solubilizing rhizobacterial isolates: Enterobacter sp. and Bacillus subtilis. These rhizobacteria behaved as "m...

  10. Computed tomography hepatic arteriography has a hepatic falciform artery detection rate that is much higher than that of digital subtraction angiography and 99mTc-MAA SPECT/CT: Implications for planning 90Y radioembolization?

    Energy Technology Data Exchange (ETDEWEB)

    Burgmans, M.C., E-mail: mburgmans@hotmail.com [Department of Diagnostic Radiology, Singapore General Hospital, Outram Road, Singapore 169608 (Singapore); Too, C.W., E-mail: too.chow.wei@singhealth.com.sg [Department of Diagnostic Radiology, Singapore General Hospital, Outram Road, Singapore 169608 (Singapore); Kao, Y.H., E-mail: yung.h.kao@gmail.com [Department of Nuclear Medicine and PET, Singapore General Hospital, Outram Road, Singapore 169608 (Singapore); Goh, A.S.W., E-mail: anthony.goh.s.w@sgh.com.sg [Department of Nuclear Medicine and PET, Singapore General Hospital, Outram Road, Singapore 169608 (Singapore); Chow, P.K.H., E-mail: gsupc@singnet.com.sg [Department of General Surgery, Singapore General Hospital, Outram Road, Singapore 169608 (Singapore); Office of Clinical Sciences, Duke-NUS Graduate Medical School Singapore, 8 College Road, Singapore 169857 (Singapore); Department of Surgical Oncology, National Cancer Center Singapore, 11 Hospital Drive, Singapore 169610 (Singapore); Tan, B.S., E-mail: tan.bien.soo@sgh.com.sg [Department of Diagnostic Radiology, Singapore General Hospital, Outram Road, Singapore 169608 (Singapore); Tay, K.H., E-mail: tay.kiang.hiong@sgh.com.sg [Department of Diagnostic Radiology, Singapore General Hospital, Outram Road, Singapore 169608 (Singapore); Lo, R.H.G., E-mail: richard.lo.h.g@sgh.com.sg [Department of Diagnostic Radiology, Singapore General Hospital, Outram Road, Singapore 169608 (Singapore)

    2012-12-15

    Purpose: To compare the hepatic falciform artery (HFA) detection rates of digital subtraction angiography (DSA), computed tomography hepatic arteriography (CTHA) and 99mTc-macroaggregated albumin (99mTc-MAA) single photon emission computed tomography with integrated CT (SPECT/CT) and to correlate HFA patency with complication rates of yttrium-90 (90Y) radioembolization. Material and methods: From August 2008 to November 2010, 79 patients (range 23–83 years, mean 62.3 years; 67 male) underwent pre-treatment DSA, CTHA and 99mTc-MAA scintigraphy (planar/SPECT/CT) to assess suitability for radioembolization with 90Y resin microspheres. Thirty-seven patients were excluded from the study, because CTHA was performed with a catheter position that did not result in opacification of the liver parenchyma adjacent to the falciform ligament. DSA, CTHA and 99mTc-MAA SPECT/CT images and medical records were retrospectively reviewed. Results: A patent HFA was detected in 22 of 42 patients (52.3%). The HFA detection rates of DSA, CTHA and 99mTc-MAA SPECT/CT were 11.9%, 52.3% and 13.3%, respectively (p < 0.0001). An origin from the segment 4 artery was seen in 51.7% of HFAs. Prophylactic HFA coil-embolization prior to 90Y microspheres infusion was performed in 2 patients. Of the patients who underwent radioembolization with a patent HFA, none developed supra-umbilical radiation dermatitis. One patient experienced epigastric pain attributed to post-embolization syndrome and was managed conservatively. Conclusion: The HFA detection rate of CTHA is superior to that of DSA and 99mTc-MAA SPECT/CT. Complications related to non-target radiation of the HFA vascular territory rarely occur, even in patients undergoing radioembolization with a patent HFA.

  11. DETECTION OF STRAND BREAKS OF DNA IN HUMAN EARLY CHORIONIC VILLUS CELLS INDUCED BY DIAGNOSTIC ULTRASOUND USING 32p-LABELED ALU HYBRIDIZATION

    Institute of Scientific and Technical Information of China (English)

    Wang Caifeng; Li Xu; Zhang Yunjing

    2006-01-01

    Objective To explore if strand breaks of DNA in human early chorionic villus cells in uterus were induced by diagnostic ultrasound and to evaluate the method used for detection of single-stranded breaks and doublestranded breaks in human DNA. Methods 60 normal pregnant women aged 20-30, who underwent artificial abortion during 6-8 weeks of gestation, were randomly divided into 2 experimental groups: All 30 cases were exposed to diagnostic ultrasound in uterus for 10 minutes, and 24 hours later chorionic villi were extracted; the other 30 cases were taken as the control group. Single-stranded DNA and double-stranded DNA in villus cells in all cases were isolated by the alkaline unwinding combined with hydroxylapatite chromatography, and were quantitatively detected using32 P-labeled Alu probe for dot-blotting hybridization. Results There was no significant difference in quantity and percentage in single-stranded DNA and double-stranded DNA between 2 groups (P>0.05). 32 P-Alu probe could only hybridize with human DNA, and could detect DNA isolated from as few as 2.5 × 103 chorionic villus cells and 0.45 ng DNA in human leukocytes. Conclusion The results suggested that there were no DNA strand damages in human chorionic villus cells when the uterus was exposed to diagnostic ultrasound for 10 minutes. The method, 32P-Alu probe for dot-blotting hybridization, was even more specific, sensitive and accurate than conventional approaches.

  12. Determination of the ATP Affinity of the Sarcoplasmic Reticulum Ca(2+)-ATPase by Competitive Inhibition of [γ-(32)P]TNP-8N3-ATP Photolabeling.

    Science.gov (United States)

    Clausen, Johannes D; McIntosh, David B; Woolley, David G; Andersen, Jens Peter

    2016-01-01

    The photoactivation of aryl azides is commonly employed as a means to covalently attach cross-linking and labeling reagents to proteins, facilitated by the high reactivity of the resultant aryl nitrenes with amino groups present in the protein side chains. We have developed a simple and reliable assay for the determination of the ATP binding affinity of native or recombinant sarcoplasmic reticulum Ca(2+)-ATPase, taking advantage of the specific photolabeling of Lys(492) in the Ca(2+)-ATPase by [γ-(32)P]2',3'-O-(2,4,6-trinitrophenyl)-8-azido-adenosine 5'-triphosphate ([γ-(32)P]TNP-8N3-ATP) and the competitive inhibition by ATP of the photolabeling reaction. The method allows determination of the ATP affinity of Ca(2+)-ATPase mutants expressed in mammalian cell culture in amounts too minute for conventional equilibrium binding studies. Here, we describe the synthesis and purification of the [γ-(32)P]TNP-8N3-ATP photolabel, as well as its application in ATP affinity measurements.

  13. Radiosynovectomy

    Energy Technology Data Exchange (ETDEWEB)

    Kim, Deog Yoon [Kyunghee University School of Medicine, Seoul (Korea, Republic of)

    2006-04-15

    Radiosynovectomy has been used as an effective treatment in patients with resistant synovitis after failure of long-term medication and intraarticular steroid injection. Although {sup 90}Y silicate/citrate, {sup 186}Re sulfide, and {sup 169}Er citrate were approved in Europe for the appropriate radiopharmaceuticals for radiosynovectomy, other radionuclides such as {sup 32}P-chromic phosphate, {sup 165}Dy-ferric hydroxide macroaggregate, {sup 188}Rh-microspheres, {sup 153}Sm-particulate, and {sup 166}Ho- ferric hydroxide macroaggregate have been used in many countries. Reported success rates range from 40% to 90% for the different joints and underlying disease. In Korea, {sup 188}Re-tin-colloid and {sup 166}Ho-chitosan complex are now using as the major radionuclides in radiosynovectomy with good clinical results. A study on radiation synovectomy using {sup 188}Re-tin-colloid for patients with Korean rheumatoid arthritis shows the treatment resulted in the improvement of arthritis and well tolerated. In our study, the radiosynovectomy with {sup 166}Ho- chitosan complex in 53 hemophilic patients markedly decreased intra-articular bleeding frequency and need for coagulation factor. This review includes general principles in the application of radiosynovectomy and the clinical experience in Korea.

  14. Tumour targeting and radiation dose of radioimmunotherapy with {sup 90}Y-rituximab in CD20+ B-cell lymphoma as predicted by {sup 89}Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab

    Energy Technology Data Exchange (ETDEWEB)

    Muylle, Kristoff [Vrije Universiteit Brussel, MIMA Research Group, Brussels (Belgium); Universite Libre de Bruxelles, Department of Nuclear Medicine, Jules Bordet Institute, Brussels (Belgium); Flamen, Patrick; Guiot, Thomas; Ghanem, Ghanem; Meuleman, Nathalie; Bourgeois, Pierre; Vanderlinden, Bruno; Vaes, Melanie; Bron, Dominique [Universite Libre de Bruxelles, Jules Bordet Institute, Brussels (Belgium); Vugts, Danielle J.; Dongen, Guus A.M.S. van [VU University Medical Centre, Amsterdam (Netherlands); Everaert, Hendrik [Vrije Universiteit Brussel, UZ Brussel, Brussels (Belgium); Vrije Universiteit Brussel, MIMA Research Group, Brussels (Belgium)

    2015-07-15

    To compare using immuno-PET/CT the distribution of {sup 89}Zr-labelled rituximab without and with a preload of unlabelled rituximab to assess the impact of preloading with unlabelled rituximab on tumour targeting and radiation dose of subsequent radioimmunotherapy with {sup 90}Y-labelled rituximab in CD20+ B-cell lymphoma. Five patients with CD20+ B-cell lymphoma and progressive disease were prospectively enrolled. All patients underwent three study phases: initial dosimetric phase with baseline {sup 89}Zr-rituximab PET/CT imaging without a cold preload, followed 3 weeks later by a second dosimetric phase with administration of a standard preload (250 mg/m{sup 2}) of unlabelled rituximab followed by injection of {sup 89}Zr-rituximab, and a therapeutic phase 1 week later with administration of unlabelled rituximab followed by {sup 90}Y-rituximab. PET/CT imaging and tracer uptake by organs and lesions were assessed. With a cold rituximab preload, the calculated whole-body dose of {sup 90}Y-rituximab was similar (mean 0.87 mSv/MBq, range 0.82-0.99 mSv/MBq) in all patients. Without a preload, an increase in whole-body dose of 59 % and 87 % was noted in two patients with preserved circulating CD20+ B cells. This increase in radiation dose was primarily due to a 12.4-fold to 15-fold higher dose to the spleen without a preload. No significant change in whole-body dose was noted in the three other patients with B-cell depletion. Without a preload, consistently higher tumour uptake was noticed in patients with B-cell depletion. Administration of the standard preload of unlabelled rituximab impairs radioconjugate tumour targeting in the majority of patients eligible for radioimmunotherapy, that is patients previously treated with rituximab-containing therapeutic regimens. This common practice may need to be reconsidered and further evaluated as the rationale for this high preload has its origin in the ''prerituximab era''. (orig.)

  15. Phase I/II {sup 90}Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma

    Energy Technology Data Exchange (ETDEWEB)

    Wiseman, G.A.; Dunn, W.L. [Dept. Radiology, Nuclear Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN (United States); White, C.A.; Berlfein, J.R.; Ding, E.; Grillo-Lopez, A.J. [IDEC Pharmaceuticals Corp., San Diego, CA (United States); Stabin, M.; Erwin, W.; Spies, S. [Division of Hematology/Oncology, Department of Medicine, Northwestern University and Robert H. Lurie Comprehensive Cancer Center, Chicago, Il (United States); Dahlbom, M.; Silverman, D.H.S. [University of California at Los Angeles, Los Angeles, CA (United States); Raubitschek, A. [City of Hope, Duarte, CA (United States); Karvelis, K. [Henry Ford Hospital, Detroit, MI (United States); Schultheiss, T. [Fox Chase Cancer Center, Philadelphia, PA (United States); Witzig, T.E. [Dept. of Internal Medicine Division of Hematology, Mayo Clinic and Mayo Foundation, Rochester, MN (United States); Belanger, R. [Ryan Belanger Associates, San Diego, CA (United States)

    2000-07-01

    Dosimetry studies in patients with non-Hodgkin's lymphoma were performed to estimate the radiation absorbed dose to normal organs and bone marrow from {sup 90}Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) treatment in this phase I/II, multicenter trial. The trial was designed to determine the dose of Rituximab (chimeric anti-CD20, Rituxan, IDEC-C2B8, MabThera), the unlabeled antibody given prior to the radioconjugate to clear peripheral blood B cells and optimize distribution, and to determine the maximum tolerated dose of {sup 90}Y-Zevalin [7.4, 11, or 15 MBq/kg (0.2, 0.3, or 0.4 mCi/kg)]. Patients received {sup 111}In-Zevalin (indium-111 ibritumomab tiuxetan, IDEC-In2B8) on day 0 followed by a therapeutic dose of {sup 90}Y-Zevalin on day 7. Both doses were preceded by an infusion of the chimeric, unlabeled antibody Rituximab. Following administration of {sup 111}In-Zevalin, serial anterior/posterior whole-body scans were acquired. Major-organ radioactivity versus time estimates were calculated using regions of interest. Residence times were computed and entered into the MIRDOSE3 computer software program to calculate estimated radiation absorbed dose to each organ. Initial analyses of estimated radiation absorbed dose were completed at the clinical site. An additional, centralized dosimetry analysis was performed subsequently to provide a consistent analysis of data collected from the seven clinical sites. In all patients with dosimetry data (n=56), normal organ and red marrow radiation absorbed doses were estimated to be well under the protocol-defined upper limit of 20 Gy and 3 Gy, respectively. Median estimated radiation absorbed dose was 3.4 Gy to liver (range 1.2-7.8 Gy), 2.6 Gy to lungs (range 0.72-4.4 Gy), and 0.38 Gy to kidneys (range 0.07-0.61 Gy). Median estimated tumor radiation absorbed dose was 17 Gy (range 5.8-67 Gy). No correlation was noted between hematologic toxicity and the following variables: red marrow radiation absorbed dose

  16. The quantitative radiation dose of 32P by chromosomal aberration%染色体畸变率估算32P的辐射剂量

    Institute of Scientific and Technical Information of China (English)

    施常备; 许建林; 袁勇; 陆建荣; 袁彬; 赵明刚; 王翔; 陈葳; 邓敬兰

    2012-01-01

    Objective To quantify the radiation dose of32P by the G-banding chromosomal aberration rate.Methods The human blood was irradiated by 4 MV X-ray of 0.5,1,2,4 Gy respectively.The doseresponse curve between the radiation dose and the dicentrics aberration rate was assayed.74 kBq 32p colloid was put into culture solution and,after 72 h,the dicentrics aberration rate was observed.The radiation dose of 32p was assayed by the dose-response curve.Results The dose-response curve between the radiation dose and the dicentrics aberration rate was y=24.05x-13.34 (R2=0.975).The dicentrics aberration rate of 74 kBq 32p was 18% and the radiation dose of 32p in 5 ml culture solution during 72 h was 1.3 Gy.Conclusion The radiation dose of radionuclide can be estimated by chromosomal aberration rate.%目的 应用G显带的染色体双着丝粒畸变率评估32p的辐射剂量.方法 应用4 MV的X射线对离体人血液进行0.5 Gy、1 Gy、2 Gy和4 Gy的照射,建立染色体双着丝粒畸变率和X射线的辐射剂量的剂量-效应曲线.将74 kBq的32p胶体加入淋巴细胞的培养液后72 h,进行G显带染色体分析,通过X射线的辐射剂量和染色体双着丝粒畸变率的剂量-效应曲线来评估32p的辐射剂量.结果 4 MV的X射线的辐射剂量和染色体的双着丝粒畸变率呈线性正相关,剂量-效应曲线为y=24.05x- 13.34 (R2=0.975).74 kBq的32P胶体产生的染色体双着丝粒畸变率为18%,即74 kBq的32p胶体在5 ml淋巴细胞培养液中72 h约产生1.3 Gy的辐射剂量.结论 应用染色体畸变率可以有效地评估放射性核素的内照射剂量.

  17. 32P-磷酸铬-聚-L-乳酸粒子植入治疗裸鼠荷人胰腺癌移植瘤的研究%Experimental study of 32P-CP-PLLA microparticle on human pancreatic carcinoma in nude mice

    Institute of Scientific and Technical Information of China (English)

    王立振; 杨敏; 徐宇平; 潘栋辉; 黄培林; 刘璐; 邵国强

    2011-01-01

    目的 探讨32p-磷酸铬-聚-L-乳酸(32P-CP-PLLA)粒子瘤体间质给药治疗BALB/c裸鼠荷人胰腺癌( BxPc-3)移植瘤的药效学及全身不良反应.方法 24只荷瘤裸鼠,随机分为4组:空白对照组、37.0、18.5、9.3 MBq组.经瘤体分别给予剂量为0、9.3、18.5和37.0 MBq 32p-CP-PLLA粒子,动态观察各组相对肿瘤增殖率、体重变化,并计数WBC和PLT.注射后14d取出瘤块,进行形态学观察及免疫组织化学分析.结果 32P-CP-PLLA粒子治疗组相对肿瘤增殖率均<40%.病理切片显示近粒子处肿瘤细胞变性坏死.与空白对照组比较,治疗组微血管密度( MVD)和Bcl-2表达强度均低于对照组,Bax表达强度高于对照组,治疗组Bcl-2/Bax比值明显下调,0、9.3、18.5和37.0 MBq 32p-CP-PLLA粒子组Bcl-2/Bax比值分别为3.83±0.43、2.19±0.57、1.10±0.32和0.47±0.13(t=2.36~2.77,P<0.05).微血管密度分别为(31.2±2.3)、(23.8±1.5)、(14.8±0.8)和(11.0±1.2)个/视野.治疗组间的免疫组织化学分析指标差异有统计学意义(t=2.30 ~2.57,P<0.05).结论 32P-CP-PLLA粒子瘤体间质给药是治疗胰腺癌安全、简便、有效的核素介入疗法.%Objective To study the therapeutic and toxic effects of 32 P-chromic phosphate-poly (L-lactic) acid (32p-CP-PLLA) microparticle intratumoral administration into BALB/c nude mice bearing BxPc-3 human pancreatic carcinoma.Methods Twenty four nude mice bearing tumors were injected with 0,9.3,18.5 and 37.0 M Bq 32p-CP-PLLA microparticle,respectively.The relative tumor growth rates were observed every day,and white blood cells,platelets and body weight were measured.At 14 d after administration,the tumors were removed,histological examination and immunohistochemical analysis were performed.Results The relative tumor growth rates of each treatment group was lower than 40%.Histological examination showed the degenerative necrosis at the site nearby the mircoparticle.Immunohistochemical analysis showed that

  18. DNA damage induced by the environmental carcinogen butadiene: identification of a diepoxybutane-adenine adduct and its detection by 32P-postlabelling.

    Science.gov (United States)

    Leuratti, C; Jones, N J; Marafante, E; Kostiainen, R; Peltonen, K; Waters, R

    1994-09-01

    To date only a few studies have been undertaken on DNA adducts formed by epoxybutene (EB) and diepoxybutane (DEB), the two active metabolites of 1,3-butadiene. Our interests have focused on further investigating DNA alkylation by the two epoxides, especially in relation to the development of a method for human biomonitoring. Here, following the reaction of deoxyadenosine monophosphate and poly(dA-dT)(dA-dT) with DEB and subsequent HPLC, we have identified an adenine adduct. MS analyses indicate the structure of an adenine adducted by DEB at the N6 position. A HPLC/32P-postlabelling method was developed for its measurement in DNA samples and the adduct was detected in calf thymus DNA and DNA from Chinese hamster ovary cells exposed to DEB. The 100% labelling efficiency during postlabelling, the amount of the adduct and its elution before the normal nucleotides during HPLC suggest it could be a suitable indicator of BUT exposure.

  19. Improvement of Arbuscular Mycorrhiza Development by Inoculation of Soil with Phosphate-Solubilizing Rhizobacteria To Improve Rock Phosphate Bioavailability ((sup32)P) and Nutrient Cycling.

    Science.gov (United States)

    Toro, M; Azcon, R; Barea, J

    1997-11-01

    The interactive effect of phosphate-solubilizing bacteria and arbuscular mycorrhizal (AM) fungi on plant use of soil P sources of low bioavailability (endogenous or added as rock phosphate [RP] material) was evaluated by using soil microcosms which integrated (sup32)P isotopic dilution techniques. The microbial inocula consisted of the AM fungus Glomus intraradices and two phosphate-solubilizing rhizobacterial isolates: Enterobacter sp. and Bacillus subtilis. These rhizobacteria behaved as "mycorrhiza helper bacteria" promoting establishment of both the indigenous and the introduced AM endophytes despite a gradual decrease in bacterial population size, which dropped from 10(sup7) at planting to 10(sup3) CFU g(sup-1) of dry rhizosphere soil at harvest. Dual inoculation with G. intraradices and B. subtilis significantly increased biomass and N and P accumulation in plant tissues. Regardless of the rhizobacterium strain and of the addition of RP, AM plants displayed lower specific activity ((sup32)P/(sup31)P) than their comparable controls, suggesting that the plants used P sources not available in their absence. The inoculated rhizobacteria may have released phosphate ions ((sup31)P), either from the added RP or from the less-available indigenous P sources, which were effectively taken up by the external AM mycelium. Soluble Ca deficiency in the test soil may have benefited P solubilization. At least 75% of the P in dually inoculated plants derived from the added RP. It appears that these mycorrhizosphere interactions between bacterial and fungal plant associates contributed to the biogeochemical P cycling, thus promoting a sustainable nutrient supply to plants.

  20. Improvement of Arbuscular Mycorrhiza Development by Inoculation of Soil with Phosphate-Solubilizing Rhizobacteria To Improve Rock Phosphate Bioavailability ((sup32)P) and Nutrient Cycling

    Science.gov (United States)

    Toro, M.; Azcon, R.; Barea, J.

    1997-01-01

    The interactive effect of phosphate-solubilizing bacteria and arbuscular mycorrhizal (AM) fungi on plant use of soil P sources of low bioavailability (endogenous or added as rock phosphate [RP] material) was evaluated by using soil microcosms which integrated (sup32)P isotopic dilution techniques. The microbial inocula consisted of the AM fungus Glomus intraradices and two phosphate-solubilizing rhizobacterial isolates: Enterobacter sp. and Bacillus subtilis. These rhizobacteria behaved as "mycorrhiza helper bacteria" promoting establishment of both the indigenous and the introduced AM endophytes despite a gradual decrease in bacterial population size, which dropped from 10(sup7) at planting to 10(sup3) CFU g(sup-1) of dry rhizosphere soil at harvest. Dual inoculation with G. intraradices and B. subtilis significantly increased biomass and N and P accumulation in plant tissues. Regardless of the rhizobacterium strain and of the addition of RP, AM plants displayed lower specific activity ((sup32)P/(sup31)P) than their comparable controls, suggesting that the plants used P sources not available in their absence. The inoculated rhizobacteria may have released phosphate ions ((sup31)P), either from the added RP or from the less-available indigenous P sources, which were effectively taken up by the external AM mycelium. Soluble Ca deficiency in the test soil may have benefited P solubilization. At least 75% of the P in dually inoculated plants derived from the added RP. It appears that these mycorrhizosphere interactions between bacterial and fungal plant associates contributed to the biogeochemical P cycling, thus promoting a sustainable nutrient supply to plants. PMID:16535730

  1. Examination of microsomal cytochrome P450-catalyzed in vitro activation of o-phenylphenol to DNA binding metabolite(s) by 32P-postlabeling technique.

    Science.gov (United States)

    Pathak, D N; Roy, D

    1992-09-01

    It has been previously reported that the reactive metabolites phenylsemiquinone and phenylbenzoquinone are generated during microsomal cytochrome P450-catalyzed redox cycling of o-phenylphenol (OPP). However, covalent modification of DNA by OPP-reactive metabolites has yet not been demonstrated. In the present study we have investigated the covalent binding in DNA by OPP-reactive metabolites using 32P-postlabeling. Analysis of adducts by 32P-postlabeling in products of chemical reaction of DNA with phenylbenzoquinone revealed four major and several minor adducts. The chemical reaction of deoxyguanosine 3'-phosphate with phenylbenzoquinone also showed four major adducts. The chromatographic mobility of major adducts of deoxyguanosine 3'-phosphate-phenylbenzoquinone was identical to that of major adducts of DNA-phenylbenzoquinone. The major adducts are demonstrated to be stable. The total covalent binding in deoxyguanosine 3'-phosphate by phenylbenzoquinone (686,000-687,000 amol/nmol nucleotide) was higher than that observed in DNA (26,500-28,000 amol/nmol nucleotides). Reaction of DNA with OPP or a hydroxylated metabolite of OPP, phenylhydroquinone, in the presence of microsomes and NADPH or cumene hydroperoxide showed four major adducts. Adduct formation in DNA by OPP or phenylhydroquinone in the presence of the microsomal activation system was drastically decreased by known inhibitors of cytochrome P450. The chromatographic mobility of major adducts in DNA by OPP or phenylhydroquinone in the presence of microsomal activation system matched with those major adducts observed in deoxyguanosine 3'-phosphate or DNA reacted with pure phenylbenzoquinone. These data demonstrate that OPP or phenylhydroquinone, a hydroxylated metabolite of OPP, is able to bind covalently to DNA in the presence of a microsomal cytochrome P450 activation system. Phenylbenzoquinone is one of the DNA-binding metabolite(s) of OPP. It is concluded that OPP is genotoxic in an in vitro system and

  2. (5'-/sup 32/P)-8-azidoguanosine-3',5'-monophosphate. I. Synthesis and properties. II. Interaction with E. coli proteins

    Energy Technology Data Exchange (ETDEWEB)

    Owens, J.R.

    1983-01-01

    Under certain conditions of nutritional deprivation, microorganisms produce the magic spot nucleotides guanosine-3'-diphosphate-5'-triphosphate(pppGpp) and the tetraphosphate ppGpp. The latter is known to be a pleiotypic effector, i.e. it inhibits (and sometimes stimulates) many biological processes including transcription, translation, and metabolic pathways. It is unknown whether pppGpp, ppGp, pGpp, and pGp, other members of this family of guanosine-3',5'-phosphates, also have regulatory properties. To begin to investigate this question, a radioactive photoaffinity analog of pGp was prepared: (5'/sup 32/P)pN/sub 3/Gp. The interaction of this photoprobe with E. coli sonicates and a purified protein (RNA polymerase) was examined. At physiological salt concentrations two proteins (RNA polymerase) was examined. At physiological salt concentrations two proteins of 86,000 and 65,000 daltons (p86 and p65) were primarily photolabeled. Competition studies with guanosine and adenosine nucleotides indicated (5 /sup 32/P)pN/sub 3/Gp was labeling a ppGpp binding site on p86, and a pGp (or GMP) site on p65. ATP phosphorylation of p86 increased photoincorporation, while it decreased labeling of p65. The data also provide evidence of a different type of regulatory mechanism, i.e. phosphorylation modulates binding of an allosteric effector (ppGpp) to a protein(enzyme). Both ATP and GTP were found to phosphorylate the same proteins, although GTP was the preferred substrate in some cases.

  3. ~(32)P-磷酸铬-聚L-乳酸粒子植入实验鼠体内降解特性及代谢%Preliminary study on in vivo degradation and metabolism of ~(32)P-chromic phosphate-poly(L-lactic) acid seeds implanted into experimental mice

    Institute of Scientific and Technical Information of China (English)

    兰兴昊; 邵国强; 刘璐; 王自正; 黄培林; 杨敏

    2009-01-01

    Objective Targeted positioning is one of the important characteristics of radionuclide brachytherapy.This study was to investigate the feasibility of preparation of ~(32)P-chromic phosphate(CP)with polymer materials poly(L-lactic)acid(PLLA)seed and to observe its in vivo degradation and metabolism in experimental mice.Methods ~(32)P-CP-PLLA seeds(with radioactivity of 20.44 kBq to 25.14 kBq)were im-planted into 72 KM mice through laparotomy or percutaneous puncture to the liver,abdominal cavity or limb muscles.The experimental mice were executed within 30 d at different time points.The seeds were taken out.~(32)P radioactive counting rate(min~(-1))in main organs was determined and the percentage of injection dosage in one gram tissue(%ID/g)was calculated.The morphological change of seeds was observed by scanning electron microscopy.The seeds were also implanted into the liver of five SD rats bred in metabolic cage.the radioactive counting rate(min~(-1))in 24 h feces and urine was determined and the ~(32)P30 d excre-tion rate was also caleulated.Results The biological distribution in KM mice revealed no displacement of seeds occurred.The released radioactivity of ~(32)P in main organs or tissues was slightly higher than that of background level.The culminated counting rate in organs or tissues within 30 d changed in different phases:the aggregated uptake in liver was very low during 1-5 d,slightly increased during6-10 d,decreased during 11-20 d and increased again during 21-25 d and reached its peak value(622±11)/min,then slightly de-creased during 26-30 d;the changes in muscle were similar to those in liver but the peak appeared earlier (15 d)with relatively lower value(403±14)/min.In abdominal cavity group,the uptake value in impor-tant organs maintained a persistent lower level with no prominent phase changes.The peak values in feces and urine appeared on 16 d and 19 d.the rates of excretion(30 d total excretion)were 4.08% and 1.33% respectivelv. Conclusions

  4. Intrahepatic arterial {sup 99M}Technetium ({sup 99M}Tc) macroaggregated albumin (MAA) scan prior to selective internal radiation therapy (SIRT) with {sup 90}Yttrium (90Y) microspheres for liver tumours

    Energy Technology Data Exchange (ETDEWEB)

    Langan, P.; Alwan, M.H.; Stubbs, R.S. [Wakefield Hospital, Wellington (New Zealand). Department of Radiology and Gastroenterology

    1998-06-01

    Full text: {sup 90}Y-microspheres is a regional treatment modality that is used for patients with inoperable primary or secondary liver tumours. Success of treatment depends on the increased uptake and retention of the {sup 90}Y by the tumour relative to normal liver, and the absence of significant extrahepatic shunting. Between February and November 1997, 32 patients were treated with SIRT at Wakefield Gastroenterology Centre. A group of these patients received subsequent hepatic arterial infusion chemotherapy (HAI) using 5-Fluorouracil (5FU). {sup 99m}Tc-MAA in a median dose of 135 MBq (3.6 mCi) [range: 120-150 MBq, or 3.4- 4.1 mCi] with >90% of the particles 10 to 90 {mu}m in size and none greater than 150 {mu}n was injected through a subcutaneously implanted port inserted at laparotomy in the gastroduodenal artery which led to the common hepatic artery (26 patients), or through a transfemoral catheter positioned in the hepatic artery (6 patients). Scintigraphic images of the liver, lungs and gastroduodenal regions were taken with a GE Statcam 4000i gamma camera. The total count rate was computed from the digitised image, and the percentages of activity were calculated as the ratio of lung counts-to-total counts. A liver/lung shunt of < 15% was a prerequisite for treatment with SIRT. There were 18 males and 14 females with a median age of 60.5 years (range: 29 to 76). Twenty eight patients had secondary tumours (23 colorectal, 5 others) and 4 patients had hepatocellular cardnoma (HCC). The median liver/lung shunt was 0.6% (range: 0% to 9.3%). The median shunt for HCC was 0.7% (range: 0% to 2%) and for the secondary tumours 0.6% (<0.1% to 9.3%). No significant shunt was detected in the gastroduodenal region. Assessment of lung shunting of {sup 99m}Tc-MAA scan is useful for excluding patients who may be at risk of pulmonary irradiation, or significant systemic toxicity after regional chemotherapy

  5. Semi-quantitative analysis of post-transarterial radioembolization {sup 90}Y Microsphere position emission tomography combined with computed tomography (PET/CT) images in advance liver malignancy: Comparison with {sup 99m}Tc macroaggregated albumin (MAA) single photon emission computed tomography (SPECT)

    Energy Technology Data Exchange (ETDEWEB)

    Rhee, Seung Hong; Kim, Sung Eun; Cho, Jae Hyuk; Park, Ju Kyung; Kim, Yun Hwan; Choe, Jae Gol [Korea University Anam Hospital, Seoul (Korea, Republic of); Eo, Jae Seon; Park, So Yeon; Lee, Eun Sub [Dept. of Nuclear Medicine, Korea University Guro Hospital, Seoul (Korea, Republic of)

    2016-03-15

    The purpose of this study is to evaluate the correlation between pretreatment planning technetium-99m ({sup 99}mTc) macroaggregated albumin (MAA) SPECT images and posttreatment transarterial radioembolization (TARE) yttirum-90 ({sup 90}Y) PET/CT images by comparing the ratios of tumor-to-normal liver counts. Fifty-two patients with advanced hepatic malignancy who underwent {sup 90}Y microsphere radioembolization from January 2010 to December 2012 were retrospectively reviewed. Patients had undergone {sup 99}mTc MAA intraarterial injection SPECT for a pretreatment evaluation of microsphere distribution and therapy planning. After the administration of {sup 90}Y microspheres, the patients underwent posttreatment {sup 90}Y PET/CT within 24 h. For semiquantitative analysis, the tumor-to-normal uptake ratios in {sup 90}Y PET/CT (TNR-yp) and {sup 99}mTc MAA SPECT (TNR-ms) as well as the tumor volumes measured in angiographic CT were obtained and analyzed. The relationship of TNR-yp and TNR-ms was evaluated by Spearman's rank correlation and Wilcoxon's matched pairs test. In a total of 79 lesions of 52 patients, the distribution of microspheres was well demonstrated in both the SPECT and PET/CT images. A good correlation was observed of between TNR-ms and TNR-yp (rho value = 0.648, p < 0.001). The TNR-yp (median 2.78, interquartile range 2.43) tend to show significantly higher values than TNR-ms (median 2.49, interquartile range of 1.55) (p = 0.012). The TNR-yp showed weak correlation with tumor volume (rho = 0.230, p = 0.041). The 99mTc MAA SPECT showed a good correlation with {sup 90}Y PET/CT in TNR values, suggesting that {sup 99}mTc MAA can be used as an adequate pretreatment evaluation method. However, the {sup 99}mTc MAA SPECT image consistently shows lower TNR values compared to 90Y PET/CT, which means the possibility of underestimation of tumorous uptake in the partition dosimetry model using {sup 99}mTc MAA SPECT. Considering that

  6. CT导引下32P-磷酸铬-聚-L-乳酸粒子植入治疗兔VX2肺肿瘤的实验研究%Experimental Study of CT Guided32P-CP-PLLA Microparticle Implantation in the Treatment of Rabbit VX2 Lung Tumor

    Institute of Scientific and Technical Information of China (English)

    潘栋辉; 杨敏; 徐宇平; 王立振; 刘璐; 黄培林

    2011-01-01

    背景与目的 新型放射性植入剂32P-磷酸铬-聚-L-乳酸(32p-CP-PLLA)粒子具有良好的生物相容性和降解性,适用于实体肿瘤的近距离放射治疗.本研究旨在探讨兔VX2肺肿瘤经32P-CP-PLLA粒子瘤体间植入近距离治疗前后PET/CT显像及病理学的变化,分析32P-CP-PLLA粒子植入对荷VX2肺癌兔肿瘤生长及凋亡相关蛋白的影响.方法 24只荷瘤兔随机分成4组.每组6只.1组-3组为治疗组;4组为对照组.在CT导引下经皮穿刺将总放射性活度为93 MBq、185 MBq和370 MBq的32P-CP-PLLA粒子分别植入1组、2组和3组肿瘤组织内.对照组不做任何干预.分别在治疗后第0天、第3天、第7天和第14天进行18F-FDG PET/CT显像,观察标准摄取值(standardized uptake value,SUV)的变化.最后1次PET/CT显像后处死荷瘤兔,取出肿瘤组织,进行病理学检查和免疫组织化学分析,比较肿瘤细胞形态和凋亡基因(bd-2,bax)表达的变化.结果 第0天时,治疗组和对照组之间SUVmax无明显差异.治疗后第14天,1组、2组和3组SUVmax值分别为1.1±0.19、0.80±0.10和2.85±0.15,均较对照组(5.61±0.50)明显下降.第7天-第14天时,1组和2组SUVmax较第3天呈现持续下降趋势,且呈剂量效应关系(P<0.05).治疗后第3天-第14天,3组SUVmax较第0天显著上升,并在第7天达到峰值,后明显下降.同期3组SUVmax明显低于对照组SUVmax.HE染色显示近粒子处的肿瘤细胞变性坏死,坏死程度随剂量的增加而严重.3组可见坏死组织周围有大量炎性细胞浸润,而1组-2组炎性细胞浸润不明显.免疫组化显示治疗组bcl-2表达强度低于对照组,bax表达强度高于对照组(P<0.05).治疗组bd-2/bax比值明显下调(P<0.05).凋亡基因的表达呈剂量效应关系.结论 32P-CP-PLLA粒子持续照射可直接杀伤VX2肿瘤细胞从而抑制其葡萄糖代谢功能.远离粒子处虽可见存活肿瘤细胞,但凋亡基因表达明显异于对照组.32P-CP-PLLA

  7. Short-course R-CHOP followed by 90Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results

    Science.gov (United States)

    Stefoni, V; Casadei, B; Bottelli, C; Gaidano, G; Ciochetto, C; Cabras, M G; Ansuinelli, M; Argnani, L; Broccoli, A; Gandolfi, L; Pellegrini, C; Zinzani, P L

    2016-01-01

    An update at 7 years was conceived for our multicenter phase II study in which 55 elderly high-risk untreated diffuse large B-cell lymphoma patients were treated with 90Y-ibritumomab tiuxetan after a short course of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) as long-term follow-up analyses of this combined therapeutic modality are lacking. The overall response rate to the entire regimen was 80%, including 73% (40/55) of complete response (CR) rate and 7% (4/55) of partial response rate. At the time of writing, 24/55 (43.6%) patients experienced a progression disease and 20 of 40 (50%) patients who obtained a CR are still alive in continuous CR. With a median follow-up of 7 years, the disease-free survival was 43.3% and the progression-free survival was 36.1%. The overall survival at 7.9 years was 38.9% (27 deaths mainly because of lymphoma). Two patients developed secondary hematological malignancies, an acute myeloid leukemia and a myelodysplastic syndrome, at 4 and 3 years from radioimmunotherapy, respectively. Our data confirm the feasibility, efficacy and safety of four cycles of R-CHOP followed by radioimmunotherapy consolidation even in the long term: this combination allows dispensing less chemotherapy in a frail group of patients without invalidating response quality and duration. PMID:27176801

  8. National pattern for the realization of the unit of the dose speed absorbed in air for beta radiation. (Method: Ionometer, cavity of Bragg-Gray implemented in an extrapolation chamber with electrodes of variable separation, exposed to a field of beta radiation of {sup 90}Sr/{sup 90}Y); Patron Nacional para la realizacion de la unidad de la rapidez de dosis absorbida en aire para radiacion beta. (Metodo: Ionometrico, cavidad de Bragg-Gray implementada en una camara de extrapolacion con electrodos de separacion variable, expuesta a un campo de radiacion beta de {sup 90}Sr/{sup 90}Y)

    Energy Technology Data Exchange (ETDEWEB)

    Alvarez R, M. T.; Morales P, J. R. [ININ, 52045 Ocoyoacac, Estado de Mexico (Mexico)

    2001-01-15

    From the year of 1987 the Department of Metrology of the ININ, in their Secondary Laboratory of Calibration Dosimetric, has a patron group of sources of radiation beta and an extrapolation chamber of electrodes of variable separation.Their objective is to carry out of the unit of the dose speed absorbed in air for radiation beta. It uses the ionometric method, cavity Bragg-Gray in the extrapolation chamber with which it counts. The services that offers are: i) it Calibration : Radioactive Fuentes of radiation beta, isotopes: {sup 90}Sr/{sup 90}Y; Ophthalmic applicators {sup 9}0{sup S}r/{sup 90}Y; Instruments for detection of beta radiation with to the radiological protection: Ionization chambers, Geiger-Muller, etc.; Personal Dosemeters. ii) Irradiation with beta radiation of materials to the investigation. (Author)

  9. Study of influence of plastic scintillators thicknesses to detect Beta particles and Gamma radiation by means of spectral analysis of {sup 90}Sr, {sup 90}Y and {sup 137}Cs sources

    Energy Technology Data Exchange (ETDEWEB)

    Cardenas, Jose Patricio Nahuel; Filho, Tufic Madi; Pereira, Maria da Conceicao Costa; Santos, Brianna B. dos; Correa, Eduardo de L.; Santos, Lucas Rodrigues dos; Lopes, Anderson Figueredo; Silva, Alexandre F.P. da; Santos, Diogo F. dos; Camilo, Douglas de S.; Purgato, Rafael T.; Aredes, Vitor O.G. [Nuclear and Energy Research Institute, IPEN-CNEN/SP, Instituto de Pesquisas Energeticas e Nucleares - IPEN-CNEN/SP, Av. Prof. Lineu Prestes 2242 Cid Universitaria CEP: 05508-000- Sao Paulo-SP (Brazil)

    2015-07-01

    The Nuclear and Energy Research Institute - IPEN, offers post-graduate programs, namely: Nuclear Technology - Applications (TNA), Nuclear Technology - Materials (TNM), Nuclear Technology - Reactors (TNR). The Institute programs mission is to form expert technicians, physicists and engineers with a strong knowledge in their discipline to work in the nuclear area. The course: 'Theoretical Fundamentals and Practices of the Instrumentation used in Nuclear Data Acquisition' covers the use of laboratory nuclear instrumentation and the accomplishment of experiments to obtain nuclear parameters. One of these experimental exercises is object of this work: 'Study of influence of plastic scintillators to detect Beta particles and Gamma radiation by means of spectral analysis of {sup 90}Sr, {sup 90}Y and {sup 137}Cs sources'. The use of scintillators plastic for the detection has the advantage of low cost, high mechanical strength, is not hygroscopic and can be manufactured in large volumes. This work aims to present the analysis of relative efficiency of detection of plastic scintillators of various thicknesses for beta particles and gamma radiation by the spectrum of {sup 137}Cs and {sup 90}Sr. Due to lack of resolution of the detectors plastic scintillators we worked with relative efficiency. The evaluation was done by reading deposited energy, using the software MAESTRO, for each detector thickness. For beta particles was observed an ideal thickness around 3 mm and the better photon efficiency was observed with increasing the thickness of the detector. The present experiment does not intend to establish a new technique for this subject: it solely aims student's practical exercises in nuclear properties of elements and detectors being part of the nuclear experimental course. (authors)

  10. Does tumoral {sup 111}In-ibritumomab accumulation correlate with therapeutic effect and outcome in relapsed or refractory low-grade B-cell lymphoma patients undergoing {sup 90}Y-ibritumomab radioimmunotherapy?

    Energy Technology Data Exchange (ETDEWEB)

    Kaneko, Koichiro; Shinozaki, Kenji [National Kyushu Cancer Center, National Hospital Organization, Department of Radiology, Minami-ku, Fukuoka (Japan); Choi, Ilseung; Uike, Naokuni [National Kyushu Cancer Center, National Hospital Organization, Division of Hematology, Minami-ku, Fukuoka (Japan); Nakagawa, Makoto [PET Imaging Center, Koga Hospital 21, Kurume (Japan)

    2014-12-15

    The aim of this study was to determine whether tumoral {sup 111}In-ibritumomab accumulation on pre-treatment imaging correlates with therapeutic responses and progression-free survival (PFS) in patients with non-Hodgkin's lymphoma (NHL) undergoing {sup 90}Y-ibritumomab radioimmunotherapy (RIT). This was a retrospective study of 39 patients with low-grade B-cell NHL treated with RIT. We classified the patients into positive and negative groups according to the presence or absence of tumoral {sup 111}In-ibritumomab accumulation on pre-treatment {sup 111}In-ibritumomab examinations. We then determined the correlation between the {sup 111}In-ibritumomab imaging findings and the patients' therapeutic responses and PFS. Tumoral {sup 111}In-ibritumomab accumulation was positive in 64.1 % and negative in 35.9 % of the patients. The {sup 111}In-positive patients had a significantly higher overall response rate (ORR) compared to the {sup 111}In-negative patients (100.0 % vs. 78.6 %, p = 0.02). The {sup 111}In-negative patients with advanced disease (stages III/IV) had a significantly lower ORR (40 %) and a significantly higher rate of progressive disease (40.0 %) compared to those of the {sup 111}In-negative patients with limited disease (stages I/II) (100 % and 0 %, p = 0.009 each). However, these two groups had similar 2-year PFS rates (65.0 % vs. 50.0 %, p = 0.80). {sup 111}In-ibritumomab imaging findings seem to correlate with ORR and the progressive disease rate after RIT, but not with PFS. (orig.)

  11. Biomonitoring the human population exposed to pollution from the oil fires in Kuwait: analysis of placental tissue using (32)P-postlabeling.

    Science.gov (United States)

    Marafie, E M; Marafie, I; Emery, S J; Waters, R; Jones, N J

    2000-01-01

    The placenta is a readily available source of material for molecular epidemiological investigations. As such, DNA damage in this tissue can be indicative of maternal exposure to environmental pollutants such as polycyclic aromatic hydrocarbons (PAHs). Previous reports have demonstrated that (32)P-postlabeling (PPL) is able to detect the presence of aromatic adducts in human placenta that are associated with maternal smoking during pregnancy. Using PPL we have assayed the DNA damage in placental samples from Kuwaiti mothers who were exposed to environmental pollution during pregnancy. This pollution arose in the aftermath of the Iraqi invasion of Kuwait, which left hundreds of oil wells burning. For comparison, further Kuwaiti samples were obtained approximately 1 year after the oil well fires and, as such, are from individuals unexposed to the airborne pollution from the oil well fires during pregnancy. In addition, placental samples were obtained from subjects in the United Kingdom. Adduct levels were measured in all samples using both the nuclease P1 and butanol extraction enhancement procedures. No elevation of adduct levels was observed in the placenta of mothers exposed to the oil well fires (n = 40) with either procedure (144 +/- 30 attomol/microg DNA for nuclease P1 enrichment, 245 +/- 50 attomol/microg DNA for butanol extraction), when compared with the nonexposed Kuwaiti mothers (180 +/- 32 and 281 +/- 39 attomol/microg DNA, respectively, n = 24). Similar adduct levels were observed in UK mothers who smoked cigarettes (178 +/- 30 and 284 +/- 52 attomol/microg DNA, n = 30), which in turn were approximately twice those observed in nonsmoking mothers (90 +/- 14 and 141 +/- 15 attomol/microg DNA, n = 12), although there is no significant difference in the distribution of adduct levels when statistical analysis is performed. Comprehensive interpretation of the Kuwaiti data is difficult as precise information on PAH levels is unavailable, although the data do

  12. 32P-postlabelling analysis of DNA adducts in the skin of mice treated with petrol and diesel engine lubricating oils and exhaust condensates.

    Science.gov (United States)

    Schoket, B; Hewer, A; Grover, P L; Phillips, D H

    1989-08-01

    Samples of unused or used petrol and diesel engine lubricating oils were applied to the shaved dorsal skin of 4- to 6-week-old male Parkes mice, either as a single treatment (50 microliters/mouse) or as four consecutive daily treatments (50 microliters/application). DNA isolated from the skin 24 h after the final treatment was digested to 3'-mononucleotides and analysed by 32P-postlabelling for the presence of aromatic adducts. Enhancement of sensitivity using butanol extraction or nuclease P1 digestion of the DNA hydrolysates led to the detection of up to eight adduct spots on polyethyleneimine-cellulose thin-layer chromatograms with samples of DNA from skin treated with used engine oils, at levels of 40-150 amol total adducts/micrograms DNA. Multiple treatments with the used oils gave rise to similar patterns of adducts in lung DNA. A single treatment of mouse skin with petrol engine exhaust condensate (50 microliters), or diesel engine exhaust condensate (50 microliters), containing 20 and 46 micrograms benzo[a]pyrene (BaP)/g respectively, gave rise to approximately 75 amol total adducts/micrograms DNA in skin. A significant proportion, 31 and 48% respectively, of the adducts formed by the petrol and diesel engine exhaust condensates co-chromatographed with the major BaP-DNA adduct, but with the used engine oils, only petrol engine oil, and not diesel engine oil, produced significant amounts of an adduct (22% of total) that corresponded to the BaP-DNA adduct.

  13. Analysis of the polycyclic aromatic hydrocarbon content of petrol and diesel engine lubricating oils and determination of DNA adducts in topically treated mice by 32P-postlabelling.

    Science.gov (United States)

    Carmichael, P L; Jacob, J; Grimmer, G; Phillips, D H

    1990-11-01

    Engine lubricating oils are known to accumulate carcinogenic polycyclic aromatic hydrocarbons (PAHs) during engine running. Oils from nine petrol-powered and 11 diesel-powered vehicles, in addition to samples of unused oil, were analysed for PAH content and ability to form DNA adducts when applied topically to mouse skin. The levels of 19 PAHs, determined by GC, were in total, approximately 22 times higher in used oils from petrol engines than in oils from diesel engines. Male Parkes mice were treated with 50 microliters of oil daily for 4 days before they were killed and DNA isolated from skin and lung tissue. DNA samples were analysed by nuclease P1-enhanced 32P-postlabelling. Used oils from both diesel and petrol engines showed several adduct spots on PEI-cellulose plates at total adduct levels of up to 0.57 fmol/microgram DNA [approximately 60 times greater than in experiments with samples of unused oil in which adduct levels (0.01-0.02 fmol adducts/microgram DNA) were close to the limit of detection]. Higher adduct levels were generally formed by petrol engine oils than by diesel engine oils. Lung DNA contained similar total adduct levels to those in skin although the adduct maps were less complex. Total adduct levels correlated with extent of oil use in the engine, the total PAH concentration in oils and with the concentrations of certain individual PAHs present in the oils. An adduct spot that co-eluted with that of the major benzo[a]pyrene-DNA adduct accounted for 9-26% of the total adducts in skin DNA, and approximately 8% of the adducts in lung DNA, of mice treated with petrol engine oils. A major, and as yet unidentified, adduct spot comprised up to 30% of the total adducts in skin DNA, and up to 89% of the total adducts in lung DNA, of these animals.

  14. Salmonella enterica serotype Typhimurium DT104 ArtA-dependent modification of pertussis toxin-sensitive G proteins in the presence of [32P]NAD.

    Science.gov (United States)

    Uchida, Ikuo; Ishihara, Ryoko; Tanaka, Kiyoshi; Hata, Eiji; Makino, Sou-ichi; Kanno, Toru; Hatama, Shinichi; Kishima, Masato; Akiba, Masato; Watanabe, Atsushi; Kubota, Takayuki

    2009-11-01

    Salmonella enterica serotype Typhimurium (S. Typhimurium) definitive phage type (DT) 104 has become a widespread cause of human and other animal infections worldwide. The severity of clinical illness in S. Typhimurium DT104 outbreaks suggests that this strain possesses enhanced virulence. ArtA and ArtB - encoded by a prophage in S. Typhimurium DT104 - are homologues of components of pertussis toxin (PTX), including its ADP-ribosyltransferase subunit. Here, we show that exposing DT104 to mitomycin C, a DNA-damaging agent, induced production of prophage-encoded ArtA/ArtB. Pertussis-sensitive G proteins were labelled in the presence of [(32)P]NAD and ArtA, and the label was released by HgCl(2), which is known to cleave cysteine-ADP-ribose bonds. ADP-dependent modification of G proteins was markedly reduced in in vitro-synthesized ArtA(6Arg-Ala) and ArtA(115Glu-Ala), in which alanine was substituted for the conserved arginine at position 6 (necessary for NAD binding) and the predicted catalytic glutamate at position 115, respectively. A cellular ADP-ribosylation assay and two-dimensional electrophoresis showed that ArtA- and PTX-induced ADP-ribosylation in Chinese hamster ovary (CHO) cells occur with the same type of G proteins. Furthermore, exposing CHO cells to the ArtA/ArtB-containing culture supernatant of DT104 resulted in a clustered growth pattern, as is observed in PTX-exposed CHO cells. Hydrogen peroxide, an oxidative stressor, also induced ArtA/ArtB production, suggesting that these agents induce in vivo synthesis of ArtA/ArtB. These results, taken together, suggest that ArtA/ArtB is an active toxin similar to PTX.

  15. Evaluation of radiation packages type A from the center of isotopes in Cuba; Evaluacion radiologica de los bultos tipo A del centro de isotopos de Cuba

    Energy Technology Data Exchange (ETDEWEB)

    Balbona, Zayda Amador; Pijuan, Saul Perez, E-mail: zabalbona@centis.edu.cu [Centro de Isotopos (CENTIS), Mayabeque (Cuba); Gual, Maritza Rodriguez, E-mail: mrgual@instec.cu [Instituto Superior de Tecnologias y Ciencias Aplicadas (InSTEC), la Habana (Cuba)

    2013-07-01

    The Isotope Center (CENTIS) of the Republic of Cuba makes the transportation of its products mainly in packaged type A. To undertake the design of packages, packaging components from 6 producing firms (including those found Amersham, CISBIO and IZOTOP) are studied. From the applicable regulations, security features and requirements are established as well as the technical characteristics of the packaging components. This study evaluated according each radioisotope, product and specific activity, high activity that can be included in a Type A package with the limitation that the dose rate on their surfaces is less than or equal to 2 mSv/h. In addition, each package is characterized taking into account the value of the maximum dose rate at maximum contact and the transport index for the day of transport. For this, the Microshield code using version 5.0.3. The dose rate in contact with the package of {sup 90}Y is calculated using the Monte Carlo code MCNPX version 2.6.0. The maximum possible activity values are obtained for each shielding transport radionuclides CENTIS produced, namely {sup 131}I, {sup 125}I, {sup 32}P, {sup 99}Mo/{sup 99m}Tc, {sup 99m}Tc, {sup 188}Re and {sup 90}Y and 69 radioactive packages type A are evaluated.

  16. Effectiveness Evaluation of Skin Covers against Intravascular Brachytherapy Sources Using VARSKIN3 Code

    Directory of Open Access Journals (Sweden)

    Baghani HR

    2013-12-01

    Full Text Available Background and Objective: The most common intravascular brachytherapy sources include 32P, 188Re, 106Rh and 90Sr/90Y. In this research, skin absorbed dose for different covering materials in dealing with these sources were evaluated and the best covering material for skin protection and reduction of absorbed dose by radiation staff was recognized and recommended. Method: Four materials including polyethylene, cotton and two different kinds of plastic were proposed as skin covers and skin absorbed dose at different depths for each kind of the materials was calculated separately using the VARSKIN3 code. Results: The results suggested that for all sources, skin absorbed dose was minimized when using polyethylene. Considering this material as skin cover, maximum and minimum doses at skin surface were related to 90Sr/90Y and 106Rh, respectively. Conclusion: polyethylene was found the most effective cover in reducing skin dose and protecting the skin. Furthermore, proper agreement between the results of VARSKIN3 and other experimental measurements indicated that VRASKIN3 is a powerful tool for skin dose calculations when working with beta emitter sources. Therefore, it can be utilized in dealing with the issue of radiation protection.

  17. Thermoluminescent characteristics (TL) of K{sub 2}F{sub 5}: Y{sub 0.99} Tb{sub 0.01} irradiated with beta particles of {sup 90}Sr/{sup 90} Y; Caracteristicas termoluminiscentes (TL) de K{sub 2}F{sub 5}: Y{sub 0.99} Tb{sub 0.01} irradiado con particulas beta de {sup 90}Sr/{sup 90} Y

    Energy Technology Data Exchange (ETDEWEB)

    Baillet, C.; Azorin, J.; Rivera, T. [Dep. de Fisica, UAM-I, 09340 Mexico D.F. (Mexico)

    2005-07-01

    In this work the results of studying the thermoluminescent characteristics of the K{sub 2}F{sub 5}: Y{sub 0.99} Tb{sub 0.01} are presented. The material was characterized irradiating samples of K{sub 2}F{sub 5}: Y{sub 0.99}Tb{sub 0.01} in powder with beta radiation of {sup 90}Sr/{sup 90}Y. The studied characteristics were TL curve, response reproducibility, TL response in function of the dose and fading of the information. The samples exhibited a thermoluminescent curve (TL) with two very defined peaks centered respectively in 167 and 307 C. The TL response of the samples under the action of the beta radiation after 10 cycles (thermal erased, irradiation and reading of the samples) presented a standard deviation of 3.09%. The TL response of K{sub 2}F{sub 5}: Y{sub 0.99} Tb{sub 0.01} in function of the absorbed dose of beta radiation resulted lineal in the interval of 3 mGy to 1.29 Gy. The fading of the information contained in the samples of K{sub 2}F{sub 5}: Y{sub 0.99} Tb{sub 0.01} was of 40% in the first 10 minutes, which is due to the first peak. The obtained results suggest that the TL material resulted as promissory for its possible use as thermoluminescent dosemeter of beta radiation using the second peak of its TL curve like dosimetric peak. (Author)

  18. Comparison of greenhouse and {sup 32}P isotopic laboratory methods for evaluating the agronomic effectiveness of natural and modified rock phosphates in some acid soils of Ghana

    Energy Technology Data Exchange (ETDEWEB)

    Owusu-Bennoah, E. [Department of Soil Science, University of Ghana, Legon, Accra (Ghana); Zapata, F. [International Atomic Energy Agency, Vienna (Austria)]. E-mail: F.Zapata@iaea.org; Fardeau, J.C. [Departement Environnement et Agronomie, INRA, Versailles (France)

    2002-05-15

    Phosphorus deficiency is one of the major constraints for normal plant growth and crop yields in the acid soils of Ghana and therefore addition of P inputs is required for sustainable crop production. This is often difficult, if not impossible for small-scale farmers due to the high cost of mineral P fertilizers and limited access to fertilizer supplies. Direct application of finely ground phosphate rocks (PRs) and their modified forms have been recommended as alternatives for P fertilization. The direct application of the natural and modified PRs to these acid soils implies the need to predict their agronomic effectiveness of the PRs in the simplest and most cost-effective manner. In this study the classical greenhouse pot experiment was compared to the {sup 32}P isotopic kinetics laboratory method for evaluating the agronomic effectiveness of natural and modified Togo PR in six highly weathered Oxisols from southwest Ghana. In the {sup 32}P isotopic kinetics laboratory experiment the six soil samples were each fertilised at the rate of 50 mg P kg{sup -1} soil in the form of triple superphosphate (TSP), Togo PAPR-50%, and Togo PR, respectively. Controls without P amendment were also included. Isotopic exchange kinetics experiments were carried out on two sets of samples, immediately after P fertilizer additions (without incubation) and after 6 weeks of incubation under wet conditions and at a room temperature of 25 deg C. In the greenhouse pot experiment, P fertilizers in the form of Togo PR, Togo PAPR, Mali PR and TSP were each applied to the six soils at rates equivalent to 0, 30, 60, and 120 kg P ha{sup -1}, respectively. The P fertilizers were mixed with the soils and maize (Zea mays L.) variety Obatanpa was grown for 42 days before harvest. The isotopic kinetics data of the control samples indicated that 5 of the studied soils had very low P fertility status as reflected by their low P concentrations in solution (C{sub P}<0.02 mg P l{sup -1}) and low

  19. Experimental study on microSPECT-CT bremsstrahlung imaging in solid tumor mesenchymal implantation of 32 P-chromic phosphate-paclitaxel-poly-L-lactic acid sustained-release seeds%32 P-磷酸铬-紫杉醇-聚L乳酸缓释粒子实体瘤间质植入microSPECT-CT韧致辐射显像的实验研究

    Institute of Scientific and Technical Information of China (English)

    刘伟; 邵国强; 孟庆乐; 杨瑞; 王峰; 王自正

    2016-01-01

    Objective To investigate the value of single photon emission computed tomography (CT) imaging and transmis‐sion CT imaging (microSPECT‐CT ) bremsstrahlung imaging for the solid tumor mesenchymal implantaion of 32 P‐chromic phos‐phate‐paclitaxel‐poly‐L‐lactic acid (32 P‐CP‐PSP‐PLLA) sustained release seeds and to investigate the 32 P in vivo biodistribution and degradation sustained release churacteristics .Methods The animal model of prostate cancer subcutaneously transplanted tumor was established .32 P‐CP‐PSP‐PLLA sustained‐release seeds were intratumorally implanted by the mediation of microSPECT‐CT brems‐strahlung imaging and the 32 P distribution in bearing tumor mouse was verified by the imaging and biological distrubtion tests .The ultrastructural changes of 32 P seeds were observed by the scanning electron microscope .Results The MicroSPECT/CT brems‐strahlung imaging could effectively guide the intratumoral implantation operation of the 32 P sustained‐release seeds with clear visu‐alization .Partial sustained‐release 32 P was remained in the tumor tissues with little distribution in important organs of spleen and liver ,which was proved by the biodistribution results .The particle surface and inside micropores and tunnels formation ,their pro‐gressive increase ,fusion and connection were found by the electronic microscope after the 32 P sustained‐release seeds intratumoral implantation .Conclusion The MicroSPECT/CT bremsstrahlung imaging can effectively monitor the 32 P sustained‐release seeds and their in vivo biodistribution and lays a foundation for the sustained‐release seeds prostatic targeted implantation .%目的:以32 P‐磷酸铬‐紫杉醇微球‐聚L乳酸(32 P‐CP‐PSP‐PLLA)缓释粒子实体瘤间质靶向植入后,行小动物单光子发射计算机断层成像‐透射断层成像(microSPECT‐CT )韧致辐射显像,探讨其32 P体内生物学分布及其降解缓释特

  20. New T=1 effective interactions for the f5/2 p3/2 p1/2 g9/2 model space; Implications for valence-mirror symmetry and seniority isomers

    CERN Document Server

    Lisetskiy, A F; Horoi, M; Grawe, H

    2004-01-01

    New shell model Hamiltonians are derived for the T=1 part of the residual interaction in the f5/2 p3/2 p1/2 g9/2 model space based on the analysis and fit of the available experimental data for 57Ni-78Ni isotopes and 77Cu-100Sn isotones. The fit procedure, properties of the determined effective interaction as well as new results for valence-mirror symmetry and seniority isomers for nuclei near 78Ni and 100Sn are discussed.

  1. 放射性核素32P治疗肝癌19例临床探讨%Clinical discussion of treating 19 cases of liver cancer with radionuclide 32P

    Institute of Scientific and Technical Information of China (English)

    胡秀芳; 何玉凡

    2005-01-01

    目的探讨32P治疗肝癌的临床疗效.方法由B超介导,经皮肝穿向瘤体内注射胶体32P,对癌细胞行内照射治疗.结果用32P放射性核素治疗肝癌后,经B超复查,病理证实,32P对肝癌治疗取得了满意的疗效.

  2. Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14

    Science.gov (United States)

    Hertzberg, Mark; Gandhi, Maher K.; Trotman, Judith; Butcher, Belinda; Taper, John; Johnston, Amanda; Gill, Devinder; Ho, Shir-Jing; Cull, Gavin; Fay, Keith; Chong, Geoff; Grigg, Andrew; Lewis, Ian D.; Milliken, Sam; Renwick, William; Hahn, Uwe; Filshie, Robin; Kannourakis, George; Watson, Anne-Marie; Warburton, Pauline; Wirth, Andrew; Seymour, John F.; Hofman, Michael S.; Hicks, Rodney J.

    2017-01-01

    In the treatment of diffuse large B-cell lymphoma, a persistently positive [18F]fluorodeoxyglucose positron emission tomography (PET) scan typically carries a poor prognosis. In this prospective multi-center phase II study, we sought to establish whether treatment intensification with R-ICE (rituximab, ifosfamide, carboplatin, and etoposide) chemotherapy followed by 90Y-ibritumomab tiuxetan–BEAM (BCNU, etoposide, cytarabine, and melphalan) for high-risk diffuse large B-cell lymphoma patients who are positive on interim PET scan after 4 cycles of R-CHOP-14 (rituximab, cyclophosphamide, doxorubicin, and prednisone) can improve 2-year progression-free survival from a historically unfavorable rate of 40% to a rate of 65%. Patients received 4 cycles of R-CHOP-14, followed by a centrally-reviewed PET performed at day 17–20 of cycle 4 and assessed according to International Harmonisation Project criteria. Median age of the 151 evaluable patients was 57 years, with 79% stages 3–4, 54% bulk, and 54% International Prognostic Index 3–5. Among the 143 patients undergoing interim PET, 101 (71%) were PET-negative (96 of whom completed R-CHOP), 42 (29%) were PET-positive (32 of whom completed R-ICE and 90Y-ibritumomab tiuxetan-BEAM). At a median follow up of 35 months, the 2-year progression-free survival for PET-positive patients was 67%, a rate similar to that for PET-negative patients treated with R-CHOP-14 (74%, P=0.11); overall survival was 78% and 88% (P=0.11), respectively. In an exploratory analysis, progression-free and overall survival were markedly superior for PET-positive Deauville score 4 versus score 5 (P=0.0002 and P=0.001, respectively). Therefore, diffuse large B-cell lymphoma patients who are PET-positive after 4 cycles of R-CHOP-14 and who switched to R-ICE and 90Y-ibritumomab tiuxetan-BEAM achieved favorable survival outcomes similar to those for PET-negative R-CHOP-14-treated patients. Further studies are warranted to confirm these promising results

  3. Feasibility of the $\\beta^-$ Radio-Guided Surgery with a Variety of Radio-Nuclides of Interest to Nuclear Medicine

    CERN Document Server

    Mancini-Terracciano, Carlo; Bencivenga, Gaia; Bocci, Valerio; Cartoni, Antonella; Collamati, Francesco; Fratoddi, Ilaria; Giordano, Alessandro; Indovina, Luca; Marafini, Michela; Morganti, Silvio; Rotili, Dante; Russomando, Andrea; Scotognella, Teresa; Camillocci, Elena Solfaroli; Toppi, Marco; Traini, Giacomo; Venditti, Iole; Faccini, Riccardo

    2016-01-01

    The $\\beta^-$ based radio-guided surgery overcomes the corresponding $\\gamma$ technique in case the background from healthy tissues is relevant. It can be used only in case a radio-tracer marked with $^{90}$Y is available since the current probe prototype was optimized for the emission spectrum of this radio-nuclide. Here we study, with a set of laboratory tests and simulations, the prototype capability in case a different radio-nuclide is chosen among those used in nuclear medicine. As a result we estimate the probe efficiency on electrons and photons as a function of energy and we evaluate the feasibility of a radio-guided surgery exploiting the selected radio-nuclides. We conclude that requiring a 0.1~ml residue to be detected within 1~s by administering 3~MBq/Kg of radio-isotope, the current probe prototype would yield a significant signal in a vast range of values of SUV and TNR in case $^{31}$Si,$^{32}$P, $^{97}$Zr, and $^{188}$Re are used. Conversely, a tuning of the detector would be needed to efficie...

  4. The application of isotopic ({sup 32}P and {sup 15}N) dilution techniques to evaluate the interactive effect of phosphate-solubilizing rhizobacteria, mycorrhizal fungi and Rhizobium to improve the agronomic efficiency of rock phosphate for legume crops

    Energy Technology Data Exchange (ETDEWEB)

    Barea, J.M. [Departamento de Microbiologia del Suelo y Sistemas Simbioticos (Spain)]. E-mail: jmbarea@eez.csic.es; Toro, M.; Azcon, R. [Departamento de Microbiologia del Suelo y Sistemas Simbioticos (Spain); Orozco, M.O. [Instituto de Sistematica y Ecologia, Academia Cubana de Ciencias, Habana (Cuba); Campos, E. [Departamento de Ciencias de la Tierra y Quimica Ambiental Estacion Experimental del Zaidin (CSIC), Granada (Spain); Azcon, R. [Departamento de Microbiologia del Suelo y Sistemas Simbioticos (Spain)

    2002-05-15

    A pot experiment was designed to evaluate the interactive effects of multifunctional microbial inoculation treatments and rock phosphate (RP) application on N and P uptake by alfalfa through the use of {sup 15}N and {sup 32}P isotopic dilution approaches. The microbial inocula consisted of a wild type (WT) Rhizobium meliloti strain, the arbuscular mycorrhizal (AM) fungus Glomus mosseae (Nicol. and Gerd.) Gerd. and Trappe, and a phosphate solubilizing rhizobacterium (Enterobacter sp.). Inoculated microorganisms were established in the root tissues and/or in the rhizosphere soil of alfalfa plants (Medicago sativa L.). Improvements in N and P accumulation in alfalfa corroborate beneficial effects of Rhizobium and AM interactions. Inoculation with selected rhizobacteria improved the AM effect on N or P accumulation in both the RP-added soil and in the non RP-amended controls. Measurements of the {sup 15}N/{sup 14}N ratio in plant shoots indicate an enhancement of the N{sub 2} fixation rates in Rhizobium-inoculated AM-plants, over that achieved by Rhizobium in non-mycorrhizal plants. Whether or not RP was added, AM-inoculated plants showed a lower specific activity ({sup 32}P/{sup 31}P) than did their comparable non-mycorrhizal controls, suggesting that the plant was using otherwise unavailable P sources. The phosphate-solubilizing, AM-associated, microbiota could in fact release phosphate ions, either from the added RP or from the indigenous 'less-available' soil phosphate. A low Ca concentrations in the test soil may have benefited P solubilization. Under field conditions, the inoculation with AM fungi significantly increased plant biomass and N and P accumulation in plant tissues. Phosphate-solubilizing rhizobacteria improved mycorrhizal responses in soil dually receiving RP and organic matter amendments. Organic matter addition favoured RP solubilization. This, together with a tailored microbial inoculation, increased the agronomic efficiency of RP in the

  5. t(7;12)(q36;p13) and t(7;12)(q32;p13)--translocations involving ETV6 in children 18 months of age or younger with myeloid disorders.

    Science.gov (United States)

    Slater, R M; von Drunen, E; Kroes, W G; Weghuis, D O; van den Berg, E; Smit, E M; van der Does-van den Berg, A; van Wering, E; Hählen, K; Carroll, A J; Raimondi, S C; Beverloo, H B

    2001-06-01

    Our retrospective karyotype review revealed two rare recurrent translocations affecting ETV6 (TEL): t(7;12)(q36;p13) and t(7;12)(q32;p13). Five patients with a t(7;12) were from a group of 125 successfully karyotyped pediatric patients enrolled in consecutive clinical AML trials of the Dutch Childhood Leukemia Study Group over a period of 7 years. During a search of available cytogenetic databases, we found 7q and 12p abnormalities in two additional Dutch patients and in three participants in Pediatric Oncology Group trials. A del(12p) had been initially identified in four of these patients and re-examination of the original karyograms revealed a t(7;12)(q36;p13) in two instances and a probable t(7;12) in the other two. FISH confirmed the presence of a t(7;12)(q36;p13) in the latter. Most (n = 7) also had trisomy 19. The t(7;12)(q36;p13) (n = 9) was more common than the t(7;12)(q32;p13) (n = 1). These subtle translocations were found only in children 18 months of age or younger. A literature search revealed that the t(7;12) with break-points at 7q31-q36 and 12p12-p13 had been reported in six children with myeloid disorders and in two with acute lymphoblastic leukemia; all were 12 months of age or younger. Only two of the 17 for whom survival data were available, were alive after at least 22 months of continuous complete remission. Our findings suggest that ETV6 rearrangements due to a t(7;12) may play an adverse role in myeloid disorders in children 18 months of age or younger. Therefore, children in this age group with myeloid disorders should be screened for both MLL and ETV6 rearrangements.

  6. 32P-玻璃微球间质给药体内生物学分布与代谢%Biodistribution and metabolism of phosphorus-32 glass microspheres through Interstitial administration

    Institute of Scientific and Technical Information of China (English)

    江波; 刘璐; 孙晋; 高海林; 兰兴昊; 黄鹰

    2008-01-01

    目的 观察32P-玻璃微球(32P-GMS)间质给药后体内生物学分布与代谢.方法 120只小鼠分别经肝脏或肌肉注射32P-GMS,每只(1.80±0.05)MBq/50μl,不同时间点处死取血及脏器计算每克组织百分注射剂量率(%ID/g);12只大鼠肝脏、肌肉每只注射(18.0±0.5)MBq/0.5 ml,收集排泄物测累积排泄率.结果 小鼠肝脏组给药肝叶%ID/g 0时最高为1.38,15 nin降至0.71,非给药肝叶峰值15 min为0.52,4 h之后左右肝叶无区别;肺组织计数率值1 h内上升,肝肺累积分流率为37.9%.肌肉组注射点%ID/g0时为31.47,15 nin~8 h为25.06~11.92(中值20.97),12 h为8.70,24 h~14 d为3.54~2.02(中值2.51),其他主要脏器放射性接近本底水平.大鼠肝脏组粪便和尿液14 d累积排泄率分别为0.0751%和0.0586%;肌肉组分别为0.0401%和0.0385%.结论 32P-GMS间质注射适用于除肝脏以外的体内组织脏器恶性实体瘤的治疗.%Objective To observe the biodistribution and the metabolism of phospborus-32 glass microspheres (32P-GMS) through interstitial administration. Methods Thirty-two P-GMS were injected into liver and muscle of 120 mice respectively by means of interstitial administration with dose of (1.80±0.05) MBq/50 μl. All of the mice were killed at different time points, blood was taken out and major or-gans were dissected,and the injection dosage rate (% ID/g) was measured. The stool and urine were col-lected after interstitial injection both in liver and muscle of 12 rata with the dose of (18.0±0.5) MBq/0.5 ml,then the accumulative radioactivity counts percentage was measured. Results In liver injection group ,the highest point of % ID/g was 1.38 at start time after administration ,and decreased to 0.71 at 15 rain. The % ID/g value at 15 min was 0.52 in none injected liver lobes,and there was the similar tendency between left and right liver lobes after 4 h. The radioactivity in lung was increased obviously in 1 h,and the liver-lung accumulate split stream

  7. Mensuration of equivalent dose with personal dosemeters and instruments of radiological protection in the new operative quantities ICRU, for external fields of beta radiation. Part II. I study of the angular response of personal dosemeters TLD-100 in secondary patron fields of beta radiation ({sup 90}Sr / {sup 90}Y); Medicion de dosis equivalente con dosimetros personales e instrumentos de proteccion radiologica en las nuevas magnitudes operativas ICRU, para campos de radiacion beta externos. Parte II. Estudio de la respuesta angular de dosimetros personales TLD-100 en campos patrones secundarios de radiacion beta ({sup 90}Sr/{sup 90}Y)

    Energy Technology Data Exchange (ETDEWEB)

    Alvarez R, J.T. [ININ, 52045 Ocoyoacac, Estado de Mexico (Mexico)

    1994-01-15

    The objective of this work is to carry out one of the possible ones test type for personal dosemeters TLD, under the recomendations of the ICRU 39, ICRU 43 and the draft of the norm ISO 6980,(1992), with the purpose of verifying the capacity of these detectors to carry out the operative unit: H' (0.07;{alpha}). Since H' (O. 07;{alpha}) this defined one in an expanded field, one of these tests type consist on determining the angular response of these detectors. 20 personal dosemeters TLD-100 was used, (card marks: Harshaw, Model: G-1, with two glasses of TLD-100 absorbed in teflon; the portadosemeters has two windows, a free one and another with a filter of Pb of 171.0 mg cm{sup -2}); these dosemeters they were previously selected, [to see, {sup S}tudy of the Homogeneity of the response of Personal Dosemeters (Cards G-l, TLD-100) in Radiation of Countrysides of {sup 60}Co{sup ,} J.T. Alvarez R. Technician Report GSR/IT/0001/94].The irradiations to effectued in secondary countryside of radiation beta of {sup 90}Sr/{sup 90}Y. The study was undertaken by means of an experimental design of blocks random that contemplate the following variables: intensity of the radiation source, (1850 MBq and 74 MBq); position of irradiation, (four positions); incidence of angle of the radiation (0, 15, 30, 45, 60 and 75 grades) and the absorbed dose in air, (0.005, 0.010, 0.020, 0.050 and 0.100 Gy). Then null hypothesis it was to suppose that there was not difference among the stockings of each treatment, to used the statistical of Duncan to carry out tests of stockings at a level of significance of 5%.These tests of stockings throw the following results in those variables of the experimental design: The irradiations carried out so much with the source pattern secondary of {sup 90}Sr/{sup 90}Y of 1850 MBq and of 74 MBq, they are equivalent reason why they can be used indistinctly. The responses of each one of the glasses of the card are strongly anisotropic for each glass

  8. 32P敷贴治疗婴幼儿血管瘤1619例疗效分析%Curative effect of 32P applicator brachytherapy for infantile hemangiom: a report of 1619 casees

    Institute of Scientific and Technical Information of China (English)

    张兰平; 李宗良

    2013-01-01

    Objective To discuss the curative effect of 32P applicator brachytherapy for infantile hemangioma.Methods A total of 1619 patients of infantile hemangioma were treated with the self-made 32p applicator and given following observation.The therapeutic schedule was adjusted according to the individual situation of patients,with the dose of 1.2 Gy/(cm2·d),8~9 days as one treatment course,for no more than 3 courses.Results The total cure rate was 87.8%,and the cure rate of infantile simple hemangioma was the highest (93.4%).The curative effect and age was negatively correlated,the younger,the better.Conclusion 31P applicator is an safe,simple,anodynia,effective method for infantile hemangioma,especially for infantile simple hemangioma.%目的 观察32P敷贴治疗婴幼儿血管瘤的疗效.方法 采用自制的32P敷贴器对1619例婴幼儿血管瘤患者进行治疗并随访观察,剂量为1.2 Gy/(cm2·d),8~9d为一个疗程,最多3个疗程,并根据患者的个体情况进行适当调整.结果 1619例婴幼儿血管瘤患者总治愈率为87.8%,其中单纯性血管瘤的治愈率达93.4%,且疗效与年龄呈负相关,年龄越小,疗效越好.结论 32P敷贴治疗婴幼儿皮肤血管瘤安全、简便、无痛、治愈率高,尤其适用于婴幼儿单纯性血管瘤的治疗.

  9. Measurement of dose speed absorbed in depth imparted by sources external secondary patterns of beta radiation. Part 1 Measurement of dose speed absorbed in the surface of soft fabric for isotopes of {sup 90}Sr/{sup 90}Y, {sup 147}Pm and {sup 204}TI; Medicion de rapidez de dosis absorbida en profundidad impartida por fuentes patrones secundarios de radiacion beta externos. Parte 1. Medicion de rapidez de dosis absorbida en la superficie de tejido blando para isotopos de {sup 90}Sr/{sup 90}Y, {sup 147}Pm y {sup 204}TI

    Energy Technology Data Exchange (ETDEWEB)

    Alvarez R, J.T. [ININ, 52045 Ocoyoacac, Estado de Mexico (Mexico)

    1993-01-15

    The dose speed was measured absorbed for depth zero, (superficial) in soft equivalent fabric, for the secondary pattern{sup s} four sources of beta radiation, (Nr. 86): {sup 90}Sr/{sup 90}Y, (1850 MBq and 74 MBq respectively); {sup 147}Pm, (518 MBq) and {sup 204}TI, (18.5 MBq). The measurement is carried out to different distances of source-detecting separation, (11.0, 30.0 and 50.0 cm for the source of 1850 MBq, 30.0 cm for that of 74 MBq; 11.00 cm for the source of {sup 147}Pmand to contact for all the sources); maintaining the radiation sheaf aligned the one axis of symmetry of the detector, ({alpha} 0 degrees). The detector employed was a extrapolation chambers of variable electrodes and electrode fixed collector, (30 mm of diameter). In accordance with the principle of Bragg-Gray the volume of the chambers is varied and they register the variations of the current of collected ionization, correcting until for a maximum of thirteen correction factors that take into account the deviation to the suppositions that it establishes this principle. The certain values of the speed of superficial absorbed dose are in the following intervals: {sup 90}Sr/{sup 90}Y, (1850 MBq, 0.0, 11.0, 30.0 and 50.0 cm): 43.164 mGy S-t, 0.544 mGy s-1 ,0.075 mGy s{sup -1} and 0.027 mGy s{sup -1}, respectively, with a Global Analysis of the order of 1.17%, 1.17%, 1.14% and 1.66%, K J; {sup 90}Sr / {sup 90}Y, (74 MBq, 0.0 and 30 cm): 1.536 mGy s{sup -1} and 0.002 mGy s{sup -1}, with Global Analysis of 1.19.0% and 5.22%, (K = 1) respectively, for the {sup 147}Pm, (0.0 and 11.0 in the interval of: 0.36 {mu}Gy s{sup -1} and 0.43 {mu}Gy s{sup -1}, with one Global Analysis of 1 .42% and 4.28%, (K = 1), respectively; and finally for the {sup 204}TI, (0.0 cm) in the interval of 0.10 {mu}Gy s{sup -1} with a Global Analysis of 1.27%. He calculates of the Global Analysis one carries out of agreement with those recommendations of the BIPM. In all the cases of source-detecting arrangement with

  10. Dosimetric studies of anti-CD20 labeled with therapeutic radionuclides at IPEN/CNEN-SP

    Energy Technology Data Exchange (ETDEWEB)

    Barrio, G.; Dias, C.R.B.R.; Osso Junior, J.A., E-mail: gracielabarrio@gmail.com [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil)

    2012-07-01

    Radioimmunotherapy (RIT) makes use of monoclonal antibodies (MAb) labeled with alpha/beta radionuclides for therapeutical purposes, leading to tumor irradiation and destruction, preserving the normal organs on the radiation excess. The therapeutic activity to be injected in a specific patient is based on information obtained in dosimetric studies. Beta emitting radionuclides such as {sup 131}I, {sup 188}Re, {sup 90}Y, {sup 177}Lu and {sup 166}Ho are useful for the development of therapeutic radiopharmaceuticals. Anti-CD20 (Rituximab) is a chimeric MAb directed against antigen surface CD20 on B-lymphocytes, used in non-Hodgkin lymphoma treatment (NHL). The association with beta radionuclides have shown greater therapeutic efficacy. Currently, two radiopharmaceuticals with Anti-CD20 for radioimmunotherapy have FDA approval for NHL treatment: {sup 131}I-AntiCD20 (Bexar) and {sup 90}Y-AntiCD20 (Zevalin). Techniques for the radiolabeling of {sup 188}Re-antiCD20 have been recently developed by IPEN-CNEN/SP in order to evaluate the clinical use of this radionuclide in particular. The use of {sup 188}Re (T{sub 1/2} 17h) produced by the decay of {sup 188}W (T{sub 1/2} 69d), from an {sup 188}W/{sup 188}Re generator system, has represented an alternative to RIT. Beyond high energy beta emission for therapy, {sup 188}Re also emits gamma rays (155keV) suitable for image. The aim of this new project is to compare the labeling of anti-CD20 with {sup 188}Re with the same MAb labeled with {sup 131}I, {sup 177}Lu, {sup 90}Y and even {sup 99m}Tc. The first step in this project is the review of the published data available concerning the labeling of this MAb with different radionuclides, along with data obtained at IPEN, taking into account labeling procedures, labeling yields, reaction time, level and kind of impurities and biodistribution studies. The pharmacokinetic code will be developed in Visual Studio.NET platform through VB.NET and C{sup ++} for biodistribution and dosimetric

  11. Use of Monte Carlo simulations with a realistic rat phantom for examining the correlation between hematopoietic system response and red marrow absorbed dose in Brown Norway rats undergoing radionuclide therapy with {sup 177}Lu- and {sup 90}Y-BR96 mAbs

    Energy Technology Data Exchange (ETDEWEB)

    Larsson, Erik; Ljungberg, Michael; Martensson, Linda; Nilsson, Rune; Tennvall, Jan; Strand, Sven-Erik; Joensson, Bo-Anders [Department of Medical Radiation Physics, Clinical Sciences, Lund University, Lund (Sweden); Department of Oncology, Clinical Sciences, Lund University, Lund (Sweden); Department of Medical Radiation Physics, Clinical Sciences, Lund University, Lund (Sweden)

    2012-07-15

    Purpose: Biokinetic and dosimetry studies in laboratory animals often precede clinical radionuclide therapies in humans. A reliable evaluation of therapeutic efficacy is essential and should be based on accurate dosimetry data from a realistic dosimetry model. The aim of this study was to develop an anatomically realistic dosimetry model for Brown Norway rats to calculate S factors for use in evaluating correlations between absorbed dose and biological effects in a preclinical therapy study. Methods: A realistic rat phantom (Roby) was used, which has some flexibility that allows for a redefinition of organ sizes. The phantom was modified to represent the anatomic geometry of a Brown Norway rat, which was used for Monte Carlo calculations of S factors. Kinetic data for radiolabeled BR96 monoclonal antibodies were used to calculate the absorbed dose. Biological data were gathered from an activity escalation study with {sup 90}Y- and {sup 177}Lu-labeled BR96 monoclonal antibodies, in which blood cell counts and bodyweight were examined up to 2 months follow-up after injection. Reductions in white blood cell and platelet counts and declines in bodyweight were quantified by four methods and compared to the calculated absorbed dose to the bone marrow or the total body. Results: A red marrow absorbed dose-dependent effect on hematological parameters was observed, which could be evaluated by a decrease in blood cell counts. The absorbed dose to the bone marrow, corresponding to the maximal tolerable activity that could safely be administered, was determined to 8.3 Gy for {sup 177}Lu and 12.5 Gy for {sup 90}Y. Conclusions: There was a clear correlation between the hematological effects, quantified with some of the studied parameters, and the calculated red marrow absorbed doses. The decline in body weight was stronger correlated to the total body absorbed dose, rather than the red marrow absorbed dose. Finally, when considering a constant activity concentration, the phantom

  12. In vitro studies of the genotoxic effects of bitumen and coal-tar fume condensates: comparison of data obtained by mutagenicity testing and DNA adduct analysis by 32P-postlabelling.

    Science.gov (United States)

    De Méo, M; Genevois, C; Brandt, H; Laget, M; Bartsch, H; Castegnaro, M

    1996-08-14

    Bitumens contain traces of polycyclic aromatic compounds (PACs), a part of which will end up in the fumes emitted during hot handling of bitumen-containing products, e.g. during roadpaving. Although exposure of workers to these fumes is low, it might lead to health problems. Studies on bitumen fume condensates (BFCs) showed weak to moderate mutagenic activities, but studies on DNA adduct formation have not been reported. Therefore, a study was initiated in which fumes were generated from two road grade bitumens, in such a way that they were representative of the fumes produced in the field. The combined vapour/particulates were tested in vitro for their ability to produce DNA adducts and in modified Ames mutation assays, using a number of different strains. An attempt was made to relate the results to chemical data, such as the content of a number of individual polycyclic aromatic hydrocarbons (PAHs) and with a measure for the total PAC content. As a reference material fume condensate from coal-tar (coal-tar pitch volatiles; CTPV) were subjected to the same tests. All fume condensates tested were mutagenic to all strains and induced the formation of DNA adducts. The patterns of DNA adducts, obtained by 32P-postlabelling, arising from the BFCs were qualitatively different from the patterns of adducts obtained from the CTPVs, implying qualitative differences in the nature of the compounds responsible for the formation of these adducts. This is corroborated by the observation that for BFCs quantitative adduct levels are higher than would be expected based on the PAH content. These data thus indicate that the PAHs analysed are not the sole components responsible for adduct formation from BFCs, but that an important contribution comes from other (hetero- and/or substituted-) PACs.

  13. Drug distribution in intracystic 32P colloid radiotherapy for treatment of craniopharyngioma:a clinical study%32P胶体囊内放疗治疗颅咽管瘤药物分布的研究

    Institute of Scientific and Technical Information of China (English)

    常洪波; 高铭; 赵思源; 卢旺盛; 王亚明; 赵虎林; 田增民

    2014-01-01

    目的研究不同药量及颅咽管瘤囊腔容积对32P胶体囊内分布及脑脊液囊内渗漏的影响,为手术穿刺路径的选择及操作技术控制等提供临床指导。方法前瞻性研究分析40例初次发病或复发性囊性颅咽管瘤病人的临床资料,按治疗剂量毫居里(mCi)分为4组:0.5 mCi组、1.0 mCi组、1.5 mCi组、2.0 mCi组。术中将32P胶体用碘帕醇300注射液按1∶1稀释后,行囊内注射立体定向放射治疗,术后2 h内行头颅CT检查观察药物分布及渗漏情况,并比较组间差异是否有统计学意义。结果因脑内穿刺路径不能避开脑室导致药物分布不均匀和脑脊液囊内渗漏,在2.0 mCi组有6例,1.5 mCi组2例,1.0 mCi组1例;渗漏后囊腔体积无明显缩小。其余病人药物分布均匀、无脑脊液囊内渗漏,术后囊腔体积明显缩小。2.0 mCi组脑脊液的渗漏率与1.0 mCi组和0.5 mCi组比较,差异均有统计学意义(P<0.05)。结论颅咽管瘤囊腔容积越大,32P胶体剂量越高,越容易发生脑脊液囊内渗漏及药物分布不均匀。%Objective To research the influence of different doses and craniopharyngioma cavity volumes on the drug distribution inside the capsule and cerebrospinal fluid leakage of 32P colloid inside the capsule, so as to provide clinical guidance for the surgical puncture path selection and operation skills control. Methods Clinical data of 40 patients with first onset or recurrent cystic craniopharyngioma were analyzed prospectively, and the patients were divided into 4 groups according to the therapeutic dose (mCi): 0.5, 1.0, 1.5 and 2.0 mCi groups. After 32P colloid diluted with iopamidol 300 injection by 1:1 proportion, the mixture was injected into the capsule for stereotactic radiotherapy, and the situation of drug distribution and leakage were observed by CT scan 2 h after the operation. The statistical differences were compared between the groups. Results There were 6 patients in 2.0 mCi group

  14. Measurement of dose equivalent with personal dosemeters and instrumentation of radiological protection in the new operative magnitudes ICRU, for external fields of radiation beta. Part IV. Survey of the angular response of instruments used in radiological protection in secondary patron fields of beta radiation ({sup 90}Sr/{sup 90}Y (1850 MBq and 74 MBq), {sup 204}TI (18.5 MBq) and {sup 147}Pm (518 MBq)); Medicion de dosis equivalente con dosimetros personales e instrumentacion de proteccion radiologica en las nuevas magnitudes operativas ICRU, para campos de radiacion beta externos. Parte IV. Estudio de la respuesta angular de instrumentos empleados en proteccion radiologica en campos patrones secundarios de radiacion beta ({sup 90}Sr/{sup 90}Y (1850 MBq y 74 MBq), {sup 204}TI (18.5 MBq) y {sup 147}Pm(518 MBq))

    Energy Technology Data Exchange (ETDEWEB)

    Alvarez R, J.T. [ININ, 52045 Ocoyoacac, Estado de Mexico (Mexico)

    1994-02-15

    Tests type were made (type test) in the following commercial instrumentation commonly used in radiological protection: Geiger-Mueller Counters (FH40 FE), Plastic Scintillators (NE-BP/6/4A), Ionization Chambers (RO-5) and Proportional Counters (HP-100A; gas:P-10). With object of checking the possibility that these they can carry out the new operative unit ICRU, H' (0.07; {alpha}). The tests consisted on determining the energy and angular response of the detectors in secondary patron fields of beta radiation, for isotopes of {sup 90}Sr/{sup 90}Y (1850 MBq and 74 MBq and {sup 147}Pm(518 MBq). The results show the inadequate of these commercial instruments for the realization of the H' operative unit (0.07; {alpha}) in beta external fields. Due to flaws in the design, construction and calibration of the instruments for this type of radiation fields (Author)

  15. The ATM kinase signaling induced by the low-energy {beta}-particles emitted by {sup 33}P is essential for the suppression of chromosome aberrations and is greater than that induced by the energetic {beta}-particles emitted by {sup 32}P

    Energy Technology Data Exchange (ETDEWEB)

    White, Jason S.; Yue Ning [Department of Radiation Oncology, University of Pittsburgh Medical School, Hillman Cancer Center, Research Pavilion, Suite 2.6, 5117 Centre Avenue, Pittsburgh, PA 15213-1863 (United States); Hu Jing [Department of Pharmacology and Chemical Biology, University of Pittsburgh Medical School, Hillman Cancer Center, Research Pavilion, Suite 2.6, 5117 Centre Avenue, Pittsburgh, PA 15213-1863 (United States); Bakkenist, Christopher J., E-mail: bakkenistcj@upmc.edu [Department of Radiation Oncology, University of Pittsburgh Medical School, Hillman Cancer Center, Research Pavilion, Suite 2.6, 5117 Centre Avenue, Pittsburgh, PA 15213-1863 (United States); Department of Pharmacology and Chemical Biology, University of Pittsburgh Medical School, Hillman Cancer Center, Research Pavilion, Suite 2.6, 5117 Centre Avenue, Pittsburgh, PA 15213-1863 (United States)

    2011-03-15

    Ataxia-telangiectasia mutated (ATM) encodes a nuclear serine/threonine protein kinase whose activity is increased in cells exposed to low doses of ionizing radiation (IR). Here we examine ATM kinase activation in cells exposed to either {sup 32}P- or {sup 33}P-orthophosphate under conditions typically employed in metabolic labelling experiments. We calculate that the absorbed dose of IR delivered to a 5 cm x 5 cm monolayer of cells incubated in 2 ml media containing 1 mCi of the high-energy (1.70 MeV) {beta}-particle emitter {sup 32}P-orthophosphate for 30 min is {approx}1 Gy IR. The absorbed dose of IR following an otherwise identical exposure to the low-energy (0.24 MeV) {beta}-particle emitter {sup 33}P-orthophosphate is {approx}0.18 Gy IR. We show that low-energy {beta}-particles emitted by {sup 33}P induce a greater number of ionizing radiation-induced foci (IRIF) and greater ATM kinase signaling than energetic {beta}-particles emitted by {sup 32}P. Hence, we demonstrate that it is inappropriate to use {sup 33}P-orthophosphate as a negative control for {sup 32}P-orthophosphate in experiments investigating DNA damage responses to DNA double-strand breaks (DSBs). Significantly, we show that ATM accumulates in the chromatin fraction when ATM kinase activity is inhibited during exposure to either radionuclide. Finally, we also show that chromosome aberrations accumulate in cells when ATM kinase activity is inhibited during exposure to {approx}0.36 Gy {beta}-particles emitted by {sup 33}P. We therefore propose that direct cellular exposure to {sup 33}P-orthophosphate is an excellent means to induce and label the IR-induced, ATM kinase-dependent phosphoproteome.

  16. A method to accurately quantitate intensities of (32)P-DNA bands when multiple bands appear in a single lane of a gel is used to study dNTP insertion opposite a benzo[a]pyrene-dG adduct by Sulfolobus DNA polymerases Dpo4 and Dbh.

    Science.gov (United States)

    Sholder, Gabriel; Loechler, Edward L

    2015-01-01

    Quantitating relative (32)P-band intensity in gels is desired, e.g., to study primer-extension kinetics of DNA polymerases (DNAPs). Following imaging, multiple (32)P-bands are often present in lanes. Though individual bands appear by eye to be simple and well-resolved, scanning reveals they are actually skewed-Gaussian in shape and neighboring bands are overlapping, which complicates quantitation, because slower migrating bands often have considerable contributions from the trailing edges of faster migrating bands. A method is described to accurately quantitate adjacent (32)P-bands, which relies on having a standard: a simple skewed-Gaussian curve from an analogous pure, single-component band (e.g., primer alone). This single-component scan/curve is superimposed on its corresponding band in an experimentally determined scan/curve containing multiple bands (e.g., generated in a primer-extension reaction); intensity exceeding the single-component scan/curve is attributed to other components (e.g., insertion products). Relative areas/intensities are determined via pixel analysis, from which relative molarity of components is computed. Common software is used. Commonly used alternative methods (e.g., drawing boxes around bands) are shown to be less accurate. Our method was used to study kinetics of dNTP primer-extension opposite a benzo[a]pyrene-N(2)-dG-adduct with four DNAPs, including Sulfolobus solfataricus Dpo4 and Sulfolobus acidocaldarius Dbh. Vmax/Km is similar for correct dCTP insertion with Dpo4 and Dbh. Compared to Dpo4, Dbh misinsertion is slower for dATP (∼20-fold), dGTP (∼110-fold) and dTTP (∼6-fold), due to decreases in Vmax. These findings provide support that Dbh is in the same Y-Family DNAP class as eukaryotic DNAP κ and bacterial DNAP IV, which accurately bypass N(2)-dG adducts, as well as establish the scan-method described herein as an accurate method to quantitate relative intensity of overlapping bands in a single lane, whether generated

  17. 平阳霉素联合32P不同治疗方式对儿童血管瘤的疗效对照%Comparative effect on different treatment methods of Bleomycin and 32P in children with hemangiomas

    Institute of Scientific and Technical Information of China (English)

    杨蕾华

    2012-01-01

    Objective To explore the clinical effect of Bleomycin combined with 32P in the treatment of children with he-mangiomas, and to provide the effective reference for the clinical treatment of hemangiomas. Methods From May 2008 to May 2010 in our hospital, 82 cases of children with hemangiomas were selected as the object of clinical observation. The children were divided into two groups, with 42 cases of the observation group and 40 cases of the control group. The observation group was treated by Bleomycin combined with 32P Injection, the control group was treated by 32P for local injection and external application. The different ages, different types of hemangioma, gender and number of lesions and the incidence of adverse reactions of two groups were compared. Results The observation group had a significant curative effect on cavernous hemangioma and mixed hemangioma, the control group had a significant curative effect on capillary hemangioma and port wine stains; the age factor had significant influence for treatment approaches of children with hemangioma in two groups, the younger, the better application therapy's effect of 32P local injection and external application, Bleomycin combined with 32P has a better effect on children over the age of 2; the gender and number of lesions had no significant effect on the efficacy of two treatment methods; there was no significant difference in the incidence of adverse reactions of two groups, but there was a significant difference in the kinds of adverse reactions of two groups. Conclusion Bleomycin combined with 32P is a good way of treating elder children with hemangioma, which is worthy of promotion.%目的 探讨联用平阳霉素和32P治疗儿童血管瘤的临床效果,为临床血管瘤的治疗提供有效的借鉴.方法 选择2008年5月~2010年5月到我院接受治疗的82例血管瘤患儿作为临床观察对象.将患儿分为观察组和对照组,其中观察组42例,对照组40例.

  18. Radionuclide Colloid 32p Used for the Treatment of Stage Ⅱ Lung Cancer by Video Enhanced Minimal Access Muscle Sparing Thoracotomy%放射性核素胶体32p在胸壁小切口胸腔镜治疗Ⅱ期肺癌中的应用

    Institute of Scientific and Technical Information of China (English)

    许栋生; 邹卫; 杨如松; 马国栋; 王科平

    2004-01-01

    Objective: To study the feasibility of radionuclide colloid 32p used for the treatment of stage Ⅱ lung cancer by video enhanced minimal access muscle sparing thoracotomy (VEMAST). Methods:Video assisted thoracoscopic surgery (VATS) was carried out under general anesthesia. A double lumen endobronchial tube was intubated into trachea. One lung ventilation of the healthy side was done during operation. An incision of 8-10 cm long was made along the 4th or 5th intercostals. The lobectomy could be performed under VATS. Radionuclide colloid 32p was injected locally into the area where surgical cleaning of lymph node around was considered to be unsatisfactory or desection of the tumor was not completed. Results: The operation with VEMAST was successful in 29 patients. A conventional lobectomy by thoracotomy had to be done due to unusual bleeding from the pulmonary artery involved during VEMAST in one case and the procedure was interrupted because the pulmonary artery cloud not be separated from the tumor in another patient. There was no dead case or the patient who had any severe complication or adverse response to the radiant. Conclusion: Radionuclide therapy was performed to the treatment of stage Ⅱ lung cancer with VEMAST in case that surgical resection was considered not to be satisfactory. Minithoractomy assisted with VATS lobectomy and radionuclide colloid 32p therapy is a safe and effective technique for some selected stage Ⅱ lung cancer.%目的探讨放射性核素胶体32p在胸壁小切口辅助电视胸腔镜肺叶切除治疗Ⅱ期肺癌中应用的可能性.方法在双腔管气管插管常规全麻下实施电视胸腔镜手术.术中健侧肺单肺通气,第4或第5肋间8~10 cm切口,辅助胸腔镜下肺叶切除及清扫淋巴结,对手术中认为淋巴结清扫不彻底及淋巴结转移区域,局部注射放射性核素胶体32pMBq(5~10mCi).结果29例病人在VEMAST下完成肺叶切除,1例因肺动脉肿瘤包裹,术中出血改在常

  19. 32P-postlabeling analysis of DNA adduction in mice by synthetic metabolites of the environmental carcinogen, 7H-dibenzo[c,g]carbazole: chromatographic evidence for 3-hydroxy-7H-dibenzo[c,g]carbazole being a proximate genotoxicant in liver but not skin.

    Science.gov (United States)

    Schurdak, M E; Stong, D B; Warshawsky, D; Randerath, K

    1987-04-01

    The DNA adduction by the environmental carcinogen 7H-dibenzo[c,g]carbazole (DBC) and chemically synthesized 2-OH, 3-OH, and 4-OH metabolites of DBC was investigated in liver and skin of female CD-1 mice. After topical application to the skin of 37 mumol/kg of DBC or the phenolic metabolites, DNA adducts were measured by a 32P-post-labeling assay employing carrier-free [gamma-32P]ATP and ATP-deficient conditions. In liver, DBC produced four major and several minor chromatographically distinct adducts of as yet undetermined chemical structure. The adduct pattern elicited by 3-OH-DBC was qualitatively similar to the DBC adduct pattern, while this was not the case for 2-OH-DBC and 4-OH-DBC. On the basis of co-chromatography experiments under various conditions, the DBC and 3-OH-DBC adducts appeared identical, and the total of adduction elicited by these compounds in liver was substantial. Similar results were observed when DBC or 3-OH-DBC were administered i.p. As a major difference between the two compounds, one 3-OH-DBC adduct (no. 3) was 4.4- and 7.0-fold lower than the corresponding DBC adduct after i.p. and topical dosing, respectively. In skin, DBC produced two major adduct fractions after topical application, one of which could be chromatographically resolved into three subcomponents. Prominent adducts produced in skin DNA by each of the three metabolites were different from those elicited by DBC, and the level of adduction by the metabolites was significantly lower than that by DBC. Comparison of the skin and liver DBC-DNA adduct patterns after topical application of DBC showed that only one of the four major chromatographically resolved skin adducts corresponded to a major liver adduct (no. 3), and that total adduction in liver was 13.5-fold higher than in skin. These results suggested that activation of DBC to DNA-binding compounds in liver occurs through at least two pathways with 3-OH-DBC being a proximate carcinogen involved in the formation of most of the

  20. Experiments in Radiochemistry: Paper Electrophorectic Separation of Superscript 90 Sr and Superscript 90 Y.

    Science.gov (United States)

    Miekely, N.; Roldao, L. A.

    1982-01-01

    Using different supporting electrolytes, the influence of complex-forming equilibria on migration velocities of strontium-90 and yttrium-90 can be demonstrated in this experiment. Includes procedures and materials needed. (SK)

  1. Development of (90)~Sr/(90)~Y Prostatic Hyperplasia Applicator(Gasbag type)

    Institute of Scientific and Technical Information of China (English)

    1994-01-01

    5.Developmentof ̄(90)Sr/ ̄(90)YProstaticHyperplasiaApplicator(Gasbagtype)CaiShanyuLuCunguo1)LiYongqiang ̄(90)Sr/ ̄(90)Yintracavit...

  2. Accounting for beta-particle energy loss to cortical bone via paired-image radiation transport (PIRT).

    Science.gov (United States)

    Shah, Amish P; Rajon, Didier A; Patton, Phillip W; Jokisch, Derek W; Bolch, Wesley E

    2005-05-01

    approximately 14% to 76% for high-energy beta emitters (32p, 188Re, and 90Y). The PIRT methodology allows for detailed modeling of the 3D macrostructure of individual marrow-containing bones within the skeleton thus permitting improved estimates of absorbed fractions and radionuclide S values for intermediate-to-high energy beta emitters.

  3. Balloon method 32P radiotherapy combined with concurrent chemotherapy for Mo temozolomide treatment of postoperative cerebral glioma%脑胶质瘤术后球囊法32p内放疗联合替莫唑胺同步化疗的临床研究

    Institute of Scientific and Technical Information of China (English)

    王艳芝; 相寿长; 付廷刚

    2012-01-01

    目的:观察球囊法32P内放疗同步替莫唑胺化疗对脑胶质瘤的临床疗效.方法:选取脑胶质瘤患者105例作为研究对象,随机分为两组,A组(52例)为球囊法32P内放疗组,B组(53例)为行球囊法32P内放疗同步替莫唑胺化疗组.比较两组肿瘤体积缓解率及1、2和3年生存率,分析其疗效;比较两组治疗后KPS评分,分析其治疗不良反应.结果:A组患者治疗后完全缓解、部分缓解、好转、稳定和进展分别为6、15、9、14和8例,B组分别为14、23、8、4和4例;1、2和3年生存率分别为78.8%、57.7%、40.4%和92.4%、77.4%、60.4%;6个月、1和3年KPS评分分别为75.89±9.23、71.97±10.73、64.31±10.11和85.22±9.40、83.96±10.33、81.97±11.01,经统计学分析组间差异均有统计学意义,P<0.05.结论:球囊法32P内放疗同步替莫唑胺化疗治疗脑胶质瘤优于单纯球囊法32P内放疗.%OBJECTIVE: To study clinical efficacy of balloon 3ZP internal radiotherapy with Mo temozolomide chemotherapy for brain glioma, and find out the more effective protocol for brain glioma. METHODS: Total 105 cases were randomly selected and divided into 2 groups. Group A (52 cases) was Balloon 3ZP Internal Radiotherapy only; Group B (53 cases) was Balloon method 32P internal radiotherapy and Mo temozolomide chemotherapy. Tumor volume response rate and 1,2,3 year survival rate of two groups were analyzed and KPS score was compared. The treatment side effects was analyzed. RESULTS: After treatment, complete remission, partial remission, better stability and progress in groups A were 6 cases, 15 cases, 9 cases, 14 cases,8 cases, and in group B those were 14 cases,23 cases,8 cases, 4 cases,4 cases; 1, 2,3 year survival rates in group A and B were 78. 8% ,57. 7% ,40. 4% and 92. 4% ,77. 4% ,60. 4% ; KPS score of 0. 5,1, 3 years were 75. 89 + 9. 23,71. 97 10. 73,64. 31 + 10. 11 and 85. 22 + 9. 40, 83. 96+10. 33,81. 97 + 11. 01, There was a significant

  4. Ação comunicativa e ética no acesso e uso sustentável da água: a experiência do saneamento rural de Marechal Cândido Rondon - PR - DOI: 10.5752/P.2175-5841.2013v11n32p1571

    Directory of Open Access Journals (Sweden)

    Alvori Ahlert

    2013-12-01

    Full Text Available TítuloAção comunicativa e ética no acesso e uso sustentável da água: a experiência do saneamento rural de Marechal Cândido Rondon - PR (Communicative action and ethics on the access and sustainable use of water: the experience of rural sanitation of Marechal Cândido Rondon – Paraná, Brazil. DOI: 10.5752/P.2175-5841.2013v11n32p1571 ResumoO texto apresenta um estudo/pesquisa sobre a ética e os recursos hídricos, problematizando a relação entre a ética e o uso sustentável da água, tendo como modelo referencial aproximações na experiência do saneamento rural de Marechal Cândido Rondon, PR que, através da organização dos próprios agricultores e com o apoio da autarquia municipal de água e esgoto, atingiu 100% de acesso à água potável na zona rural do município.  A discussão propõe uma sinergia entre comunidades, gestores de sistemas e pesquisadores, que possibilite a criação de contextos comunicativos nos quais se partilha e socializa informações para o debate dos temas e situações que defendam um acesso democrático aos recursos hídricos e ao uso sustentável da água. Os fundamentos para este debate se encontram na obra de Lord Selborne, A Ética do Uso da Água Doce: um levantamento. (2001, e no paradigma da Teoria da Ação Comunicativa de Jürguen Habermas (1989, como um instrumento para propor o debate público sobre o acesso democrático aos recursos hídricos e, assim, criar contextos comunicativos que possibilitem a socialização de conhecimentos necessários relativos aos recursos hídricos e potencializar o debate sobre o uso desse bem natural como um direito humano universal. Palavras-chave: Ética. Água. Uso sustentável. Ação comunicativa. Saneamento rural.   Abstract The text presents a study/research on ethics and water resources, questioning the relationship between ethics and sustainable water use, taking as reference model approaches in the experience of rural sanitation of Marechal

  5. A mini X-ray generator as an alternative to a 90Sr/90Y beta source in luminescence dating

    DEFF Research Database (Denmark)

    Andersen, C.E.; Bøtter-Jensen, L.; Murray, A.S.

    2003-01-01

    We have carried out an investigation to test whether mini X-ray generators are a suitable alternative to radioactive sources in luminescence dating. The study has mainly been motivated by the need for high dose rates (similar to 1 Gy/s) to make dating of older samples using regeneration protocols...... more practical. Furthermore, X-ray generators are more suited for field work and work in countries where regulations restrict the use of radioactive sources. The system tested here (a 50 kV I mA Varian VF-50J tube with tungsten target and a matched Spellman high-voltage power supply) was found...... to provide: (i) excellent linearity between tube current (as set by the user on the control computer) and dose rate, (ii) a wide dynamic range: 2-30 mGy/s at 10 kV and 10-2000 mGy/s at 50 kV, (iii) short-term stability better than 0.2%, and (iv) a highly uniform irradiation of the sample area. Tests...

  6. PET/CT and Bremsstrahlung Imaging After 90Y DOTANOC Therapy for Rectal Net With Liver Metastases.

    Science.gov (United States)

    Abdülrezzak, Ümmühan; Kula, Mustafa; Tutuş, Ahmet; Buyukkaya, Fikret; Karaca, Halit

    2015-10-01

    Peptide receptor radionuclide therapy with Lu or Y is promising with successful results in somatostatin receptor-positive tumors. In all radiation therapies, knowledge of the radiation dose received by the target, and other organs in the body is essential to evaluate the risks and benefits of any procedure. We report a case of liver metastases from a rectal neuroendocrine tumor, which was treated with Y DOTANOC. Posttreatment whole-body planar images were acquired through Bremsstrahlung radiations of Y on a γ-camera, and thoracolumbar PET/CT images were acquired on PET.

  7. Robust evidence for long-term survival with {sup 90}Y radioembolization in chemorefractory liver-predominant metastatic colorectal cancer

    Energy Technology Data Exchange (ETDEWEB)

    Jakobs, T.F. [Barmherzige Brueder Munich, Department of Diagnostic and Interventional Radiology, Munich (Germany); Paprottka, K.J.; Raessler, F.; Strobl, F.; Trumm, C.G.; Sommer, W.; Paprottka, P.M. [LMU - University of Munich, Department of Clinical Radiology, Munich (Germany); Lehner, S.; Ilhan, H.; Fendler, W.P. [LMU - University of Munich, Department of Nuclear Medicine, Munich (Germany)

    2017-01-15

    Our aim was to provide further evidence for the efficacy/safety of radioembolization using yttrium-90-resin microspheres for unresectable chemorefractory liver metastases from colorectal cancer (mCRC). We followed 104 consecutively treated patients until death. Overall survival (OS) was calculated from the day of the first radioembolization procedure. Response was defined by changes in tumour volume as defined by Response Evaluation Criteria in Solid Tumours (RECIST) v1.0 and/or a ≥30 % reduction in serum carcinoembryonic antigen (CEA) at 3 months. Survival varied between 23 months in patients who had a complete response to prior chemotherapy and 13 months in patients with a partial response or stable disease. Median OS also significantly improved (from 5.8 months to 17.1 months) if response durability to radioembolization extended beyond 6 months. Patients with a positive trend in CEA serum levels (≥30 % reduction) at 3 months post-radioembolization also had a survival advantage compared with those who did not: 15.0 vs 6.7 months. Radioembolization was well tolerated. Grade 3 increases in bilirubin were reported in 5.0 % of patients at 3 months postprocedure. After multiple chemotherapies, many patients still have a good performance status and are eligible for radioembolization. This single procedure can achieve meaningful survivals and is generally well tolerated. (orig.)

  8. The role of (90)Y-radioembolization in downstaging primary and secondary hepatic malignancies : a systematic review

    NARCIS (Netherlands)

    Braat, M N G J A; Samim, M; van den Bosch, Maurice; Lam, M G E H

    2016-01-01

    Radioembolization (RE) is an emerging treatment strategy for patients with primary hepatic malignancies and metastatic liver disease. Though RE is primarily performed in the palliative setting, a shift toward the curative setting is seen. Currently, hepatic resection and in selected cases liver tran

  9. Radiometric trace analysis quantitative paper chromatography of lead with phosphate-32P

    NARCIS (Netherlands)

    Erkelens, P.C. van

    1961-01-01

    A method is described for the selective determination of lead in paper chromatograms, down to 1 μg (standard deviation 11%). After development and drying, the lead spot is sprayed with a Na2H32PO4 solution and dried. Excess reagent and alkaline earth phosphates are eluted with a borax—oxalate buffer

  10. Radio-embolization for hepatocellular carcinoma; Traitement des carcinomes hepatocellulaires par injection intra-arterielle de radio-isotopes

    Energy Technology Data Exchange (ETDEWEB)

    Raoul, J.L. [Departement d' oncologie medicale, centre Eugene-Marquis, rue de la bataille Flandres-Dunkerque, CS 44229, 35042 Rennes cedex (France); Inserm U911, centre Eugene-Marquis, CS 44229, 35042 Rennes cedex (France); Edeline, J.; Pracht, M.; Boucher, E. [Departement d' oncologie medicale, centre Eugene-Marquis, rue de la bataille Flandres-Dunkerque, CS 44229, 35042 Rennes cedex (France); Rolland, Y. [Departement d' imagerie medicale, centre Eugene-Marquis, CS 44229, 35042 Rennes cedex (France); Garin, E. [Inserm U911, centre Eugene-Marquis, CS 44229, 35042 Rennes cedex (France); Departement d' imagerie medicale, centre Eugene-Marquis, CS 44229, 35042 Rennes cedex (France)

    2011-02-15

    Hepatocellular carcinoma is now a major public health concern. In intermediate stages (one third of hepatocellular carcinoma patients), chemo-embolization is the standard of care despite a poor tolerance and a moderate efficacy. Moreover, despite recent improvements, this technique seems in a dead end. Radio-embolization could be an excellent tool for such patients. Currently {sup 131}I-Lipiodol, {sup 188}Re-Lipiodol, {sup 90}Y-glass or resin microspheres are available. More recent and promising data come from microspheres, but phase II and III studies are needed before drawing any conclusion. In the future, the combination of radio-embolization with systemic chemotherapy or targeted agents (particularly anti-angiogenic drugs) seems very promising. (authors)

  11. Influence of voxel size on specific absorbed fractions and S-values in a mouse voxel phantom.

    Science.gov (United States)

    Mohammadi, A; Kinase, S

    2011-02-01

    Photon and electron specific absorbed fractions (SAFs) and S-values have been evaluated using mouse voxel phantoms. In voxel phantoms, it is important to choose the voxel size carefully since it affects the accuracy of results. In this study, two mouse voxel phantoms were constructed, with cubic voxels, one with 0.1-mm sides and the other with 0.4-mm sides. The sources were considered to be distributed uniformly in the main organs and the radiation transport was simulated using the Monte Carlo code EGS4. It was found that the effect of voxel size on SAFs for self-irradiation was not high (voxel size was investigated on S-values for some beta emitters such as (131)I, (153)Sm, (188)Re and (90)Y.

  12. Radioisotopes production for applications on the health; Produccion de radioisotopos para aplicaciones en la salud

    Energy Technology Data Exchange (ETDEWEB)

    Monroy G, F.; Alanis M, J., E-mail: fabiola.monroy@inin.gob.m [ININ, Departamento de Materiales Radiactivos, Carretera Mexico-Toluca s/n, 52750 Ocoyoacac, Estado de Mexico (Mexico)

    2010-07-01

    In the Radioactive Materials Department of the Instituto Nacional de Investigaciones Nucleares (ININ) processes have been studied and developed for the radioisotopes production of interest in the medicine, research, industry and agriculture. In particular five new processes have been developed in the last 10 years by the group of the Radioactive Materials Research Laboratory to produce: {sup 99}Mo/{sup 99m}Tc and {sup 188}W/{sup 188}Re generators, the radio lanthanides: {sup 151}Pm, {sup 147}Pm, {sup 161}Tb, {sup 166}Ho, {sup 177}Lu, {sup 131}I and the {sup 32}P. All these radioisotopes are artificial and they can be produced in nuclear reactors and some of them in particle accelerators. The radioisotope generators are of particular interest, as those of {sup 99}Mo/{sup 99m}Tc and {sup 188}W/{sup 188}Re presented in this work, because they are systems that allow to produce an artificial radioisotope of interest continually, in these cases the {sup 99m}Tc and the {sup 188}Re, without the necessity of having a nuclear reactor or an particle accelerator. They are compact systems armored and sure perfectly of manipulating that, once the radioactive material has decayed, they do not present radiological risk some for the environment and the population. These systems are therefore of supreme utility in places where it is not had nuclear reactors or with a continuous radioisotope supply, due to their time of decaying, for its cost or for logistical problems in their supply, like it is the case of many hospital centers, of research or industries in our country. (Author)

  13. A Brief Review of Chelators for Radiolabeling Oligomers

    Directory of Open Access Journals (Sweden)

    Yuxia Liu

    2010-05-01

    Full Text Available The chemical modification of oligomers such as DNA, PNA, MORF, LNA to attach radionuclides for nuclear imaging and radiotherapy applications has become a field rich in innovation as older methods are improved and new methods are introduced. This review intends to provide a brief overview of several chelators currently in use for the labeling of oligomers with metallic radionuclides such as 99mTc, 111In and 188Re. While DNA and its analogs have been radiolabeled with important radionuclides of nonmetals such as 32P, 35S, 14C, 18F and 125I, the labeling methods for these isotopes involve covalent chemistry that is quite distinct from the coordinate-covalent chelation chemistry described herein. In this review, we provide a summary of the several chelators that have been covalently conjugated to oligomers for the purpose of radiolabeling with metallic radionuclides by chelation and including details on the conjugation, the choice of radionuclides and labeling methods.

  14. Differences among Monte Carlo codes in the calculations of voxel S values for radionuclide targeted therapy and analysis of their impact on absorbed dose evaluations

    Energy Technology Data Exchange (ETDEWEB)

    Pacilio, M.; Lanconelli, N.; Lo Meo, S.; Betti, M.; Montani, L.; Torres Aroche, L. A.; Coca Perez, M. A. [Department of Medical Physics, Azienda Ospedaliera S. Camillo Forlanini, Piazza Forlanini 1, Rome 00151 (Italy); Department of Physics, Alma Mater Studiorum University of Bologna, Viale Berti-Pichat 6/2, Bologna 40127 (Italy); Department of Medical Physics, Azienda Ospedaliera S. Camillo Forlanini, Piazza Forlanini 1, Rome 00151 (Italy); Department of Medical Physics, Azienda Ospedaliera Sant' Andrea, Via di Grotarossa 1035, Rome 00189 (Italy); Department of Medical Physics, Center for Clinical Researches, Calle 34 North 4501, Havana 11300 (Cuba)

    2009-05-15

    Several updated Monte Carlo (MC) codes are available to perform calculations of voxel S values for radionuclide targeted therapy. The aim of this work is to analyze the differences in the calculations obtained by different MC codes and their impact on absorbed dose evaluations performed by voxel dosimetry. Voxel S values for monoenergetic sources (electrons and photons) and different radionuclides ({sup 90}Y, {sup 131}I, and {sup 188}Re) were calculated. Simulations were performed in soft tissue. Three general-purpose MC codes were employed for simulating radiation transport: MCNP4C, EGSnrc, and GEANT4. The data published by the MIRD Committee in Pamphlet No. 17, obtained with the EGS4 MC code, were also included in the comparisons. The impact of the differences (in terms of voxel S values) among the MC codes was also studied by convolution calculations of the absorbed dose in a volume of interest. For uniform activity distribution of a given radionuclide, dose calculations were performed on spherical and elliptical volumes, varying the mass from 1 to 500 g. For simulations with monochromatic sources, differences for self-irradiation voxel S values were mostly confined within 10% for both photons and electrons, but with electron energy less than 500 keV, the voxel S values referred to the first neighbor voxels showed large differences (up to 130%, with respect to EGSnrc) among the updated MC codes. For radionuclide simulations, noticeable differences arose in voxel S values, especially in the bremsstrahlung tails, or when a high contribution from electrons with energy of less than 500 keV is involved. In particular, for {sup 90}Y the updated codes showed a remarkable divergence in the bremsstrahlung region (up to about 90% in terms of voxel S values) with respect to the EGS4 code. Further, variations were observed up to about 30%, for small source-target voxel distances, when low-energy electrons cover an important part of the emission spectrum of the radionuclide

  15. Targeted Radiotherapy of Estrogen Receptor Positive Tumors

    Energy Technology Data Exchange (ETDEWEB)

    Raghavan Rajagopalan

    2006-08-31

    The overall objectives of the proposal were to develop estrogen receptor (ER) binding small molecule radiopharmaceuticals for targeted radiotherapy of ER positive (ER+) tumors. In particular, this proposal focused on embedding a {sup 186,188}Re or a {sup 32}P radionuclide into an estrogen steroidal framework by isosteric substitution such that the resulting structure is topologically similar to the estrogen (estrogen mimic). The estrogen mimic molecules expected to bind to the ER and exhibit biodistribution akin to that of native estrogen due to structural mimicry. It is anticipated that the {sup 186,188}Re- or a {sup 32}P-containing estrogen mimics will be useful for targeted molecular radiotherapy of ER+ tumors. It is well established that the in vivo target tissue uptake of estrogen like steroidal molecules is related to the binding of the steroids to sex hormone binding globulin (SHBG). SHBG is important in the uptake of estrogens and testosterone in target tissues by SHBG receptors on the cell surface. However, hitherto the design of estrogen like small molecule radiopharmaceuticals was focused on optimizing ER binding characteristics without emphasis on SHBG binding properties. Consequently, even the molecules with good ER affinity in vitro, performed poorly in biodistribution studies. Based on molecular modeling studies the proposal focused on developing estrogen mimics 1-3 which were topologically similar to native estrogens, and form hydrogen bonds in ER and SHBG in the same manner as those of native estrogens. To this end the technical objectives of the proposal focused on synthesizing the rhenium-estrone and estradiol mimics 1 and 2 respectively, and phosphorous estradiol mimic 3 and to assess their stability and in vitro binding characteristics to ER and SHBG.

  16. Study of phosphorus absorption by eucalypt and rice using the {sup 32}P isotope; Estudo da absorcao de fosforo por eucalipto e arroz com auxilio do isotopo {sup 32}P

    Energy Technology Data Exchange (ETDEWEB)

    Luca, Edgar Fernando de; Boaretto, Antonio Enedi; Muraoka, Takashi [Centro de Energia Nuclear na Agricultura (CENA), Piracicaba, SP (Brazil); Chitolina, Jose Carlos [Sao Paulo Univ., Piracicaba, SP (Brazil). Escola Superior de Agricultura Luiz de Queiroz

    2000-07-01

    An experiment was carried out in greenhouse conditions with the objective of compare the different concepts of 'nutritional efficiency' and to test the hypothesis that the eucalypt is more efficient than the rice in absorbing the phosphorus of sources few soluble ones synthesised, being used the isotopic tracer technique. It was ended that the nutritional efficiency is relative, because the rice was more efficient than the eucalypt in absorbing the phosphorus of few soluble sources, but the eucalypt had larger biological use of the phosphorus. X-ray diffractometry and thermal differential analyses proved that the laboratory procedures allowed, in fact, to obtain the compositions Ca(H{sub 2}{sup 32}PO{sub 4}).H{sub 2}O, CaH{sup 32}PO{sub 4}.2H{sub 2}O and Ca{sub 3}({sup 32}PO{sub 4}){sub 2}. The 'difference' method (conventional), employee to determine P recovery by plants, underestimated the absorption of this nutrient from eucalypt and rice cultures in relation to the isotopic method. (author)

  17. Efficiency of phosphorus (32 P) uptake and use by eucalyptus seedlings and rice; Eficiencia de absorcao e utilizacao de fosforo ({sup 32} P) por mudas de eucalipto e arroz

    Energy Technology Data Exchange (ETDEWEB)

    Luca, Edgar Fernando de; Boaretto, Antonio Enedi [Centro de Energia Nuclear na Agricultura (CENA), Piracicaba, SP (Brazil). Lab. de Nutricao Mineral de Plantas; Muraoka, Takashi [Centro de Energia Nuclear na Agricultura (CENA), Piracicaba, SP (Brazil). Lab. de Fertilidade do Solo; Chitolina, Jose Carlos [Sao Paulo Univ., Piracicaba, SP (Brazil). Escola Superior de Agricultura Luiz de Queiroz (ESALQ)

    2002-09-01

    The knowledge on different plant abilities to take up soil phosphorus and its use for growth can be important to improve markedly the efficiency of phosphorus fertilization. Having this in mind, an experiment was carried out under greenhouse conditions to test the hypothesis that eucalyptus seedlings are more efficient than rice in absorbing phosphorus from low solubility sources applied to a Quartzamment soil, testing different efficiency concepts. The phosphorus sources Ca(H{sub 2}{sup 32}PO{sub 4}).H{sub 2}O, CaH{sup 32}PO{sub 4}.2H{sub 2}O and Ca{sub 3}({sup 32}PO{sub 4}){sub 2} , synthesised in laboratory and identified by X-ray diffractometry and thermal differential analyses, were used as radioactive tracers. It was concluded that rice is more efficient in absorbing phosphorus from these low solubility sources, while eucalyptus presents a higher coefficient of biologic P utilisation. The 'difference' method (conventional) that in based on P recovery by plants, underestimated the absorption of this nutrient for both species in relation to the isotopic method. (author)

  18. Los sindicatos en la Argentina kirchnerista : Entre la herencia de los ´90 y la emergencia de un nuevo sindicalismo de base

    OpenAIRE

    Varela, Paula

    2015-01-01

    El nuevo protagonismo sindical en Argentina es un hecho ineludible. Eso ha abierto una serie de interpretaciones entre las que predomina la mirada ?estatalista? que atribuye dicho protagonismo a la política gubernamental de implantación de un ?nuevo modelo de relaciones laborales? que revertiría el modelo neoliberal. En este trabajo presentaremos tres hipótesis que debaten con estas interpretaciones. La primera, que el fortalecimiento estatal de los sindicatos se enfrenta, desde el origen, a ...

  19. Peptide Receptor Radionuclide Therapy with (90)Y-DOTATOC and (177)Lu-DOTATOC in Advanced Neuroendocrine Tumors: Results from a Danish Cohort Treated in Switzerland

    DEFF Research Database (Denmark)

    Pfeifer, Andreas Klaus; Gregersen, Tine; Grønbæk, Henning

    2011-01-01

    Limited therapeutic options have highlighted the demand for new treatment modalities for patients with advanced neuroendocrine tumors (NET). Promising results of initial studies have warranted the implementation of peptide receptor radionuclide therapy (PRRT) in clinical practice. However, this t...

  20. Localization of colorectal carcinoma by rhenium-188-labeled B72.3 antibody in xenografted mice

    Energy Technology Data Exchange (ETDEWEB)

    Hosono, Masako N. [Osaka City Univ. (Japan). Medical School; Hosono, Makoto; Zamora, P.O.; Guhlke, S.; Haberberger, T.; Bender, H.; Knapp, F.F.R.; Biersack, H.J.

    1998-04-01

    In order to evaluate the feasibility of {sup 188}Re-labeled antibodies for radioimmunotargeting, monoclonal antibody B72.3, recognizing TAG-72, expressed on the surface membranes of colorectal cancer cells, was directly labeled with {sup 188}Re, obtained from a {sup 188}W/{sup 188}Re generator, using stannous tartrate and compared with {sup 125}I-labeled B72.3. As a control, a human IgG was also radiolabeled with {sup 188}Re and {sup 125}I. Prepared antibodies for {sup 188}Re labeling could be stored as kits. Biodistribution was determined in nude mice inoculated with human colorectal carcinoma LoVo. Labeling efficiency and immunoreactivity of {sup 188}Re-B72.3 were 80.3% and 64.7%, respectively. {sup 188}Re-B72.3 localized specifically in the LoVo tumors. Although the absolute tumor accumulation level of {sup 188}Re-B72.3 was lower than {sup 125}I-B72.3, {sup 188}Re-B72.3 demonstrated higher tumor-to-blood contrast than the {sup 125}I-labeled counterpart, 2.04{+-}0.44 vs. 1.05{+-}0.28 at 96 hours, because of fast clearance from the blood. {sup 188}Re-B72.3 seemed efficient for the imaging and therapy of colorectal carcinoma. (author)

  1. Comparision of {sup 188}Rhenuim-tin colloid and {sup 188}Rhenium-sulfur colloid as a radiation synovectomy agent

    Energy Technology Data Exchange (ETDEWEB)

    Lee, Y. J.; Jung, J. M.; Kim, Y. J.; Jang, Y. S.; Lee, D. S.; Jung, J. K.; Song, Y. W.; Lee, M. C. [KAERI, Taejon (Korea, Republic of)

    1999-10-01

    Beta-emitting radiocolloids have been used for the treatment of rheumatoid arthritis. As a generator produced beta-emitting radionuclide, the importance of Re-188 for radionuclide therapy is increasing rapidly. We compared the radiochemistry of two {sup 188}Re labeled radiocolloids: {sup 188}Re-tin colloid and {sup 188}Re-sulfur colloid. {sup 188}Re-tin colloid was obtained by reacting 10 mg SnCl{sub 2}{center_dot}H{sub 2}O and {sup 188}Re perrhenate. {sup 188}Re-sulfur colloid was labeled by boiling 40 mg sodium thiosulfate, 0.8 mg Na{sub 2}{center_dot}EDTA, and 0.8 mg potassium perrhenate with {sup 188}Re perrhenate. Radiochemical purity was checked by ITLC-SG/ saline. Labeling efficiencies reached >98% for tin colloid at 2 hr and 89{approx}94% for sulfur colloid at 3 hr. All the preparations were stable for 72 hr in water, serum, and synovial fluid. If labeled at higher temperature, particle size of tin colloid increased. Remained radioactivity of {sup 188}Re-sulfur colloid in disposable polypropylene syringe after injecting to mice was high (62.0{+-}7.0%) due to its hydrophobic nature, although, tin colloid did not show high remained radioactivity (2.9{+-}1.6%). Biodistribution in Antigen induced arthratitis model rabbit after synovial space injection showed that {sup 188}Re-tin colloid was well retained in synovial space for 48 hr. Although, both {sup 188}Re-tin colloid and {sup 188}Re-sulfur colloid might be useful for radionuclide therapy, we concluded that {sup 188}Re-tin colloid is more adventageous over {sup 188}Re-sulfur colloid, due to higher labeling efficency, size-controllable property, and lower residual activity in syringe.

  2. Evaluation of a pyrex glass shield for the dose reduction in extremities to manipulate a {sup 90} Sr- {sup 90} Y generator; Evaluacion de un blindaje de vidrio pyrex para la reduccion de las dosis en extremidades al manipular un generador de {sup 90} Sr- {sup 90} Y

    Energy Technology Data Exchange (ETDEWEB)

    Ayra P, F.E.; Xiques C, A.; Torres B, M.B. [Centro de Isotopos, Carretera La Rada, Km 3 1/2, Guanabacoa, La Habana (Cuba)]. e-mail: feayra@centis.edu.cu

    2006-07-01

    The production of Y-90 of high activity it specifies (free of payee) for their use in radioimmunotherapy uses the Strontium 90 as isotope source. Depending on the method employee for the separation of both isotopes several types of generators are described in different bibliographies. The column generator used in the facilities of the Center of Isotopes requires of a frequent manipulation causing significant dose in the skin of the extremities due to the exhibition to the radiation beta of high energy. The properties of the shieldings for this radiation type have been well studied Y they consist in several publications. To be in correspondence with requirements of radiological protection in the Cuban legislation, the column was covered with a tube of glass pyrex of 5 mm of thickness and it was monitored the exposure with an ionization chamber. At the own time, the shielding using the Monte Carlo method was evaluated. It was used the MCNP 4C code to simulate the absorption of the beta particles generated in the process of disintegration of the Sr-90 and Y-90 in the glass shielding. The column generator and the fluence of beta particles were modeled in different points inside the shielding to determine if the experimentally measured values correspond to electrons that were not absorbed or to the weak stopping radiation generated in the glass due to the deceleration of these particles. A cylinder of 4 mm of diameter simulates the source (it dilutes) and a tube of walls of 6 mm of thickness simulates the shielding more the wall of the column around the generator. This it was divided in cells of 1 mm of thickness and the energy deposited in them was evaluated. The results show that all the electrons generated in the source are absorbed in the shielding and the exposure rates decrease in more of 78 times using the 5 mm of pyrex glass. The doses in extremities to the operators of the generator don't surpass the 70 mSv by year that is the dose restriction imposed in the Center of Isotopes. This is of special importance keeping in mind a future escalate in the production of Y-90 in our facilities. (Author)

  3. MCM-41 mesoporous silica nanoparticles functionalized with aptamer and radiolabelled with {sup 90}Y and {sup 159}Gd as a potential therapeutic agent against colorectal cancer; Nanoparticulas de silica mesoporosa MCM-41 funcionalizadas com aptamero e radiomarcadas com {sup 90}Y e {sup 159}Gd como um potencial agente terapeutico contra cancer colorretal

    Energy Technology Data Exchange (ETDEWEB)

    Ferreira, Carolina de Aguiar

    2014-06-01

    Colorectal cancer (CRC) is a malignancy that affects large intestine and rectum, and it is the most common malignancy of the gastrointestinal tract, the third most commonly diagnosed type of cancer in the world and the second leading cause of cancer-related death in the United States. Nowadays, available therapeutic procedures for this type of cancer are limited and ineffective. Conventional radiotherapy is not an often used approach in the treatment of CRC due to the fact that peristaltic movements hamper the targeting of ionizing radiation and this type of treatment is used as adjuvant and palliative to control symptoms. Therefore, surgical intervention is the primary therapeutic choice against this disease. Researches based on the combination of radioisotopes and nanostructured carriers systems have demonstrated significant results in improving the selectivity action as well as reducing the radiation dose into healthy tissues. MCM-41 mesoporous silica nanoparticles have unique characteristics such as high surface area and well-defined pore diameters making these nanoparticles an ideal candidate of therapeutic agent carrier. Thus, the objective of this work is to synthesize and characterize MCM-41 mesoporous silica nanoparticles conjugated with yttrium-90 and gadolinium-159 and evaluate this system as a potential therapeutic agent. The nanoparticles were synthesized via sol-gel method. The sample was characterized using FTIR, SAXS, PCS, Zeta Potential analysis, Thermal analysis, CHN elemental analysis, nitrogen adsorption, scanning and transmission electron microscopy. The ability to incorporate Y{sup +3} and Gd{sup +3} ion was determined in vitro using different ratios (1:1, 1:3, 1:5 v/v) of YCL{sub 3} and Gd{sub 2}O{sub 3} and silica nanoparticles dispersed in saline, pH 7.4. The non-incorporated Y{sup +3} and Gd{sup +3} ions were removed by ultracentrifugation procedure and the concentration of ions in the supernatant was determined by ICP-AES. Cell viability was assessed by colorimetric MTT assay in which specific colorectal cancer cells T84 were used. The results showed that the nanoparticles were successfully synthesized, obtaining nanoparticles with spherical morphology, particle size of 400 nm, PDI 0,1, zeta potential of -25, 8 meV, hexagonal arrangement of pores with 3 nm diameters and superficial area of 1400 m2.g{sup -1}. Cell viability assay results suggest the use of incorporated nanoparticles as a potential therapeutic agent. (author)

  4. Use of a contamination detector to monitor the injected activity in hepatic radio embolization with microspheres of {sup 9}0Y; Uso de un detector de contaminacion para monitorizar la actividad inyectada en radioembolizacion hepatica con microesferas de {sup 9}0Y

    Energy Technology Data Exchange (ETDEWEB)

    Maneru Camara, F.; Otal Palacin, A.; Fuentemilla Urio, N.; Olasolo Alonso, J.; Lozares Cordero, S.; Pellejero Pellejero, S.; Miquelez Alonso, S.; Serra Arbeloa, P.; Goni Girones, P.; Martinez de la Cuesta, A.

    2013-07-01

    In this paper shows a system of measurement of activity in vial in real time very reproducible, free of radiation in the environment and that does not add discomfort to interventionist staff. (Author)

  5. 内放射治疗肝细胞癌%Radionuclide therapy of hepatocellular carcinoma

    Institute of Scientific and Technical Information of China (English)

    许颖

    2011-01-01

    肝细胞癌(HCC)的恶性程度非常高,全球每年大约有五十万人死于HCC,且亚洲为高发地区.针对不宜行手术的患者,内放射治疗是一种有效的手段.目前临床内放射治疗较常用的放射性核素有钇-90(90Y)微球、碘-131 (131I)和铼-188 (188Re)碘化油等.本文综述其特点及研究现状,并重点讨论90Y微球内放射治疗与动脉化疗栓塞(TACE)治疗的比较.%Hepatocellular carcinoma (HCC) is a high-grade malignant tumour of the hepatocyte. It causes almost half a million deaths annually, Asia is a high risk area. Radionuclide therapy is an effective treatment for the most patients who are not eligible for surgery. Radiopharmaceuticals used for transarterial treatment of HCC were Yttrium-90 microspheres, Iodine-131 lipiodol and Rhenium-188 lipiodol. This review summarizes characteristics and research of these radiopharmaceuticals for HCC with an emphasis on Yttrium-90 microspheres compared with transcatheter arterial chemoembolization.

  6. Calculation of electron and isotopes dose point kernels with FLUKA Monte Carlo code for dosimetry in nuclear medicine therapy

    CERN Document Server

    Mairani, A; Valente, M; Battistoni, G; Botta, F; Pedroli, G; Ferrari, A; Cremonesi, M; Di Dia, A; Ferrari, M; Fasso, A

    2011-01-01

    Purpose: The calculation of patient-specific dose distribution can be achieved by Monte Carlo simulations or by analytical methods. In this study, FLUKA Monte Carlo code has been considered for use in nuclear medicine dosimetry. Up to now, FLUKA has mainly been dedicated to other fields, namely high energy physics, radiation protection, and hadrontherapy. When first employing a Monte Carlo code for nuclear medicine dosimetry, its results concerning electron transport at energies typical of nuclear medicine applications need to be verified. This is commonly achieved by means of calculation of a representative parameter and comparison with reference data. Dose point kernel (DPK), quantifying the energy deposition all around a point isotropic source, is often the one. Methods: FLUKA DPKS have been calculated in both water and compact bone for monoenergetic electrons (10-3 MeV) and for beta emitting isotopes commonly used for therapy ((89)Sr, (90)Y, (131)I, (153)Sm, (177)Lu, (186)Re, and (188)Re). Point isotropic...

  7. Intra-arterial injection of lipid nano-capsules charged in rhenium-188, for the treatment of hepatocellular carcinomas among the rat; Injection intra-arterielle de nanocapsules lipidiques chargees en rhenium-188, pour le traitement des carcinomes hepatocellulaires chez le rat

    Energy Technology Data Exchange (ETDEWEB)

    Vanpouille, C.; Lacoeuille, F.; Hindre, F. [Inserm U646, Angers, (France); Roux, J. [service commun animalerie, hospitalo-universitaire, Angers, (France); Aube, C. [service de radiologie, CHU d' Angers, (France); Oberti, F. [service de gastro-enterologie et hepatologie, CHU d' Angers, (France); Lejeune, J.J.; Couturier, O. [service de medecine nucleaire, CHU d' Angers, (France)

    2009-05-15

    The objective of this study was to evaluate the therapy efficiency of the {sup 188}Re incorporated in the middle of lipid capsules (N.C.L. {sup 188}Re-S.S.S.) on a hepato carcinoma model of rat. The preliminary results are encouraging and show the efficiency of a single injection of N.C.L.{sup 188}Re-S.S.S. in a hepato carcinoma model of rat. (N.C.)

  8. Comparative therapeutic efficacy of rhenium-188 radiolabeled-liposome and 5-fluorouracil in LS-174T human colon carcinoma solid tumor xenografts.

    Science.gov (United States)

    Hsu, Chin-Wei; Chang, Ya-Jen; Chang, Chih-Hsien; Chen, Liang-Cheng; Lan, Keng-Li; Ting, Gann; Lee, Te-Wei

    2012-10-01

    Nanoliposomes are important carriers capable of packaging drugs for various delivery applications. Rhenium-188-radiolabeled liposome ((188)Re-liposome) has potential for radiotherapy and diagnostic imaging. To evaluate the targeting of (188)Re-liposome, biodistribution, microSPECT/CT, whole-body autoradiography (WBAR), and pharmacokinetics were performed in LS-174T human tumor-bearing mice. The comparative therapeutic efficacy of (188)Re-liposome and 5-fluorouracil (5-FU) was assessed according to inhibition of tumor growth and the survival ratio. The highest uptake of (188)Re-liposome in LS-174T tumor was found at 24 hours by biodistribution and microSPECT/CT imaging, showing a positive correlation for tumor targeting of (188)Re-liposome using the Pearson's correlation analysis (r=0.997). Pharmacokinetics of (188)Re-liposome showed the properties of high circulation time and high bioavailability (mean residence time [MRT]=18.8 hours, area under the curve [AUC]=1371%ID/g·h). For therapeutic efficacy, the tumor-bearing mice treated with (188)Re-liposome (80% maximum tolerated dose [MTD], 23.7 MBq) showed better tumor growth inhibition and longer survival time than those treated with 5-FU (80% MTD, 144 mg/kg). The median survival time for mice treated with (188)Re-liposome (58.5 days; p0.05) and normal saline-treated mice (43.63 days). Dosimetry study revealed that the (188)Re-liposome did not lead to high absorbed doses in normal tissue, but did in small tumors. These results of imaging and biodistribution indicated the highly specific accumulation of tumor after intravenous (i.v.) injection of (188)Re-liposome. The therapeutic efficacy of radiotherapeutics of (188)Re-liposome have been confirmed in a LS-174T solid tumor animal model, which points to the potential benefit and promise of passive nanoliposome delivered radiotherapeutics for cancer treatment.

  9. Sonographic genital ambiguity in a fetus due to a mosaic 45,X/46,X,idic(Y)(qter-p11.32 : p11.32-qter) karyotype

    NARCIS (Netherlands)

    Marcus-Soekarman, D; Hamers, G; Mulder, ALM; Offermans, J; Offermans, J; Engelen, J; van Lent-Albrechts, JCM; Robben, SGF; Keizer-Schrama, SD; Wolffenbuttel, KP; Looijenga, LHJ; Schrander-Stumpel, C; Nijhuis, J

    2005-01-01

    Nowadays, improved ultrasound techniques enable the detection of more subtle congenital abnormalities at an earlier stage of fetal development. Current cytogenetic techniques can characterize a chromosomal abnormality in greater detail. These advancements in both diagnostic possibilities have helped

  10. Contribution by two arbuscular mycorrhizal fungi to P uptake by cucumber (Cucumis sativus L.) from 32P-labelled organic matter during mineralization in soil

    DEFF Research Database (Denmark)

    Joner, E.J.; Jakobsen, I.

    1994-01-01

    An experiment was set up to investigate the role of arbuscular mycorrhiza (AM) in utilization of P from organic matter during mineralization in soil. Cucumber (Cucumis sativus L.) inoculated with one of two AM fungi or left uninoculated were grown for 30 days in cross-shaped PVC pots. One of two...... horizontal compartments contained 100 g soil (quartz sand : clay loam, 1:1) with 0.5 g ground clover leaves labelled with P-32. The labelled soil received microbial inoculum without AM fungi to ensure mineralization of the added organic matter. The labelling compartment was separated from a central root...... compartment by either 37 mu m or 700 mu m nylon mesh giving only hyphae or both roots and hyphae, respectively, access to the labelled soil. The recovery of P-32 from the hyphal compartment was 5.5 and 8.6 % for plants colonized with Glomus sp. and G. caledonium, respectively, but only 0.6 % for the non...

  11. Cloning of a New Gene/s in Chromosome 17p3.2-p13.1 that Control Apoptosis

    Science.gov (United States)

    2005-04-01

    Burk, F.G. Barr, B.S. Emanuel, Evidence for a 17p tumor related locus distinct from p53 in pediatric primitive neuroectodermal tumors . Cancer Res., 52...previous work of our laboratory shown LOH in the transformed cell line BP1E [18]. The tumor suppressor gene TP53 is located in l7p13.1 at 1.5cM centromeric...profiling 1 has been suggested as a tumor suppressor gene in breast cancer cells (69). By RT-PCR, no differences were found in TP53 and PFN1 expression

  12. The research progress of 32 p protein and tumor relations%磷蛋白32与肿瘤关系的研究进展

    Institute of Scientific and Technical Information of China (English)

    贾颖娜; 张林燕

    2015-01-01

    phosphoprotein 32 (PP32) is also known as Anp32a.In recent years,studies have found that tumor occurrence,development and transfer and PP32 have close relations,PP32 as a tumor suppressor can inhibit a variety of proto-oncogene.Through a lot of PP32 related literatures published at home and abroad,mainly from PP32 in tumors (liver cancer,prostate cancer,ovarian cancer,etc.),the paper summarizes the related research to provide some references for antitumor strategies.%磷蛋白32(PP32)又称为Anp32a。近年来研究发现,肿瘤的发生,发展及转移与PP32有着密切的关系, PP32作为一种肿瘤抑制因子能够抑制多种原癌基因。通过大量国内外已发表的PP32相关文献,主要从PP32在肿瘤(肝癌、前列腺癌、卵巢癌等)中的相关研究进行归纳总结,为抗肿瘤策略提供一些参考。

  13. A DIGNIDADE NATURAL DO SER HUMANO E O PROBLEMA DO ABORTO - DOI 10.5752/P.2318-7999.2013v16n32p22

    OpenAIRE

    Oliveira, Larah Beatrissia Queiroz; UFMT - UNIVERSIDADE FEDERAL DE MATO GROSSO

    2013-01-01

    O texto oferece uma perspectiva de leitura para os vilipêndios praticados contra a vida não nascida, especificamente para o aborto provocado e para o aborto espontâneo decorrente do uso indevido de agrotóxicos no campo. Adota-se, para considerações acerca da dignidade humana e para a análise sistemática dos tipos de aborto, o ponto de vista do direito natural, a saber, que a inviolabilidade da vida humana é um princípio inerente à humanidade, cabendo ao Estado simplesmente assegurá-lo. Por fi...

  14. DETECTION OF STRAND BREAKS OF DNA IN HUMAN EARLY CHORIONIC VILLUS CELLS INDUCED BY DIAGNOSTIC ULTRASOUND USING ~(32)P-LABELED ALU HYBRIDIZATION

    Institute of Scientific and Technical Information of China (English)

    2006-01-01

    Genetic effects of ultrasound on fetus havebeen extensively studied since ultrasonograph waswidely appliedin obstetric practice.In recent years,there have been reports onin vivomolecular geneticeffects of diagnostic ultrasound[1-4].In vitroexperi-ments have found that single-stranded breaks(ssbs)and double-stranded breaks(dsbs)in DNA are themain indices for DNA lesions induced by ultra-sound[5].But,no reports on whether ultrasound cancausein vivossbs and dsbs in DNAare available.Tofurther explore the potent...

  15. Dosimetric aspects of the treatment of metastatic bone pain with radiopharmaceuticals; Aspectos dosimetricos de los tratamientos del dolor oseo metastasico con radiofarmacos

    Energy Technology Data Exchange (ETDEWEB)

    Garcia, T.; Marti, J. F.; Olivas, C.; Vercher, J. L.; Repetto, R.; Bello, P.

    2014-02-01

    Within the context of treatment of metastatic bone pain with bone seeking radiopharmaceuticals, this paper expounds the results of an analysis of available molecules (both approved for clinical use or still under study) intended to obtain a detailed comparison of their dosimetric characteristics. These can be used to supplement the list of already know differences between them, such as efficacy, appearance and length of the palliative effect, eventual tumoricidal effect, myelotoxicity, sale price and availability. Seven radiopharmaceuticals have been analysed, five of them are based on beta emission radionuclides: {sup 3}2P, {sup 1}53Sm, {sup 1}86Re and {sup 1}88Re and the other two ones are based on high Linear energy Transference emission radionuclides: {sup 1}17mSn and {sup 2}23Ra a series of estimates of the main dosimetric parameters for each radiopharmaceutical analysed have been obtained. The values obtained might be worth being incorporated to the risk/benefit analysis that precedes every choice of the specific radiopharmaceutical to be used with an individual patient. In this way, we hope these results will be of some help for those Nuclear Medicine specialists interested in the treatment of oncological bone pathologies. (Author)

  16. Absorbed doses profiles vs Synovia tissue depth for the Y-90 and P-32 used in radiosynoviortesis treatment; Perfiles de dosis absorbida vs profundidad de tejido sinovial para el Y-90 y el P-32 empleados en tratamiento de radiosinoviortesis

    Energy Technology Data Exchange (ETDEWEB)

    Torres B, M.B.; Ayra P, F.E. [Centro de Isotopos (Cuba); Garcia R, E. [Hospital General Docente Enrique Cabrera (Cuba); Cornejo D, N. [CPHR, (Cuba); Yoriyaz, H. [IPEN, (Brazil)]. e-mail: nestor@cphr.edu.cu

    2006-07-01

    The radiosynoviortesis treatment has been used during more of 40 years as an alternative to the chemical and surgical synovectomy to alleviate the pain and to reduce the inflammation in suffered patients of rheumatic arthropathies, haemophilic arthropathies and other articulation disorders. It consists on the injection of radioactive isotopes inside a synovial cavity. For to evaluate the dosimetry of the radiosynoviortesis treatment is of great interest to know the absorbed dose in the volume of the target (synovia). The precise calculation of the absorbed dose in the inflamed synovia it is difficult, for numerous reasons, since the same one will depend on the thickness of the synovial membrane, the size of the articular space, the structure of the synovial membrane, the distribution in the articulation, the nature of the articular liquid, etc. Also the presence of the bone and the articular cartilage, components also of the articulation, it even complicated more the calculations. The method used to evaluate the dosimetry in radioactive synovectomy is known as the Monte Carlo method. The objective of our work consists on estimating with the Monte Carlo code MCNP4B the absorbed dose of the Y-90 and the P-32 in the depth of the synovial tissue. The results are presented as absorbed dose for injected millicurie (Gy/mCi) versus depth of synovial tissue. The simulation one carries out keeping in mind several synovia areas, of 50 cm{sup 2} to 250 cm{sup 2} keeping in mind three states of progression of the illness. Those obtained values of absorbed dose using the MCNP4B code will allow to introduce in our country an optimized method of dose prescription to the patient, to treat the rheumatic arthritis in medium and big articulations using the Y-90 and the P-32, eliminating the fixed doses and fixed radionuclides for each articulation like it happens in many clinics of Europe, as well as the empiric doses. (Author)

  17. Evolution calculations of fuel for a GFR using MCNPX-C90 and Tripoli-4-D; Calculos de evolucion de combustible para un GFR usando MCNPX-C90 y TRIPOLI-4-D

    Energy Technology Data Exchange (ETDEWEB)

    Reyes R, R.; Martin del Campo M, C.; Francois L, J. L. [UNAM, Facultad de Ingenieria, Departamento de Sistemas Energeticos, Paseo Cuauhnahuac 8532, 62550 Jiutepec, Morelos (Mexico); Brun, E.; Dumonteil, E.; Malvagi, F., E-mail: emeric.brun@cea.fr [Commissariat a l' Energie Atomique et aux Energies Alternative, Service d' Etude des Reacteurs et de Mathematiques Appliquees, Saclay, DEN/DM2S/SERMA/LTSD, Bat 470, 91191 Gif-sur-Yvette Cedex (France)

    2011-11-15

    Burnt calculations were realized for a fuel model based on the technology of the Gas-cooled Fast Reactor, GFR. The fuel design is based on bars. The code MCNPX-CINDER90 and the CSADA method for the burnt calculations were used. Models of homogeneous and heterogeneous fuel assembly were studied; for the burnt calculations of the fuel homogeneous model was considered the tracking of three series (Tiers) of evolution of the fission products. The Tier 1 tracks a reduced group of fission products, the Tier 2 tracks to the arrangement of fission products that are contained in the library of cross sections XSDIR of MCNPX; and the Tier 3 tracks 1325 fission products. The results were compared with those obtained with Tripoli-4-D in function of the calculation methods: 1) Explicit Euler, as method of first order; and 2) CSADA, as method of second order. According to the results was observed that the infinite multiplication factor varies in function of the fission products quantity that are tracked. The calculation time used by MCNPX-C90 with the series Tier 3 is more than double than the used by Tripoli-4-D, therefore this last code has advantage over MCNPX-C90 in the case of neutrons analysis of fast reactors. (Author)

  18. Evaluation of the occupational radiation dose to 90Sr/90Y prostate hyperplasia applicators%90Sr/90Y前列腺增生治疗器的职业照射剂量评估

    Institute of Scientific and Technical Information of China (English)

    梁石强; 朱旭; 宋易阳

    2006-01-01

    目的 估算使用前列腺增生治疗器人员(医生)职业照射的个人剂量上限和评价使用前列腺增生治疗器的辐射安全.方法 用辐射防护仪表测量前列腺增生治疗器周围的辐射剂量[定向剂量当量H'(d)和周围剂量当量H*(d)],调查医院前列腺增生治疗器临床试用情况和测量临床试用中的辐射剂量来估算医生的个人剂量上限.结果 患者治疗1疗程,医生个人剂量上限分别为6.0 μSv(尿道型)和4.5 μSv(直肠型).结论 在正常条件下使用前列腺增生治疗器的辐射安全是有保障的.

  19. Comparative analyses of 90Sr/90Y90 decay measurements at the Physikalisch-Technische Bundesanstalt and 222Rn decay measurements at the Geological Survey of Israel. Evidence of a solar influence

    CERN Document Server

    Sturrock, Peter; Fischbach, Ephraim; Parkhomov, Alexander; Scargle, Jeffrey

    2016-01-01

    Kossert and Nahle of the Physikalisch-Technische Bundesanstalt (PTB) have recently studied measurements from their beta-decay experiment that registers triple coincidences in a TDCR (Triple-to-Double Coincidence Ratio) system. Our analysis of the PTB data reveals evidence (which is a function of solar elevation) of an oscillation at 11 year-1, which we interpret as an influence of internal solar rotation. For comparison, we have analyzed radon beta-decay data for exactly the same time interval acquired at the Geological Survey of Israel (GSI). This analysis yields strong confirmation of the 11 year-1 rotational signal and of its dependence on solar elevation. These results are compatible with the proposition that beta decays may be stimulated by solar neutrinos.

  20. Myeloablative radioimmunotherapies in the conditioning of patients with AML, MDS and multiple myeloma prior to stem cell transplantation; Myeloablative Radioimmuntherapien zur Konditionierung bei Patienten mit AML, MDS und multiplem Myelom vor Stammzelltransplantation

    Energy Technology Data Exchange (ETDEWEB)

    Buchmann, I. [Abt. fuer Nuklearmedizin, Universitaetsklinik Heidelberg (Germany)

    2008-06-15

    Aggressive consolidation chemotherapy and hematopoietic stem cell transplantation have improved the prognosis of patients with acute myeloid leukemia (AML), myelodyplastic syndrome (MDS) and multiple myeloma. Nevertheless, only a minor fraction of patients achieve long-term disease-free survival after stem cell transplantation with disease recurrence being the most common cause of treatment failure. In addition, therapy-related effects such as toxicity of chemotherapy and complications of stem cell transplantation increase mortality rates significantly. Myeloablative radioimmunotherapy uses radiolabeled monoclonal antibodies (mAb) with affinity for the hematopoietic marrow. It applies high radiation doses in the bone marrow but spares normal organs. Adding myeloablative radioimmunotherapy to the conditioning schemes of AML, MDS and multiple myeloma before stem cell transplantation allows for the achievement of a pronounced antileukemic/antimyeloma effect for the reduction of relapse rates without significant increase of acute organ toxicity and therapy-related mortality. In order to optimise therapy, a rational design of the nuclide-antibody combination is necessary. {sup 90}Y, {sup 188}Re and {sup 131}I are the most frequently used {beta}{sup -}-particles. Of these, {sup 90}Y is the most qualified nuclide for myeloablation. Backbone stabilised DTPA are ideal chelators to stably conjugate {sup 90}Y to antibodies so far. For myeloablative conditioning, anti-CD66-, -45- and -33-mAb are used. The anti-CD66-antibody BW250/183 binds to normal hematopoietic cells but not to leukemic blasts and myeloma cells. The {sup 90}Y-2B3M-DTPA-BW250/183 is the most suited radioimmunoconjugate for patients with an infiltration grade of leukemic blasts in the bone marrow < 25%. The specific doses (Gy/GBq) are 10.2 {+-} 1.8 (bone marrow), 2.7 {+-} 2 (liver) and < 1 (kidneys). In contrast, radiolabeled anti-CD33- and anti-CD45-antibodies bind to both, most of white blood cells and

  1. Dry-boxes for manipulation of high-energy {beta} emitters; Bottes pour manipulation d'emetteurs {beta} energiques

    Energy Technology Data Exchange (ETDEWEB)

    Boclet, K.; Laurent, H. [Commissariat a l' Energie Atomique, Saclay (France). Centre d' Etudes Nucleaires

    1958-07-01

    Because of the thinners of latex or neoprene gloves and the high intensity of Bremsstrahlung radiation, manipulation of pure high-energy {beta}{sup -} emitters is impossible in ordinary dry-boxes. There are many types of box equipped with heavy lead or steel protection, but their use for radioelements such as {sup 32}P, {sup 90}Sr, {sup 90}Y is not justified. We have devised units known as 'tong boxes' which, while retaining much of the flexibility of operation found in dry-boxes, provide adequate protection. 1 curie of {sup 32}P placed in the centre of the enclosure gives about 15 mR/ 8 h. at the part of the wall closest to the source. (author) [French] La faible epaisseur des gants de latex ou de neoprene et l'importance du rayonnement de freinage rendent impossible la manipulation des emetteurs {beta}{sup -} purs energiques dans des boites a gants normales. Il existe de nombreux types d'enceintes dotees d'une forte protection de plomb ou d'acier dont l'emploi n'est pas justifie pour des radioelements tels que {sup 32}P, {sup 90}Sr, {sup 90}Y. Nous avons realise des ensembles appeles 'Boites a Pinces', qui tout en conservant une grande partie de la souplesse d'utilisation des boites a gants sont dotees d'une protection suffisante. 1 curie de {sup 32}P place au centre de l'enceinte donne environ 15 mR/ 8 h au contact de la paroi la plus rapprochee de la source. (auteur)

  2. A free database of radionuclide voxel S values for the dosimetry of nonuniform activity distributions

    Science.gov (United States)

    Lanconelli, N.; Pacilio, M.; Lo Meo, S.; Botta, F.; Di Dia, A.; Torres Aroche, L. A.; Coca Pérez, M. A.; Cremonesi, M.

    2012-01-01

    The increasing availability of SPECT/CT devices with advanced technology offers the opportunity for the accurate assessment of the radiation dose to the biological target volume during radionuclide therapy. Voxel dosimetry can be performed employing direct Monte Carlo radiation transport simulations, based on both morphological and functional images of the patient. On the other hand, for voxel dosimetry calculations the voxel S value method can be considered an easier approach than patient-specific Monte Carlo simulations, ensuring a good dosimetric accuracy at least for anatomic regions which are characterized by uniform density tissue. However, this approach has been limited because of the lack of tabulated S values for different voxel dimensions and radionuclides. The aim of this work is to provide a free dataset of values which can be used for voxel dosimetry in targeted radionuclide studies. Seven different radionuclides (89Sr, 90Y, 131I, 153Sm, 177Lu, 186Re, 188Re), and 13 different voxel sizes (2.21, 2.33, 2.4, 3, 3.59, 3.9, 4, 4.42, 4.8, 5, 6, 6.8 and 9.28 mm) are considered. Voxel S values are calculated performing simulations of monochromatic photon and electron sources in two different homogeneous tissues (soft tissue and bone) with DOSXYZnrc code, and weighting the contributions on the basis of the radionuclide emission spectra. The outcomes are validated by comparison with Monte Carlo simulations obtained with other codes (PENELOPE and MCNP4c) performing direct simulation of the radionuclide emission spectra. The differences among the different Monte Carlo codes are of the order of a few per cent when considering the source voxel and the bremsstrahlung tail, whereas the highest differences are observed at a distance close to the maximum continuous slowing down approximation range of electrons. These discrepancies would negligibly affect dosimetric assessments. The dataset of voxel S values can be freely downloaded from the website www.medphys.it.

  3. A free database of radionuclide voxel S values for the dosimetry of nonuniform activity distributions.

    Science.gov (United States)

    Lanconelli, N; Pacilio, M; Lo Meo, S; Botta, F; Di Dia, A; Aroche, A Torres; Pérez, M A Coca; Cremonesi, M

    2012-01-21

    The increasing availability of SPECT/CT devices with advanced technology offers the opportunity for the accurate assessment of the radiation dose to the biological target volume during radionuclide therapy. Voxel dosimetry can be performed employing direct Monte Carlo radiation transport simulations, based on both morphological and functional images of the patient. On the other hand, for voxel dosimetry calculations the voxel S value method can be considered an easier approach than patient-specific Monte Carlo simulations, ensuring a good dosimetric accuracy at least for anatomic regions which are characterized by uniform density tissue. However, this approach has been limited because of the lack of tabulated S values for different voxel dimensions and radionuclides. The aim of this work is to provide a free dataset of values which can be used for voxel dosimetry in targeted radionuclide studies. Seven different radionuclides (89Sr, 90Y, 131I, 153Sm, 177Lu, 186Re, 188Re), and 13 different voxel sizes (2.21, 2.33, 2.4, 3, 3.59, 3.9, 4, 4.42, 4.8, 5, 6, 6.8 and 9.28 mm) are considered. Voxel S values are calculated performing simulations of monochromatic photon and electron sources in two different homogeneous tissues (soft tissue and bone) with DOSXYZnrc code, and weighting the contributions on the basis of the radionuclide emission spectra. The outcomes are validated by comparison with Monte Carlo simulations obtained with other codes (PENELOPE and MCNP4c) performing direct simulation of the radionuclide emission spectra. The differences among the different Monte Carlo codes are of the order of a few per cent when considering the source voxel and the bremsstrahlung tail, whereas the highest differences are observed at a distance close to the maximum continuous slowing down approximation range of electrons. These discrepancies would negligibly affect dosimetric assessments. The dataset of voxel S values can be freely downloaded from the website www.medphys.it.

  4. The recent development of isotope and radiation application in Taiwan, ROC

    Energy Technology Data Exchange (ETDEWEB)

    Ting, Gann; Tsai, Zei-Tsan; Huang, Henton [Institute of Nuclear Energy Research, Lung-Tan, TW (China)

    1996-10-01

    The Institute of Nuclear Energy Research (INER) plays a vital role in both isotope and radiation application in Taiwan, ROC. For research and development of reactor-produced radioisotopes, both Sr-90/Y-90 and W-188/Re-188 generators for therapeutic application were emphasized. For production of cyclotron-produced radioisotopes, I-123, Tl-201, Ga-67, In-111, Co-67 and F-18 were generated using a TR-30/15 cyclotron with H{sup -}/D{sup -} 30MeV/15MeV and maximum beam current of 400{mu}A/150{mu}A. For preparation of radiopharmaceuticals, a number of organic ligands have been synthesized such as d,1-hexamethylpropyleneamine oxime (HMPAO), N- (S-benzoylmercaptoacetyl) triglycine (S-Bz-MAG{sub 3}), 2-alkoxyisobutylisonitrile and metaiodobenzylguanidine (MIBG) and octreotide. R/D and production of radiopharmaceuticals have been carried out in cooperation with domestic hospitals. Some research work related to target radiotherapeutic and radiopharmaceuticals has also been carried out with cooperation of domestic hospitals. The C-13 urea breath test (C-13-UBT) has been extensively studied clinically to investigate the prevalence of Helicobacter pylori infection. The detection of this bacteria in the stomach ulcer becomes very important in both diagnosis and therapy monitoring. There are three large Co-60 irradiation plant in Taiwan. The radiosterilization of medical devices has been used in Taiwan for more than 14 years. Besides INER conducted R/D on (1) radiosterilization study of porcine serum, (2) insect sterilization, (3) treatment of condensate microphone with gamma ray, and (4) radiation polymerization for industry and medical applications. In conclusion, the prospects of isotope and radiation applications in Taiwan are very promising and encouraging. The R/D and development of the applications will contribute technical, economic and social benefits to the society. (J.P.N.)

  5. Individual monitoring of internal exposure for nuclear medicine workers in Switzerland.

    Science.gov (United States)

    Baechler, S; Stritt, N; Bochud, F O

    2011-03-01

    Monitoring of internal exposure for nuclear medicine workers requires frequent measurements due to the short physical half-lives of most radionuclides used in this field. The aim of this study was to develop screening measurements performed at the workplace by local staff using standard laboratory instrumentation, to detect whether potential intake has occurred. Such measurements do not enable to determine the committed effective dose, but are adequate to verify that a given threshold is not exceeded. For radioiodine, i.e. (123)I, (124)I, (125)I and (131)I, a calibrated surface contamination monitor is placed in front of the thyroid to detect whether the activity threshold has been exceeded. For radionuclides with very short physical half-lives (≤ 6 h), such as (99m)Tc and those used in positron emission tomography imaging, i.e. (11)C, (15)O, (18)F and (68)Ga, screening procedures consist in performing daily measurements of the ambient dose rate in front of the abdomen. Other gamma emitters used for imaging, i.e. (67)Ga, (111)In and (201)Tl, are measured with a scintillation detector located in front of the thorax. For pure beta emitters, i.e. (90)Y and (169)Er, as well as beta emitters with low-intensity gamma rays, i.e. (153)Sm, (177)Lu, (186)Re and (188)Re, the procedure consists in measuring hand contamination immediately after use. In Switzerland, screening procedures have been adopted by most nuclear medicine services since such measurements enable an acceptable monitoring while taking into account practical and economic considerations.

  6. Use of the ORNL Tungsten-188/Rhenium-188 Generator for Preparation of the Rhenium-188 HDD/Lipiodol Complex for Transarterial Liver Cancer Therapy

    Energy Technology Data Exchange (ETDEWEB)

    Knapp Jr, Russ F [ORNL; Jeong, J M [Seoul National University

    2008-01-01

    This work describes the installation, use, and quality control (QC) of the alumina-based tungsten-188 ({sup 188}W)/rhenium-188 ({sup 188}Re) generators provided by the Oak Ridge National Laboratory (ORNL). In addition, methods used for concentration of the {sup 188}Re-perrhenate bolus and preparation of {sup 188}Re-labeled HDD (4-hexadecyl-2,2,9,9-tetramethyl-4,7-diaza-1,10-decanethiol) for trans-arterial administration for therapy of nonresectable liver cancer also are described. The {sup 188}W/{sup 188}Re generator has a long useful shelf-life of several months and is a convenient on-site {sup 188}Re production system. {sup 188}Re has excellent therapeutic and imaging properties (T{sub 1/2} 16.9 hours; E{beta}{sub max} 2.12 MeV; 155-keV gamma ray, 15%) and is cost effectively obtained on demand by saline elution of the generator. The clinical efficacy of a variety of {sup 188}Re-labeled agents has been demonstrated for several therapeutic applications. Because of the favorable physical properties of {sup 188}Re, several {sup 188}Re-labeled agents are being developed and evaluated for the treatment of nonresectable/refractory liver cancer. {sup 188}Re-labeled HDD has been the most widely studied of these agents for this application and has been introduced into clinical trials at a number of institutions. The trans-arterial administration of {sup 188}Re-labeled agents for treatment of inoperable liver cancer requires use of high-level (1-2 Ci) {sup 188}W/{sup 188}Re generators. The handling of such high levels of {sup 188}Re imposes radiological precautions normally not encountered in a radiopharmacy and adequate care and ALARA (ie, 'As Low As Reasonably Achievable') principles must be followed. The ORNL generator provides consistently high {sup 188}Re yields (>75%) and low {sup 188}W parent breakthrough (<10{sup -3}%) over an extended shelf-life of several months. However, the high elution volumes (20-40 mL for 1-2 Ci generators) can require

  7. Use of the Oak Ridge National Laboratory tungsten-188/rhenium-188 generator for preparation of the rhenium-188 HDD/lipiodol complex for trans-arterial liver cancer therapy

    Energy Technology Data Exchange (ETDEWEB)

    Jeong, J M [Seoul National University; Knapp Jr, Russ F [ORNL

    2008-01-01

    This work describes the installation, use, and quality control (QC) of the alumina-based tungsten-188 ({sup 188}W)/rhenium-188 ({sup 188}Re) generators provided by the Oak Ridge National Laboratory (ORNL). In addition, methods used for concentration of the {sup 188}Re-perrhenate bolus and preparation of {sup 188}Re-labeled HDD (4-hexadecyl-2,2,9,9-tetramethyl-4,7-diaza-1,10-decanethiol) for trans-arterial administration for therapy of nonresectable liver cancer also are described. The {sup 188}W/{sup 188}Re generator has a long useful shelf-life of several months and is a convenient on-site {sup 188}Re production system. {sup 188}Re has excellent therapeutic and imaging properties (T{sub 1/2} 16.9 hours; E{sub {beta}max} 2.12 MeV; 155-keV gamma ray, 15%) and is cost effectively obtained on demand by saline elution of the generator. The clinical efficacy of a variety of {sup 188}Re-labeled agents has been demonstrated for several therapeutic applications. Because of the favorable physical properties of {sup 188}Re, several {sup 188}Re-labeled agents are being developed and evaluated for the treatment of nonresectable/refractory liver cancer. {sup 188}Re-labeled HDD has been the most widely studied of these agents for this application and has been introduced into clinical trials at a number of institutions. The trans-arterial administration of {sup 188}Re-labeled agents for treatment of inoperable liver cancer requires use of high-level (1-2 Ci) {sup 188}W/{sup 188}Re generators. The handling of such high levels of {sup 188}Re imposes radiological precautions normally not encountered in a radiopharmacy and adequate care and ALARA (i.e., 'As Low As Reasonably Achievable') principles must be followed. The ORNL generator provides consistently high {sup 188}Re yields (>75%) and low {sup 188}W parent breakthrough (<10{sup -3}%) over an extended shelf-life of several months. However, the high elution volumes (20-40 mL for 1-2 Ci generators) can require

  8. Beta Bremsstrahlung dose in concrete shielding

    Science.gov (United States)

    Manjunatha, H. C.; Chandrika, B. M.; Rudraswamy, B.; Sankarshan, B. M.

    2012-05-01

    In a nuclear reactor, beta nuclides are released during nuclear reactions. These betas interact with shielding concrete and produces external Bremsstrahlung (EB) radiation. To estimate Bremsstrahlung dose and shield efficiency in concrete, it is essential to know Bremsstrahlung distribution or spectra. The present work formulated a new method to evaluate the EB spectrum and hence Bremsstrahlung dose of beta nuclides (32P, 89Sr, 90Sr-90Y, 90Y, 91Y, 208Tl, 210Bi, 234Pa and 40K) in concrete. The Bremsstrahlung yield of these beta nuclides in concrete is also estimated. The Bremsstrahlung yield in concrete due to 90Sr-90Y is higher than those of other given nuclides. This estimated spectrum is accurate because it is based on more accurate modified atomic number (Zmod) and Seltzer's data, where an electron-electron interaction is also included. Presented data in concrete provide a quick and convenient reference for radiation protection. The present methodology can be used to calculate the Bremsstrahlung dose in nuclear shielding materials. It can be quickly employed to give a first pass dose estimate prior to a more detailed experimental study.

  9. From {sup 3}H to {sup 195m}Pt

    Energy Technology Data Exchange (ETDEWEB)

    Akaboshi, Mitsuhiko [Kyoto Univ., Kumatori, Osaka (Japan). Research Reactor Inst.

    2000-01-01

    Prof. M. Akaboshi reported his works from 1960 to 1990 ages. He started his studies at the biological using {sup 31}P(n, {gamma}) {sup 32}P. This research determined the direction of his groups researches in order that {sup 31}P(n, {gamma}) {sup 32}P reaction has two sides such as reunion and free of {sup 32}P to the parent compound. A noncatalytic phosphorylation was studied by using {sup 31}P formed from {beta} decay of {sup 31}Si. {sup 32}S from {beta} decay of {sup 32}P easily synthesized Cystein. {sup 14}C, {sup 32}P, {sup 3}H water and {sup 90}Y were used as the {beta}-ray irradiation field. By joint use of {sup 195m}Pt-cisplatin, the lethal mechanisms of new kinds of platinum anticancer agents and platinum compounds to cell were researched by a target dose analysis method developed. Cispaladium from {sup 109}Pd was studied, too. His group studied rare earth metal elements and many results were obtained such as they were concentrated specifically by a kind of organisms and the enrichment patterns were changed by elements. Pteridophytes concentrated them, especially Eu and Tb. Ce (IV) and other elements showed strong hydrolysis activity to phosphoric monoester compounds. The activity was 0.11 umole/umole-Ce(IV).hr{sup -1}at 20degC. But breakage of phosphoric acid ester by Ce(IV) was controlled in the presence of protein-peptides. {sup 141}Ce, {sup 160}Tb and {sup 170}Tm proved that they bonded very fast to only proteins. These results indicated that protein existed in the primitive earth before the rare earth elements. (S.Y.)

  10. Safety and Efficacy of 188-Rhenium-Labeled Antibody to Melanin in Patients with Metastatic Melanoma

    Directory of Open Access Journals (Sweden)

    M. Klein

    2013-01-01

    Full Text Available There is a need for effective “broad spectrum” therapies for metastatic melanoma which would be suitable for all patients. The objectives of Phase Ia/Ib studies were to evaluate the safety, pharmacokinetics, dosimetry, and antitumor activity of 188Re-6D2, a 188-Rhenium-labeled antibody to melanin. Stage IIIC/IV metastatic melanoma (MM patients who failed standard therapies were enrolled in both studies. In Phase Ia, 10 mCi 188Re-6D2 were given while unlabeled antibody preload was escalated. In Phase Ib, the dose of 188Re-6D2 was escalated to 54 mCi. SPECT/CT revealed 188Re-6D2 uptake in melanoma metastases. The mean effective half-life of 188Re-6D2 was 12.4 h. Transient HAMA was observed in 9 patients. Six patients met the RECIST criteria for stable disease at 6 weeks. Two patients had durable disease stabilization for 14 weeks and one for 22 weeks. Median overall survival was 13 months with no dose-limiting toxicities. The data demonstrate that 188Re-6D2 was well tolerated, localized in melanoma metastases, and had antitumor activity, thus warranting its further investigation in patients with metastatic melanoma.

  11. NEW TECHNIQUE OF COUNTING RADIOACTIVE 32P USING PLASTIC SCINTILLATION CUP%用塑料闪烁杯法测量32P核素的新技术

    Institute of Scientific and Technical Information of China (English)

    冯音捷; 肖京城; 温贤芳

    1984-01-01

    本文阐述了在液体闪烁谱仪上,应用塑料闪烁杯法测量32P植物样品的新方法.本方法比常规的切伦科夫计数法的计数效率提高了1.5倍.本法具有操作简便、测量重复性好,经济实用并适合于大量样品的测量等特点.本方法曾用于利用32P标记过磷酸钙研究碳铵与过磷酸钙混合肥对玉米、谷子、水稻吸收利用磷的影响.

  12. Application of 32phosphorus (32P) applicator in the treatment of hemangioma%32磷敷贴在治疗皮肤血管瘤中的应用

    Institute of Scientific and Technical Information of China (English)

    张国旭; 张彤; 毕占华

    2012-01-01

    Objective To observe the clinical efficacy of P application in Irealmenl of skin hemangioma, evaluating the difference with othr methods. Methods The radioactive applicator was supplied onto the surface of hemangioma, then p-ray from P in the applicator was used to irradiating the pathological part to make the hemangioma atrophied and occluded. Results The group of 300 patients were followed up for 1 to 3 years. Among them, the cure rate of capillary hemangioma in 139 cases was almost 100% , and effective rate was almost 100% , The cure rate of ponceau stain naevus was 80% ( 48/60) , and effective rate was 55% ( 33/60) , the cure rate of cavernous angioma was 38. 7% (12/31), and effective rate was 9.6% (3/31), the cure rate of mixed hemangioma was 35.7% (25/70) , and effective rate was 8.6% ( 6/70) . About 80% patients appeared skin depigmenta-tion in early period after treatment, most of them returned to normal over time. The cases of capillary hemangioma and ponceau stain naevus showed no recurrence. Though cavernous angioma and mixed hemangioma tended to recur, showed no functional disorders. Conclusion The treatment effectiveness of superficial hemangiomas ( limi-tated strawberry-like) using the P Sticking was better with slight side effects, no scars, and well view, which is worthy of wide application.%目的 观察放射性核素32 磷敷贴治疗皮肤血管瘤的临床疗效,评价该法与其他方法的差异.方法 将放射性核素敷贴器敷于血管瘤表面,利用敷贴器中32 磷发射的β射线,对病变部位进行照射治疗,使血管瘤发生萎缩、闭塞.结果 本组共300例患者,治疗后随访1~3年.其中,草莓状血管瘤139例,有效率和治愈率分别为100%;鲜红斑痣有效率为80%(48/60),治愈率为55%(33/60);海绵状血管瘤有效率为38.7%(12/31),治愈率为9.6%(3/31);混合型血管瘤有效率为35.7%(25/70),治愈率为8.6%(6/70).约80%患者在治疗后早期出现皮肤色素脱失,随着时间推移,逐渐恢复正常.草莓状血管瘤和鲜红斑痣未见复发;海绵状及混合型血管瘤易复发,但均不会出现功能障碍.结论 32磷敷贴治疗表浅性血管瘤(局限性草莓状)效果较好,且不良反应轻,不遗留瘢痕,外观效果好,值得临床推广应用.

  13. The effect of using 32P internal irradiation therapy on the hematopoietic stem cell of contact%32P内照射对密切接触者造血干细胞影响的实验研究

    Institute of Scientific and Technical Information of China (English)

    刘静; 薛美华; 盛贻; 李世荣

    2006-01-01

    @@ 内照射治疗是在影像引导下,将核素注射到肿瘤靶区,临床已应用于肝癌、食管癌、胃癌、前列腺癌、脑胶质瘤的治疗,并取得了明显的局部控制效果.晚期肿瘤患者内照射治疗取得好的疗效,离不开护士配合治疗及细致周到的护理.为揭示核素治疗的职业危害、消除护理人员的心理障碍,我们开展了局部注射内照射治疗过程中密切接触者的辐射剂量和造血干细胞影响的实验研究,研究护理和其他工作人员所受到的伤害,现报道如下.

  14. A rare prenatal case with two de novo inversions and a translocation: 48, XX,t(9;12)(q32;p24.3), inv(11)(p15.1q25), inv(13)(q12.q22)

    Energy Technology Data Exchange (ETDEWEB)

    Harrison, B.; Balaban, L.; Eldred, C. [Albany Medical College, Albany, NY (United States)] [and others

    1994-09-01

    Ultrasound examination of a para 1, gravida 2, 26 y.o. showed severe hydrocephalus and polyhydramnios. Amniocentesis was performed at 27 weeks. High resolution chromosome analysis revealed a karyotype with a 9;12 translocation, a pericentric inversion of chromosome 11, and a paracentric inversion of chromosome 13. Parental chromosome studies were normal. The mother was not on medication prior to her pregnancy and there was no known exposure to radiation. Delivery was at 34 weeks gestation. The phenotype consisted of micrognathia, low set ears, hypertelorism, and hydrodcephaly. Review of the literature revealed a single report with multiple de novo aberrations consisting of a 6;14 translocation and a deleted 7. This was diagnosed in the child of a woman with systemic lupus erythematous treated with azathioprine. These types of abnormalities have been known to be induced by chemical and radiation exposure. High resolution banding combined with molecular studies presently improve our ability to detect subtle structural aberrations.

  15. 32P关节腔内注射治疗类风湿关节炎疗效及护理%Treatment of rheumatoid arthritis by injection of 32P in joint cavity and the nursing measures

    Institute of Scientific and Technical Information of China (English)

    李利

    2003-01-01

    @@ 我科选择32P作为治疗类风湿关节炎的放射性核素.自1999年5月至2000年8月对22例类风湿关节炎(Rheumatoid arthritis,RA)病人的28个关节进行了32P关节腔注射治疗,取得较好的效果,现报告如下.

  16. 用32P后标法检测三氯乙烯所致DNA损伤的研究%Determination of trichloroethylene induced DNA damage with 32P-Postlabeling

    Institute of Scientific and Technical Information of China (English)

    胡训军; 卢伟; 王文静; 肖萍; 陈良

    2006-01-01

    目的探讨三氯乙烯(TCE)4周静式吸入下对雄性大鼠所致DNA损伤.方法将TCE分为4个浓度组,对雄性大鼠静式吸入染毒,用32后标法检测肝脏组织和外周血白细胞(WBC)DNA损伤.结果与对照组比较,剂量组放射自显影指纹图多2~3个斑点;1~4周各剂量组肝脏组织和外周血WBC TCE-DNA加合物含量增加,与对照组比较,差异均有统计学意义(P<0.05);各浓度组TCE-DNA加合物含量均随TCE染毒剂量量的增加而增加,呈一定的线性趋势和剂量-效应关系;经4周染毒后再饲养1周的大鼠肝脏组织和外周血WBC TCE-DNA加合物各浓度组间差异无统计学意义(P>0.05);同一剂量组1~4周肝脏组织TCE-DNA加合物含量均先升高后降低再升高,而外周血WBCTCE-DNA加合物含量同一剂量组各时间点差异无统计学意义(P>0.05);各剂量组肝脏组织和外周血WBC TCE-DNA加合物相关性良好.结论4周静式吸入TCE对受试动物有一定的DNA损伤.

  17. Avidin chase reduces side effects of radioimmunotherapy in nude mice bearing human colon carcinoma

    Institute of Scientific and Technical Information of China (English)

    Gui-Ping Li; Yong-Xian Wang; Kai Huang; Hui Zhang; Chun-Fu Zhang

    2005-01-01

    AIM: To evaluate the influence of avidin chase on the side effects of radioimmunotherapy (RIT) in nude mice bearing human colon carcinoma and therapeutic outcome.METHODS: Purified anti-CEA monoclonal antibody (McAb)was biotinylated with NHS-biotin, and then radiolabeled with 188Re by the direct method. 188Re-labeledbiotinylated anti-CEA McAb (188Re-CEA McAb-Bt) was intravenously injected followed by intravenous injection of avidin after 24 h. SPECT imaging and biodistribution study were performed at 28-48 h after the injection of 188Re-CEA McAb-Bt. Three groups of nude mice subcutaneously grafted with human colon carcinoma were treated 7 d after the graft. Mice in the avidin chase group received intravenous injection of 188Re-CEA McAb-Bt (11.1 MBq/20 μg) followed by intravenous injection of cold avidin (80 μg) after 24 h. Mice in the control group (treated group without avidin chase) only received the injection of 188Re-CEA McAb-Bt (11.1 MBq/20 μg), another control group (non-treated group) only received 0.1 mL normal saline solution. Toxicity was evaluated on the basis of change of body weight and peripheral WBC counts, and therapy effects were determined by variation in tumor volume. Histological analysis of tumors was also performed.RESULTS: Avidin chase markedly accelerated the clearance of 188Re-CEA McAb-Bt from the blood and normal tissues. The tumor uptakes of 188Re-CEA Mc Ab-Bt at 28 h were 5.90 and 6.42% ID/g, respectively, in chase group and in non-chase group, while the tumor-to-background (T/NT) ratios were 3.19 and 0.56, respectively. The tumor uptake was slightly decreased by avidin chase, but the T/NT ratios were increased. In treated groups the growth rate of body weight and the number of WBC decreased after injection of 188Re-CEA McAb-Bt, and the WBC counts recovered earlier in the group with avidin chase than in the group without avidin chase. Compared to the nontreated group, treated groups with and without avidin chase showed significant anti

  18. Pentavalent rhenium-188 dimercaptosuccinic acid for targeted radiotherapy: synthesis and preliminary animal and human studies

    Energy Technology Data Exchange (ETDEWEB)

    Blower, P.J. [Nuclear Medicine Department, Kent and Canterbury Hospital, Canterbury (United Kingdom)]|[Department of Biosciences, University of Kent, Canterbury (United Kingdom); Lam, A.S.K. [Department of Biosciences, University of Kent, Canterbury (United Kingdom); O`Doherty, M.J.; Kettle, A.G.; Coakley, A.J. [Nuclear Medicine Department, Kent and Canterbury Hospital, Canterbury (United Kingdom); Knapp, F.F. Jr. [Nuclear Medicine Group, Oak Ridge National Laboratory (ORNL), Oak Ridge, Tenn. (United States)

    1998-06-01

    The aim of this study was to develop the kit-based synthesis of the agent on a therapeutic scale, to assess its stability in vivo, and to obtain preliminary biodistribution and dosimetry estimates, prior to evaluation of its potential as a targeted radiotherapy agent. The organ distribution of {sup 188}Re in mice was determined 2 h after injection of 3 MBq {sup 188}Re(V)DMSA prepared from eluate from a {sup 188}W/{sup 188}Re generator. Three patients with cancer of the prostate and three with cancer of the bronchus, all with bone metastases, were given 370 MBq {sup 188}Re(V)DMSA and imaged at 3 h and 24 h using the 155-keV {gamma}-photon (15%). Blood and urine samples were collected to determine clearance and to analyse the speciation of {sup 188}Re. Organ residence times were estimated from the scans, and used to estimate radiation doses using MIRDOSE 3. In mice, {sup 188}Re(V)DMSA was selective for bone and kidney. In patients, it showed selectivity for bone metastases (particularly those from prostate carcinoma) and kidney, but uptake in normal bone was not significantly greater than in surrounding soft tissues. Of the normal tissues the kidneys received the highest radiation dose (0.5-1.3 mGy/MBq). The images were strongly reminiscent of {sup 99m}Tc(V)DMSA scans in similar patients. High-performance liquid chromatography analysis of blood and urine showed no evidence of {sup 188}Re in any chemical form other than {sup 188}Re(V)DMSA up to 24 h. In conclusion, {sup 188}Re(V)DMSA and its {sup 186}Re analogue warrant further clinical assessment as generator/kit-derived agents for treatment of painful bone metastases. These agents should also be assessed in medullary thyroid carcinoma and other soft tissue tumours which have been shown to accumulate {sup 99m}Tc(V)DMSA.(orig./MG) (orig.) With 10 figs., 1 tab., 34 refs.

  19. Re-188 Enhances the Inhibitory Effect of Bevacizumab in Non-Small-Cell Lung Cancer

    Directory of Open Access Journals (Sweden)

    Jie Xiao

    2016-09-01

    Full Text Available The malignant behaviors of solid tumors such as growth, infiltration and metastasis are mainly nourished by tumor neovascularization. Thus, anti-angiogenic therapy is key to controlling tumor progression. Bevacizumab, a humanized anti-vascular endothelial growth factor (VEGF antibody, plus chemotherapy or biological therapy can prolong survival for cancer patients, but treatment-related mortality is a concern. To improve inhibitory effect and decrease side-effects on non-small-cell lung cancer (NSCLC, we used Re-188, which is a β emitting radionuclide, directly labeled with bevacizumab for radioimmunotherapy in a human A549 tumor model. Cytotoxic assay data showed that, after 188ReO4− or 188Re-bevacizumab at different concentration for 4 and 24 h, a time- and radioactivity does-dependent reduction in cell viability occurred. Also, an apoptosis assay conformed great apoptosis in the 188Re-bevacizumab group compared with controls and other treatment groups. In vivo, tumor volumes in the 188Re-bevacizumab (11.1 MBq/mice group were not reduced but growth was delayed compared with other groups. Thus, 188Re-bevacizumab enhanced the therapeutic effect of bevacizumab, suggesting a potential therapeutic strategy for NSCLC treatment.

  20. Effect of electromagnetic fields at 2.45 GHz on the levels of cellular stress proteins HSP-90 and 70 in the rat thyroid; Efecto de los campos electromagneticos a 2,45 GHz sobre los niveles de proteinas de estres celular HSP-90 y 70 en el toroides de rata

    Energy Technology Data Exchange (ETDEWEB)

    Misa Agustino, M. J.; Alvarez-Folgueras, M.; Jorge-Mora, M. T.; Jorge Barreiro, F. J.; Ares Pena, F. J.; Lleiro, J.; Lopez Martin, M. E.

    2011-07-01

    In this study we analyzed the cellular stress levels achieved by heat shock proteins (HSP) 90 and 70 in rat thyroid tissue after exposure to radio waves in TWG experimental system. Parallel measurements of body stress in animals by rectal temperature probes allow us to determine whether there is any interaction between temperature increases and cellular stress.

  1. A preclinical simulated dataset of S-values and investigation of the impact of rescaled organ masses using the MOBY phantom

    Science.gov (United States)

    Kostou, Theodora; Papadimitroulas, Panagiotis; Loudos, George; Kagadis, George C.

    2016-03-01

    Nuclear medicine and radiation therapy, although well established, are still rapidly evolving, by exploiting animal models, aiming to define precise dosimetry in molecular imaging protocols. The purpose of the present study was to create a dataset based on the MOBY phantom for the calculation of organ-to-organ S-values of commonly used radionuclides. S-values of most crucial organs were calculated using specific biodistributions with a whole-body heterogeneous source. In order to determine the impact of the varying organs’ size on the S-values, and based on the fact that the anatomic properties of the organs are correlated with S-values, dosimetric calculations were performed by simulating the MOBY-version 2 model with different whole-body masses. The GATE Monte Carlo simulation toolkit was used for all simulations. Two mouse models of different body masses were developed to calculate the S-values of eight commonly used radioisotopes in nuclear imaging studies, namely 18F, 68Ga, 131I, 111In, 177Lu, and 99mTc, 90Y and 188Re. The impact of modified mass of the source organs in S-values was investigated with 18F, and 90Y in five different scalings of the source organs. Based on realistic preclinical exams, three mouse models, 22, 28 and 34 g, were used as input in the GATE simulator based on realistic preclinical exams to calculate the S-values of the six radioisotopes used. Whole body activity distributions were used as the source organ. The simulation procedure was validated in terms of extracting individual organ-to-organ S-values, and consequently in calculating the new S-values using a heterogeneous activity distribution as a source. The calculation was validated with 18F source in a 30 g mouse model. For the generation of the new S-values with heterogeneous activity sources, four organs were used for the calculation of a single S-value. The absorbed doses per organ were compared with previously published reports. The validation procedure of 18F indicates

  2. Radiopharmaceuticals for the therapy of metastatic bone pain

    Energy Technology Data Exchange (ETDEWEB)

    Ahn, Byeong Cheol [Kyungpook National University Medicine School, Daegu (Korea, Republic of)

    2006-04-15

    Bone metastasis is a common sequelae of solid malignant tumors such as prostate, breast, lung, and renal cancers, which can lead to various complications, including fractures, hypercalcemia, and bone pain, as well as reduced performance status and quality of life. It occurs as a result of a complex pathophysiologic process between host and tumor cells leading to cellular invasion, migration adhesion, and stimulation of osteoclastic and osteoblastic activity. Several sequelae occur as a result of osseous metastases and resulting bone pain can lead to significant debilitation. A multidisciplinary approach is usually required not only to address the etiology of the pain and is complicating factors but also to treat the patient appropriately. Pharmaceutical therapy of bone pain, includes non-steroidal analgesics, opiates, steroids, hormones, bisphosphonates, and chemotherapy. While external beam radiation therapy remains the mainstay of pain palliation of a solitary lesions, bone seeking radiopharmaceuticals have entered the therapeutic armamentarium for the treatment of multiple painful osseous lesion. {sup 32}P, {sup 89}SrCl, {sup 153}Sm-EDTMP, {sup 188}Re/{sup 186}Re-HEDP, and {sup 177}Lu-EDTMP can be used to treat painful osseous metastases. These various radiopharmaceuticals have shown good efficacy in relieving bone pain secondary to bone metastasis. This systemic from of metabolic radiotherapy is simple to administer and complements other treatment options. This has been associated with improved mobility in many patients, reduced dependence on narcotic and non-narcotic analgesics, improved performance status and quality of life, and in some studies, improved survival. All of these agents, although comprising different physical and chemical characteristics, offer certain advantages in that they are simple to administer, are well tolerated by the patient if used appropriately, and can be used alone or in combination with the other forms of treatment. This article

  3. Synthesis of gels with basis of titanium tungstates as matrixes of radioactive generators; Sintesis de geles a base de titanio tungstenatos como matrices de generadores radiactivos

    Energy Technology Data Exchange (ETDEWEB)

    Galico C, L

    2005-07-01

    The heteropolyanions, compounds formed by the union of molybdates or tungstates polyanions with atoms of metals like zirconium, titanium, cerium, thorium, tin, etc., have been used as generator matrixes of {sup 99m} Tc or {sup 188} Re. Particularly they have been studied and produced successfully in our laboratory, generators of {sup 99} Mo/ {sup 99}m Tc at basis of gels zirconium molybdates and titanium molybdates. Considering that the molybdenum and tungsten, as well as the technetium and the rhenium, its belong to the same groups of transition metals, it is feasible that gels can be synthesized at basis of titanium tungstates, continuing a methodology similar to that of the gels titanium molybdates or zirconium molybdates, to produce generators {sup 188} W/ {sup 188} Re. The {sup 188} Re possess nuclear characteristics that make it attractive for therapeutic applications, since, it emits {beta}{sup -} particles of a great energy (2.12 MeV); joined to the possibility of being able to unite to different ligands (bifunctional agents) and biomolecules (antibodies or fragments of proteins), as it makes the {sup 99m} Tc, useful in radioimmunotherapy. Commercially the {sup 188} Re generators use a chromatographic column loaded with alumina where the {sup 188} Re, it is adsorbed and eluted the {sup 188} ReO{sub 4}{sup -} by means of a saline solution The alumina adsorbs around 0.2% of the {sup 188} Re, situation that forces to use {sup 188} Re of a high specific activity. The use of the gels technology, allows to work with medium or low specific activities of {sup 188} Re, opening the possibility of their production in countries whose nuclear capacity is medium or low. In particular, the synthesized gels with basis of titanium offer the possibility of being synthesized with non active material, for later on to be irradiated and directly produce the generator, since, the titanium {sup 51} Ti, unique radioisotope produced by the titanium, has a half life of 5.79 min. This

  4. SU-E-T-154: Calculation of Tissue Dose Point Kernels Using GATE Monte Carlo Simulation Toolkit to Compare with Water Dose Point Kernel

    Energy Technology Data Exchange (ETDEWEB)

    Khazaee, M [shahid beheshti university, Tehran, Tehran (Iran, Islamic Republic of); Asl, A Kamali [Shahid Beheshti University, Tehran, Iran., Tehran, Tehran (Iran, Islamic Republic of); Geramifar, P [Shariati Hospital, Tehran, Iran., Tehran, Tehran (Iran, Islamic Republic of)

    2015-06-15

    Purpose: the objective of this study was to assess utilizing water dose point kernel (DPK)instead of tissue dose point kernels in convolution algorithms.to the best of our knowledge, in providing 3D distribution of absorbed dose from a 3D distribution of the activity, the human body is considered equivalent to water. as a Result tissue variations are not considered in patient specific dosimetry. Methods: In this study Gate v7.0 was used to calculate tissue dose point kernel. the beta emitter radionuclides which have taken into consideration in this simulation include Y-90, Lu-177 and P-32 which are commonly used in nuclear medicine. the comparison has been performed for dose point kernels of adipose, bone, breast, heart, intestine, kidney, liver, lung and spleen versus water dose point kernel. Results: In order to validate the simulation the Result of 90Y DPK in water were compared with published results of Papadimitroulas et al (Med. Phys., 2012). The results represented that the mean differences between water DPK and other soft tissues DPKs range between 0.6 % and 1.96% for 90Y, except for lung and bone, where the observed discrepancies are 6.3% and 12.19% respectively. The range of DPK difference for 32P is between 1.74% for breast and 18.85% for bone. For 177Lu, the highest difference belongs to bone which is equal to 16.91%. For other soft tissues the least discrepancy is observed in kidney with 1.68%. Conclusion: In all tissues except for lung and bone, the results of GATE for dose point kernel were comparable to water dose point kernel which demonstrates the appropriateness of applying water dose point kernel instead of soft tissues in the field of nuclear medicine.

  5. A gravidade do trauma em vítimas de traumatismo crânio-encefálico avaliada pelo manual AIS/90 e mapas CAIS/85 La gravedad del trauma en víctimas de traumatismo cráneo-encefálico por medio del manual AIS/90 y mapas CAIS/85 Injury severity measures by AIS/90 manual and CAIS/85 chart in head injured patients

    Directory of Open Access Journals (Sweden)

    Regina Marcia Cardoso de Sousa

    1998-01-01

    Full Text Available Estudo comparativo do uso do manual da ABBREVIATED INJURY SCALE (AIS e dos mapas da CONDENSED ABBREVIATED INJURY SCALE (CAIS, como bases para cálculo do INJURY SEVERITY SCORE (ISS em vítimas de trauma crânio-encefálico. Os resultados evidenciaram que o valor do ISS foi coincidente na maioria (59,51% das vítimas passíveis de codificação pelos dois instrumentos. Quanto à indicação da faixa de gravidade do trauma (grave, moderado e leve não existiram diferenças estatisticamente significantes entre os dois instrumentos. Quanto a capacidade de cobertura da CAIS/85 para a identificação da gravidade das lesões constatou-se que a CAIS/85 permitiu a pontuação de 61,38% das lesões pontuadas com a AIS/90.Estudio comparativo del uso del Manual de la ABBREVIATED INJURY SCALE (AIS y de los mapas de la CONDENSED ABBREVIATED INJURY SCALE (CAIS, como base para el cálculo del INJURY SEVERITY SCORE (ISS en víctimas de trauma cráneo-encefálico. Los resultados mostraron que el valor del ISS coincidía en la mayoría (58,51% de las víctimas posibles de codificación por los dos instrumentos. En cuanto a la indicación de la faja de gravedad del trauma (grave, moderado y leve no existian diferencias estadísticamente significantes entre los dos instrumentos. En cuanto a la capacidad de cobertura de la CAIS/85 para la identificación de la gravedad de las lesiones, se constató que la CAIS/85 permitió la puntuación de 61,38% de las lesiones puntiadas con la AIS/90.This study was developed in order to compare the use of the ABBREVIATED INJURY SCALE (AIS and the CONDENSED ABBREVIATED INJURY SCALE (CAIS as basis to calculate INJURY SEVERITY SCORE (ISS in head injured patients. The results showed that the ISS value was equivalent in the majority of the patients (58,51% codified by both scales. Also no statistic differences between the scales were perceived when we compared the severity levels as severe, moderate and minor. 61,38% of the lesions scored by AIS/90 were scored by CAIS/85, too.

  6. 188Re直接法标记CD45单抗及其体内生物分布研究%Direct-radiolabeling of CD45 monoclonal antibody with rhenium-188 and its biodistribution in normal mice

    Institute of Scientific and Technical Information of China (English)

    郑文莉; 李贵平; 黄宝丹; 杜丽; 黄凯

    2013-01-01

    Objective With direct-labeling method of CD45 McAb with 188Re, to investigate its bio-distribution character in normal mice. Methods The disulfide bond in the molecule of CD45 monoclonal antibody was reduced to form a mercapto group by the mercaptoethanol (2-ME). The labeling was conducted by stannous chloride used as reductant of 188Re, and sodium glucoheptonate as intermediate.weak ligands, then 188Re was directly labeled CD45 mAb alone; The reaction mixture was separated and purified throuth the PD-10 column;Labeling efficiency and radiochemical purity were measured by the paper chromatography. Then stability of 188Re labeled CD45 McAb was determined in vitro. The biodistribution in the healthy Kunming mice after intravenous injection of 188Re-CD45 McAb was determined. Results The labeling efficiency of 188Re-CD45 McAb was (85.25±2.63)%, and radiochemical purity was (92.54±3.56)%. The specific activity was (2.06±0.07) TBq/mmol;The radiochemical purity of 188Re-CD45 McAb was (64.33±1.53)% after incubating 24 h in room temperature. While mixed the saline and healthy rat serum at 37℃for 24 h, the radiochemical purity was (64. 2±3. 77)%and(56. 7±4. 16)%, respectively. The biodistribution result showed that the radioactivity in body was mainly distributed in kidney and liver, followed by lung, bone and blood. Conclusion The method of direct-labeling CD45 McAb with 188Re is not only simple, but also has high labeling efficiency. 188Re-CD45 McAb has good stability in vitro. After injected intravenously, radioactive label is mainly excreted through kidneys with a higher accumulation in liver, and it accords with the in vivo kinetics characteristic of labeled antibody.%目的:利用188Re直接法标记CD45单抗,探讨其在正常小鼠体内的生物学分布特性。方法应用2-巯基乙醇(2-ME)还原CD45单抗分子中的二硫键形成巯基;以氯化亚锡作为188Re的还原剂,葡庚糖酸钠为中间弱配体,188Re直接标记CD45

  7. A busca pelo espiritual e a busca de sentido no mundo contemporâneo (The search for the spiritual and the search for meaning in the contemporary world - DOI: 10.5752/P.2175-5841.2013v11n32p1605

    Directory of Open Access Journals (Sweden)

    Anete Roese

    2013-12-01

    Full Text Available O artigo identifica as instâncias subjetivas do que leva o ser humano à busca por experiências de cunho espiritual e religioso. Situa a contemporânea busca religiosa e a crise de sentido que afeta a humanidade como uma busca de realização espiritual e do ser-si-próprio, diante de um mundo onde a potencialidade espiritual se encontra cada vez mais devastada. Viktor Frankl, Karl Jaspers, Paul Tillich, todos originários das contribuições da fenomenologia, são os principais autores a sustentar a reflexão em torno do tema. Frankl sustenta a ideia de um inconsciente espiritual, de uma transcendência da consciência, e Jaspers e Tillich se ocupam com a análise da “situação espiritual do nosso tempo”, uma era cujos reflexos colhemos sobremodo no terceiro milênio. Todos tratam de decifrar a intrínseca relação da não realização espiritual, da busca de um sentido do ser humano para a sua existência com a crise mais generalizada no mundo ocidental. A conclusão do texto segue na perspectiva de que a busca espiritual é inerente ao ser humano, pois se trata da realização do ser humano como ser-si-próprio no mundo. A impossibilidade de realização desta dimensão leva a uma profunda frustração existencial cujas consequências são patentes no modo de vida da humanidade na contemporaneidade. Palavras-chave: Espiritual. Busca de vida. Psicologia da religião. Viktor Frankl. Karl Jaspers. Paul Tillich.  Abstract The article identifies the subjective instances of what makes humans to search for experiences of spiritual and religious nature. It places the contemporary religious quest and the crisis of meaning that affects humanity as a search of spiritual fulfillment and of the being-oneself, facing a world where spiritual potentiality is increasingly devastated. Viktor Frankl, Karl Jaspers, Paul Tillich, all originating from the contributions of Phenomenology, are the main authors that sustain the reflection around the topic. Frankl holds the idea of an spiritual unconscious, a transcendence of consciousness, and Jaspers and Tillich deal with the analysis of the "spiritual situation of our time", an era whose reflexes we mostly reap in the third millennium. All of them try to decipher the intrinsic relationship of not spiritual realization and of the human being search for a sense of its own existence with the most generalized crisis in the western world. The conclusion of the text follows the perspective that the spiritual quest is inherent in the human being, because it is about the realization of the human being as being-oneself in the world. The impossibility of realization of this dimension leads to a profound existential frustration whose consequences are patent on the way of life of mankind in contemporary times. Keywords: Spiritual. Search for meaning. Psychology of religion. Viktor Frankl. Karl Jaspers. Paul Tillich. 

  8. A epistemologia e o método da Teologia da Libertação no pensamento de Clodovis Boff (The epismetology and method of liberation theology according to Clodovis Boff - DOI: 10.5752/P.2175-5841.2013v11n32p1403

    Directory of Open Access Journals (Sweden)

    Agenor Brighenti

    2013-12-01

    Full Text Available Este artigo pretende oferecer uma síntese dos principais elementos que caracterizam a epistemologia e o método da Teologia da Libertação, no pensamento de Clodovis Boff, autor que deu à Teologia da Libertação sistematização de sua semântica e de sua sintática. Em seus escritos em relação à questão, cronologicamente, identificam-se três fases distintas: a Teologia da Libertação como Teologia do Político (1, a libertação como perspectiva de uma teologia global, (2 e a Teologia da Libertação como libertação na Teologia (3. Entre os elementos selecionados para esta abordagem sintética estão: a questão da identidade da Teologia da Libertação em relação a outras teologias, o ponto de partida da articulação do discurso teológico, o lugar do pobre na epistemologia da teologia e as mediações teóricas do método da Teologia da Libertação. O texto, em grande medida, reproduz o pensamento do autor, privilegiando, o máximo possível, citações textuais de sua ampla e consistente bibliografia sobre a questão. Palavras-chave: Teologia. Libertação. Método. Fé. Pobre.   Abstract This article aims to present an overview of the main elements which characterize the method and epistemology of Liberation Theology, according to Clodovis Boff´s view. It was him who provided Liberation Theology with the systematization of its semantics and syntax. In his writings on the issue, chronologically, three distinct phases can be identified: Liberation Theology as the Politician´s Theology (1; the liberation as a global theology perspective (2; and Liberation Theology as the liberation in Theology. Among the selected elements are: the identity of Liberation Theology in relation to other theologies; the starting point of articulation of theological discourse; the place of the poor in the epistemology of theology; and theoretical mediations of the Liberation Theology method. The text reproduces the author's thought, focusing as much as possible, textual citations of his extensive and consistent bibliography on the issue. Keywords: Theology. Liberation. Method. Faith. Poor. 

  9. O Enigma do Mal: uma leitura do 'De casu diaboli'de Santo Anselmo (The enigma of evil: a reading of St. Anselm’s De casu diaboli - DOI: 10.5752/P.2175-5841.2013v11n32p1551

    Directory of Open Access Journals (Sweden)

    Manoel Luís Cardoso Vasconcellos

    2013-12-01

    Full Text Available O presente artigo quer investigar o problema do mal na perspectiva de Santo Anselmo, tomando como ponto de partida sua obra De casu diaboli, onde o tema é abordado, a partir da íntima ligação entre mal e pecado. Ao enfocar o mal na perspectiva da queda diabólica, o Doutor Magnífico intenta mostrar a conexão entre vontade, liberdade e justiça. Sua preocupação é investigar o significado moral da má escolha, realizada por uma criatura racional e puramente espiritual, feita boa e para ser boa. O pecado, consoante o autor, não está em almejar a felicidade, pois tal desejo é dádiva divina; o mal praticado pelo anjo está, precisamente, em querer a felicidade fora da justiça, isto é, ao querer ser feliz, ele foi de encontro ao que ele deveria ser: quis ser semelhante a Deus, extrapolando a sua própria natureza, pois ele desejou algo que, enquanto criatura, não caberia a ele almejar. Este é o ponto de partida para analisar o mal e sua mais dramática consequência, o sofrimento. Palavras-chave: Mal. Vontade. Justiça. Anselmo.   Abstract This article aims to investigate the problem of evil in Saint Anselm, especially in his treatise De casu diaboli. He approaches this issue from the close connection between evil and sin. Upon analyzing evil from the diabolic fall perspective, Dr. Magnificent tries to establish a connection between will, freedom and justice. This text investigates the moral meaning of misconduct, carried out by a rational and purely spiritual creature that was created good and meant to be good. Seeking for happiness is not itself a sin, according to the author, for such a wish is a gift from God. The evil done by the angel lies in the act of wanting happiness without justice, that is, on wanting to be happy, the angel contradicted what he was supposed to be: he wanted to be like God, transcending his own nature, as he wished for something that, as a creature, he was not fit to wish for. This is the starting point to analyze evil and its most dramatic consequence: suffering. Key-words: Evil. Will. Justice. Anselm. 

  10. A Cáritas brasileira e a Economia Popular Solidária: O Agente de Cáritas e a Caridade Libertadora (Brazilian Caritas and the Popular Solidarity Economy: The Agent of Caritas and the Charity Liberating - DOI: 10.5752/P.2175-5841.2013v11n32p1506

    Directory of Open Access Journals (Sweden)

    Joannes Paulus Silva Forte

    2013-12-01

    Full Text Available O presente artigo analisa as ligações entre a Cáritas Brasileira e a Economia Popular Solidária a partir do trabalho do Agente de Cáritas. A problemática central do artigo remete às representações sociais que esses Agentes constroem em seus relatos sobre os princípios da Teologia da Libertação que norteiam os projetos em economia solidária da referida instituição religiosa. A metodologia de base qualitativa e etnográfica consistiu na realização da revisão bibliográfica, consulta a materiais institucionais, observação in loco e entrevistas semiestruturadas com Agentes que atuam na Economia Popular Solidária no estado do Ceará. A análise das representações sinaliza que a própria noção de “Reino de Deus” na terra pressupõe a vinculação profunda entre religião e economia, mística e movimentos sociais, religião e Estado, configurando, dessa forma, um projeto de sociedade contra hegemônico que se vislumbra mediante a transformação radical da base econômica e moral do tecido social contrapondo individualismo à solidariedade. Palavras-chave: Cáritas Brasileira. Economia Popular Solidária. Caridade Libertadora. Teologia da Libertação.  Abstract This article examines the links between Brazilian Caritas and Popular Solidarity Economy from the work of Caritas Agent. The central issue of the article refers to the social representations that these agents build in his histories about the principles of Liberation Theology that guide the projects in solidarity economy of that religious institution. The basic methodology used was qualitative and ethnographic; It consisted in literature review, consultation to institutional materials, observation in loco and semi-structured interviews with agents who act in the Popular Solidarity Economy in the state of Ceará. The analysis of representations indicates that the very notion of "Kingdom of God" on earth presupposes deep linking between religion and economics, mystic and social movements, religion and state configuring a project of a counter hegemonic society who sees through the radical transformation of the economic and moral base of the social tissue opposing solidarity to individualism.Keywords: Brazilian Caritas. Popular Solidarity Economy. Liberating Charity. Liberation theology

  11. O caso dos judeus laicos: a complexidade das identidades étnicas e religiosas nas classificações censitárias (The Jewish Laic: the complexity of the ethnic and religious identities in the census classifications - DOI: 10.5752/P.2175-5841.2013v11n32p1525

    Directory of Open Access Journals (Sweden)

    Denise dos Santos Rodrigues

    2013-12-01

    Full Text Available Este artigo avalia o impacto das transformações da contemporaneidade em religiões tradicionais como o judaísmo, cujos membros podem assumir uma faceta secular, interferindo no monitoramento de sua presença num território.  A restrição da classificação censitária de certos grupos étnicos unicamente ao quesito religião pode confundir a interpretação das oscilações de certos grupos, uma vez que pode camuflar sua real representatividade numérica.  Lembramos que um membro de um grupo étnico pode sentir-se livre para assumir uma identidade religiosa diferente de sua etnia ou, ainda, afastar elementos religiosos de sua biografia, apresentando-se como sem religião.  Os critérios autodeclarados, que dispensam comprovação, ratificam o pleno exercício das liberdades individuais que, num ambiente de alta refletividade, pode convidar o individuo a transitar livremente, rompendo com laços tradicionais, optando por identidades alternativas, algumas vezes distantes de sua origem étnica. Palavras-chave: Judaísmo laico. Sem religião. Recenseamentos. Reflexividade. Destradicionalização.  Abstract This article evaluates the impact of the contemporary transformations on traditional religions as the Judaism, that may adopt a secular expression, interfering in the control of its presence in a territory.  The isolation of certain ethnic groups inside the field reserved to religion in the census classification may confuse the interpretation of the oscillations of certain goups, once it can produce a camouflage of the real numeric representation.  We remind that a member of an ethnic group can feel free to assume a religious identity  distant of his familial tradition or, still, to remove the religious elements of his biography, becoming a person without religion.  So, at the same time that the census fields that are selfdeclared, with no need of comprobation ratifies the full exercise of the individual freedom in an scenery of high reflexivity, it  may invite people to transit freely, breaking up with traditional liaisons, opting for alternative identities, sometimes distant of its ethnic origin. Key-words: Laic Judaism. Without religion. Census. Reflexivity. Detradicionalization. 

  12. À margem de uma comemoração: considerações sobre a TdL no seu quarentenário (On the sidelines of a celebration: considerations on Liberation Theology on its fortieth anniversary - DOI: 10.5752/P.2175-5841.2013v11n32p1378

    Directory of Open Access Journals (Sweden)

    Sinivaldo Silva Tavares

    2013-12-01

    Full Text Available O autor propõe algumas considerações sobre a TdL na celebração de seus 40 anos de existência. Num primeiro momento, ele destaca três características que justificam a pretensão avançada pela TdL latino-americana de se apresentar como “uma nova maneira de fazer teologia”: 1 nova relação para com a práxis; 2 nova perspectiva a partir da qual discernir os desafios postos pela práxis; 3 nova metodologia capaz de unir espiritualidade e método teológico. Num segundo momento, a TdL é reconhecida e apresentada como uma autêntica theologia crucis. Isto significa que a cruz de Jesus é acolhida pela TdL em um tríplice modo: eixo gnosiológico, princípio epistemológico e critério formal. Por fim, o autor salienta o círculo virtuoso testemunhado pela TdL entre o local e o global. Epistemologicamente, a TdL é materialmente global e formalmente particular. Historicamente, ao longo de seus quarenta anos, a TdL tem se revelado como uma verdadeira teologia glocal, testemunhando um relação circular entre particular e universal. Palavras-chave: Teologia da Libertação. Práxis. Theologia crucis. Epistemologia teológica. Teologica glocal.   Abstract The author proposes some considerations about Liberation Theology in celebration of its 40 years of existence. At first, he highlights three features that justify the claim put forth by Latin-American Liberation Theology of presenting itself as "a new way of doing theology": 1 new relationship vis-à-vis the Praxis; 2 new perspective from which we can discern the challenges posed by the Praxis; 3 new methodology able to unite spirituality and theological method. In a second moment, Liberation Theology is recognized and presented as an authentic theologia crucis. This means that the cross of Jesus is accepted by Liberation Theology in a threefold manner: agnostical axis, epistemological principle and formal criteria. Finally, the author stresses the virtuous circle witnessed by Liberation Theology between the local and the global. Epistemologically, Liberation Theology is materially global and formally private. Historically, throughout its forty years, Liberation Theology has been revealed as a true “glocal” theology, witnessing a circular relationship between the particular and the universal. Keywords: Theology of Liberation. Praxis. Theologia crucis. Theological epistemology. “Glocal” (global + local theology. 

  13. Calculation of electron and isotopes dose point kernels with fluka Monte Carlo code for dosimetry in nuclear medicine therapy

    Energy Technology Data Exchange (ETDEWEB)

    Botta, F; Di Dia, A; Pedroli, G; Mairani, A; Battistoni, G; Fasso, A; Ferrari, A; Ferrari, M; Paganelli, G

    2011-06-01

    The calculation of patient-specific dose distribution can be achieved by Monte Carlo simulations or by analytical methods. In this study, fluka Monte Carlo code has been considered for use in nuclear medicine dosimetry. Up to now, fluka has mainly been dedicated to other fields, namely high energy physics, radiation protection, and hadrontherapy. When first employing a Monte Carlo code for nuclear medicine dosimetry, its results concerning electron transport at energies typical of nuclear medicine applications need to be verified. This is commonly achieved by means of calculation of a representative parameter and comparison with reference data. Dose point kernel (DPK), quantifying the energy deposition all around a point isotropic source, is often the one.Methods: fluka DPKs have been calculated in both water and compact bone for monoenergetic electrons (10–3 MeV) and for beta emitting isotopes commonly used for therapy (89Sr, 90Y, 131I, 153Sm, 177Lu, 186Re, and 188Re). Point isotropic sources have been simulated at the center of a water (bone) sphere, and deposed energy has been tallied in concentric shells. fluka outcomes have been compared to penelope v.2008 results, calculated in this study as well. Moreover, in case of monoenergetic electrons in water, comparison with the data from the literature (etran, geant4, mcnpx) has been done. Maximum percentage differences within 0.8·RCSDA and 0.9·RCSDA for monoenergetic electrons (RCSDA being the continuous slowing down approximation range) and within 0.8·X90 and 0.9·X90 for isotopes (X90 being the radius of the sphere in which 90% of the emitted energy is absorbed) have been computed, together with the average percentage difference within 0.9·RCSDA and 0.9·X90 for electrons and isotopes, respectively.Results: Concerning monoenergetic electrons, within 0.8·RCSDA (where 90%–97% of the particle energy is deposed), fluka and penelope agree mostly within 7%, except for 10 and 20 keV electrons (12% in water, 8

  14. Calculation of electron and isotopes dose point kernels with fluka Monte Carlo code for dosimetry in nuclear medicine therapy

    Energy Technology Data Exchange (ETDEWEB)

    Botta, F.; Mairani, A.; Battistoni, G.; Cremonesi, M.; Di Dia, A.; Fasso, A.; Ferrari, A.; Ferrari, M.; Paganelli, G.; Pedroli, G.; Valente, M. [Medical Physics Department, European Institute of Oncology, Via Ripamonti 435, 20141 Milan (Italy); Istituto Nazionale di Fisica Nucleare (I.N.F.N.), Via Celoria 16, 20133 Milan (Italy); Medical Physics Department, European Institute of Oncology, Via Ripamonti 435, 20141 Milan (Italy); Jefferson Lab, 12000 Jefferson Avenue, Newport News, Virginia 23606 (United States); CERN, 1211 Geneva 23 (Switzerland); Medical Physics Department, European Institute of Oncology, Milan (Italy); Nuclear Medicine Department, European Institute of Oncology, Via Ripamonti 435, 2014 Milan (Italy); Medical Physics Department, European Institute of Oncology, Via Ripamonti 435, 20141 Milan (Italy); FaMAF, Universidad Nacional de Cordoba and CONICET, Cordoba, Argentina C.P. 5000 (Argentina)

    2011-07-15

    Purpose: The calculation of patient-specific dose distribution can be achieved by Monte Carlo simulations or by analytical methods. In this study, fluka Monte Carlo code has been considered for use in nuclear medicine dosimetry. Up to now, fluka has mainly been dedicated to other fields, namely high energy physics, radiation protection, and hadrontherapy. When first employing a Monte Carlo code for nuclear medicine dosimetry, its results concerning electron transport at energies typical of nuclear medicine applications need to be verified. This is commonly achieved by means of calculation of a representative parameter and comparison with reference data. Dose point kernel (DPK), quantifying the energy deposition all around a point isotropic source, is often the one. Methods: fluka DPKs have been calculated in both water and compact bone for monoenergetic electrons (10{sup -3} MeV) and for beta emitting isotopes commonly used for therapy ({sup 89}Sr, {sup 90}Y, {sup 131}I, {sup 153}Sm, {sup 177}Lu, {sup 186}Re, and {sup 188}Re). Point isotropic sources have been simulated at the center of a water (bone) sphere, and deposed energy has been tallied in concentric shells. fluka outcomes have been compared to penelope v.2008 results, calculated in this study as well. Moreover, in case of monoenergetic electrons in water, comparison with the data from the literature (etran, geant4, mcnpx) has been done. Maximum percentage differences within 0.8{center_dot}R{sub CSDA} and 0.9{center_dot}R{sub CSDA} for monoenergetic electrons (R{sub CSDA} being the continuous slowing down approximation range) and within 0.8{center_dot}X{sub 90} and 0.9{center_dot}X{sub 90} for isotopes (X{sub 90} being the radius of the sphere in which 90% of the emitted energy is absorbed) have been computed, together with the average percentage difference within 0.9{center_dot}R{sub CSDA} and 0.9{center_dot}X{sub 90} for electrons and isotopes, respectively. Results: Concerning monoenergetic electrons

  15. Development of Radiolabeled compounds using reactor-produced radionuclides

    Energy Technology Data Exchange (ETDEWEB)

    Choi, Sun Ju; Park, K. B.; Park, S. H.

    2007-06-15

    To establish a robust technology for radiopharmaceutical development, we focused on the configuration of fundamental development of radiolabeled compounds for radioimmunotherapy and drug delivery as well as the development of bifunctional chelating agents and radiolabeling methods for the radiopharmaceuticals with highly specific activity to deliver sufficient number of radionuclides to the target site. In this project, we aim to improve the quality of life and the public welfare by fostering the medical application of radioisotopes for the effective treatment of malignant diseases and by developing efficient radiolabeling methods of specific bio-active materials with radioisotopes and new candidates for radiopharmaceutical application. We have established the procedure for the preparation of radiolabeled antibody and biotin with radioisotopes such as {sup 166}Ho, {sup 131}I, {sup 90}Y and {sup 111}In for tumour targeting. In the future, these technologies will be applicable to development of radioimmunotherapeutic drug. The combination treatment of radioisotope with anti-cancer agents or chemotherapeutic agents may produce a synergistic static effects in the tumour and this synergism would be exerted via gene level through the activation of a cell death pathway. The combination therapy may be very beneficial for cancer treatment and this can overcome not only the hazards of unnecessary exposure to high radiation level during therapy, but also the tendency for drug resistance caused by chemotherapy. To develop new drug delivery system suitable for CT imaging agent, a chitosan derivative and radiolabed Folate-targeted polymer with {sup 131}I were synthesized. We also carried out the development of DTPA derivatives for CT imaging agent, radiolabeled precursor, and established a highly efficient radiolabeling methodology with lanthanide nuclide. In order to develop neuroreceptor targeting compounds, we synthesized WAY-100635 compound and {sup 99m}Tc(CO){sub 3

  16. Current Status of Nuclear Medicine Practice in the Middle East.

    Science.gov (United States)

    Paez, Diana; Becic, Tarik; Bhonsle, Uday; Jalilian, Amir R; Nuñez-Miller, Rodolfo; Osso, Joao Alberto

    2016-07-01

    availability of (68)Ge-(68)Ga generators is increasing and studies involving prostate-specific membrane antigen or DOTA-chelated peptides or both are performed in at least seven countries. Although therapeutic radionuclide agents are mostly imported from outside the region, this does not limit the availability of therapies with (90)Y, (153)Sm, (177)Lu, (131)I, (188)Re, and (89)Sr. Nevertheless, therapies based on alpha particle emitters are still largely not available in the region and are currently only available in Israel and Turkey. Regarding human resources, according to the data provided there are 1157 NM physicians, 1953 technologists, 586 medical physicists, and 173 radiopharmacists or radiochemists in the region. Approximately half of all available human resources are accounted for by Turkey. The region has great potential for expanding the applications of NM; this becomes especially important in view of the high prevalence of non-communicable diseases. Further increasing awareness of the clinical applications of NM in healthcare and strengthening technical and human capacities including the establishment of training programs for all professionals and disciplines in the field are recognized as key components in advancing the practice of NM in the Middle East.

  17. Development of Radioreagents using Green Chemistry

    Energy Technology Data Exchange (ETDEWEB)

    Park, Sang Hyun; Choi, Sang Moo; Park, Eung Woo; Jang, Seung Ho; Kwon, Hee Jung

    2006-01-15

    The interest for radiopharmaceuticals for the treatment of serious illness such as cancer and rheumatism, has increased during the last decade. Radioisotopes of 89Sr, 186Re, 153Sm, 90Y and 166Ho are currently used in the routine practice of medical clinics. Many methods for radioisotope extraction separation have been proposed with growth of nuclear medicine. Crown ethers have an important advantage for metal ion separations, but on the other hand it has difficulties in synthesis and expensive. In recent years, ionic liquids have been developed to save specific synthetic problems. They are considered as green solvents since they are non-volatile, non-flammable, non-toxic, thermally stable and recyclable. Ionic liquid-type crown ether(IL-CE) has been found to behave like a multifunctional compound which is cheep, easy to extraction separation, possibility of recycle and discriminates metal cation according to its size. Dichloro-poly(oxyethylene) was synthesized by chlorination of polyethylene glycol. And it was treated with imidazole and sodium ethoxide to give the 1N,1N'- poly(oxyethyl)- diimidazole, which was then converted to IL-CE with the reaction of dichloro-poly(oxyethylene). Further, anion of IL-CE was exchanged by anion exchange method. Ultimately, we developed very efficient synthetic pathway for IL-CE have various physical and chemical characteristics by the modification of polyethylene glycol chain length and anions. 85/89/90Sr was successfully extracted into cyclo-bis-{l_brace}1N,1N'-[(3,6,9-Trioxa)-1,11-undecyl]{r_brace}-diimidazolium chloride {l_brace}[(3,2)OEtIm][Cl]{r_brace} phases, but no extracting into [(3,3)OEtIm][Cl] and [(4,3)OEtIm][Cl] are observed. The extraction of 99mTc and 188Re are highly detected at four IL-CEs 99mTc-Labeled N-(3-bromo-2,4,6-trimethylacetanilido)iminodiacetic acid (99mTc-meb- rofenin) has been used to assess the functional integrity of the hepatobiliary system. A fast and convenient procedure was established

  18. Dose calculation formalisms and consensus dosimetry parameters for intravascular brachytherapy dosimetry: recommendations of the AAPM Therapy Physics Committee Task Group No. 149.

    Science.gov (United States)

    Chiu-Tsao, Sou-Tung; Schaart, Dennis R; Soares, Christopher G; Nath, Ravinder

    2007-11-01

    Since the publication of AAPM Task Group 60 report in 1999, a considerable amount of dosimetry data for the three coronary brachytherapy systems in use in the United States has been reported. A subgroup, Task Group 149, of the AAPM working group on Special Brachytherapy Modalities (Bruce Thomadsen, Chair) was charged to develop recommendations for dose calculation formalisms and the related consensus dosimetry parameters. The recommendations of this group are presented here. For the Cordis 192Ir and Novoste 90Sr/90Y systems, the original TG-43 formalism in spherical coordinates should be used along with the consensus values of the dose rate constant, geometry function, radial dose function, and anisotropy function for the single seeds. Contributions from the single seeds should be added linearly for the calculation of dose distributions from a source train. For the Guidant 32P wire system, the modified TG-43 formalism in cylindrical coordinates along with the recommended data for the 20 and 27 mm wires should be used. Data tables for the 6, 10, 14, 18, and 22 seed trains of the Cordis system, 30, 40, and 60 mm seed trains of the Novoste system, and the 20 and 27 mm wires of the Guidant system are presented along with our rationale and methodology for selecting the consensus data. Briefly, all available datasets were compared with each other and the consensus dataset was either an average of available data or the one obtained from the most densely populated study; in most cases this was a Monte Carlo calculation.

  19. Therapeutic radionuclides in nuclear medicine: current and future prospects.

    Science.gov (United States)

    Yeong, Chai-Hong; Cheng, Mu-hua; Ng, Kwan-Hoong

    2014-10-01

    The potential use of radionuclides in therapy has been recognized for many decades. A number of radionuclides, such as iodine-131 ((131)I), phosphorous-32 ((32)P), strontium-90 ((90)Sr), and yttrium-90 ((90)Y), have been used successfully for the treatment of many benign and malignant disorders. Recently, the rapid growth of this branch of nuclear medicine has been stimulated by the introduction of a number of new radionuclides and radiopharmaceuticals for the treatment of metastatic bone pain and neuroendocrine and other malignant or non-malignant tumours. Today, the field of radionuclide therapy is enjoying an exciting phase and is poised for greater growth and development in the coming years. For example, in Asia, the high prevalence of thyroid and liver diseases has prompted many novel developments and clinical trials using targeted radionuclide therapy. This paper reviews the characteristics and clinical applications of the commonly available therapeutic radionuclides, as well as the problems and issues involved in translating novel radionuclides into clinical therapies.

  20. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia

    Energy Technology Data Exchange (ETDEWEB)

    Decker, Mario de [Department of Radiopharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ghent (Belgium); Department of Nuclear Medicine and Molecular Imaging, University Medical Centre Groningen, Groningen (Netherlands)], E-mail: mario.dedecker@health.wa.gov.au; Bacher, Klaus; Thierens, Hubert [Department of Medical Physics and Radiation Protection, Ghent University, Ghent (Belgium); Slegers, Guido [Department of Medical Imaging of Domestic Animals, Ghent University, Ghent (Belgium); Dierckx, Rudi A. [Department of Nuclear Medicine and Molecular Imaging, University Medical Centre Groningen, Groningen (Netherlands); Vos, Filip de [Department of Radiopharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ghent (Belgium)

    2008-07-15

    Alemtuzumab (Campath, Berlex) is a humanized IgG1 rat monoclonal antibody directed against the cell surface CD52 antigen, found on lymphocytes and monocytes. It is being developed for the treatment of chronic lymphocytic leukemia (CLL), autoimmune disease and for the prevention of transplant rejection. This study focused on synthesis, quality control, in vitro evaluation and biodistrubution of {sup 188}Re-labeled alemtuzumab for radioimmunotherapy of B-cell CLL. {sup 188}Re-alemtuzumab was synthesized using a direct radiolabeling method. Reduction of the intramolecular disulfide bonds of the antibody was performed with tris-(carboxyethyl)-phosphine (Pierce), using a 1:60 molar excess. Reaction took place at room temperature for 20 min. A PD-10 desalting column was used to purify the reduced antibody from excess phospine. Complexation and transchelation of {sup 188}ReO{sub 4}{sup -} was achieved using sodium gluconate as weak chelator and SnCl{sub 2} as reducing agent. Quality control was done using instant thin-layer chromatography. Binding assays were performed on a CD52-positive cell line (HuT-78). Female NMRI mice were injected intravenously with 20 {mu}g radiolabeled alemtuzumab and killed at preset time intervals for biodistribution studies. Tissues were dissected, weighed and counted for determination of radioactivity. Data were expressed as percentage injected activity per gram of tissue (% IA/g tissue) or as percentage injected activity (% IA). {sup 188}Re-alemtuzumab was prepared achieving high radiochemical yields. Labeling efficiency of more than 95% can be obtained using optimal reaction conditions. {sup 188}Re-alemtuzumab showed good in vitro stability, remaining intact at 24 h after radiolabeling. In mice, {sup 188}Re-alemtuzumab showed high uptake in the blood (25.10{+-}1.36% IA at 1 h p.i.), followed by a biexponential clearance (t{sub 1/2{alpha}}=4.790 h and t{sub 1/2{beta}}=55.45 h). Increased uptake was observed in kidneys and heart (9

  1. Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins.

    Directory of Open Access Journals (Sweden)

    Ekaterina Dadachova

    2006-11-01

    Full Text Available BACKGROUND: The HIV epidemic is a major threat to health in the developing and western worlds. A modality that targets and kills HIV-1-infected cells could have a major impact on the treatment of acute exposure and the elimination of persistent reservoirs of infected cells. The aim of this proof-of-principle study was to demonstrate the efficacy of a therapeutic strategy of targeting and eliminating HIV-1-infected cells with radiolabeled antibodies specific to viral proteins in vitro and in vivo. METHODS AND FINDINGS: Antibodies to HIV-1 envelope glycoproteins gp120 and gp41 labeled with radioisotopes bismuth 213 ((213Bi and rhenium 188 ((188Re selectively killed chronically HIV-1-infected human T cells and acutely HIV-1-infected human peripheral blood mononuclear cells (hPBMCs in vitro. Treatment of severe combined immunodeficiency (SCID mice harboring HIV-1-infected hPBMCs in their spleens with a (213Bi- or (188Re-labeled monoclonal antibody (mAb to gp41 resulted in a 57% injected dose per gram uptake of radiolabeled mAb in the infected spleens and in a greater than 99% elimination of HIV-1-infected cells in a dose-dependent manner. The number of HIV-1-infected thymocytes decreased 2.5-fold in the human thymic implant grafts of SCID mice treated with the (188Re-labeled antibody to gp41 compared with those treated with the (188Re-control mAb. The treatment did not cause acute hematologic toxicity in the treated mice. CONCLUSIONS: The current study demonstrates the effectiveness of HIV-targeted radioimmunotherapy and may provide a novel treatment option in combination with highly active antiretroviral therapy for the eradication of HIV.

  2. Radiobiological characterization of post-lumpectomy focal brachytherapy with lipid nanoparticle-carried radionuclides

    Science.gov (United States)

    Hrycushko, Brian A.; Gutierrez, Alonso N.; Goins, Beth; Yan, Weiqiang; Phillips, William T.; Otto, Pamela M.; Bao, Ande

    2011-02-01

    Post-operative radiotherapy has commonly been used for early stage breast cancer to treat residual disease. The primary objective of this work was to characterize, through dosimetric and radiobiological modeling, a novel focal brachytherapy technique which uses direct intracavitary infusion of β-emitting radionuclides (186Re/188Re) carried by lipid nanoparticles (liposomes). Absorbed dose calculations were performed for a spherical lumpectomy cavity with a uniformly injected activity distribution using a dose point kernel convolution technique. Radiobiological indices were used to relate predicted therapy outcome and normal tissue complication of this technique with equivalent external beam radiotherapy treatment regimens. Modeled stromal damage was used as a measure of the inhibition of the stimulatory effect on tumor growth driven by the wound healing response. A sample treatment plan delivering 50 Gy at a therapeutic range of 2.0 mm for 186Re-liposomes and 5.0 mm for 188Re-liposomes takes advantage of the dose delivery characteristics of the β-emissions, providing significant EUD (58.2 Gy and 72.5 Gy for 186Re and 188Re, respectively) with a minimal NTCP (0.046%) of the healthy ipsilateral breast. Modeling of kidney BED and ipsilateral breast NTCP showed that large injected activity concentrations of both radionuclides could be safely administered without significant complications.

  3. Monte Carlo dosimetry in simple geometries with interfaces: applications in radiotherapy; Dosimetria Monte Carlo en geometrias simples con interfases: aplicaciones en radioterapia

    Energy Technology Data Exchange (ETDEWEB)

    Rojas C, E.L

    2004-07-01

    distributions of radionuclides in presence of interfaces, particularly we deal with the injection of radiocolloids with {sup 165} Dy, {sup 32} P and {sup 90} Y into the knee joint with different healing purposes. The model is described and similar studies to those of chapter two, involving heterogeneities of the joint are presented. In chapter four, dosimetric studies of simulated treatments of radiosurgery of the head with the Leksell Gamma Knife are done. We describe the unit, give the simulation details and parameters and describe the targets. To make our investigation spheric interfaces of different materials in the phantoms are considered. Finally, a chapter with the conclusions is presented. References are given after this chapter. (Author)

  4. Electron absorbed fractions of energy and S-values in an adult human skeleton based on {mu}CT images of trabecular bone

    Energy Technology Data Exchange (ETDEWEB)

    Kramer, R; Cassola, V F; Khoury, H J; De O Lira, C A B [Department of Nuclear Energy, Federal University of Pernambuco, Avenida Professor Luiz Freire, 1000, CEP 50740-540, Recife (Brazil); Richardson, R B [Radiation Protection Research and Instrumentation Branch, Atomic Energy of Canada Limited, Chalk River Laboratories, Chalk River, ON, K0J 1J0 (Canada); Vieira, J W [Federal Institute of Education, Science and Technology of Pernambuco, Recife (Brazil); Brown, K Robson, E-mail: rkramer@uol.com.br [Imaging Laboratory, Department of Archaeology and Anthropology, University of Bristol, Bristol (United Kingdom)

    2011-03-21

    When the human body is exposed to ionizing radiation, among the soft tissues at risk are the active marrow (AM) and the bone endosteum (BE) located in tiny, irregular cavities of trabecular bone. Determination of absorbed fractions (AFs) of energy or absorbed dose in the AM and the BE represent one of the major challenges of dosimetry. Recently, at the Department of Nuclear Energy at the Federal University of Pernambuco, a skeletal dosimetry method based on {mu}CT images of trabecular bone introduced into the spongiosa voxels of human phantoms has been developed and applied mainly to external exposure to photons. This study uses the same method to calculate AFs of energy and S-values (absorbed dose per unit activity) for electron-emitting radionuclides known to concentrate in skeletal tissues. The modelling of the skeletal tissue regions follows ICRP110, which defines the BE as a 50 {mu}m thick sub-region of marrow next to the bone surfaces. The paper presents mono-energetic AFs for the AM and the BE for eight different skeletal regions for electron source energies between 1 keV and 10 MeV. The S-values are given for the beta emitters {sup 14}C, {sup 59}Fe, {sup 131}I, {sup 89}Sr, {sup 32}P and {sup 90}Y. Comparisons with results from other investigations showed good agreement provided that differences between methodologies and trabecular bone volume fractions were properly taken into account. Additionally, a comparison was made between specific AFs of energy in the BE calculated for the actual 50 {mu}m endosteum and the previously recommended 10 {mu}m endosteum. The increase in endosteum thickness leads to a decrease of the endosteum absorbed dose by up to 3.7 fold when bone is the source region, while absorbed dose increases by {approx}20% when the beta emitters are in marrow.

  5. Active and passive vectorization of technetium{sup 99m} and {sup 188}rhenium radiopharmaceuticals for medical imaging and radiotherapy; Vectorisations active et passive de radiopharmaceutiques du technetium-99m et du rhenium-188 pour l'imagerie medicale et la therapie

    Energy Technology Data Exchange (ETDEWEB)

    Lepareur, N

    2003-11-15

    Research for new molecules for nuclear medicine is a field in constant development. Over the past few years, development of new radiopharmaceuticals for radiotherapy has renewed interest for rhenium chemistry. Indeed, its two isotopes {sup 186}Re and {sup 188}Re, owing to their ideal properties and their similitude with {sup 99m}Tc, which is widely used as a radiotracer for diagnostic imaging, seem very promising for the preparation of radiopharmaceuticals. In the first part of this manuscript, the synthesis of rhenium and technetium-99 complexes, [M(RPhCS3)2(RPhCS2)] (M = Re, Tc), is described. The preparation of technetium{sup 99m} based radiopharmaceuticals, analogues to the pondered complexes, is also described. The stability/reactivity of these complexes has been studied by exchange reactions with potential ligands, specially dithiocarbamates, and also by UV-visible absorption spectroscopy and thermogravimetry. The reactivity of the complexes towards dithiocarbamates leads to the possibility to bind biomolecules to the metallic core, via the dithiocarbamate moiety. This method represents a potential alternative to current ones using the so-called bifunctional approach. In the second part of this manuscript, a new kit formulation for the {sup 188}Re labeling of lipiodol is described, using a complex analogous to those described in the previous part. The labeled oil is a potential cure for hepatocellular carcinoma. The in vitro and in vivo stability of this {sup 188}Re-SSS lipiodol and of its analogue {sup 99m}Tc-SSS lipiodol has been studied, and also their in vivo behavior in healthy pigs. This study has shown the quasi-exclusive hepatic fixation of the radiopharmaceutical, and has proven its good stability. Its selectivity for tumors remains to be shown before trying it on humans. (author)

  6. Radiolabeling of anti-CD20 with Re-188 for treatment of non-Hodgkin's lymphoma: radiochemical control

    Energy Technology Data Exchange (ETDEWEB)

    Dias, Carla R.; Osso Junior, Joao A., E-mail: carladias@usp.b, E-mail: jaosso@ipen.b [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil)

    2009-07-01

    The development of tumor-selective radiopharmaceuticals is clinically desirable as a means of detecting or confirming the presence and location of primary and metastatic lesions and monitoring tumor response to (chemo)therapy. In addition, the application of targeted radiotherapeutics provides a unique and effective modality for direct tumor treatment. In this manner the radioimmunotherapy (RIT) uses the targeting features of monoclonal antibody to deliver radiation from an attached radionuclide. Antibody therapy directed against the CD20 antigen on the surface of B-cells is considered one of the first successful target-specific therapies in oncology. The radionuclide rhenium-188 ({sup 188}Re) is currently produced from the father nuclide tungsten-188 ({sup 188}W) through a transportable generator system. Because of its easy availability and suitable nuclear properties (EbetaMAX = 2.1 MeV, t{sub 1/2} = 16.9 h, Egamma = 155 keV), this radionuclide is considered an attractive candidate for application as therapeutic agent and could be conveniently utilized for imaging and dosimetric purposes. The purpose of this work is to show the radiochemical control of the optimized formulation (solution) and lyophilized formulation (kit) of labeled rituximab (anti-CD20) with {sup 188}Re. Rituximab was reduced by incubation with 2-mercaptoethanol at room temperature. The number of resulting free sulfhydryl groups was assayed with Ellman's reagent. Radiochemical purity of {sup 188}Re-rituximab was evaluated using instant thin layer chromatography-silica gel (ITLC-SG). Quality control methods for evaluation of radiochemical purity showed good labeling yield of the antibody. (author)

  7. Beta emitters and radiation protection

    DEFF Research Database (Denmark)

    Jødal, Lars

    2009-01-01

    preparing 90Y-Zevalin were measured. CONCLUSIONS. Good laboratory practice is important to keep radiation doses low. To reduce bremsstrahlung, 90Y should not be shielded by lead but instead perspex (10 mm) or aluminium (5 mm). Bremsstrahlung radiation can be further reduced by adding a millimetre of lead...

  8. 86Y based PET radiopharmaceuticals: radiochemistry and biological applications.

    Science.gov (United States)

    Nayak, Tapan K; Brechbiel, Martin W

    2011-09-01

    Development of targeted radionuclide therapy with (90)Y labeled antibodies and peptides has gained momentum in the past decade due to the successes of (90)Y-ibritumomab tiuxetan and (90)Y-DOTA-Phe(1)-Tyr(3)-octreotide in treatment of cancer. (90)Y is a pure β(-)-emitter and cannot be imaged for patient-specific dosimetry which is essential for pre-therapeutic treatment planning and accurate absorbed dose estimation in individual patients to mitigate radiation related risks. This review article describes the utility of (86)Y, a positron emitter (33%) with a 14.7-h half-life that can be imaged by positron emission tomography and used as an isotopically matched surrogate radionuclide for (90)Y radiation doses estimations. This review discusses various aspects involved in the development of (86)Y labeled radiopharmaceuticals with the specific emphasis on the radiochemistry and biological applications with antibodies and peptides.

  9. Pharmacokinetics of BMEDA after Intravenous Administration in Beagle Dogs

    Directory of Open Access Journals (Sweden)

    Chih-Hsien Chang

    2014-01-01

    Full Text Available The pharmacokinetics of N,N-bis(2-mercapatoethly-N',N'-diethylenediamine (BMEDA, a molecule that can form a chelate with rhenium-188 (188Re to produce the 188Re-BMEDA-liposomes, was studied. In this work, beagles received a single injection of BMEDA, at doses of 1, 2, or 5 mg/kg; the concentration of BMEDA in the beagles’ plasma was then analyzed and determined by liquid chromatography-mass spectrometry/mass spectrometry. Based on the pharmacokinetic parameters of BMEDA, we found that male and female animals shared similar patterns indicating that the pharmacokinetics of BMEDA is independent of gender differences. In addition, the pharmacokinetics of BMEDA was seen to be non-linear because the increase of mean AUC0–t and AUC0–∞ values tend to be greater than dose proportional while the mean Vss and CL values of BMEDA appeared to be dose dependent. The information on the pharmacokinetics of BMEDA generated from this study will serve as a basis to design appropriate pharmacology and toxicology studies for future human use.

  10. Pharmacokinetic properties of new antitumor radiopharmaceutical on the basis of diamond nanoporous composites labeled with rhenium-188

    Science.gov (United States)

    Petriev, V. M.; Tishchenko, V. K.; Kuril’chik, A. A.; Skvortsov, V. G.

    2017-01-01

    Today the development of address therapeutic radionuclide delivery systems directly to tumor tissue is of current interest. It can be achieved by the design of drug containers of specific sizes and shapes from carbon-based composite materials. It will be allowed to enhance the efficacy of anticancer therapy and avoid serious side effects. In this work we studied the pharmacokinetic properties of nanodiamond nanoporous composite labeled with rhenium-188 in rats with hepatocholangioma PC-1 after intratumoral injection. It was established that substantial part of injected radioactivity remained in tumor tissue. Within three hours after 188Re-nanoporous composites injection activity in tumor constituted 79.1–91.3% of injected dose (ID). Then activity level declined to 45.9% ID at 120 hours. No more than 1.34% ID entered the bloodstream. In soft organs and tissues, except thyroid gland, the content of compound didn’t exceed 0.3% ID/g. The highest activity in thyroid gland was 6.95% ID/g. In conclusion, received results suggest 188Re-nanoporous composites can be promising radionuclide delivery systems for cancer treatment.

  11. Evaluating the potential of a new isotope-labelled glyco-ligand for estimating the remnant liver function of schistosoma-infected mice.

    Science.gov (United States)

    Cheng, P-C; Chiang, P-F; Lee, K-M; Yeh, C-H; Hsu, K-L; Liu, S-W; Shen, L-H; Peng, C-L; Fan, C-K; Luo, T-Y

    2013-01-01

    A new glyco-derivative compound (OCTAM) was developed and labelled with isotope to form (188) Re-OCTAM as a candidate nuclear medicine imaging agent for testing the liver function. We evaluated the potential of isotope-labelled OCTAM for estimating the remnant liver function in vitro and in vivo schistosoma-infected mice. The affinity of OCTAM to liver asialoglycoprotein receptors (ASGPR) was assessed by competitive inhibition assay in vitro. In vivo assessments were performed to score the remnant liver function in mice at different schistosomal infection stages. OCTAM binds specifically to ASGPR and showed competitive inhibition of anti-ASGPR antibody binding to hepatocytes, and was higher than that of other galactosyl ligands. Micro-SPECT/CT images of uninfected mice revealed strong liver uptake. Quantified serial images of mice infected for 9, 12 and 18 weeks showed delayed liver uptake, and the retention of uptake was inversely correlated with stage and grade of schistosoma infection. Pathological and biochemical analysis demonstrated that gradually accumulating liver injury caused by infection significantly influenced uptake of (188) Re-OCTAM. Hepatic ASGPR expression diminished only in the chronic infection stage. This study demonstrated that the isotope-labelled OCTAM could accumulate in the liver, might have potential as an imaging agent for in vivo hepatic function evaluation of schistosomiasis.

  12. Preparation and biodistribution of 186,188Re—HEDP for bone tumor therapy

    Institute of Scientific and Technical Information of China (English)

    罗顺忠; 谯健; 等

    1996-01-01

    Radionuclides186,188Re,suitable for tumor therapy and with high specific activity,are prepared through irradiating natural metallic rhenium,instead of costly enriched target,Complexation of rhenium with HEDP(1-hydroxy ethylidene diphosphonate)is mainly dependent on pH values and the reductant concentrations in the medium,and the yield is not less than 0.95 in pH2.0-4.0 and SnⅡconcentration of 0.012-0.018mol/L.The 186,188ReHEDP complex has high stability in vitro and in vivo in the presence of protecting agent,and gives superior biological properties in small animals,similar to those of 153Sm-EDTMP including faster blood clearance,lower soft tissue residue and higher skeletal uptake with the peak of 0.2576 ID/g at 1h post injection(overseas report 0.0101 ID/g)comparable to that of 153m-EDTMP(0.2644ID/g) at 3h post injection.

  13. MOLECULAR ANALYSIS OF RADIATION-INDUCED MUTATION IN EXON 7/8 OF RAT HPRT GENE

    Institute of Scientific and Technical Information of China (English)

    任晓庆; 黄定九; 黄钢; 王利民

    2003-01-01

    Objective To investigate the relationship between the radiation dose and the HPRT gene locus mutation in rat smooth muscle cells, and provide the molecular basis for prevention of restenosis after percutaneous transluminal coronary angioplasty (PTCA).MethodsThe smooth muscle cells cultured in vitro were irradiated by radionuclide 188Re in different doses. HPRT gene mutation colonies were selected and isolated by 6 thioguanine. Analysis of mutation in exon 7/8 of HPRT gene were accomplished by polymerase chain reaction and single strand conformation polymorphism.ResultsThe HPRT gene mutation frequency of rat smooth muscle cells that were irradiated by radionuclide 188Re ranged from 5.5×10-6 to 13×10-6. Of 91 HPRT gene mutation colonies, 13(14.3%) contained exon 7/8 deletion and 15(16.5%) had point mutation. The exon 7/8 mutation frequency was 30.8%. There were significant relationships between radiation dose and mutation frequency of HPRT gene and exon 7/8.ConclusionThe DNA damage and gene mutation induced by radiation has positive relationship with radiation dose, and is a basis of proliferation inhibition and apoptosis of smooth muscle cells.

  14. Therapeutic radionuclides in nuclear medicine:current and future prospects%核医学放射性核素治疗的研究现状及前景

    Institute of Scientific and Technical Information of China (English)

    Chai-Hong YEONG; Mu-hua CHENG; Kwan-Hoong NG

    2014-01-01

    本文目的:本文综述了临床常用的放射性治疗方式和应用现状以及新的放射性核素从科研至临床应用所存在的问题。  本文概放射性核素的临床应用及研究已历数十载,已有碘-131、磷-32、锶-90及钇-90等众多放射性核素被成功用于治疗良恶性疾病。随着新的放射性核素及药物不断应用于骨转移瘤疼痛治疗、神经内分泌肿瘤及其他良恶性肿瘤治疗,放射性核素治疗得到了快速发展。目前,放射性核素治疗已进入蓬勃发展期;在亚洲,由于甲状腺和肝脏肿瘤的高发病率,促进了放射性核素治疗及其靶向治疗研究的日益发展。随着放射性核素与其他药物的联合应用,放射性核素治疗肿瘤的临床价值必将显著提高。%The potential use of radionuclides in therapy has been recognized for many decades. A number of ra-dionuclides, such as iodine-131 (131I), phosphorous-32 (32P), strontium-90 (90Sr), and yttrium-90 (90Y), have been used successfully for the treatment of many benign and malignant disorders. Recently, the rapid growth of this branch of nuclear medicine has been stimulated by the introduction of a number of new radionuclides and radiopharmaceuticals for the treatment of metastatic bone pain and neuroendocrine and other malignant or non-malignant tumours. Today, the field of radionuclide therapy is enjoying an exciting phase and is poised for greater growth and development in the coming years. For example, in Asia, the high prevalence of thyroid and liver diseases has prompted many novel de-velopments and clinical trials using targeted radionuclide therapy. This paper reviews the characteristics and clinical applications of the commonly available therapeutic radionuclides, as well as the problems and issues involved in translating novel radionuclides into clinical therapies.

  15. Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases: A Single Institution Experience

    Directory of Open Access Journals (Sweden)

    Gary W. Nace

    2011-01-01

    Full Text Available Purpose. We sought to evaluate our experience using yttrium-90 (90Y resin microsphere hepatic radioembolization as salvage therapy for liver-dominant metastatic colorectal cancer (mCRC. Methods. A retrospective review of consecutive patients with unresectable mCRC who were treated with 90Y after failing first and second line systemic chemotherapy. Demographics, treatment dose, biochemical and radiographic response, toxicities, and survival were examined. Results. Fifty-one patients underwent 90Y treatments of which 69% were male. All patients had previously undergone extensive chemotherapy, 31% had undergone previous liver-directed therapy and 24% had a prior liver resection. Using RECIST criteria, either stable disease or a partial response was seen in 77% of patients. Overall median survival from the time of first 90Y treatment was 10.2 months (95% CI = 7.5–13.0. The absence of extrahepatic disease at the time of treatment with 90Y was associated with an improved survival, median survival of 17.0 months (95% CI = 6.4–27.6, compared to those with extrahepatic disease at the time of treatment with 90Y, 6.7 months (95% CI = 2.7–10.6 Conclusion: 90Y therapy is a safe locoregional therapy that provides an important therapeutic option to patients who have failed first and second line chemotherapy and have adequate liver function and performance status.

  16. Decrease of survivin, p53 and Bcl-2 expression in chemorefractory colorectal liver metastases may be predictive of radiosensivity radiosensivity after radioembolization with yttrium-90 resin microspheres.

    Science.gov (United States)

    Melucci, Elisa; Cosimelli, Maurizio; Carpanese, Livio; Pizzi, Giuseppe; Izzo, Francesco; Fiore, Francesco; Golfieri, Rita; Giampalma, Emanuela; Sperduti, Isabella; Ercolani, Cristiana; Sciuto, Rosa; Mancini, Raffaello; Garufi, Carlo; Diodoro, Maria Grazia; Mottolese, Marcella

    2013-03-06

    In a prospective multicenter phase II trial of radioembolization with yttrium-90 ((90)Y-RE) in chemorefractory liver-dominant metastatic colorectal cancer (mCRC), we showed that median survival was 12.6 months (95% CI 7.0-18.3) with 48% of 50 patients achieving disease control. In this extension retrospective study, we analyzed whether a panel of biomarkers, known to be associated to an adverse clinical outcome, underwent variations in CRC liver metastases pre and post (90)Y-RE.Of the 50 patients included in the study, 29 pre-(90)Y-RE therapy and 15 post-(90)Y-RE had liver biopsy specimens available. In these series we investigated survivin, p53, Bcl-2 and Ki-67 expression pre- and post-(90)Y-RE by immuhistochemistry (IHC). Our findings evidenced a decrease of survivin (77% vs 33%), p53 (93% vs 73%), Bcl-2 (37% vs 26%) expression as well as of Ki-67 proliferation index (62.5% vs 40%) on liver biopsies collected post-(90)Y-RE as compared to pre-(90)Y-RE. In the subset of 13 matched liver metastases we further confirmed the reduction of survivin (92.3% vs 53.8%; p = 0.06), p53 (100% vs 69.2%; p = 0.05) and Bcl-2 (69.2% vs 53.8%; p = 0.05) expression post-(90)Y-RE. This biomarker modulation was accompanied by morphological changes as steatohepatitis, hepatocyte necrosis, collagen deposition, proliferating and/or bile duct ectasia, focal sinusoidal dilatation and fibrosis.Although our analysis was conducted in a very limited number cases, these changes appear strictly related to the response to (90)Y-RE therapy and may deserve further investigation on a larger series of patients.

  17. Collimator and energy window optimization for ⁹⁰Y bremsstrahlung SPECT imaging: A SIMIND Monte Carlo study.

    Science.gov (United States)

    Roshan, Hoda Rezaei; Mahmoudian, Babak; Gharepapagh, Esmaeil; Azarm, Ahmadreza; Islamian, Jalil Pirayesh

    2016-02-01

    Treatment efficacy of radioembolization using Yttrium-90 ((90)Y) microspheres is assessed by the (90)Y bremsstrahlung single photon emission computed tomography (SPECT) imaging following radioembolization. The radioisotopic image has the potential of providing reliable activity map of (90)Y microspheres distribution. One of the main reasons of the poor image quality in (90)Y bremsstrahlung SPECT imaging is the continuous and broad energy spectrum of the related bremsstrahlung photons. Furthermore, collimator geometry plays an impressive role in the spatial resolution, sensitivity and image contrast. Due to the relatively poor quality of the (90)Y bremsstrahlung SPECT images, we intend to optimize the medium-energy (ME) parallel-hole collimator and energy window. The Siemens e.cam gamma camera equipped with a ME collimator and a voxelized phantom was simulated by the SImulating Medical Imaging Nuclear Detectors (SIMIND) program. We used the SIMIND Monte Carlo program to generate the (90)Y bremsstrahlung SPECT projection of the digital Jaszczak phantom. The phantom consist of the six hot spheres ranging from 9.5 to 31.8mm in diameter, which are used to evaluate the image contrast. In order to assess the effect of the energy window on the image contrast, three energy windows ranging from 60 to 160 KeV, 160 to 400 KeV, and 60 to 400 KeV were set on a (90)Y bremsstrahlung spectrum. As well, the effect of the hole diameter of a ME collimator on the image contrast and bremsstrahlung spectrum were investigated. For the fixed collimator and septa thickness values (3.28 cm and 1.14 mm, respectively), a hole diameter range (2.35-3.3mm) was chosen based on the appropriate balance between the spatial resolution and sensitivity. The optimal energy window for (90)Y bremsstrahlung SPECT imaging was extended energy window from 60 to 400 KeV. Besides, The optimal value of the hole diameter of ME collimator was obtained 3.3mm. Geometry of the ME parallel-hole collimator and energy

  18. Non-target activity detection by post-radioembolization yttrium-90 PET/CT: Image assessment technique and case examples

    Directory of Open Access Journals (Sweden)

    Yung Hsiang eKao

    2014-02-01

    Full Text Available High-resolution yttrium-90 (90Y imaging of post-radioembolization microsphere biodistribution may be achieved by conventional positron emission tomography with integrated computed tomography (PET/CT scanners that have time-of-flight capability. However, reconstructed 90Y PET/CT images have high background noise, making non-target activity detection technically challenging. This educational article describes our image assessment technique for non-target activity detection by 90Y PET/CT which qualitatively overcomes the problem of background noise. We present selected case examples of non-target activity in untargeted liver, stomach, gallbladder, chest wall and kidney, supported by angiography and 90Y bremsstrahlung single photon emission computed tomography with integrated computed tomography (SPECT/CT or technetium-99m macroaggregated albumin SPECT/CT.

  19. Chemoembolic Hepatopulmonary Shunt Reduction to Allow Safe Yttrium-90 Radioembolization Lobectomy of Hepatocellular Carcinoma

    Energy Technology Data Exchange (ETDEWEB)

    Gaba, Ron C., E-mail: rgaba@uic.edu [University of Illinois Medical Center at Chicago, Department of Radiology, Section in Interventional Radiology (United States); VanMiddlesworth, Kyle A. [Midwestern University School of Medicine (United States)

    2012-12-15

    Yttrium-90 ({sup 90}Y) radioembolization represents an emerging transcatheter treatment option for the management of hepatocellular carcinoma (HCC). Elevation of the hepatopulmonary shunt fraction risks nontarget radiation to the lungs and may limit the use of {sup 90}Y therapy in patients with locally advanced disease with vascular invasion, who often demonstrate increased shunting. We present two cases in which patients with HCC and portal vein invasion resulting in elevated hepatopulmonary shunt fractions underwent chemoembolic shunt closure to allow safe {sup 90}Y radioembolization. Both patients demonstrated excellent tumor response and patient survival. On this basis, we propose a role for chemoembolic reduction of the lung shunt fraction before {sup 90}Y radioembolization in patients with extensive tumor-related hepatopulmonary shunting.

  20. Non-Target Activity Detection by Post-Radioembolization Yttrium-90 PET/CT: Image Assessment Technique and Case Examples.

    Science.gov (United States)

    Kao, Yung Hsiang; Tan, Andrew E H; Lo, Richard H G; Tay, Kiang Hiong; Tan, Bien Soo; Chow, Pierce K H; Ng, David C E; Goh, Anthony S W

    2014-01-01

    High resolution yttrium-90 ((90)Y) imaging of post-radioembolization microsphere biodistribution may be achieved by conventional positron emission tomography with integrated computed tomography (PET/CT) scanners that have time-of-flight capability. However, reconstructed (90)Y PET/CT images have high background noise, making non-target activity detection technically challenging. This educational article describes our image assessment technique for non-target activity detection by (90)Y PET/CT, which qualitatively overcomes the problem of background noise. We present selected case examples of non-target activity in untargeted liver, stomach, gallbladder, chest wall, and kidney, supported by angiography and (90)Y bremsstrahlung single-photon emission computed tomography with integrated computed tomography (SPECT/CT) or technetium-99m macroaggregated albumin SPECT/CT.

  1. Targeted bone marrow irradiation in the conditioning of high-risk leukaemia prior to stem cell transplantation

    Energy Technology Data Exchange (ETDEWEB)

    Reske, S.N.; Buchmann, I.; Seitz, U.; Glatting, G.; Neumaier, B.; Kotzerke, J.; Buck, A. [Ulm Univ. (Germany). Abt. Nuklearmedizin; Bunjes, D.; Doehner, H. [Abteilung Innere Medizin III, Haematologie und Onkologie, Universitaetsklinikum Ulm (Germany); Martin, H.; Bergmann, L. [Klinik fuer Haematologie und Onkologie, Johann-Wolfgang-Goethe Universitaet Frankfurt (Germany)

    2001-07-01

    Disease recurrence following stem cell transplantation (SCT) remains a major problem. Despite the sensitivity of leukaemias to chemotherapy and irradiation, conventional conditioning before SCT is limited by significant organ toxicity. Targeted irradiation of bone marrow and spleen by radioimmunotherapy may provide considerable dose escalation, with limited toxicity to non-target organs. In this study, 27 patients with high-risk or relapsing leukaemia were treated with rhenium-188-labelled CD66a,b,c,e radioimmunoconjugates ({sup 188}Re-mAb) specific for normal bone marrow in addition to conventional conditioning with high-dose chemotherapy and 12 Gy total body irradiation prior to SCT. A mean activity of 10.2{+-}2.1 (range 6.9-15.8) GBq {sup 188}Re-mAb was administered intravenously. Acute side-effects were assessed according to the CTC classification and patient outcome was determined. Mean radiation doses (Gy; range in parentheses) to relevant organs and whole body were as follows: 13.1 (6.5-22) to bone marrow, 11.6 (1.7-31.1) to spleen, 5.0 (2.0-11.7) to liver, 7.0 (2.3-11.6) to kidneys, 0.7 (0.3-1.3) to lungs and 1.4 (0.8-2.1) to the whole body. Stem cells engrafted in all patients within 9-18 days post SCT. Acute organ toxicity of grade II or less was observed. During follow-up for 25.4{+-}5.3 (range 18-34) months, 4/27 (15%) patients died from relapse, and 9/27 (33%) from transplantation-related complications. Fourteen patients (52%) are still alive and in ongoing complete clinical remission. Radioimmunotherapy with the bone marrow-seeking {sup 188}Re-labelled CD66 mAb can double the dose to bone marrow and spleen without undue extramedullary acute organ toxicity, when given in addition to high-dose chemotherapy and 12 Gy TBI before allogeneic SCT. This intensified conditioning regimen may reduce the relapse rate of high-risk leukaemia. (orig.)

  2. Biokinetics and dosimetry of target-specific radiopharmaceuticals for molecular imaging and therapy

    Energy Technology Data Exchange (ETDEWEB)

    Ferro F, G.; Torres G, E. [ININ, 52045 Ocoyoacac, Estado de Mexico (Mexico); Gonzalez V, A. [UAEM, Facultad de Medicina, Toluca (Mexico); Murphy, C.A. de [INCMNSZ, Mexico D.F. (Mexico)

    2006-07-01

    Molecular imaging techniques directly or indirectly monitor and record the spatiotemporal distribution of molecular or cellular processes for biochemical, biologic, diagnostic or therapeutic applications. {sup 99m}Tc-HYNlC-TOC has shown high in vitro and in vivo stability, rapid background clearance and rapid detection of somatostatin receptor-positive tumors. Therapies using radiolabeled anti-CD20 have demonstrated their efficacy in patients with B-cell non Hodgkin's Iymphoma (NHL). The aim of this study was to establish biokinetic models for {sup 99m}Tc-HYNlC-TOC and {sup 188}Re-anti-CD20 prepared from Iyophilized kits, and to evaluate their dosimetry as target-specific radiopharmaceuticals. Whole-body images were acquired at different times after {sup 99m}Tc-HYNlC-TOC or {sup 188}Re-anti-CD20 administration obtained from instant freeze-dried kit formulations with radiochemical purities > 95 %. Regions of interest (ROls) were drawn around source organs on each time frame. The cpm of each ROI was converted to activity using the conjugate view counting method. The image sequence was used to extrapolate time-activity curves in each organ, to adjust the biokinetic model using the SAAM software, and to calculate the total number of disintegrations (N) that occurred in the source regions. N data were the input for the OLINDA/EXM code to calculate internal radiation dose estimates. {sup 99m}Tc-HYNlC-TOC images showed an average tumor/blood (heart) ratio of 4.3 {+-} 0.7 in receptor-positive tumors at 1 h and the mean radiation absorbed dose calculated for a study using 740 MBq was 24, 21.5, 5.5 and 1.0 mSv for spleen, kidneys, liver and bone marrow respectively and the effective dose was 4.4 mSv. Results showed that after administration of 7 GBq of {sup 188}Re-anti-CD20 the absorbed dose to whole body would be 0.7 Gy (0.1 mGy/MBq) which is the indicated dose for non Hodgkin's Iymphome therapies. (Author)

  3. Melanoma Therapy with Rhenium-Cyclized Alpha Melanocyte Stimulating Hormone Peptide Analogs

    Energy Technology Data Exchange (ETDEWEB)

    Thomas P Quinn

    2005-11-22

    Malignant melanoma is the 6th most commonly diagnosed cancer with increasing incidence in the United States. It is estimated that 54,200 cases of malignant melanoma will be newly diagnosed and 7,600 cases of death will occur in the United States in the year 2003 (1). At the present time, more than 1.3% of Americans will develop malignant melanoma during their lifetime (2). The average survival for patients with metastatic melanoma is about 6-9 months (3). Moreover, metastatic melanoma deposits are resistant to conventional chemotherapy and external beam radiation therapy (3). Systematic chemotherapy is the primary therapeutic approach to treat patients with metastatic melanoma. Dacarbazine is the only single chemotherapy agent approved by FDA for metastatic melanoma treatment (5). However, the response rate to Dacarbazine is only approximately 20% (6). Therefore, there is a great need to develop novel treatment approaches for metastatic melanoma. The global goal of this research program is the rational design, characterization and validation of melanoma imaging and therapeutic radiopharmaceuticals. Significant progress has been made in the design and characterization of metal-cyclized radiolabeled alpha-melanocyte stimulating hormone peptides. Therapy studies with {sup 188}Re-CCMSH demonstrated the therapeutic efficacy of the receptor-targeted treatment in murine and human melanoma bearing mice (previous progress report). Dosimetry calculations, based on biodistribution data, indicated that a significant dose was delivered to the tumor. However, {sup 188}Re is a very energetic beta-particle emitter. The longer-range beta-particles theoretically would be better for larger tumors. In the treatment of melanoma, the larger primary tumor is usually surgically removed leaving metastatic disease as the focus of targeted radiotherapy. Isotopes with lower beta-energies and/or shorter particle lengths should be better suited for targeting metastases. The {sup 177}Lu

  4. Yttrium-90 Radioembolization of Hepatocellular Carcinoma-Performance, Technical Advances, and Future Concepts.

    Science.gov (United States)

    Molvar, Christopher; Lewandowski, Robert

    2015-12-01

    Hepatocellular carcinoma (HCC) is a lethal tumor, claiming over half a million lives per year. Treatment of HCC is commonly performed without curative intent, and palliative options dominate, including catheter-based therapies, namely, transarterial chemoembolization and yttrium-90 ((90)Y) radioembolization. This review will showcase the performance of (90)Y radioembolization for the treatment of HCC, focusing on recent seminal data and technical advances. In particular, novel radioembolization treatment concepts are discussed and compared with conventional HCC therapy.

  5. Yttrium-90 labeled monoclonal antibody as a potential agent for radioimmunotherapy

    Energy Technology Data Exchange (ETDEWEB)

    Doherty, P.W.; Hnatowich, D.

    1984-01-01

    The features that make /sup 90/Y an attractive candidate are: It is available as a generator (/sup 90/Sr-/sup 90/Y). It is a pure beta emitter (0.93 MeV); has a half-life of 2.7 days and is a metal ion which forms complexes with DTPA. Using an anti-CEA antibody (C-19) and DTPA (cyclic anhydride), the authors evaluated the labeling parameters, in vitro and in vivo stability, and functional integrity of the /sup 90/Y labeled C-19. The results were compared to those obtained with /sup 111/In labeled to the same antibody. Quality control showed that the /sup 90/Y complexed with free DTPA at a concentration necessary for protein labeling. Using a DTPA: antibody molar ratio of 2.5:1, a specific activity of 5..mu..Ci/1..mu..g of protein was achieved. There was no nonspecific protein binding. Affinity chromotography and HPLC analysis showed a dissociation of 15% of the /sup 90/Y from the C-19 over 72 hours in serum with preservation of functional integrity and without evidence for radiolysis. Binding to Lovo cells (known to have CEA on their surface) showed saturation kinetics. In vivo biodistribution in mice showed identical values for the /sup 90/Y and /sup 111/In labeled C-19 at 1 hour. At 24 hours, there was less kidney and liver uptake and more bone uptake in the case of /sup 90/Y. The authors conclude DTPA coupled antibodies can be stably labeled with /sup 90/Y at a specific activity appropriate for Radiotherapy.

  6. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis

    Energy Technology Data Exchange (ETDEWEB)

    Vente, M.A.D.; Wondergem, M.; Bosch, M.A.A.J. van den; Lam, M.G.E.H.; Schip, A.D. van het; Nijsen, J.F.W. [University Medical Center Utrecht, Department of Radiology and Nuclear Medicine, Utrecht (Netherlands); Tweel, I. van der [Utrecht University, Centre for Biostatistics, Utrecht (Netherlands); Zonnenberg, B.A. [University Medical Center Utrecht, Department of Internal Medicine, Utrecht (Netherlands)

    2009-04-15

    Radioembolization with yttrium-90 microspheres ({sup 90}Y-RE), either glass- or resin-based, is increasingly applied in patients with unresectable liver malignancies. Clinical results are promising but overall response and survival are not yet known. Therefore a meta-analysis on tumor response and survival in patients who underwent {sup 90}Y-RE was conducted. Based on an extensive literature search, six groups were formed. Determinants were cancer type, microsphere type, chemotherapy protocol used, and stage (deployment in first-line or as salvage therapy). For colorectal liver metastases (mCRC), in a salvage setting, response was 79% for {sup 90}Y-RE combined with 5-fluorouracil/leucovorin (5-FU/LV), and 79% when combined with 5-FU/LV/oxaliplatin or 5-FU/LV/irinotecan, and in a first-line setting 91% and 91%, respectively. For hepatocellular carcinoma (HCC), response was 89% for resin microspheres and 78% for glass microspheres. No statistical method is available to assess median survival based on data presented in the literature. In mCRC, {sup 90}Y-RE delivers high response rates, especially if used neoadjuvant to chemotherapy. In HCC, {sup 90}Y-RE with resin microspheres is significantly more effective than {sup 90}Y-RE with glass microspheres. The impact on survival will become known only when the results of phase III studies are published. (orig.)

  7. Comparison of yttrium-90 quantitative imaging by TOF and non-TOF PET in a phantom of liver selective internal radiotherapy

    Energy Technology Data Exchange (ETDEWEB)

    Van Elmbt, Larry; Walrand, Stephan; Pauwels, Stanislas; Jamar, Francois [Department of Nuclear Medicine, Universite Catholique de Louvain, Brussels (Belgium); Vandenberghe, Stefaan, E-mail: Larry.vanElmbt@uclouvain.be [MEDISIP Research Group ELIS-IBITECH, University Hospital Ghent, Ghent University, Ghent (Belgium)

    2011-11-07

    The aim of this study is to determine the feasibility of achieving quantitative measurement in {sup 90}Y-microspheres liver selective internal radiotherapy (SIRT) by imaging {sup 90}Y with a conventional non-time of flight (TOF) PET device. Instead of the bremsstrahlung x-rays of the {beta}-decay, the low branch of e{sup -}- e{sup +} pair production in the {sup 90}Y-decay was used. The activity distribution in a phantom-simulated liver SIRT was obtained by direct {sup 90}Y-PET imaging. We tested a LYSO TOF PET and two GSO and BGO non-TOF PET scanners using a 3.6-l cylindrical phantom filled with the {sup 90}Y solution containing two sets of hot and cold spheres. The best hot contrast was obtained with the LYSO TOF. It was close to the expected value and remained constant, even for short acquisition times. The LYSO non-TOF was about 10% lower. The GSO performed similarly but degraded for shorter times whilst the BGO was the worst with 40% loss. For the cold spheres, the LYSO TOF and the GSO provided the best results, while the LYSO non-TOF and the BGO were the worst. {sup 90}Y PET imaging in liver SIRT is achievable with LYSO TOF. Conventional LYSO and GSO show a loss of contrast and require longer acquisition times. BGO imaging is not feasible for dosimetry calculation.

  8. [Advances in research on radioiodine therapy of carcinoma mediated by gene transfer technology].

    Science.gov (United States)

    Mu, Da; Kuang, Anren

    2010-10-01

    Radioiodine therapy of carcinoma could be mediated by transferring the genes which participate in the process of iodine metabolism in thyroid. The correlative genes are sodium/iodine symporter gene, thyroid peroxidase gene and the specific thyroid transcription factors, and others. The objective gene can specifically express in carcinoma by inserting the tissue-specific promoter/enhancer upstream of them, so radioiodine could be used to treat varied carcinomas. The radioiodine uptake in carcinoma cells was obviously increased and the radioiodine therapy of carcinoma was effective after those genes had expressed in carcinoma cells. The main problem was that the effective half-time of radioiodine in cells was too short to produce the ideal effect of radioiodine therapy. Moreover, 211At and 188Re could be transferred by sodium/iodine symporter and they could be used to treat the carcinoma that is capable of radioiodine uptake.

  9. Production of tungsten-188 and osmium-194 in a nuclear reactor for new clinical generators

    Energy Technology Data Exchange (ETDEWEB)

    Mirzadeh, S.; Knapp, F.F. Jr.; Callahan, A.P.

    1991-01-01

    Rhenium-188 and iridium-194 are potential candidates for radioimmunotherapy with monoclonal antibodies directed against tumor-associated antigens. Both nuclei are short-lived and decay by high energy {Beta}{minus} emission. In addition, both nuclei emit {gamma}-rays with energy suitable for imaging. An important characteristics is availability of {sup 188}Re and {sup 194}Ir from decay of reactor-produced parents ({sup 188}W and {sup 194}Os, respectively) in convenient generator systems. The {sup 188}W and {sup 194}Os are produced by double neutron capture of {sup 186}W and {sup 192}Os, respectively. The large scale production yields of {sup 188}W in several nuclear reactors will be presented. We also report a new management for the cross-section of {sup 193}Os(n,{gamma}){sup 194}Os reaction and discuss the feasibility of producing sufficient quantities of {sup 194}Os. 17 refs., 1 fig., 2 tabs.

  10. A phase I study of combined docetaxel and repeated high activity {sup 186}Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial)

    Energy Technology Data Exchange (ETDEWEB)

    Dodewaard-de Jong, Joyce M. van; Bloemendal, Haiko J. [Meander Medical Centre, Department of Internal Medicine, Amersfoort (Netherlands); Klerk, John M.H. de; Haas, Marie J. de [Meander Medical Centre, Department of Nuclear Medicine, Amersfoort (Netherlands); Bezooijen, Bart P.J. van [Meander Medical Centre, Department of Urology, Amersfoort (Netherlands); Wilson, Richard H.; O' Sullivan, Joe M. [Queen' s University Belfast, Centre for Cancer Research and Cell Biology, Belfast, N. Ireland (United Kingdom)

    2011-11-15

    Bone-seeking radiopharmaceuticals have palliative benefit in castration-resistant prostate cancer (CRPC) metastatic to bone. Recent studies have shown improvement of survival and quality of life when radiopharmaceuticals were given repeatedly or in combination with chemotherapy. We designed a phase I study combining docetaxel and {sup 186}Re-labelled hydroxyethylidene diphosphonate (HEDP) in men with CRPC and bone metastases to evaluate toxicity. A dose escalation schedule was designed consisting of four dose levels with a standard dosage of docetaxel (75 mg/m{sup 2} 3-weekly). {sup 186}Re-HEDP was given in increasing activities (1,250 MBq up to 2,500 MBq) after the third and sixth cycle of docetaxel. Dose limiting toxicity (DLT) was defined as any grade 4 toxicity lasting more than 7 days or any grade 3 toxicity that did not recover within 10 days. Three patients were planned for each dose level expanding to six if a DLT occurred. Fourteen patients were recruited with a median age of 64.6 years. One DLT, grade 3 thrombocytopenia lasting >10 days, occurred at dose level 3 leading to expansion of this group to six. One of these patients had an episode of acute renal failure which resolved. Because of production problems of {sup 186}Re-HEDP dose level 4 was not started. Combined therapy with docetaxel and {sup 186}Re-HEDP is generally well tolerated in patients with CRPC metastatic to bone. We will conduct a randomized phase II study using three cycles of docetaxel 75 mg/m{sup 2} 3-weekly followed by {sup 188}Re-HEDP 40 MBq/kg body weight, followed by another three cycles of docetaxel 75 mg/m{sup 2}, followed by {sup 188}Re-HEDP 20 MBq/kg body weight. (orig.)

  11. {sup 99m}Tc-SSS lipiodol: development and study of its biodistribution following injection intra-hepatic artery of healthy pigs; {sup 99m}Tc-SSS lipiodol: mise au point du marquage et biodistribution apres injection au niveau de l'artere hepatique du porc

    Energy Technology Data Exchange (ETDEWEB)

    Garin, E.; Dazord, L.; Moisan, A.; Lecloirec, J.; Herry, J.Y.; Bourguet, P. [Centre Eugene-Marquis, UPRES EA 1794, Service de Medecine Nucleaire, 35 - Rennes (France); Noiret, N.; Lepareur, N.; Roucoux, A. [Ecole Nationale Superieure de Chimie, UMR CNRS 6052, 35 - Rennes (France); Malbert, C. [Institut National de Recherches Agronomiques (INRA/UMR VP), 35 - Saint Gilles (France); Caulet-Maugendre, S.; Turlin, B. [Centre Hospitalier Universitaire Pontchaillou, Service d' Anatomopathologie, 35 - Rennes (France); Tribut, O. [Centre Hospitalier Universitaire Pontchaillou, Service de Pharmacologie Clinique, 35 - Rennes (France)

    2003-12-01

    Aims. Intra-arterial metabolic radiotherapy with {sup 131}I-lipiodol is a therapeutic approach witch can be used for hepatocellular carcinoma, but several drawbacks limit its use. We report here the development of lipiodol labelling with {sup 99m}Tc and its biodistribution after infusion in the hepatic artery in healthy pigs. In fact, labelling lipiodol with {sup 99m}Tc is the first step towards the development of labelling Lipiodol with {sup 188}Re and {sup 99m}Tc lipiodol could be used for dosimetric purpose. Method. The {sup 99m}Tc lipiodol is obtained after dissolving in lipiodol a lipophilic chelating agent labelled with {sup 99m}Tc: the {sup 99m}Tc-(PhCS3)2(PhCS2). The radiochemical purity was assessed immediately after the labelling and 24 hours later. {sup 99m}Tc-lipiodol was injected through the hepatic artery in 7 pigs. Scintigraphic acquisitions were performed 1 and 24 hours after injection. Pigs were killed after 1 or 24 hours for removal of organs and in vitro counting. Results. The labelling of lipiodol with {sup 99m}Tc is achieved with a very high yield, 96 {+-} 0,8%. The radiochemical purity is satisfactory: 92 {+-} 2,6% immediately after labelling and at least 88 {+-} 3,5% at 24 hours. Scintigraphic acquisitions showed a predominant liver uptake and a faint lung uptake without other site of uptake at one hour and the apparition of a faint digestive elimination at 24 hours. Those results are confirmed by ex-vivo counting. Conclusion. This preliminary study point out that labelling lipiodol with {sup 99m}Tc can be performed with a good yield and a good radiochemical purity. It's biodistribution in healthy pigs is satisfactory. Labelling lipiodol with {sup 188}Re is now under development with the same chelating agent. (author)

  12. Effect of Temperature and Mole Ratio on the Synthesis Yield of Rhenium-Tetrofosmin

    Directory of Open Access Journals (Sweden)

    Widyastuti

    2015-08-01

    Full Text Available Technetium-99m (99mTc tetrofosmin is widely used in nuclear medicine as a diagnostic agent for myocardial perfusion and as a tumor imaging agent. As a parenteral preparation it requires an evaluation of its pharmacokinetics and stability in-vivo. Since 99mTc has a short half-life and is only available in very low concentrations, it is impossible to characterize its chemical properties and presence in the body. Due to this reason, only technetium-99 (T1/2 = 5 × 105 years, which is available in macro quantities, or natural rhenium can be used for this purpose. In this study rhenium-188 (188Re tetrofosmin will be synthesized and applied, because non-radioactive Re can be easily obtained. Synthesis and radiochemical purity analysis of carrier-added 188Re-tetrofosmin were carried out as a model to study the in-vivo stability of technetium-99m tetrofosmin. Rhenium-188 was used as a tracer to identify the formation of rhenium tetrofosmin. Rhenium gluconate was synthesized first prior to the formation of rhenium tetrofosmin. The quality of labeling for both rhenium gluconate and rhenium tetrofosmin was analyzed using paper- and thin-layer chromatography, respectively. Rhenium gluconate can be synthesized with high labeling yield within 1 hour, whereas rhenium tetrofosmin was synthesized both in room temperature and in an elevated temperature with various tetrofosmin-to-rhenium mole ratios.The results showed that heating at 95oC led to a higher yield of more than 90% within 30 minutes. Rhenium tetrofosmin could be produced in high radiochemical purity using an excess of tetrofosmin with mole ratio of 2000. It is concluded that rhenium tetrofosmin could be synthesized through the formation of rhenium gluconate, and a higher yield could be obtained in a shorter time by heating process.

  13. The in vivo phosphorylation sites in multiple isoforms of amphiphysin I from rat brain nerve terminals

    DEFF Research Database (Denmark)

    Craft, George E; Graham, Mark E; Bache, Nicolai;

    2008-01-01

    -proline-directed kinases, Ser-626, -250, -252, and -539, contained low amounts of 32P and were not depolarization-responsive. At least one alternatively spliced amphI isoform was identified in synaptosomes as being constitutively phosphorylated because it did not incorporate 32P during the 1-h labeling period. Multiple......, incorporating 16 and 23% of the 32P. The multiple phosphopeptides containing Ser-268, Ser-276, Ser-272, and Ser-285 had 27% of the 32P. Evidence for a role for at least one proline-directed protein kinase and one non-proline-directed kinase was obtained. Four phosphosites predicted for non...

  14. Phosphorylation of acidic ribosomal proteins from rabbit reticulocytes by a ribosome-associated casein kinase

    DEFF Research Database (Denmark)

    Issinger, O G

    1977-01-01

    Two acidic proteins from 80-S ribosomes were isolated and purified to homogeneity. The purified acidic proteins could be phosphorylated by casein kinase using [gamma-32P]ATP and [gamma-32P]GTP as a phosphoryl donor. The proteins became phosphorylated in situ, too. Sodium dodecyl sulfate polyacryl......Two acidic proteins from 80-S ribosomes were isolated and purified to homogeneity. The purified acidic proteins could be phosphorylated by casein kinase using [gamma-32P]ATP and [gamma-32P]GTP as a phosphoryl donor. The proteins became phosphorylated in situ, too. Sodium dodecyl sulfate...

  15. Preparation and in vivo evaluation of multifunctional ⁹⁰Y-labeled magnetic nanoparticles designed for cancer therapy.

    Science.gov (United States)

    Radović, Magdalena; Calatayud, María Pilar; Goya, Gerardo Fabián; Ibarra, Manuel Ricardo; Antić, Bratislav; Spasojević, Vojislav; Nikolić, Nadežda; Janković, Drina; Mirković, Marija; Vranješ-Đurić, Sanja

    2015-01-01

    Two different types of magnetic nanoparticles (MNPs) were synthesized in order to compare their efficiency as radioactive vectors, Fe₃O₄-Naked (80 ± 5 nm) and polyethylene glycol 600 diacid functionalized Fe₃O₄(Fe₃O₄-PEG600) MNPs (46 ± 0.6 nm). They were characterized based on the external morphology, size distribution, and colloidal and magnetic properties. The obtained specific power absorption value for Fe₃O₄-PEG600 MNPs was 200 W/g, indicated their potential in hyperthermia based cancer treatments. The labeling yield, in vitro stability and in vivo biodistribution profile of (90) Y-MNPs were compared. Both types of MNPs were (90)Y-labeled in reproducible high yield (>97%). The stability of the obtained radioactive nanoparticles was evaluated in saline and human serum media in order to optimize the formulations for in vivo use. The biodistribution in Wistar rats showed different pharmacokinetic behaviors of nanoparticles: a large fraction of both injected MNPs ended in the liver (14.58%ID/g for (90)Y-Fe₃O₄-Naked MNPs and 19.61%ID/g for (90)Y-Fe₃O₄-PEG600 MNPs) whereas minor fractions attained in other organs. The main difference between the two types of MNPs was the higher accumulation of (90)Y-Fe₃O₄-Naked MNPs in the lungs (12.14%ID/g vs. 2.00%ID/g for (90)Y-Fe₃O₄-PEG600 MNPs) due to their in vivo agglomeration. The studied radiolabeled magnetic complexes such as (90)Y-Fe₃O₄-PEG600 MNPs constitute a great promise for multiple diagnostic-therapeutic uses combining, for example, MRI-magnetic hyperthermia and regional radiotherapy.

  16. SIRT of liver metastases: physiological and pathophysiological considerations.

    Science.gov (United States)

    Van de Wiele, Christophe; Maes, Alex; Brugman, Eddy; D'Asseler, Yves; De Spiegeleer, Bart; Mees, Gilles; Stellamans, Karin

    2012-10-01

    Available literature on the differences in circulation and microcirculation of normal liver and liver metastases as well as in rheology of the different radiolabelled microspheres [(99m)Tc-labelled macroaggregates of albumin (MAA), (90)Y-TheraSpheres and (90)Y-SIR-spheres] used in selective internal radiation therapy (SIRT) are reviewed and implications thereof on the practice of SIRT discussed. As a result of axial accumulation and skimming, large microspheres are preferentially deposited in regions of high flow, whereas smaller microspheres are preferentially diverted to regions of low flow. As flow to normal liver tissue is considerably variable between segments and also within one segment, microspheres will be delivered heterogeneously within the microvasculature of normal liver tissue. This non-uniformity in microsphere distribution in normal liver tissue has a significant "liver-sparing" effect on the dose distribution of (90)Y-labelled microspheres. Arterial flow to liver metastases is most pronounced in the hypervascular rim of metastases, followed by the smaller metastases and finally by the central hypoperfused region of the larger metastases. Because of the wide variability in size of labelled MAAs and because of the skimming effect, existing differences in flow between metastatic lesions of variable size are likely exaggerated on (99m)Tc-MAA scintigraphy when compared to (90)Y-TheraSpheres and (90)Y-SIR-spheres (smaller variability in size and probably also in specific activity). Ideally, labelled MAAs would contain a size range similar to that of (90)Y-SIR-spheres or (90)Y-TheraSpheres. Furthermore, the optimal number of MAA particles to inject for the pretreatment planning scintigraphy warrants further exploration as it was shown that concentrated suspensions of microspheres produce more optimal tumour to normal liver distribution ratios. Finally, available data suggest that the flow-based heterogeneous distribution of microspheres to metastatic

  17. Phosphorylation of the C proteins in heterogeneous ribonucleoprotein (hnRNP) particles in HeLa cells: Characterization of in vivo phosphorylation, comparison with in vitro phosphorylation using casein kinase II, and preliminary studies on the effects of phosphorylation on particle structure

    Energy Technology Data Exchange (ETDEWEB)

    Kleiman, N.J.

    1989-01-01

    Newly formed pre-messenger RNA associates with protein to form heterogeneous ribonucleoprotein (hnRNP) particles. In HeLa cells, hnRNP particles contain six core proteins. Two proteins, termed C{sub 1} and C{sub 2}, are phosphorylated in vitro by casein kinase 11 (CKII). C{sub 1} protein became {sup 32}P-labeled after HeLa cells were incubated with ({sup 32}P)-orthophosphate in vivo (ibid). Because phosphorylation is a ubiquitous regulatory mechanism, C protein phosphorylation was studied in greater detail. C protein phosphorylation in hnRNP particles was investigated in HeLa cells incubated with ({sup 32}P)-orthophosphate in vivo. Immunoblotting in pH 3.5-10 isoelectric focusing (IEF) gels indicated that C proteins focus only at pH 5.0. In pH 4.5-5.5 IEF gels, individually purified C, and 2 proteins resolve into the same four closely spaced, {sup 32}P-labeled bands. A fifth, unlabeled, more basic species was detached when hnRNP particles were purified without NaF. All {sup 32}P-labeled species contained identical amounts of {sup 32}P per unit protein suggesting that charge heterogeneity is not due to differential phosphorylation. Attempts to detect bound carbohydrate were unsuccessful. {sup 32}P-labeled phosphate was readily removed by potato acid phosphatase. E. coli alkaline phosphatase and snake venom phosphodiesterase were ineffective. {sup 32}P-label was found exclusively in phosphoserine. One-dimensional peptide mapping with chymotrypsin and S. aureus protease detected two phosphorylated peptides. C protein phosphorylation was also investigated in vitro. Incubation of hnRNP particles with rabbit liver CKII and {sup 32}P-ATP followed by IEF in pH 4.5-5.5 gels indicated that all four C protein species were {sup 32}P-labeled. {sup 32}P-label was found exclusively in phosphoserine.

  18. Patient Selection and Activity Planning Guide for Selective Internal Radiotherapy With Yttrium-90 Resin Microspheres

    Energy Technology Data Exchange (ETDEWEB)

    Lau, Wan-Yee, E-mail: josephlau@surgery.cuhk.edu.hk [Faculty of Medicine, Chinese University of Hong Kong, Shatin, New Territories (Hong Kong); Kennedy, Andrew S. [Wake Radiology Oncology, Cary, NC (United States); Department of Biomedical Engineering, North Carolina State University, Raleigh, NC (United States); Kim, Yun Hwan [Department of Radiology, Anam Hospital, Korea University College of Medicine, Seoul (Korea, Republic of); Lai, Hee Kit [Nuclear Medicine and PET Centre, Mount Elizabeth Hospital, Singapore (Singapore); Lee, Rheun-Chuan [Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan (China); Leung, Thomas W.T. [Comprehensive Oncology Centre, Hong Kong Sanatorium and Hospital (Hong Kong); Liu, Ching-Sheng [Department of Nuclear Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (China); Salem, Riad [Division of Interventional Radiology, Northwestern University, Chicago, IL (United States); Sangro, Bruno [Liver Unit, Clinica Universitaria de Navarra and Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas, Pamplona (Spain); Shuter, Borys [Department of Diagnostic Imaging, National University Hospital, Singapore (Singapore); Wang, Shih-Chang [Parker-Hughes Professor of Diagnostic Radiology, University of Sydney, Sydney, NSW (Australia)

    2012-01-01

    Purpose: Selective internal radiotherapy (SIRT) with yttrium-90 ({sup 90}Y) resin microspheres can improve the clinical outcomes for selected patients with inoperable liver cancer. This technique involves intra-arterial delivery of {beta}-emitting microspheres into hepatocellular carcinomas or liver metastases while sparing uninvolved structures. Its unique mode of action, including both {sup 90}Y brachytherapy and embolization of neoplastic microvasculature, necessitates activity planning methods specific to SIRT. Methods and Materials: A panel of clinicians experienced in {sup 90}Y resin microsphere SIRT was convened to integrate clinical experience with the published data to propose an activity planning pathway for radioembolization. Results: Accurate planning is essential to minimize potentially fatal sequelae such as radiation-induced liver disease while delivering tumoricidal {sup 90}Y activity. Planning methods have included empiric dosing according to degree of tumor involvement, empiric dosing adjusted for the body surface area, and partition model calculations using Medical Internal Radiation Dose principles. It has been recommended that at least two of these methods be compared when calculating the microsphere activity for each patient. Conclusions: Many factors inform {sup 90}Y resin microsphere SIRT activity planning, including the therapeutic intent, tissue and vasculature imaging, tumor and uninvolved liver characteristics, previous therapies, and localization of the microsphere infusion. The influence of each of these factors has been discussed.

  19. Effects of intra-tumoral injection an anti-tumor and immunological function with phoshorus-32 glass microsphere%32P玻璃微球瘤内注射抗肿瘤作用及对免疫功能的影响

    Institute of Scientific and Technical Information of China (English)

    车嘉琳; 何子毅; 刘赴平; 孟庆勇

    2006-01-01

    目的观察32P玻璃微球(32P-GMS)的抑瘤效果及对免疫功能的影响.方法称重法检测32P-GMS对小鼠S180肉瘤的抑瘤率,脾淋巴细胞转化实验检测32P-GMS对S180肉瘤小鼠淋巴细胞转化功能的影响,观察小鼠淋巴细胞对豆刀素A(ConA)和脂多糖(LPS)的刺激增殖作用.结果32P-GMS瘤内注射抗肿瘤的抑瘤率分别为15.1%,20.3%,32.4%,模型组和32P-GMS治疗组小鼠胸腺细胞和脾淋巴细胞的免疫功能均有不同程度抑制,并随32P-GMS剂量的增大,抑制愈明显.结论 32P-GMS瘤内注射很强的抗肿瘤作用,32P-GMS照射亦可加重小鼠免疫功能抑制.

  20. Improvement of the obtention process of phosphorus-32 of the ININ through the application of nuclear analytical techniques; Perfeccionamiento del proceso de obtencion de fosforo-32 del ININ, mediante la aplicacion de tecnicas analiticas nucleares

    Energy Technology Data Exchange (ETDEWEB)

    Zepeda R, C.P. [UMSNH, Facultad de Ingenieria Quimica, Morelia, Michoacan (Mexico)

    2007-07-01

    The phosphorus-32, is radioisotope emitting pure {beta}{sup -}, of maximum energy 1.71 MeV with an average life of 14.28 days, and that has application in the industry, agriculture, medicine and biology. The {sup 32} P, produced by means of two nuclear reactions {sup 32} S(n,p){sup 32} P and {sup 31} P (n,{gamma}){sup 32} P; by the facility of handling of sulfur, his low cost and its fast acquisition in the market. I selected the reaction {sup 32} S(n,p){sup 32} P. To produce {sup 32} P it is necessary to prepare and to characterize the target (S-{alpha}) that is obtained from the purification of the raw material, make the mathematical calculations of irradiation, irradiation of the target in the nuclear reactor TRIGA Mark III, radiochemical separation of {sup 32} P of {sup 32} S by a dry distillation method and an hydrolysis of {sup 32} P with diluted HCl obtaining H{sub 3}{sup 32}PO{sub 4} and finally quality control. In the order to make the radiochemistry separation it was necessary to make previous modifications to the process guarantee the quality of product ({sup 32} P), and security of the operator. (Author)

  1. The roles of haemolymphatic lipoproteins in the oogenesis of Rhodnius prolixus

    Directory of Open Access Journals (Sweden)

    Katia Calp Gondim

    1987-01-01

    Full Text Available The fates of purified 32P-vitellin and 32P-lipophorin were followed in vitellogenic females of Rhodnius prolixus. While the radioactivity from 32P-vitellin 6 hours after injection was found almost exclusively in the ovary, the radioactivity from injected 32P-lipophorin was found distributed among several organs. In the ovary, the radioactivity from 32P-vitellin was associated with the contents of the yolk granules. 32P-lipophorin delivered a great amount of radioactive phospholipids to the ovary with no accumulation of its protein moiety, as observed after its iodination with 131I. The delivery of phospholipids was inhibited at 0ºC and by the metabolic inhibitors, sodium azide and sodium fluoride. Comparison of the radioactivity incorporation from 32P-lipophorin with that of 14C-inulin suggests that the 32P-phospholipids from lipophorin are not taken up by fluid phase endocytosis. The data presented here are compatible with the concept of lipophorin as a carrier of lipids in insects and provide evidence that lipophorin transports phospholipids as shown previously for other classes of lipids. The utilization by the oocytes of the phospholipids transported by lipophorin is discussed.

  2. Yeast Interacting Proteins Database: YGR004W, YPR028W [Yeast Interacting Proteins Database

    Lifescience Database Archive (English)

    Full Text Available n of peroxisome size; partially functionally redundant with Pex30p and Pex32p; probably acts at a step downstream of steps...ctionally redundant with Pex30p and Pex32p; probably acts at a step downstream of steps mediated by Pex28p a

  3. Optimization of image reconstruction for yttrium-90 SIRT on a LYSO PET/CT system using a Bayesian penalized likelihood reconstruction algorithm.

    Science.gov (United States)

    Rowley, Lisa M; Bradley, Kevin M; Boardman, Philip; Hallam, Aida; McGowan, Daniel R

    2016-09-29

    Imaging on a gamma camera with Yttrium-90 ((90)Y) following selective internal radiotherapy (SIRT) may allow for verification of treatment delivery but suffers relatively poor spatial resolution and imprecise dosimetry calculation. (90)Y Positron Emission Tomography (PET) / Computed Tomography (CT) imaging is possible on 3D, time-of-flight machines however images are usually poor due to low count statistics and noise. A new PET reconstruction software using a Bayesian penalized likelihood (BPL) reconstruction algorithm (termed Q.Clear) released by GE was investigated using phantom and patient scans to optimize the reconstruction for post-SIRT imaging and clarify if this leads to an improvement in clinical image quality using (90)Y.

  4. [Studies of biologic activation associated with molecular receptor increase and tumor response in ChL6/L6 protocol patients; Studies in phantoms; Quantitative SPECT; Preclinical studies; and Clinical studies]. DOE annual report, 1994--95

    Energy Technology Data Exchange (ETDEWEB)

    DeNardo, S.J.

    1995-12-31

    The authors describe results which have not yet been published from their associated studies listed in the title. For the first, they discuss Lym-1 single chain genetically engineered molecules, analysis of molecular genetic coded messages to enhance tumor response, and human dosimetry and therapeutic human use radiopharmaceuticals. Studies in phantoms includes a discussion of planar image quantitation, counts coincidence correction, organ studies, tumor studies, and {sup 90}Y quantitation with Bremsstrahlung imaging. The study on SPECT discusses attenuation correction and scatter correction. Preclinical studies investigated uptake of {sup 90}Y-BrE-3 in mice using autoradiography. Clinical studies discuss image quantitation verses counts from biopsy samples, S factors for radiation dose calculation, {sup 67}Cu imaging studies for lymphoma cancer, and {sup 111}In MoAb imaging studies for breast cancer to predict {sup 90}Y MoAb therapy.

  5. Identification of the 64 kilodalton chloroplast stromal phosphoprotein as phosphoglucomutase. [Pisum sativum

    Energy Technology Data Exchange (ETDEWEB)

    Salvucci, M.E.; Drake, R.R.; Broadbent, K.P.; Haley, B.E. (Univ. of Kentucky, Lexington (USA)); Hanson, K.R.; McHale, N.A. (Connecticut Agricultural Experiment Station, New Haven, CT (USA))

    1990-05-01

    Phosphorylation of the 64 kilodalton stromal phosphoprotein by incubation of pea (Pisum sativum) chloroplast extracts with ({gamma}-{sup 32}P)ATP decreased in the presence of Glc-6-P and Glc-1,6-P{sub 2}, but was stimulated by glucose. Two-dimensional gel electrophoresis following incubation of intact chloroplasts and stromal extracts with ({gamma}-{sup 32}P)ATP, or incubation of stromal extracts and partially purified phosphoglucomutase (EC 2.7.5.1) with ({sup 32}P)Glc-1-P showed that the identical 64 kilodalton polypeptide was labeled. A 62 kilodalton polypeptide was phosphorylated by incubation of tobacco (Nicotiana sylvestris) stromal extracts with either ({gamma}-{sup 32}P)ATP or ({sup 32}P)Glc-1-P. In contrast, an analogous polypeptide was not phosphorylated in extracts from a tobacco mutant deficient in plastid phosphoglucomutase activity. The results indicate that the 64 (or 62) kilodalton chloroplast stromal phosphoprotein is phosphoglucomutase.

  6. Biodistribution of Yttrium-90-Labeled Anti-CD45 Antibody in a Nonhuman Primate Model

    Energy Technology Data Exchange (ETDEWEB)

    Nemecek, Eneida; Hamlin, Donald K.; Fisher, Darrell R.; Krohn, Kenneth A.; Pagel, John M.; Applebaum, F. R.; Press, Oliver W.; Matthews, Dana C.

    2005-01-15

    Radioimmunotherapy may improve the outcome of hematopoietic cell transplantation for hematologic malignancies by delivering targeted radiation to hematopoietic organs while relatively sparing nontarget organs. We evaluated the organ localization of yttrium-90-labeled anti-CD45 (90Y-anti-CD45) antibody in macaques, a model that had previously predicted iodine-131-labeled anti-CD-45 (131I-anti-CD45) antibody biodistribution in humans. Experimental Design: Twelve Macaca nemestrina primates received anti-CD45 antibody labeled with 1 to 2 mCi of 90Y followed by serial blood sampling and marrow and lymph node biopsies, and necropsy. The content of 90Y per gram of tissue was determined by liquid scintillation spectrometry. Time-activity curves were constructed using average isotope concentrations in each tissue at measured time points to yield the fractional residence time and estimate radiation absorbed doses for each organ per unit of administered activity. The biodistribution of 90Y-anti-CD45 antibody was then compared with that previously obtained with 131I-anti-CD45 antibody in macaques. Results: The spleen received 2,120, marrow 1,060, and lymph nodes 315 cGy/mCi of 90Y injected. The liver and lungs were the nontarget organs receiving the highest radiation absorbed doses (440 and 285 cGy/mCi, respectively). Ytrrium-90-labeled anti-CD45 antibody delivered 2.5- and 3.7-fold more radiation to marrow than to liver and lungs, respectively. The ratios previously observed with 131I-antiCD45 antibody were 2.5-and 2.2-fold more radiation to marrow than to liver and lungs, respectively. Conclusions: This study shows that 90Y-anti-CD45 antibody can deliver relatively selective radiation to hematopoietic tissues, with similar ratios of radiation delivered to target versus nontarget organs, as compared with the 131I immunoconjugate in the same animal model.

  7. Towards tailored radiopeptide therapy

    Energy Technology Data Exchange (ETDEWEB)

    Radojewski, Piotr [University Hospital Bern, Institute of Nuclear Medicine, Bern (Switzerland); Dumont, Rebecca [University Hospital Basel, Institute of Nuclear Medicine, Basel (Switzerland); UCLA, Department of Radiology, David Geffen School of Medicine, Los Angeles, CA (United States); Marincek, Nicolas; Walter, Martin A. [University Hospital Bern, Institute of Nuclear Medicine, Bern (Switzerland); University Hospital Basel, Institute of Nuclear Medicine, Basel (Switzerland); Brunner, Philippe; Mueller-Brand, Jan [University Hospital Basel, Institute of Nuclear Medicine, Basel (Switzerland); Maecke, Helmut R. [University Hospital Basel, Division of Radiological Chemistry, Basel (Switzerland); Briel, Matthias [University Hospital Basel, Basel Institute for Clinical Epidemiology and Biostatistics, Basel (Switzerland)

    2015-07-15

    Somatostatin receptor-targeted radiopeptide therapy is commonly performed using single radioisotopes. We evaluated the benefits and harms of combining radioisotopes in radiopeptide therapy in patients with neuroendocrine tumor. Using multivariable-adjusted survival analyses and competing risk analyses we evaluated outcomes in patients with neuroendocrine tumor receiving {sup 90}Y-DOTATOC, {sup 177}Lu-DOTATOC or their combination. {sup 90}Y-DOTATOC plus {sup 177}Lu-DOTATOC treatment was associated with longer survival than {sup 90}Y-DOTATOC (66.1 vs. 47.5 months; n = 1,358; p < 0.001) or {sup 177}Lu-DOTATOC alone (66.1 vs. 45.5 months; n = 390; p < 0.001). {sup 177}Lu-DOTATOC was associated with longer survival than {sup 90}Y-DOTATOC in patients with solitary lesions (HR 0.3, range 0.1 - 0.7; n = 153; p = 0.005), extrahepatic metastases (HR 0.5, range 0.3 - 0.9; n = 256; p = 0.029) and metastases with low uptake (HR 0.1, range 0.05 - 0.4; n = 113; p = 0.001). {sup 90}Y-DOTATOC induced higher hematotoxicity rates than combined treatment (9.5 % vs. 4.0 %, p = 0.005) or {sup 177}Lu-DOTATOC (9.5 % vs. 1.4 %, p = 0.002). Renal toxicity was similar among the treatments. Using {sup 90}Y and {sup 177}Lu might facilitate tailoring radiopeptide therapy and improve survival in patients with neuroendocrine tumors. (orig.)

  8. Analysis of 90Sr in Environmental Water Samples Using SPE Disks

    Institute of Scientific and Technical Information of China (English)

    YANG; Su-liang; YANG; Zhi-hong; DING; You-qian; LIANG; Xia-hu; SUN; Hong-qing

    2012-01-01

    <正>90 Sr is produced through nuclear fission. It is an important radionuclide in the environment and mainly comes from atmospheric nuclear tests. However, the operation of nuclear facilities (such as repro- cessing plant) may also release 90Sr and contaminate the environment. Therefore, analysis of 90Sr in the environment has been an important task in the routine environmental radiological monitoring. 90Sr and its daughter, 90Y, both are pure beta-emitter radionuclides. It is necessary to isolate 90Sr or 90Y from environ-

  9. Quantitative Evaluation of Scintillation Camera Imaging Characteristics of Isotopes Used in Liver Radioembolization

    OpenAIRE

    Mattijs Elschot; Johannes Franciscus Wilhelmus Nijsen; Alida Johanna Dam; Hugo Wilhelmus Antonius Maria de Jong

    2011-01-01

    BACKGROUND: Scintillation camera imaging is used for treatment planning and post-treatment dosimetry in liver radioembolization (RE). In yttrium-90 (90Y) RE, scintigraphic images of technetium-99m (99mTc) are used for treatment planning, while 90Y Bremsstrahlung images are used for post-treatment dosimetry. In holmium-166 (166Ho) RE, scintigraphic images of 166Ho can be used for both treatment planning and post-treatment dosimetry. The aim of this study is to quantitatively evaluate and compa...

  10. Dynamics of ryegrass P in red soils

    Institute of Scientific and Technical Information of China (English)

    XiHai-Fu; ZhangQin-Zheng; 等

    1998-01-01

    An investigation on the dynamics of transformation of P from 32P-labelled ryegrass in red soils was conducted in laboratory.The results showed thast the rapid increase in flush 32P related with biomass P was accompanied with the decrease in extractable 32P on the first 3d of incubation in both sandy and clayey soils,and afterwards,itdisplayed great fluctuation in sandy soil,but hadlittle fluctuaston in clayey soil during 3-20d of incubation.At the later stage of incubation,the increase in extractable 32P was accompanied with decrease in flush 32P.The opposite changes in content of extractable 32P and flush 32P suggested transformation of ryegrass P was clkosely related to its utilization and its release from microorganisms in red soils.It can be concluded that addition of organic matter accelerated the release of soil native P according to the changes in the extractable soil P during incubation.

  11. Elaboration of a method for internal labelling of migrantes alatae of Phorodon humuli (Schrank)

    Energy Technology Data Exchange (ETDEWEB)

    Taimr, L.

    1982-03-01

    The average value of the effective half-life of /sup 32/P in migrantes alatae of Phorodon humuli (Schrank) was 3.794 days during 11 days following termination of feeding NaH/sub 2//sup 32/PO/sub 4/ in 20% sucrose solution on 'Parafilm' membranes under the given experimental conditions (temperature 20 +- 4/sup 0/C, imposed limitation of movement). During the first three days and partly also during 5 further days the aphids excret